2020
ANNUAL REPORT
Every Second Counts! ™
Dear Fellow Shareholders,
Thanks to the commitment and dedication of our employees, 2020
was a remarkable year for Kiniksa. Relentless execution throughout
the pandemic drove advancements across our portfolio of immune-
modulating assets, bringing us closer to delivering novel therapies to
patients with unmet need.
At Kiniksa, we aim to achieve massive success for patients by
discovering, acquiring, developing, and commercializing therapeutic
medicines for debilitating diseases with significant unmet need. Our
assets, ARCALYST® (rilonacept), mavrilimumab, vixarelimab, and KPL-404
are designed to modulate immunological pathways across a spectrum of
diseases. They are based on validated mechanisms, target underserved
conditions, and offer potential differentiation. We reported encouraging
clinical data from each of our assets in 2020 and enhanced the value and
optionality of our portfolio, setting the stage for a transformational 2021.
ARCALYST
In March 2021, the U.S. Food and Drug Administration (FDA) approved
ARCALYST, an interleukin-1 alpha (IL-1(cid:696)) and interleukin-1 beta (IL-1(cid:697))
cytokine trap, for the treatment of recurrent pericarditis and reduction in
risk of recurrence. ARCALYST is the first and only FDA-approved therapy
for recurrent pericarditis, a debilitating cardiovascular disease. The FDA
granted ARCALYST Breakthrough Therapy designation in 2019 for the
treatment of recurrent pericarditis and Orphan Drug designation in 2020
for the treatment of pericarditis.
The FDA approved ARCALYST in recurrent pericarditis following positive
data from RHAPSODY, a pivotal Phase 3 trial of ARCALYST in recurrent
pericarditis. In 2020, RHAPSODY met its prespecified primary efficacy
endpoint of time-to-first adjudicated recurrence in the randomized
withdrawal period and all major secondary efficacy endpoints with
statistical significance. The data showed that ARCALYST treatment in
the trial improved clinically meaningful outcomes associated with high
unmet medical need in recurrent pericarditis. As a company deeply
rooted in clinical trial execution and data analysis, we were pleased to
have the data from RHAPSODY published in The New England Journal
of Medicine simultaneously with a late-breaking scientific presentation
at the American Heart Association’s Scientific Sessions 2020.
We are committed to bringing this breakthrough therapy to patients
as fast as possible and believe we can efficiently capitalize on the
opportunity. We have a specialty cardiology sales team in place, two-
thirds of whom have extensive cardiovascular experience and the
remainder of whom have experience in biologics or rare diseases.
They will promote ARCALYST to high-volume specialists, treating
a well-defined population of approximately 14,000 patients who
experience multiple recurrences annually. We also launched Kiniksa
One Connect™, our patient support program that provides one-on-one
personalized support for patients throughout their treatment journey
and assistance pertaining to treatment access and affordability.
MAVRILIMUMAB
We believe mavrilimumab, a monoclonal antibody inhibitor targeting
granulocyte macrophage colony stimulating factor receptor alpha (GM-
CSFR(cid:696)), has potential broad utility across a host of immune-mediated
diseases. Our lead indication for mavrilimumab is giant cell arteritis
(GCA), a chronic inflammatory disease of the medium-to-large arteries.
In 2020, we reported positive data from a global Phase 2 trial. The trial
achieved both the primary efficacy endpoint, time-to-first adjudicated
GCA flare by Week 26 in all treated patients, and the secondary
efficacy endpoint, sustained remission at Week 26 in all treated
patients, with statistical significance. These data were presented
at the American College of Rheumatology Convergence 2020 and
underscore the potential for mavrilimumab, with its upstream inhibition
of two immune pathways implicated in GCA, to provide differentiation
from current standard of care therapies by addressing the underlying
pathophysiology of the disease. The FDA granted mavrilimumab
Orphan Drug designation for the treatment of GCA in 2020.
We are also evaluating mavrilimumab in severe COVID-19 pneumonia
and hyperinflammation. In 2020, data from an open-label treatment
protocol in Italy showed mavrilimumab-treated patients experienced
earlier and improved clinical outcomes compared to control-group
patients. Additionally, a placebo-controlled U.S. investigator-initiated
study showed encouraging trends of reduced mortality and duration
of mechanical ventilation in patients treated with mavrilimumab on top
of standard of care therapy. The data from these studies were each
published in The Lancet Rheumatology. More recently, in April 2021,
data from the Phase 2 portion of a Phase 2/3 trial in non-mechanically
ventilated patients treated with mavrilimumab demonstrated a reduction
in mechanical ventilation and death at Day 29 pooled across dose
levels. These data support continued evaluation of mavrilimumab
in severe COVID-19 pneumonia and hyperinflammation, for which
enrollment in the Phase 3 portion of the Phase 2/3 trial is ongoing.
VIXARELIMAB
Vixarelimab is a monoclonal antibody inhibitor of signaling through
oncostatin M receptor beta (OSMR(cid:697)), which mediates signaling of
both interleukin-31 (IL-31) and oncostatin M (OSM). We believe this dual
mechanism represents a unique opportunity to provide differentiated
efficacy in the treatment of prurigo nodularis and various pruritic,
inflammatory, and fibrotic conditions.
Our lead indication for vixarelimab is prurigo nodularis, a chronic
inflammatory skin condition. In 2020, we reported positive data from
a Phase 2a trial of vixarelimab in prurigo nodularis. The trial achieved
its primary efficacy endpoint with statistical significance: the reduction
in weekly-average Worst Itch Numeric Rating Scale from baseline
at Week 8. Additionally, a statistically significant percentage of
vixarelimab recipients achieved a prurigo nodularis-investigator’s global
assessmentscore of 0/1 (Clear/Almost Clear) at Week 8 compared
to placebo recipients. These data were presented at the European
Academy of Dermatology and Venereology Virtual Congress and
support our continued evaluation of vixarelimab in prurigo nodularis.
We are currently conducting a Phase 2b trial of vixarelimab in prurigo
nodularis across a range of once-monthly dosing regimens. The
FDA granted vixarelimab Breakthrough Therapy designation for the
treatment of pruritus associated with prurigo nodularis in 2020.
In 2020, we also reported encouraging data from 4 out of 5 cohorts in
an exploratory Phase 2 trial of vixarelimab in diseases characterized by
chronic pruritus, including plaque psoriasis, chronic idiopathic pruritus,
lichen simplex chronicus, chronic idiopathic urticaria and lichen planus.
KPL-404
KPL-404 is an investigational humanized monoclonal antibody that is
designed to mediate CD40-CD154 (CD40 ligand) signaling, a well-
known pathway that plays a critical role in regulating B cell proliferation
and T cell activation as well as antibody production. In 2020, we
reported encouraging preliminary data from a single-ascending-dose
Phase 1 trial of KPL-404 in healthy volunteers. Based on these data,
we believe KPL-404 has the potential to be a best-in-class molecule
across a range of autoimmune diseases, including rheumatoid arthritis,
Sjogren’s syndrome, Graves’ disease, systemic lupus erythematosus
and the prevention of solid organ transplant graft rejection.
Over the course of 2020, we strengthened our balance sheet,
raising approximately $220 million through two public offerings and
concurrent private placements.
Looking ahead to 2021, we are focused on the commercial launch of
ARCALYST in recurrent pericarditis and execution across our pipeline
of product candidates. We believe we are well-positioned to drive
towards our goal of advancing therapies for patients with unmet need.
Thank you for your ongoing support.
Every Second Counts!™
Sanj K. Patel
CEO and Chairman of the Board
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
(cid:1409) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2020
OR
(cid:1407) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission file number: 001-38492
Kiniksa Pharmaceuticals, Ltd.
(Exact name of registrant as specified in its charter)
Bermuda
(State or other jurisdiction of
incorporation or organization)
98-1327726
(I.R.S. Employer
Identification Number)
Kiniksa Pharmaceuticals, Ltd.
Clarendon House
2 Church Street
Hamilton HM11, Bermuda
+ (44) 808-189-6257
(Address, zip code and telephone number, including area code of principal executive offices)
Kiniksa Pharmaceuticals Corp.
100 Hayden Avenue
Lexington, MA, 02421
(781) 431-9100
(Address, zip code and telephone number, including area code of agent for service)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Class A Common Shares
Trading Symbol(s)
KNSA
Name of each exchange on which registered
The Nasdaq Global Select Market
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes (cid:1409) No (cid:1407)
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes (cid:1407) No (cid:1409)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes (cid:1409) No (cid:1407)
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding
12 months (or for such shorter period that the registrant was required to submit such files). Yes (cid:1409) No (cid:1407)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See
the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer (cid:1409) Accelerated Filer (cid:1407)
Non-accelerated Filer (cid:1407)
Smaller Reporting Company (cid:1409)
Emerging Growth Company (cid:1407)
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. (cid:1407)(cid:3)
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under
Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. (cid:1409)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes (cid:1407) No (cid:1409)
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the common shares on The Nasdaq Global
Select Market on June 30, 2020, was approximately $712.6 million.
As of January 31, 2021, there were 68,232,304 common shares outstanding in aggregate, comprised of:
31,922,546 Class A common shares, par value $0.000273235 per share
2,227,614 Class B common shares, par value $0.000273235 per share
18,024,526 Class A1 common shares, par value $0.000273235 per share
16,057,618 Class B1 common shares, par value $0.000273235 per share
Portions of the registrant’s definitive proxy statement for its 2021 Annual Meeting of Shareholders, which the registrant intends to file with the Securities and Exchange Commission
pursuant to Regulation 14A within 120 days after the end of the registrant’s fiscal year ended December 31, 2020, are incorporated by reference into Part III of this Annual Report on
Form 10-K.
DOCUMENTS INCORPORATED BY REFERENCE
Kiniksa Pharmaceuticals, Ltd.
FORM 10-K
FOR THE YEAR ENDED DECEMBER 31, 2020
TABLE OF CONTENTS
PART I
Page
Item 1. Business . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Item 1A. Risk Factors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6
47
Item 1B. Unresolved Staff Comments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
119
Item 2. Properties . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
119
Item 3. Legal Proceedings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
119
Item 4. Mine Safety Disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
119
EXECUTIVE OFFICER AND DIRECTOR BIOGRAPHIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
120
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
Securities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
123
Item 6. Selected Financial Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
124
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations . . . . . . . . . . . .
126
Item 7A. Quantitative and Qualitative Disclosures About Market Risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
144
Item 8. Financial Statements and Supplementary Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
144
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure . . . . . . . . . . . .
144
Item 9A. Controls and Procedures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
144
Item 9B. Other Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
145
PART III
Item 10. Directors, Executive Officers and Corporate Governance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
145
Item 11. Executive Compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
145
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters .
145
Item 13. Certain Relationships and Related Transactions, and Director Independence . . . . . . . . . . . . . . . . . . . . . . .
146
Item 14. Principal Accounting Fees and Services . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
146
Item 15. Exhibits and Financial Statement Schedules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
147
Item 16. Form 10-K Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
152
PART IV
2
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K, or Annual Report, contains forward-looking statements. All statements
other than statements of historical facts contained in this Annual Report including statements regarding our future results
of operations and financial position, expected timeline for our cash, cash equivalents and short-term investments,
business strategy, product development, prospective products and product candidates, their expected properties,
performance, market opportunity and competition, drug product supply, collaborators, license and other strategic
arrangements, the expected timeline for achievement of our clinical milestones, the timing of, and potential results from,
clinical and other trials, potential marketing authorization from the FDA or regulatory authorities in other jurisdictions,
potential coverage and reimbursement for our product candidates, if approved, commercial strategy and pre-commercial
activities, research and development costs, timing of regulatory filings and feedback, timing and likelihood of success,
plans and objectives of management for future operations and funding requirements and future results of anticipated
products are forward-looking statements.
These statements involve known and unknown risks, uncertainties and other important factors that may cause
our actual results, performance or achievements to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements.
In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,”
“plan,” “anticipate,” “could,” “intend,” “goal,” “design,” “target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all
forward-looking statements contain these identifying words. The forward-looking statements in this Annual Report are
only predictions. We have based these forward-looking statements largely on our current expectations and projections
about future events and financial trends that we believe may affect our business, financial condition and results of
operations. These forward-looking statements speak only as of the date of this Annual Report and are subject to a
number of risks, uncertainties and assumptions described under the sections in this Annual Report entitled “Risk
Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere
in this Annual Report. These forward-looking statements are subject to numerous risks and uncertainties, including,
without limitation, the following:
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
the impact of the coronavirus disease 2019, or COVID-19, pandemic on our business, including our clinical
trials and operations;
our status as a clinical-stage biopharmaceutical company and our expectation to incur losses in the future;
our future capital needs and our need to raise additional funds;
the lengthy and expensive clinical development process with its uncertain outcome and potential for
clinical failure or delay, including due to the COVID-19 pandemic;
the decision by any applicable regulatory authority whether to clear our product candidates for clinical
development and, ultimately, whether to approve them for marketing and sale;
our ability to anticipate and prevent adverse events caused by our product candidates;
our ability to identify, in-license, acquire, discover or develop additional product candidates;
our ability to have our product candidates manufactured in accordance with regulatory requirements;
the market acceptance of our product candidates;
our ability to timely and successfully develop and commercialize our existing and future product
candidates, if approved;
competitive and potentially competitive products and technologies;
3
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
physician awareness and adoption of our product candidates;
the size of the market for our product candidates;
our ability to meet the quality expectations of physicians or patients;
our ability to improve our product candidates;
the decision of third-party payors not to cover our product candidates or to require extensive or
independently performed clinical trials prior to covering or maintaining coverage of our product
candidates;
our ability to successfully manage our growth;
our ability to avoid product liability claims and maintain adequate product liability insurance;
our ability to obtain regulatory exclusivity;
our ability to obtain, maintain, protect and enforce our intellectual property rights related to our product
candidates;
federal, state and foreign regulatory requirements applicable to our product candidates;
ownership concentration of our executive officers and certain members of senior management may prevent
our shareholders from influencing significant corporate decisions;
our ability to attract and retain skilled personnel; and
our ability to execute on our strategy.
Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be
predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking
statements as predictions of future events. The events and circumstances reflected in our forward-looking statements
may not be achieved or occur and actual results could differ materially from those projected in the forward-looking
statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time
to time, and it is not possible for management to predict all risk factors and uncertainties. As a result of these factors, we
cannot assure you that the forward-looking statements in this Annual Report will prove to be accurate. Except as
required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein,
whether as a result of any new information, future events, changed circumstances or otherwise.
You should read this Annual Report and the documents that we reference in this Annual Report completely and
with the understanding that our actual future results may be materially different from what we expect. We qualify all of
our forward-looking statements by these cautionary statements.
SUMMARY RISK FACTORS
Our business is subject to numerous risks and uncertainties, including those described in Part I, Item 1A. “Risk Factors”
in this Annual Report. You should carefully consider these risks and uncertainties when investing in our Class A common
shares. The principal risks and uncertainties affecting our business include the following:
•(cid:3)
the COVID-19 pandemic, and related measures taken in response or the easing of such measures, could
have an adverse impact on our business and operations as well as those of our manufacturers, contract
research organizations and other third parties with whom we conduct business or otherwise engage,
including regulatory authorities, and has impacted and could continue to impact the global economy, which
may have a material adverse effect on our business, operations and financial position;
4
•(cid:3) we have never generated any product revenue, have incurred significant operating losses since our
inception, and expect to incur significant operating losses for the foreseeable future and may never achieve
or maintain profitability;
•(cid:3) we will require significant additional funding to complete the development and commercialization of our
product candidates, if approved, and to identify, discover, develop or acquire additional product candidates,
and if we are unable to raise capital on acceptable terms when needed, or at all, we could be forced to
delay, reduce or cease one or more of our product development plans, research and development programs
or other operations or commercialization efforts;
•(cid:3) we depend heavily on the success of one or more of our product candidates, which are in various stages of
product developments, and cannot give any assurance that we will be able to advance our product
candidates in clinical development, obtain regulatory approval and ultimately commercialize one or more
of our product candidates on a timely basis, if at all;
•(cid:3)
clinical development of our product candidates is a lengthy and expensive process with uncertain timelines,
costs and outcomes;
•(cid:3) we may encounter substantial delays in our current or planned pre-clinical and clinical trials, including as a
result of delays in obtaining regulatory approvals for indications, site activation, enrollment, and conduct of
the trials, which could delay or prevent our product development activities;
•(cid:3) we rely on third parties, including independent contract resource organizations, or CROs, to activate our
sites, conduct or otherwise support our research activities, preclinical and clinical trials for our product
candidates, and these third parties may not perform satisfactorily, which could delay, prevent or impair our
product development activities;
•(cid:3) we contract with third parties, including independent contract manufacturing organizations, or CMOs, to
manufacture our product candidates for preclinical and clinical development and expect to do so for our
commercial supply as well as for supply of drug substance and drug product for each of our product
candidates, and these third parties may not perform satisfactorily, which could delay, prevent or impair our
product development activities, regulatory approval, and commercialization efforts for our product
candidates;
•(cid:3) we have not obtained marketing approvals for any of our product candidates nor, as a company have we
commercialized a therapeutic, and have limited experience establishing sales, marketing, distribution and
general infrastructure either directly and/or through agreements with third parties and have never sold,
marketed or distributed any therapeutic products; as a result we may not be successful in commercializing
rilonacept in recurrent pericarditis, if approved, or any future approved product candidates, thus potentially
impairing the commercial potential of rilonacept and our other product candidates to generate any revenue;
•(cid:3)
•(cid:3)
•(cid:3)
our current or future product candidates may not gain market acceptance by physicians, patients, or third-
party payors, in which case our ability to generate product revenues will be impaired;
successful commercialization of our product candidates will depend in part on the extent to which third-
party payors provide funding, establish favorable coverage and pricing policies and set adequate
reimbursement levels for our product candidates, and failure to obtain or maintain coverage and adequate
reimbursement for our product candidates, if approved, could limit our ability to market those products and
decrease our ability to generate revenue;
the incidence and prevalence for target patient populations of our product candidates have not been
established with precision, and if the market opportunities for our product candidates are smaller than we
estimate, or if any approval that we obtain is based on a narrower definition of the patient population, our
revenue and ability to achieve profitability may be materially adversely affected;
5
•(cid:3)
all of our product candidates have been licensed or acquired from other parties; if we are unable to
adequately protect our product candidates, or to secure and maintain freedom to operate, others could
preclude us from commercializing our product candidates or compete against us more directly;
•(cid:3) we face significant competition from other biotechnology and pharmaceutical companies, which may result
in others discovering, developing or commercializing drugs before or more successfully than us;
•(cid:3) we may not be successful in executing our growth strategy to identify, discover, develop, license or acquire
additional product candidates or technologies, and our strategy may not deliver anticipated results or we
may refine or otherwise alter our growth strategy;
•(cid:3) we may seek to acquire businesses or undertake business combinations, collaborations or other strategic
transactions which may not be successful or on favorable terms, if at all, and we may not realize the
intended benefits of such transactions;
•(cid:3)
concentration of ownership of the voting power of our common shares may prevent new investors in from
influencing significant corporate decisions and may have an adverse effect on the price of our Class A
common shares; and
•(cid:3) we believe we may be classified as a passive foreign investment company for the current taxable year
ended December 31, 2020 and will likely be a controlled foreign corporation for the same period, which
may result in adverse U.S. federal income tax consequences to U.S. holders of our Class A common shares.
INDUSTRY AND OTHER DATA
Unless otherwise indicated, certain industry data and market data included in this Annual Report were obtained
from independent third-party surveys, market research, publicly available information, reports of governmental agencies
and industry publications and surveys. All of the market data used in this Annual Report involves a number of
assumptions and limitations, and you are cautioned not to give undue weight to such estimates. We believe that the
information from these industry publications and surveys included in this Annual Report is reliable.
ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc. and Yescarta® is a registered
trademark of Gilead Sciences, Inc., or its related companies.
PART I
ITEM 1. BUSINESS.
Overview
We are a biopharmaceutical company focused on discovering, acquiring, developing and commercializing
therapeutic medicines for patients with significant unmet medical need. Our product candidates, rilonacept,
mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target
underserved conditions and offer the potential for differentiation. This pipeline of product candidates are designed to
modulate immunological pathways across a spectrum of diseases.
Rilonacept is a protein cytokine trap for inhibiting interleukin-1alpha, or IL-1(cid:302), and interleukin-1beta, or IL-1(cid:533).
Cytokines are small proteins that play a role in cell signaling. Rilonacept was discovered and developed by Regeneron
Pharmaceuticals, Inc., or Regeneron, and is approved by the U.S. Food and Drug Administration, or FDA, under the
brand name ARCALYST for the treatment of cryopyrin-associated periodic syndrome, or CAPS, specifically familial
cold autoinflammatory syndrome and muckle-wells syndrome, and for the treatment of deficiency of IL-1 receptor
antagonist, or DIRA. We licensed rilonacept from Regeneron in 2017.
We are initially developing rilonacept for the potential treatment of recurrent pericarditis, a painful
inflammatory cardiovascular disease with an estimated U.S. prevalent population of approximately 40,000 patients
6
seeking and receiving medical treatment. Currently there is no FDA-approved therapy for the treatment of recurrent
pericarditis. We received Breakthrough Therapy designation from the FDA for rilonacept for the treatment of recurrent
pericarditis in 2019 and Orphan Drug designation from the FDA for rilonacept for the treatment of pericarditis, which
includes the treatment of recurrent pericarditis, in 2020. In June 2020, we reported final results from RHAPSODY, our
pivotal Phase 3 clinical trial of rilonacept in subjects with recurrent pericarditis. RHAPSODY met its prescribed primary
and all major secondary efficacy endpoints with statistical significance, showing that rilonacept improved clinically
meaningful outcomes associated with unmet medical need in recurrent pericarditis. RHAPSODY data were also
published in The New England Journal of Medicine simultaneously with a late-breaking scientific presentation at the
American Heart Association’s Scientific Sessions 2020.
The FDA accepted the supplemental Biologics License Application, or sBLA, for rilonacept in recurrent
pericarditis with priority review and assigned a Prescription Drug User Fee Act, or PDUFA, goal date of March 21,
2021. If approved by the FDA for recurrent pericarditis, we expect the potential commercial launch of rilonacept in
recurrent pericarditis in the first half of 2021 and consequently would take responsibility for sales and distribution of
rilonacept for all approved indications in the United States and evenly split profits on sales with Regeneron, after
deducting certain commercialization expenses subject to specified limits.
Mavrilimumab is a fully-human monoclonal antibody that antagonizes granulocyte-macrophage colony
stimulating factor, or GM-CSF. We licensed mavrilimumab from MedImmune Limited, or MedImmune, in 2017.
We are evaluating mavrilimumab for the potential treatment of giant cell arteritis, or GCA, a chronic
inflammatory disease of the medium-to-large arteries with an estimated U.S. prevalence of approximately 75,000 to
150,000 patients. There is only one FDA-approved therapy for GCA, which is an adjunct to corticosteroid therapy, and
we believe that an unmet need persists. We received Orphan Drug designation from the FDA for mavrilimumab for the
treatment of GCA in 2020. In November 2020, we presented results from our Phase 2 proof-of-concept trial of
mavrilimumab in subjects with GCA at the late-breaking abstracts session during the American College of
Rheumatology, or ACR, Convergence 2020. The Phase 2 trial met both its prescribed primary efficacy endpoint of time-
to-first adjudicated GCA flare by Week 26 in all treated patients and the secondary efficacy endpoint of sustained
remission at Week 26 in all treated patients with statistical significance. In addition, while the trial was not powered for
individual disease cohorts, there was a consistent trend of efficacy across the new onset and relapsing/refractory cohorts.
We expect to provide next steps for mavrilimumab, including in GCA, in the first half of 2021.
We are also evaluating mavrilimumab for the potential treatment of severe coronavirus 2019 disease, or
COVID-19, pneumonia and hyperinflammation. In June 2020, we announced 28-day clinical outcomes from an open-
label investigator-initiated treatment protocol with mavrilimumab conducted in Italy in 13 non-mechanically ventilated
patients with severe COVID-19 pneumonia and hyperinflammation. Mavrilimumab-treated patients experienced earlier
and improved clinical outcomes compared to control-group patients, including earlier weaning from supplemental
oxygen, shorter hospitalizations, and no deaths. These data were published in The Lancet Rheumatology. In
December 2020, we reported results from a placebo-controlled investigator-initiated study in the same patient population
across a consortium of academic sites in the United States showing encouraging trends of reduced mortality and duration
of mechanical ventilation in patients treated with mavrilimumab on top of standard of care therapy. We are conducting a
placebo-controlled Phase 2/3 clinical trial of mavrilimumab in severe COVID-19 pneumonia and hyperinflammation.
We expect to provide data from the Phase 2 portion of the Phase 2/3 trial in the first half of 2021.
Vixarelimab is a fully-human monoclonal antibody that simultaneously inhibits the signaling of the cytokines
interleukin 31, or IL-31, and oncostatin M, or OSM, by targeting their common receptor subunit, oncostatin M receptor
beta, or OSMR(cid:533). We believe vixarelimab is the only monoclonal antibody in development that simultaneously targets
both pathways. We licensed vixarelimab from Biogen MA, Inc., or Biogen, in 2016.
We are evaluating vixarelimab for the potential treatment of prurigo nodularis, a chronic inflammatory skin
condition with an estimated U.S. prevalence of approximately 300,000 patients. We received Breakthrough Therapy
designation for vixarelimab for the treatment of pruritus associated with prurigo nodularis in 2020. In April 2020, we
reported results from our Phase 2a trial of vixarelimab in prurigo nodularis. The Phase 2a trial met its primary efficacy
endpoint, as there was a statistically significant reduction in weekly-average Worst-Itch Numeric Rating Scale, or WI-
7
NRS, from baseline at Week 8 in vixarelimab recipients compared to placebo recipients. In addition, the majority of
vixarelimab recipients showed a clinically meaningful greater-than-or-equal-to 4-point weekly-average WI-NRS
reduction at Week 8 and a statistically significant percentage of vixarelimab recipients achieved a prurigo nodularis-
investigator’s global assessment, or PN-IGA score of 0/1 at Week 8 compared to placebo recipients. We are conducting
a Phase 2b dose ranging study of vixarelimab in patients with prurigo nodularis.
KPL-404 is a humanized monoclonal antibody that is designed to inhibit the CD40-CD40 ligand, or CD40L,
interaction, a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity. We believe that
disrupting the CD40-CD40L interaction is an attractive approach for multiple autoimmune disease pathologies such as
rheumatoid arthritis, Sjogren’s syndrome, Graves’ disease, systemic lupus erythematosus and solid organ transplant graft
rejection. We acquired all of the outstanding securities of Primatope Therapeutics, Inc., or Primatope, the company that
owned or controlled the intellectual property related to KPL-404 in 2019.
We are conducting a single-ascending-dose Phase 1 clinical trial of KPL-404 in healthy volunteers to evaluate
the safety and tolerability of KPL-404 as well as pharmacokinetics, CD40 receptor occupancy, or RO, the immune
response to the novel test antigen keyhole limpet hemocyanin, or KLH, in clinically relevant dose cohorts, and T-cell
dependent antibody response, or TDAR, in these subjects. The study is divided into two parts: a single dose of KPL-404
0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg or 10 mg/kg intravenously, or IV, and a single dose of KPL-404 1 mg/kg or 5
mg/kg subcutaneously, or SC. In November 2020, we reported preliminary data from the Phase 1 trial. All dose
escalations occurred as per protocol with no dose limiting safety findings. All six subjects dosed with KPL-404 3 mg/kg
IV showed full receptor occupancy through Day 29, which corresponded with complete suppression of TDAR to KLH
through Day 29. Consistent dose relatedness was shown in the lower dose level cohorts, including 0.03 mg/kg, 0.3
mg/kg, 1 mg/kg IV and 1 mg/kg SC. We believe that the data support further evaluation in patients, including potential
IV or SC monthly administration. Further, we expect final data and safety follow-up from all cohorts of the Phase 1 trial
in the first half of 2021.
8
The following table summarizes our current pipeline of product candidates:
(1)
(2)
(3)
Rilonacept (ARCALYST®) is approved and marketed for cryopyrin-associated periodic syndrome (CAPS) and maintenance of remission of
Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in the United States by Regeneron Pharmaceuticals, Inc.
The FDA granted Breakthrough Therapy designation to rilonacept for recurrent pericarditis in 2019 and Orphan Drug designation to rilonacept
for pericarditis in 2020. The FDA granted Orphan Drug designation to mavrilimumab for giant cell arteritis in 2020. The FDA granted
Breakthrough Therapy designation to vixarelimab for the treatment of pruritus associated with prurigo nodularis in 2020.
IL-1(cid:302) = interleukin-1(cid:302) ; IL-1(cid:533) = interleukin-1(cid:533); GM-CSFR(cid:302) = granulocyte macrophage colony stimulating factor receptor alpha; OSMR(cid:533) =
oncostatin M receptor beta; PDUFA = Prescription Drug User Fee Act ; MENA = Middle East North Africa.
We evaluate options across our portfolio in an effort to maximize value and improve capital allocation based on
data, including potential additional indications for rilonacept, mavrilimumab and vixarelimab, being opportunistic in our
business development activities, considering appropriate opportunities to partner or out-license our programs, as well as
conducting internal research to discover and develop molecules to expand our portfolio.
Our Strategy
We are a biopharmaceutical company focused on discovering, acquiring, developing and commercializing
therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Our product
candidates, rilonacept, mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated
mechanisms, target underserved conditions, and offer the potential for differentiation. These pipeline assets are designed
to modulate immunological pathways across a spectrum of diseases.
Critical components of our business strategy include the following:
•(cid:3) Advance Our Product Candidates Through the Development Process. We are pursuing multiple
product candidates in parallel and have advanced these programs with the goal of delivering differentiated
therapies to patients. We believe that each of our product candidates have the potential to address
significant unmet medical needs and intend to develop them efficiently in a data-driven manner.
•(cid:3) Commercialize Our Product Candidates to Bring Therapies to Patients. We intend to market and
commercialize our product candidates, if approved, in the United States and potentially in select
international markets by developing sales, marketing, medical affairs, access and reimbursement
capabilities as well as implementing disease awareness campaigns, among other things, as appropriate for
the potential commercial opportunity – starting with the potential commercial launch of rilonacept in
recurrent pericarditis if approved by the FDA. We believe this approach will enable us to effectively reach
9
patients and prescribers that our product candidates target and leverage the commercial potential of our
product candidates.
•(cid:3) Explore Opportunities to Drive Value and Maximize the Potential of Our Existing Portfolio. We
believe that our product candidates have potential in multiple indications. Our assets are designed to
modulate immunological signaling pathways that are implicated across a spectrum of diseases. We may
also seek collaborations, licenses and other strategic relationships to assist in advancing and expanding our
current programs, as appropriate to drive value.
•(cid:3) Work to Identify, Discover, Acquire and Develop New Therapies. We aim to leverage our internal
discovery efforts and business development capabilities to complement our existing portfolio. We evaluate
a variety of factors for potential product candidates, technologies and discovery targets, including biologic
rationale for addressing the disease, potential for regulatory approval, commercial viability, intellectual
property position, prospects for favorable pricing and reimbursement and the impact of competition. We
also look at assets that could potentially address multiple indications. We intend to continue to be
opportunistic in our business development activities.
Our Product Candidates
Rilonacept
Overview
Rilonacept was approved by the FDA for the treatment of CAPS, which includes cold auto-inflammatory
syndrome and Muckle-Wells syndrome, and DIRA and has been commercially sold as ARCALYST in the United States
by Regeneron for CAPS since 2008. We licensed rilonacept in 2017 from Regeneron. We believe that rilonacept has
potential to treat certain diseases mediated by both IL-1(cid:302) and IL-1(cid:533). Our lead indication for rilonacept is recurrent
pericarditis, a painful autoinflammatory cardiovascular disease with an estimated U.S. prevalent population of
approximately 40,000 patients seeking and receiving medical treatment. We received Breakthrough Therapy designation
from the FDA for rilonacept for the treatment of recurrent pericarditis in 2019 and Orphan Drug designation from the
FDA for rilonacept for the treatment of pericarditis, which includes the treatment of recurrent pericarditis, in 2020.
In June 2020, we reported final results from RHAPSODY, our global, double-blind, placebo-controlled,
randomized-withdrawal design, pivotal Phase 3 clinical trial of rilonacept in subjects with recurrent pericarditis.
RHAPSODY met its prescribed primary and all major secondary efficacy endpoints with statistical significance,
showing that rilonacept improved clinically meaningful outcomes associated with unmet medical need in recurrent
pericarditis. RHAPSODY data were also published in The New England Journal of Medicine simultaneously with a late-
breaking scientific presentation at the American Heart Association’s Scientific Sessions 2020.
The FDA accepted the sBLA for rilonacept in recurrent pericarditis with priority review and assigned a PDUFA
goal date of March 21, 2021. If approved by the FDA for recurrent pericarditis, we expect the potential commercial
launch of rilonacept in recurrent pericarditis in the first half of 2021 and consequently would take responsibility for sales
and distribution of rilonacept for all approved indications in the United States and evenly split profits on sales with
Regeneron, after deducting certain commercialization expenses subject to specified limits.
There is currently no FDA-approved therapy for the treatment of recurrent pericarditis. There is currently one
other FDA-approved agent that blocks both IL-1(cid:302) and IL-1(cid:533) signaling, anakinra (KINERET), produced by Sobi, Inc, or
Sobi, is approved for other indications, and one that blocks only IL-1(cid:533), canakinumab (ILARIS), produced by Novartis
Pharmaceuticals Corporation, or Novartis, is approved for other indications. We believe both therapies have limitations.
Anakinra requires once-daily injections, and canakinumab blocks only IL-1(cid:533), making it less effective or potentially
ineffective in diseases driven by IL-1(cid:302) pathology. We believe that rilonacept with its more moderate, once-weekly
dosing schedule and its ability to inhibit both IL-1(cid:302) and IL-1(cid:533) could provide an improved therapeutic option for a variety
of diseases mediated by both IL-1(cid:302) and IL-1(cid:533).
10
Mechanism of Action
Rilonacept is an inhibitor of IL-1(cid:302) and IL-1(cid:533). IL-1(cid:302) and IL-1(cid:533) have been demonstrated to play a key role in
inflammatory diseases. IL-1(cid:302) and IL-1(cid:533) provoke potent, pro-inflammatory events by engaging the IL-1(cid:302) and IL-1(cid:533)
receptor. Following tissue insult, the release of IL-1(cid:302) acts as the primary initiating signal to coordinate the mobilization
of immune cells to the damaged area, while IL-1(cid:533) is secreted mostly by macrophages and is a prototypical cytokine of
the canonical NLRB-3 inflammasome. IL-1(cid:302) and IL-1(cid:533) signaling results in a dramatic increase in the production of
cytokines that orchestrate the proliferation and recruitment of phagocytes to the site of damage, resulting in
inflammation. Moreover, IL-1(cid:302) and IL-1(cid:533) signaling also affect other immune-system cells, such as T-cells and B-cells.
IL-1(cid:533)’s role in the inflammation process has been extensively studied, while in comparison, much is still
unknown about the independent function of IL-1(cid:302) in disease pathology. Despite driving similar immunological
outcomes, IL-1(cid:302) and IL-1(cid:533) differ substantially in their expression and regulation, and non-redundant roles for IL-1(cid:302) or
IL-1(cid:533) have been demonstrated in multiple inflammatory diseases. There are disease states in which IL-1(cid:533) inhibition
alone does not appear to be sufficient for disease remission in the absence of IL-1(cid:302) inhibition. Published studies suggest
certain autoinflammatory diseases may, in fact, be pathologically driven primarily by IL-1(cid:302).
An investigator-initiated study of anakinra successfully demonstrated mechanistic proof-of-concept for
inhibiting both IL-1(cid:302) and IL-1(cid:533) in the treatment of recurrent pericarditis. In a published case study, a patient with a
refractory form of recurrent pericarditis, who was well-controlled on anakinra, was switched from anakinra to
canakinumab, which inhibits only IL-1(cid:533), for tolerability reasons. The patient’s disease returned despite further dose
escalation of canakinumab. When the patient was switched back to anakinra, which inhibits IL-(cid:302) and IL-(cid:533), the disease
promptly went back into remission. These data, together with clinical data from our open-label Phase 2 proof-of-concept
study and confirmatory market research, may indicate that IL-1(cid:302) and IL-1(cid:533) play unique roles in recurrent pericarditis
and other autoinflammatory diseases in which the pathology may be driven primarily by IL-1(cid:302).
Background and Market Opportunity for Recurrent Pericarditis
Pericarditis is the most common disorder involving the pericardium, the two-layered sac that surrounds the
heart. Pericarditis is an inflammation of this sac and is typically characterized by significant chest pain, shortness of
breath, coughing and fatigue and is often misconstrued by patients as a heart attack. In addition, typical signs of
pericarditis include pericardial friction rub, electrocardiogram changes or pericardial effusion, which is a build-up of
fluid around the heart. Pericarditis is described as recurrent if, following an initial occurrence of pericarditis, it recurs
after a symptom-free period of about four to six weeks. Pericarditis is considered chronic if symptoms of any one
episode last longer than three months, typically causing significant pain and frustration. If pericarditis is left untreated,
patients can develop thickening and scarring of the pericardium, potentially requiring invasive surgical stripping.
Pericardial effusion, if large enough, can compress the heart externally, requiring emergent drainage.
We intend to focus our development of rilonacept for the treatment of recurrent pericarditis initially in the
United States, and we are exploring opportunities for potential expansion into other countries. Claims analysis, cross
validated with published estimates, support a prevalent population of patients with recurrent pericarditis seeking and
receiving medical treatment to be approximately 40,000 patients in the United States per year. Within this estimated
diagnosed and treated recurrent pericarditis patient population, there are certain subgroups of patients totaling
approximately 14,000 with particularly high unmet medical needs consisting of:
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
patients who are refractory to all conventional treatments (approximately 3,000);
patients who are refractory to nonsteroidal anti-inflammatory drugs, or NSAIDs and/or colchicine but
where steroid usage is not appropriate (approximately 5,000);
patients otherwise not well-managed and have multiple recurrences despite previously responding to
NSAIDs, colchicine and/or steroids (approximately 5,000); and
patients who are dependent on steroids (approximately 1,000).
11
There may be other thoracic inflammatory syndromes where rilonacept may prove beneficial, such as
pericarditis associated with post-pericardiotomy syndrome, an inflammatory reaction of the pericardium in patients who
have undergone surgery that involves opening the pericardium. Post-pericardiotomy syndrome occurs in up to 30% of
the 300,000 patients in the United States undergoing post-cardiac injury, and we believe rilonacept may be a therapeutic
option for a subset of these patients.
Current Treatment Landscape for Recurrent Pericarditis
We are not aware of any current therapies approved by the FDA for the treatment of recurrent pericarditis. A
patient’s initial acute episode of pericarditis is typically treated with over-the-counter or prescription NSAIDs or
colchicine, both of which are used off-label. Recurrent episodes are treated in a similar manner or by adding systemic
corticosteroids which are also used off-label. Both colchicine and corticosteroids often have deleterious effects when
used at high doses or for long periods of time, including, for colchicine, gastrointestinal distress and neutropenia and, for
corticosteroids, glaucoma, fluid retention, hypertension, mood changes, memory changes, other psychological effects,
weight gain and diabetes. Fourth-line treatment for these patients may include other immunosuppressants such as
methotrexate and azathioprine, as well as anakinra.
Our Solution
Rilonacept is a weekly, subcutaneously-injected, recombinant fusion protein that blocks IL-1(cid:302) and IL-1(cid:533)
signaling. Beyond recurrent pericarditis, we believe there is significant potential for rilonacept to address additional
indications, including other pericarditis populations. More broadly, we believe diseases characterized by painful serosal
inflammation may be driven by IL-1(cid:302), and we intend to consider development of rilonacept in these indications and in
others where we believe IL-1(cid:302) or IL-1(cid:533) play a key role in disease pathophysiology.
Phase 3 Clinical Trial in Recurrent Pericarditis
We conducted a global, randomized withdrawal design, pivotal Phase 3 clinical trial of rilonacept in recurrent
pericarditis, named RHAPSODY. Eligible patients presented at screening with at least a third pericarditis episode,
defined as at least 1 day with pericarditis pain of (cid:149) 4 on the 11-point NRS and a CRP value (cid:149) 1 mg/dL within the 7-day
period prior to first study drug administration. Patients could be receiving concomitant NSAIDs and/or colchicine and/or
oral corticosteroid treatment in any combination. The study was comprised of 4 periods: a screening period; a single-
blind run-in period during which patients received a loading dose of rilonacept 320 mg injected SC followed by 160 mg
SC weekly while background pericarditis medications were tapered and discontinued; a double-blind, placebo-controlled
randomized withdrawal period during which clinical responders to rilonacept were randomized 1:1 and received 160 mg
SC weekly rilonacept or placebo; and a long-term extension treatment period with up to 24 months of open-label
rilonacept 160 mg SC weekly. The primary efficacy endpoint was time-to-first pericarditis-recurrence in the randomized
withdrawal period. The Clinical Endpoint Committee adjudicated all suspected pericarditis recurrences for inclusion in
the primary efficacy endpoint analysis.
Phase 3 Clinical Trial Results in Recurrent Pericarditis
In June 2020, we announced RHAPSODY met its prespecified primary and all major secondary efficacy
endpoints, showing that rilonacept improved clinically meaningful outcomes associated with the unmet medical need in
recurrent pericarditis. RHAPSODY data were also published in The New England Journal of Medicine simultaneously
with a late-breaking scientific presentation at the American Heart Association’s Scientific Sessions in November 2020.
The primary efficacy endpoint of time-to-first adjudicated pericarditis recurrence in the randomized withdrawal
period was highly statistically significant.
•(cid:3) Median [95% CI] time to pericarditis recurrence for rilonacept recipients in the randomized withdrawal period
could not be estimated due to the low number of recurrences in the rilonacept treatment arm. The median time-
to-recurrence for placebo recipients was 8.6 [4.0-11.7] weeks (Hazard Ratio = 0.04, p<0.0001).
12
•(cid:3) Rilonacept recipients experienced a 96% reduction in risk of recurrent pericarditis events.
All major secondary efficacy endpoints in the randomized withdrawal period were also highly statistically
significant.
•(cid:3)
81% of rilonacept recipients maintained clinical response at Week 16 of the randomized withdrawal period,
compared to 20% of placebo recipients (p=0.0002). Consistent results were observed at Week 8 and Week 24
and were also highly statistically significant (p<0.0001 and p=0.0022, respectively).
•(cid:3) The proportion of rilonacept recipients with absent or minimal pericarditis symptoms at Week 16 of the
randomized withdrawal period was 81% compared to 25% for placebo recipients (p=0.0006). Consistent results
were observed at Week 8 and Week 24 and were also highly statistically significant (p<0.0001 and p=0.0002,
respectively).
Rilonacept was well-tolerated in the study, with adverse events consistent with the FDA-approved label for the
treatment of CAPS. The most common adverse events were injection site reactions.
Commercial Strategy for Rilonacept
We intend to have a focused and targeted launch effort, with a specialty cardiology salesforce of approximately
30 representatives calling on high-volume accounts and high-volume specialists. The salesforce will be complemented
by our current medical affairs, payor and patient services teams, as well as an efficient digital marketing effort. Through
a data-driven market assessment, we have developed what we believe to be a highly efficient launch model built around
four key strategic imperatives. The first of which is, establishing the unmet need and working to ensure recurrent
pericarditis is viewed as a serious, debilitating disease, that is primarily driven by IL-1. The second is, working to ensure
rilonacept is viewed as the product of choice for the treatment and prevention of recurrent pericarditis. The third strategic
imperative relates to reimbursement and working to ensure broad patient access at a price that reflects rilonacept’s value
as a first-in-class IL-1 inhibitor of inflammation. The final strategic imperative is building robust patient support
programs to optimize the patient and customer experience with rilonacept as well as with Kiniksa. Overall, our efforts
are focused on developing a program and tactics to help with broad uptake and adoption of rilonacept as well as ensuring
a positive patient experience.
Commercial History of Rilonacept
The FDA approved rilonacept under the brand name ARCALYST for the treatment of CAPS, specifically
familial cold autoinflammatory syndrome and muckle-wells syndrome, in 2008, and subsequently approved it for the
treatment of DIRA in 2020.
Mavrilimumab
Overview
Mavrilimumab is a fully-human monoclonal antibody that antagonizes GM-CSF signaling by binding to the
alpha subunit of the GM-CSF receptor. Our lead indication for mavrilimumab is GCA, a chronic inflammatory disease
of medium-large blood vessels with an estimated U.S. prevalence of approximately 75,000 to 150,000 patients. We
received Orphan Drug designation from the FDA for mavrilimumab for the treatment of GCA in 2020. In
November 2020, we presented results from our randomized, double-blind, placebo-controlled, global Phase 2
proof-of-concept trial of mavrilimumab in subjects with GCA at the late-breaking abstracts session during the ACR
Convergence 2020. Before we licensed mavrilimumab in 2017, MedImmune was developing mavrilimumab for the
treatment of RA. MedImmune had received authorization to conduct clinical trials for RA in Europe and executed an
extensive Phase 1 and Phase 2 clinical program where the company studied mavrilimumab in over 550 patients with RA
through Phase 2b. All of MedImmune’s European clinical trials achieved their prospectively defined primary endpoints
of safety or efficacy.
13
We are also evaluating mavrilimumab for the potential treatment of COVID-19 pneumonia and
hyperinflammation. In June 2020, we announced 28-day clinical outcomes from an open-label investigator-initiated
treatment protocol with mavrilimumab conducted in Italy in 13 non-mechanically ventilated patients with severe
COVID-19 pneumonia and hyperinflammation. Additionally, in December 2020, we reported results from a randomized,
double-blind, placebo-controlled, investigator-initiated study in the same patient population across a consortium of
academic sites in the United States. We are conducting a global, randomized, double-blind, placebo-controlled Phase 2/3
clinical trial of mavrilimumab in severe COVID-19 pneumonia and hyperinflammation. We expect to provide data from
the Phase 2 portion of the Phase 2/3 trial in the first half of 2021.
Mechanism of Action
Mavrilimumab is designed to inhibit the signaling of GM-CSF, a growth factor that stimulates the production of
certain types of white blood cells. Studies have demonstrated that with GM-CSF overexpression, pathological changes
almost always follow. Reported data suggest GM-CSF is a key player in the immune system, as follows:
o(cid:3) GM-CSF enhanced trafficking of myeloid cells through activated endothelium of blood vessels and
contributed to monocyte and macrophage accumulation in blood vessels during inflammation;
o(cid:3) GM-CSF promoted activation, differentiation, survival and proliferation of monocytes and macrophages, as
well as resident tissue macrophages in inflamed tissues;
o(cid:3) GM-CSF production led to activation of the vasculature and bone marrow and also promoted the
differentiation of effector T cells at inflamed sites and draining lymph nodes; and
o(cid:3) GM-CSF regulated the phenotype of antigen-presenting cells in inflamed tissues by promoting the
differentiation of infiltrating monocytes into M1 macrophages and monocyte-derived dendritic cells, or
MoDCs.
Additionally, GM-CSF has been shown to be a confirmed mediator in RA based on the results from the
Phase 2b clinical trial in RA conducted by MedImmune. In this trial, mavrilimumab achieved the co-primary endpoints
of change from baseline in disease activity score, or DAS, at week 12 and a response of 20% or greater improvement in
the American College of Rheumatology criteria, or ACR20, at week 24. Patients treated with mavrilimumab showed a
statistically significant reduction in DAS scores at all dosages compared to placebo, and significantly more
mavrilimumab-treated patients achieved ACR20 at all dosages compared to placebo.
Background and Market Opportunity for Giant Cell Arteritis
GCA is an inflammatory disease of the medium-to-large arteries that strikes older adults and causes headaches,
jaw and other muscle claudication, and possible ischemic visual loss. Many of the symptoms and signs of GCA result
from involvement of the cranial branches of arteries that originate from the aortic arch, but the disease is systemic, and
vascular involvement can be widespread. GCA is characterized by infiltration of monocytes, macrophages and the
formation of giant cells (i.e., multinucleated fusions of macrophages). GCA generally occurs in adults over 50 years old
with a 3:1 imbalance of women to men. We estimate there to be approximately 75,000 to 150,000 prevalent patients with
GCA in the United States with similar prevalence rates for other major markets and believe that the incidence of GCA
will increase over time as the population ages.
Current Treatment Landscape for Giant Cell Arteritis
Glucocorticoids, a type of corticosteroid, are the mainstay for the treatment of GCA because they normalize
inflammatory markers and resolve patient symptoms. Many patients receive long courses of this therapy to prevent
disease flare-up, which are associated with significant and serious side effects, including glaucoma, fluid retention,
hypertension, mood changes, memory changes, other psychological effects, weight gain and diabetes. Up to 80% of
patients suffer from glucocorticoid toxicity as a result of GCA treatment.
14
Despite being effective for some patients, many are unable to wean off of corticosteroids because they continue
to experience disease flares as the dose is reduced. In one study cohort published in the literature that followed 106
patients with GCA for 4.5 to 10.1 years, 68 patients (64%) experienced at least one relapse during or after weaning, and
38 patients (36%) experienced two or more. Experimental evidence in mice suggests that corticosteroid treatment does
not adequately suppress tissue-infiltrating macrophage function, a key cell type generated and maintained by GM-CSF
signaling, and may explain why many patients require long-term chronic treatment and are unable to wean off
corticosteroids. We believe by blocking GM-CSF signaling, mavrilimumab may provide additional benefit to these
patients by reducing long-term sequelae that results from chronic vessel inflammation.
In addition, tocilizumab, an inhibitor of interleukin-6, or IL-6, is approved in the United States in GCA for use
on top of a concomitant corticosteroid taper. However, up to nearly half of the patients studied in the Phase 3 clinical
trial for tocilizumab experienced disease flares during the 52 weeks treatment period that included a 26-week
corticosteroid taper. We believe this indicates a persistent unmet medical need exists.
Our Solution
We chose GCA as our first indication for mavrilimumab due to the mechanistic rationale of inhibiting
GM-CSF. GM-CSF is a key growth factor for many of these key inflammatory cell types and is found in high
concentrations at the site of damage in the vessel wall. We believe that data provide a solid rationale for antagonizing
this signaling with mavrilimumab.
Phase 2 Clinical Trial for GCA
We conducted a randomized, double-blind, placebo-controlled, global Phase 2 trial consisting of a 6-week
screening period, a 26-week double-blind placebo-controlled treatment period, and a 12-week washout safety follow-up
period. Patients age 50 to 85 years with active GCA, confirmed by temporal artery biopsy and/or imaging, with
erythrocyte sedimentation rate, or ESR, (cid:149) 30 mm/hour or C-reactive protein, or CRP, (cid:149) 1 mg/dL, and symptoms of GCA
within 6 weeks from randomization, were included. All patients were required to have achieved corticosteroid-induced
remission (resolution of symptoms, ESR < 20 mm/hour, CRP < 1 mg/dL) prior to randomization. Seventy (70) patients
were randomized 3:2 to mavrilimumab 150 mg or placebo biweekly injected SC, co-administered with a protocol-
defined 26-week oral corticosteroid taper. Patients were stratified by new onset (n=35) or relapsing/refractory (n=35)
disease. The primary efficacy endpoint was time-to-first adjudicated GCA flare by Week 26 in all treated patients and
the secondary efficacy endpoint was sustained remission at Week 26 in all treated patients with statistical significance.
Phase 2 Clinical Trial Results for GCA
In November 2020, we announced that results from our randomized, double-blind, placebo-controlled, global
Phase 2 proof-of-concept trial of mavrilimumab in subjects with GCA were presented at the late-breaking abstracts
session during the ACR Convergence 2020. The Phase 2 trial met both its prescribed primary and efficacy endpoint of
time-to-first adjudicated GCA flare by Week 26 in all treated patients and the secondary efficacy endpoint of sustained
remission at Week 26 in all treated patients with statistical significance. In addition, while the trial was not powered for
individual disease cohorts, there was a consistent trend of efficacy across the new onset and relapsing/refractory cohorts.
Mavrilimumab was well-tolerated in the Phase 2 trial; there were no drug-related SAEs, and the rates of drug-related
treatment-emergent adverse events between mavrilimumab recipients and placebo recipients were similar. We expect to
provide next steps for the development of mavrilimumab, including in GCA, in the first half of 2021.
The primary efficacy endpoint of time-to-first adjudicated GCA flare by Week 26 in all treated patients was
statistically significant (Hazard Ratio = 0.38, p=0.0263).
•(cid:3) Median time-to-flare by Week 26 could not be estimated in mavrilimumab recipients due to the low number of
flares in the mavrilimumab treatment arm. The median time-to-flare for placebo recipients was 25.1 weeks.
There was a 62% lower risk of flare in mavrilimumab recipients compared to placebo recipients.
15
The secondary efficacy endpoint of sustained remission at Week 26 in all treated patients was also statistically
significant.
•(cid:3) The sustained remission rate at Week 26 was 33.3 percentage points higher in mavrilimumab recipients (83.2%)
compared to placebo recipients (49.9%) (p=0.0038).
Mavrilimumab was well-tolerated; there were no drug-related SAEs, and the rates of drug-related treatment-
emergent adverse events between mavrilimumab recipients and placebo recipients were similar.
Clinical Development for Mavrilimumab in COVID-19 Pneumonia and Hyperinflammation
In June 2020, we announced 28-day clinical outcomes from an open-label investigator-initiated treatment
protocol with mavrilimumab conducted in Italy in 13 non-mechanically ventilated patients with severe COVID-19
pneumonia and hyperinflammation. Mavrilimumab-treated patients experienced earlier and improved clinical outcomes
compared to control-group patients, including earlier weaning from supplemental oxygen, shorter hospitalizations, and
no deaths. These data were published in The Lancet Rheumatology.
In December 2020, we reported results from a randomized, double-blind, placebo-controlled investigator-
initiated study in the same patient population across a consortium of academic sites in the United States showing
encouraging trends of reduced mortality and duration of mechanical ventilation in patients treated with mavrilimumab on
top of standard of care therapy. There was no difference in SAEs between the mavrilimumab arm and the placebo arm in
the investigator-initiated study.
We are conducting a global, randomized, double-blind, placebo-controlled Phase 2/3 clinical trial of
mavrilimumab in severe COVID-19 pneumonia and hyperinflammation. We expect to provide data from the Phase 2
portion of the Phase 2/3 trial in the first half of 2021.
Clinical History in Rheumatoid Arthritis
MedImmune had received authorization to conduct clinical trials for RA in Europe and executed an extensive
Phase 1 and Phase 2 clinical program where the company studied mavrilimumab in over 550 patients with RA through
Phase 2b. All of MedImmune’s European clinical trials achieved their prospectively defined primary endpoints of safety
or efficacy.
MedImmune’s investigational new drug application, or IND, for the clinical development of mavrilimumab for
the treatment of RA in the United States was initially put on clinical hold in 2010 before human data had been generated
due to certain effects that were observed in non-clinical studies, which coincides with a theoretical risk of developing
pulmonary alveolar proteinosis, or PAP, possibly in the setting of GM-CSF inhibition. Since then, in 2014, the FDA
acknowledged that clinical studies in refractory RA may be appropriate based on MedImmune’s clinical studies in
Europe in which it dosed over 550 RA patients with mavrilimumab with no evidence of PAP attributable to
mavrilimumab following long-term administration. MedImmune did not engage in further dialogue with the FDA and
withdrew the IND for mavrilimumab for the treatment of RA.
We believe that the trials conducted by MedImmune provide substantial support for the potential of
mavrilimumab in autoimmune diseases. In these trials, mavrilimumab was observed to be well-tolerated. The most
common adverse event was infection, with all dose groups (30 mg, 100 mg, 150 mg) in a Phase 2b clinical trial reporting
similar rates of infection compared to the placebo group. We believe that these safety results provide an accurate early
representation of the safety profile of mavrilimumab, which we believe to be at least competitive with and potentially
better than existing systemically administered agents for autoimmune diseases.
Mavrilimumab’s results from MedImmune’s European Phase 2b clinical trials in RA have provided important
information about its safety and efficacy profile and helped solidify our choice for focusing our development efforts in
GCA as a lead indication. In addition to the reductions to the primary endpoint demonstrated in MedImmune’s European
Phase 2b trials, other markers of inflammation, such as CRP, ESR, and IL-6, were similarly reduced, as shown in the
16
graphs below. CRP, ESR and IL-6 are key markers of disease activity for GCA. We believe that these results may also
provide evidence for mavrilimumab’s potential utility across a broad range of indications with a similar biomarker
profile.
Source: Burmester GR, et al. Ann Rheum Dis 2017. *p<0.05, **p<0.01, ***p<0.001 mavrilimumab versus placebo
Vixarelimab
Overview
Vixarelimab is a fully-human monoclonal antibody that targets OSMR(cid:533), which mediates signaling of IL-31 and
OSM, two key cytokines implicated in inflammation, pruritus and fibrosis. We believe vixarelimab to be the only
monoclonal antibody in development that targets both pathways simultaneously. We acquired the assets relating to
vixarelimab from Biogen, in 2016. We are evaluating vixarelimab for the potential treatment of prurigo nodularis, a
chronic inflammatory skin condition with an estimated U.S. prevalence of approximately 300,000 patients. We received
Breakthrough Therapy designation for vixarelimab for the treatment of pruritus associated with prurigo nodularis in
2020. In April 2020, we reported results from our randomized, double-blind, placebo-controlled Phase 2a trial of
vixarelimab in prurigo nodularis. We are conducting a randomized, double-blind, placebo-controlled Phase 2b dose
ranging study of vixarelimab in patients with prurigo nodularis designed to investigate the efficacy, safety, and
pharmacokinetics.
Mechanism of Action
The OSMR(cid:533) subunit is an IL-6 type receptor which combines with one of two other subunits to form two
distinct cytokine receptors used for the signaling of two different cytokines: IL-31, and OSM. IL-31 binds to the IL-31
receptor on keratinocytes, epidermal cells, leading to a sensation of pruritus and further inflammatory responses in the
skin. In addition to interacting with IL-31 receptors on keratinocytes, IL-31 also stimulates pruritus directly through
IL-31 receptors expressed on unmyelinated C-fibers in the skin responsible for the sensation and transmission of pruritic
signaling.
OSM is produced primarily under inflammatory conditions and stimulates dermal fibroblast proliferation and
migration as well as synthesis of collagen and glycosaminoglycan in the skin, leading to fibrosis. In addition to these
functions, OSM signaling through the type II OSM receptor upregulates interleukin-4, or IL-4, interleukin-13 receptor,
or IL-13R(cid:302)1, and interleukin-4 receptor, or IL-4R(cid:302), in human skin equivalent cultures, upregulates IL-4R(cid:302) in primary
human keratinocytes and also impairs expression of filaggrin, loricrin and involucrin (classical “differentiation” markers
of the epidermal differentiation complex cluster) in human skin equivalent cultures. These data implicate OSM signaling
as important in many autoimmune diseases characterized by barrier dysfunction, fibrosis and inflammation.
17
Vixarelimab inhibits both IL-31 and OSM activities at their respective receptors, potentially disrupting the
pruritus, inflammation and fibrosis mediated by these cytokine pathways.
Background and Market Opportunity for Prurigo Nodularis
Prurigo nodularis is a chronic inflammatory skin condition that affects primarily older adults and is
characterized by multiple firm and extremely pruritic nodules typically located on the arms and legs. The etiology of
prurigo nodularis is largely unknown, however, human biopsy studies have shown that the cytokines IL-31 and OSM
and the receptor chains IL-31R(cid:302) and OSMR(cid:533) are highly expressed in prurigo nodularis lesions. The pruritus is severe
and distressing and can be sudden, sporadic or continuous, worsening with heat, sweating or irritation from clothing. The
itching sensation in prurigo nodularis is extreme and often leads to scratching to the point of bleeding, infection or pain.
Our market research to-date with physicians and patients highlights the severe and debilitating nature of this disease and
the significant levels of unmet need. Multiple physicians have reported suicidal tendencies among their prurigo nodularis
patients due to an overwhelming inability to control the unrelenting itch. The exact prevalence of prurigo nodularis is
unknown, however, we estimate there to be approximately 300,000 prevalent cases in the United States.
Current Treatment Landscape for Prurigo Nodularis
Prurigo Nodularis
We are not aware of any FDA-approved therapies for treating prurigo nodularis, and the treatment approach
ranges from topical corticosteroids and occlusive steroid containing bandages for more mild patients to systemic
corticosteroid, ultraviolet phototherapy and systemic therapies such as thalidomide, methotrexate and cyclosporine for
those patients who fail initial treatments. Patients have reported using opioid pain medications to attempt to control the
disease in its most severe form.
Our Solution
Vixarelimab is a fully-human monoclonal antibody that targets two key pathways for the development of
pruritus, inflammation and fibrosis through inhibition of OSMR(cid:533). Chronic pruritic diseases are often characterized by a
complex interplay among pruritus, inflammation and fibrosis. The pathogenesis of chronic pruritic diseases involves
interlocking positive feedback loops in which pruritus causes scratch, and scratch causes reactive inflammation through
mechanical disruption of the skin architecture. The decline in skin barrier function and resulting bacterial colonization or
infection ultimately increase extracellular matrix formation and collagen deposition, leading to fibrosis. Fibrosis then
begets more pruritus through disruption and dysregulation of sensory nerve fiber expression.
Current therapies target only one or two aspects of this complex pathophysiology and are inevitably limited in
their effectiveness. Targeting only one pathway may address a single aspect of the symptomatology, e.g., pruritus, but
not the full spectrum of the pathophysiologic components of the disease. This point is particularly relevant since OSM is
upregulated in many chronic inflammatory skin diseases and synergistically interacts with pruritic and inflammatory
pathways. Of particular relevance is the central role of OSM in inflammation and barrier function and its autocrine
effects on type II OSM receptor in IL-31-dependent epidermal proliferation and remodeling as well as inflammation.
There is a relatively large body of literature linking inflammatory pruritic and inflammatory diseases to both
IL-31 and OSM via signaling though OSMR(cid:533). Vixarelimab has been specifically designed to target both pathways
simultaneously and thus vixarelimab may disrupt this pathologic cycle in patients afflicted by prurigo nodularis and
atopic dermatitis.
OSMR(cid:533) Axis Identified in Prurigo Nodularis
In 2019 at the Annual Meeting of the Society for Investigative Dermatology, we presented preclinical data
identifying the OSMR(cid:533) axis in prurigo nodularis subjects. Data from our longitudinal observational study in prurigo
nodularis, or LOTUS-PN suggest that the OSMR(cid:533) axis (IL-31, OSM, IL-31 receptor alpha (IL-31R(cid:302)) and OSMR(cid:533)) may
play a role in the pathogenesis of prurigo nodularis given its prevalent expression in lesional prurigo nodularis. IL-31
18
messenger ribonucleic acid was expressed in approximately two-thirds of lesional biopsies from prurigo nodularis
patients with WI-NRS (cid:149) 7 compared to one-tenth in healthy volunteers. Additionally, lesional biopsies from prurigo
nodularis patients contained mononuclear cells expressing OSM, OSMR(cid:533), IL-31 and IL-31R(cid:302) protein compared with
non-lesional biopsies.
Phase 2a Clinical Trial in Prurigo Nodularis
We conducted a Phase 2a randomized, double blind, placebo-controlled clinical trial to evaluate the efficacy,
safety, tolerability, PK and immunogenicity of vixarelimab administered SC in subjects with moderate-to-severe prurigo
nodularis experiencing moderate-to-severe pruritus.(cid:3)The trial enrolled and treated 49 patients with moderate-to-severe
prurigo nodularis (mean PN-IGA of 3.4) experiencing moderate-to-severe pruritus (mean WI-NRS score of 8.3). Patients
were randomized 1:1 to receive a loading dose of vixarelimab 720 mg (n=23) or placebo (n=26) SC followed by
vixarelimab 360 mg or placebo SC weekly. The primary efficacy endpoint was percent change versus baseline in
weekly-average WI-NRS at Week 8 (using the last observation carried forward analysis).
Phase 2a Clinical Trial Results in Prurigo Nodularis
In April 2020, we reported results from our randomized, double-blind, placebo-controlled Phase 2a trial of
vixarelimab in prurigo nodularis. The Phase 2a trial met its primary efficacy endpoint, as there was a statistically
significant reduction in weekly-average WI-NRS from baseline at Week 8 in vixarelimab recipients compared to placebo
recipients. In addition, the majority of vixarelimab recipients showed a clinically meaningful greater-than-or-equal-to
4-point weekly-average WI-NRS reduction at Week 8 and a statistically significant percentage of vixarelimab recipients
achieved a prurigo nodularis-investigator’s global assessment, or PN-IGA, score of 0/1 at Week 8 compared to placebo
recipients.
•(cid:3) Least squares-mean change from baseline in weekly-average WI-NRS at Week 8 was -50.6% in vixarelimab
recipients compared to -29.4% in placebo recipients (mean difference 21.1%; p=0.035).
•(cid:3) Median change from baseline in weekly-average WI-NRS at Week 8 was -69.8% in vixarelimab recipients
compared to -36.1% in placebo recipients.
•(cid:3)
•(cid:3)
30.4% of vixarelimab recipients achieved a PN-IGA score of 0/1 at Week 8 compared to 7.7% of placebo
recipients (p=0.032).
52.2% of vixarelimab recipients demonstrated a (cid:149) 4-point reduction in weekly-average WI-NRS at Week 8
compared to 30.8% of placebo recipients (p=0.109).
In this Phase 2a trial, vixarelimab was well-tolerated by all subjects and no dose-limiting adverse experiences
were observed. There were no SAEs or atopic dermatitis flares.
Phase 2b Clinical Trial in Prurigo Nodularis
In December 2020, we announced the commencement of dosing in the Phase 2b clinical trial of vixarelimab in
prurigo nodularis. The Phase 2b trial is a randomized, double-blind, placebo-controlled study designed to investigate the
efficacy, safety, and pharmacokinetics of vixarelimab in patients with prurigo nodularis. The trial is expected to enroll
approximately 180 patients experiencing severe pruritus. Patients will be randomized 1:1:1:1 to receive vixarelimab 540
mg, 360 mg, 120 mg, or placebo as a once-monthly SC injection. The primary efficacy endpoint is the percent change
from baseline in the weekly-average WI-NRS at Week 16. Key secondary endpoints include the proportion of patients
achieving greater-than-or-equal-to 4-point weekly-average WI-NRS reduction at Week 16 and the proportion of patients
achieving a 0/1 score (clear/almost clear) on the PN-IGA at Week 16.
KPL-404
19
Overview
KPL-404 is a humanized monoclonal antibody that is designed to inhibit the CD40-CD40L interaction, a key
T-cell co-stimulatory signal critical for B-cell maturation and immunoglobulin class switching. Since September 2017,
we have had a license to conduct research and development on KPL-404 from Primatope, the company that owned or
controlled the intellectual property related to KPL-404 and, in March 2019, we acquired the company. In connection
with our acquisition of Primatope, we acquired an exclusive world-wide license with Beth Israel Deaconess Medical
Center for certain patent applications and patents related to KPL-404.
Mechanism of Action and External Clinical Proof of Concept
KPL-404 is designed to block the CD40/CD40L interaction by binding to and inhibiting signaling through the
CD40 receptor. CD40 is a member of the Tumor Necrosis Factor Receptor superfamily which is constitutively or
inducibly expressed on the surface of a variety of immune and non-immune cell types including B cells, macrophages,
dendritic cells, microglia, endothelial cells, epithelial cells, and keratinocytes and can also be upregulated on other cell
types in the context of autoimmune disease. Interactions between B cell-expressed CD40 and its binding partner,
CD40L, mainly expressed on activated CD4+ T cells, play a critical role in promoting germinal center formation and the
production of class-switched antibodies. The role of CD40 in B cells has been extensively characterized and has been
shown to be essential for productive primary and secondary humoral immune responses to T dependent antigens.
External clinical data that point to the broad potential power of the mechanism has been established in RA, systemic
lupus erythematosus, primary Sjogren’s syndrome, Graves’ disease and prevention of kidney transplant rejection.
Ongoing Phase 2 trials from competitors implicate additional indications for potential development, including type 1
diabetes, inflammatory bowel disease, prevention of liver transplant rejection, hidradenitis suppurativa, lupus nephritis
and multiple sclerosis.
Our Solution
KPL-404 inhibits the signaling of CD40 and CD40L with low-single digit nanomolar affinity in vitro. The
presentation of KPL-404 is as a high-concentration, liquid formulation potentially suitable for SC administration at doses
of up to 5mg/kg, which we believe may, allow for a higher delivered dose in one SC injection than all other competitors
who are mainly limited to high dose IV formulations or SC formulations. We believe high-dose IV and SC formulations
do not fully antagonize signaling as evidenced by the generation of anti-drug antibodies ever at maximum delivered dose
levels.
Preclinical Development
In preclinical development, KPL-404 has been observed to have a favorable pharmacokinetic and toxicology
profile and has shown activity in multiple non-human primate models of organ transplant rejection, as well as in multiple
TDAR models. The data in the graphs below show in a non-human primate TDAR model that KPL-404 had linear
pharmacokinetics with low variability which translated into complete suppression of antibody responses to a novel
antigen (KLH) at drug levels achieving 100% receptor occupancy.
20
Phase 1 Program
We are conducting a Phase 1 trial of KPL-404. The Phase 1 trial is a randomized, double-blind, placebo-
controlled, single-ascending-dose, first-in-human study that is divided into two parts: a single dose of KPL-404 0.03
mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg or 10 mg/kg IV and a single dose of KPL-404 1 mg/kg or 5 mg/kg SC. The primary
objective is to assess the safety and tolerability of KPL-404. Secondary endpoints include pharmacokinetics, CD40
receptor occupancy, the immune response to the novel test antigen KLH in clinically relevant dose cohorts, and the anti-
drug antibody response.
In November 2020 we announced preliminary data from the Phase 1 clinical trial. All dose escalations occurred
as per protocol with no dose limiting safety findings. All 6 subjects dosed with KPL-404 3 mg/kg IV showed full
receptor occupancy through Day 29, which corresponded with complete suppression of the TDAR to KLH through Day
29. Consistent dose relatedness was shown in the lower dose level cohorts, including 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg IV
and 1 mg/kg SC. Data collection for the higher dose level cohorts, 10 mg/kg IV and 5 mg/kg SC, is ongoing.
We believe the data support subsequent study in patients, including potential IV or SC monthly administration.
We expect final data and safety follow-up from all cohorts in the first half of 2021.
Discovery Activities
We conduct internal discovery activities directed toward wholly owned molecules for the treatment of
debilitating disease targets where we believe there to be a strong mechanistic rationale and potential for clear
differentiation from existing approved agents or those in development.
License and Acquisition Agreements
License Agreement with Regeneron
In September 2017, we entered into a license agreement with Regeneron, or the Regeneron Agreement.
Pursuant to the Regeneron Agreement, Regeneron granted us an exclusive license under certain intellectual property
rights controlled by Regeneron to develop and commercialize rilonacept worldwide, aside from Israel, Egypt, Turkey
and select countries in the Middle East and northern Africa, which we refer to collectively as the excluded territory, or
the Excluded Territory. In the United States and Japan, our license is initially for all indications other than those
involving local administration to the eye or ear, oncology, deficiency of the interleukin-1 receptor antagonist, or DIRA,
and CAPS. If we are successful in receiving marketing approval for rilonacept in the United States for a new indication,
the scope of the license granted to us will automatically expand to include DIRA and CAPS in the United States and
Japan, and we will assume the sales and distribution of rilonacept in these additional indications. Outside the United
States and Japan, our license is for all indications other than local application to the eye or ear, oncology, DIRA, CAPS
and certain periodic fever syndromes set forth in the Regeneron Agreement, collectively the Excluded Indications. Under
the Regeneron Agreement, we are obligated to use commercially reasonable efforts to develop and commercialize
21
rilonacept outside of the excluded indications, or the Excluded Indications, in our territory. Upon receiving positive data
in a Phase 3 clinical trial, Regeneron transferred the biologics license application, or BLA, for rilonacept to us.
Under the Regeneron Agreement, we made an upfront payment of $5.0 million. In addition, we made a $7.5
million payment in the fourth quarter of 2020 in connection with the achievement of a specified regulatory milestone
event. We are obligated to make a regulatory milestone payment of $20.0 million, which may be met in the first quarter
of 2021. If we are successful in receiving marketing approval for rilonacept in the United States for a new indication,
such as recurrent pericarditis, we will assume the sales and distribution of rilonacept in DIRA and CAPS. Thereafter, we
have agreed to evenly split profits on our sales of rilonacept with Regeneron after deducting certain commercialization
expenses subject to specified limits.
Regeneron has a right of first negotiation over our engagement of third parties to support our promotional
activities in excess of a specified level and over the assignment or sale of our rights to any product we develop under the
Regeneron Agreement to a third-party. Furthermore, under certain circumstances, we will need Regeneron’s prior
consent to assign our rights under the Regeneron Agreement.
The Regeneron Agreement will expire on the date on which we, our affiliates or sublicensees are no longer
developing or commercializing any product containing rilonacept. We may terminate the agreement for convenience at
any time after the date that is eighteen months after the effective date of the agreement with 180 days’ written notice or
one year’s written notice if we terminate the agreement following U.S. marketing approval of a rilonacept product
developed by us. We may also terminate with three months’ written notice if we reasonably determine that rilonacept is
unsafe in the indications we are pursuing. Regeneron may terminate the agreement if there is a consecutive twelve month
period during which we do not conduct any material development or commercialization activities or we do not grant a
sublicense to a third-party to do so, or if we challenge Regeneron’s patent rights in any country in our territory. Either
party may terminate the agreement in the event of a material breach by the other party that remains uncured for 90 days
(or 30 days for payment-related breaches), or by either party due to the insolvency or bankruptcy of the other party.
We have also entered into a clinical supply agreement with Regeneron, or the Supply Agreement. Pursuant to
the Supply Agreement, Regeneron has the exclusive right to manufacture and supply all of our requirements of
rilonacept for clinical development. If Regeneron determines to discontinue the supply of rilonacept to us, it must use its
reasonable efforts to transfer all relevant documentation, materials and technology necessary for the manufacture of
rilonacept to us or our designee. The Supply Agreement terminates upon the termination of the Regeneron Agreement or
the transfer of technology related to the bulk manufacture of rilonacept.
License Agreement with MedImmune
In December 2017, we entered into a license agreement with MedImmune, or the MedImmune Agreement.
Pursuant to the MedImmune Agreement, MedImmune granted us an exclusive, worldwide license under certain
intellectual property rights controlled by MedImmune to make, use, develop and commercialize mavrilimumab and any
other product containing an antibody to the GM-CSF receptor alpha that is covered by certain MedImmune patent rights
for all indications. We also acquired non-exclusive licenses to other MedImmune technology for use in exploiting
licensed products. We may sublicense these rights subject to consent of MedImmune and any applicable licensors of
rights under which we are licensed. We also acquired reference rights to relevant manufacturing and regulatory
documents, and existing inventory of mavrilimumab drug substance. We must use commercially reasonable efforts to
develop and commercialize the licensed products.
Under the MedImmune Agreement, we made an upfront payment of $8.0 million. In addition, we made a $5
million pass-through payment and a $10 million milestone payment in year ended December 31, 2019 related to the
achievement of specified clinical milestone events achieved during the year ended December 31, 2018. We are also
obligated to make future clinical, regulatory and initial sales milestone payments of up to $57.5 million in the aggregate
for the first two indications. In addition, we are also obligated to make future clinical and regulatory milestone payments
of up to $15.0 million in the aggregate for each subsequent indication. In July 2020, we entered into an amendment to
the MedImmune Agreement to establish a new coronavirus field and defer the payment of certain development and
regulatory milestones as applied to the new coronavirus field. We are obligated to make milestone payments to
22
MedImmune of up to $85.0 million upon the achievement of annual net sales thresholds up to, but excluding,
$1.0 billion in annual net sales as well as additional milestone payments aggregating up to $1.1 billion upon the
achievement of additional annual net sales thresholds starting at $1.0 billion and higher. Commencing on the first
commercial sale of licensed products, we are obligated to pay tiered royalties on escalating tiers of annual net sales of
licensed products starting in the low double-digit percentages and ending at twenty percent. We must pay such royalties
on a product-by-product and country-by-country basis until the latest to occur of the expiration of licensed patents, the
expiration of regulatory exclusivity or the tenth anniversary of first commercial sale of such product in such country.
In countries where licensed patents have issued, the statutory expiration date is 2027, not including any patent
term extensions or adjustments. While the current expected patent expiration dates are known in countries where
licensed patents have issued, these expiration dates are subject to significant uncertainty. For example, the patents may
be challenged, and accordingly, the relevant expiration dates could be shortened. In addition, as we continue to file and
prosecute new patent applications related to mavrilimumab, the granting of such pending applications or future patent
applications could extend the relevant statutory expiration dates beyond 2027. The expiration date of regulatory
exclusivity is determined on a country-by country-basis if the applicable product is approved in such country and if any
applicable regulatory exclusivity applies and is granted. The actual expiration date of any such regulatory exclusivity,
however, is subject to significant uncertainty. For instance, the applicable regulatory exclusivity period is often triggered
by the date a product candidate obtains regulatory approval, and we cannot predict with any certainty whether and if so,
when, the applicable product would receive regulatory approval in any given jurisdiction. Furthermore, the type, scope
and duration of such exclusivities will vary on a country-by-country basis depending on the jurisdictions in which a
product candidate is approved and the particular regulatory exclusivity for which the product is eligible as of the time of
approval. For example, in the United States, a reference biological product is granted 12 years of data exclusivity from
the time of first licensure of the product, which means that the FDA cannot make effective the approval of a biosimilar
product that references the biologic product until 12 years from the date on which the reference product was first
licensed. In the EEA, new products authorized for marketing (i.e. reference products) may qualify for eight years of data
exclusivity and an additional two years of market exclusivity upon marketing authorization. The two-year period may be
extended to three years if during the first eight years the marketing authorization holder obtains an authorization for one
or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring
a significant clinical benefit in comparison with existing therapies. Furthermore, if a product candidate that has received
orphan designation is subsequently approved for the disease or condition for which it has such designation, the product
may be entitled to orphan drug exclusivity, which generally grants seven years of market exclusivity in the United States
and up to 10 years of market exclusivity in the EEA, and such period may run contemporaneously with the other
exclusivities that may apply. In the EEA, the ten-year period of market exclusivity is extended by two years for drugs
that also have complied with an agreed pediatric investigation plan, or PIP, granted at the time of review of the orphan
drug designation. In the United States, an additional six-month period of pediatric exclusivity may be available as an
extension to any existing non-patent regulatory exclusivity period if the sponsor has conducted and submitted pediatric
studies in response to a written request from the FDA. Additionally, our eligibility for regulatory exclusivity may depend
in part on the indications for which we seek regulatory approval of our product candidates, which may depend on the
data we receive from our clinical studies, and accordingly, may change over time, and the laws and regulations
governing regulatory exclusivity may change in various jurisdictions as the political focus on drug exclusivity increases.
For risk related to regulatory exclusivity matters, see “Risk Factors—Risks related to product development and
regulatory approval.”
The MedImmune Agreement will remain in effect until the expiration of the royalty term in all countries for all
licensed products. The MedImmune Agreement may be terminated earlier at any time by us with at least 90 days’ prior
notice, by either party in the event of material breach by the other party that remains uncured for 90 days, by either party
for insolvency or bankruptcy of the other party, or immediately by MedImmune if we challenge the licensed patents.
Biogen Asset Purchase Agreement
In September 2016, we completed the acquisition of certain assets of Biogen pursuant to an asset purchase
agreement, or the Biogen Agreement. Pursuant to the Biogen Agreement, we acquired all of Biogen’s right, title and
interest in and to certain assets used in or relating to vixarelimab and other antibodies covered by certain patent rights,
together the Acquired Assets, including patents and other intellectual property rights, clinical data, certain contracts,
23
know-how and inventory, which we refer to collectively as the acquired assets, or the Acquired Assets. In addition,
Biogen granted us a non-exclusive, sublicensable, worldwide license to certain background patent rights related the
vixarelimab program. Under the Biogen Agreement, we are obligated to use commercially reasonable efforts to develop
and commercialize the Acquired Assets.
Under the Biogen Agreement, we made an upfront payment of $11.5 million and a technology transfer payment
of $0.5 million to Biogen. In addition, we made a milestone payment of $4.0 million during the year ended
December 31, 2017, associated with the achievement of a specified clinical milestone event. We made milestone
payments of $10.3 million during the year ended December 31, 2019, primarily associated with the achievement of a
specified clinical milestone event. We are also obligated to make future milestone payments for each antibody product
that includes the Acquired Assets, or an Antibody Product, of up to $315.0 million in the aggregate upon the
achievement of specified milestones. These milestone payments relate to multiple indications for an Antibody Product,
and are comprised of up to $165.0 million in the aggregate upon achievement of specified clinical and regulatory
milestone events and $150.0 million in the aggregate upon the achievement of specified annual net sales thresholds.
Commencing on the first commercial sale of an Antibody Product, we are obligated to pay tiered royalties on escalating
tiers of annual net sales of licensed products starting in the high single-digit percentages and ending below the teens. We
must pay such royalties on a product-by-product and country-by-country basis until the latest to occur of the expiration
of patents that cover an Antibody Product, the expiration of regulatory exclusivity or the tenth anniversary of first
commercial sale of such product in such country. We have also agreed to pay certain obligations under third-party
contracts retained by Biogen that relate to vixarelimab.
In countries where patents covering Antibody Products have issued, the statutory expiration date is 2034, not
including any patent term extensions or adjustments. While the current expected patent expiration dates are known in
countries where licensed patents have issued, these expiration dates are subject to significant uncertainty. For example,
the patents may be challenged, and accordingly, the relevant expiration dates could be shortened. In addition, as we
continue to file and prosecute new patent applications related to Antibody Products, the granting of such pending
applications or future patent applications could extend the relevant statutory expiration dates beyond 2034. The
expiration date of regulatory exclusivity is determined on a country-by country-basis if the applicable product is
approved in such country and if any applicable regulatory exclusivity applies and is granted. The actual expiration date
of any such regulatory exclusivity, however, is subject to significant uncertainty. For instance, the applicable regulatory
exclusivity period is often triggered by the date a product candidate obtains regulatory approval, and we cannot predict
with any certainty whether and if so, when, the applicable product would receive regulatory approval in any given
jurisdiction. Furthermore, the type, scope and duration of such exclusivities will vary on a country-by-country basis
depending on the jurisdictions in which a product candidate is approved and the particular regulatory exclusivity for
which the product is eligible as of the time of approval. For example, in the United States, a reference biological product
is granted 12 years of data exclusivity from the time of first licensure of the product, which means that the FDA cannot
make effective the approval of a biosimilar product that references the biologic product until 12 years from the date on
which the reference product was first licensed. In the EEA, new products authorized (i.e. reference products) for
marketing may qualify for eight years of data exclusivity and an additional two years of market exclusivity upon
marketing authorization. The two-year period may be extended to three years if the marketing authorization holder
obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their
authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Furthermore, if a
product candidate that has received orphan designation is subsequently approved for the disease or condition for which it
has such designation, the product may be entitled to orphan drug exclusivity, which generally grants seven years of
market exclusivity in the United States and up to 10 years of market exclusivity in the EEA, and such period may run
contemporaneously with the other exclusivities that may apply. In the EEA, the ten-year period of market exclusivity is
extended by two years for drugs that also have complied with an agreed pediatric investigation plan, or PIP, granted at
the time of review of the orphan drug designation. In the United States, an additional six-month period of pediatric
exclusivity may be available as an extension to any existing non-patent regulatory exclusivity period if the sponsor has
conducted and submitted pediatric studies in response to a written request from the FDA. Additionally, our eligibility for
regulatory exclusivity may depend in part on the indications for which we seek regulatory approval of our product
candidates, which may depend on the data we receive from our clinical studies, and accordingly, may change over time,
and the laws and regulations governing regulatory exclusivity may change in various jurisdictions as the political focus
24
on drug exclusivity increases. For risk related to regulatory exclusivity matters, see “Risk Factors—Risks related to
product development and regulatory approval.”
Under the Biogen Agreement, Biogen has a time-limited right of first negotiation to purchase the assets we
acquired from Biogen or obtain a license to exploit Antibody Products, in each case, in the event we decide to sell the
acquired assets, including through the sale of our company, or out-license the rights to the Antibody Products.
The Biogen Agreement will remain in effect until expiration of all payment obligations in all countries related
to the last antibody product subject to the Biogen Agreement. The Biogen Agreement may be terminated by us with
90 days’ prior notice, by either party in the event of a material breach by the other party that remains uncured for 90 days
(or 30 days for payment-related breaches) or by both parties upon mutual consent. In the event of a termination, the
Acquired Assets, including certain licenses and rights related thereto, will revert to Biogen, and, upon written request by
Biogen, we are required to grant to Biogen an exclusive, worldwide, sub-licensable license to certain of our intellectual
property related to the Acquired Assets, including know-how and patent rights.
Primatope Stock Purchase Option Agreement
In September 2017, we entered into a stock purchase option agreement, or the Primatope Agreement, with
Primatope, pursuant to which we were granted a license to certain intellectual property rights owned or controlled by
Primatope to research, develop, and manufacture the preclinical antibody, KPL-404, and an exclusive call option through
April 2018 to purchase all of the outstanding securities of Primatope with up to three extensions periods through mid-
January 2019. Upon execution of the agreement, we made $0.5 million in upfront payments for the initial option period
and we made payments totaling $0.8 million for extending option period through mid-January 2019. During the option
periods, we conducted research and preclinical work to assess the viability of the program.
In January 2019, we exercised the call option and in March 2019, we acquired all of the outstanding securities
of Primatope, or Primatope Acquisition. The aggregate amount of upfront and contingent payments we paid to the
former Primatope shareholders to acquire Primatope was comprised of (1) $15.0 million paid at closing in March 2019,
comprised of upfront consideration of $10.0 million and milestone payments of $5.0 million which had been achieved as
of the closing date, and (2) $3.0 million paid in June 2019 for the final milestone payment, which was achieved
following the closing during the six months ended June 30, 2019, each paid in a combination of cash and our Class A
common shares (inclusive of escrow and holdback share amounts) in accordance with the Primatope Agreement. We
released the escrow and issued Class A common shares that were held back at closing in June 2020 and issued the Class
A common shares that were held back at the final milestone payment in September 2020.
As a result of the Primatope Acquisition, we acquired the rights to an exclusive license to certain intellectual
property rights controlled by Beth Israel Deaconess Medical Center, Inc., or BIDMC, to make, use, develop and
commercialize KPL-404 under the BIDMC license agreement, or BIDMC Agreement. Under the BIDMC Agreement,
we are solely responsible for all development, regulatory and commercial activities and costs. We are also responsible
for costs related to filing, prosecuting and maintaining the licensed patent rights. Under the BIDMC Agreement, we are
obligated to pay an insignificant annual maintenance fee as well as clinical and regulatory milestone payments of up to
an aggregate of $1.2 million to BIDMC. We are also obligated to pay a low single-digit royalty on annual net sales of
products licensed under the agreement, if approved.
Manufacturing
We do not currently own or operate any late stage manufacturing facilities. Although we have built a
development and manufacturing facility to produce drug substance to support certain research, preclinical and other
clinical development for our product candidates, we rely, and expect to continue to rely, on third parties for the
manufacture of our late-stage product candidates and certain of our early-stage product candidates for the majority of our
clinical development efforts, as well as for the potential commercial manufacture of our product candidates, if approved.
We have also entered into a Supply Agreement with Regeneron pursuant to which Regeneron has the exclusive right to
manufacture and supply all of our requirements of rilonacept for clinical development. If Regeneron determines to
discontinue the supply of rilonacept to us, it must use its reasonable efforts to transfer all relevant documentation,
25
materials and technology necessary for the manufacture of rilonacept to us or our designee. The Supply Agreement
terminates upon the termination of the Regeneron Agreement or the transfer of technology related to the bulk
manufacture of rilonacept. Regeneron, in turn, relies upon a third-party CMO to conduct fill/finish operations for
rilonacept. Under certain circumstances, we or Regeneron could initiate a technology transfer to either us or another
CMO to manufacture rilonacept.
We also have entered into an agreement with a CMO to produce mavrilimumab beyond our current inventory
and have engaged CMOs to manufacture vixarelimab drug substance and drug product currently in use in our on-going
clinical trials. We intend to use CMOs for development and scale-up work for any future clinical trials and eventual
commercialization of mavrilimumab and vixarelimab, if approved.
We have also engaged CMOs to produce our clinical drug substance for certain preclinical studies, but we
intend to produce our preclinical product candidates for Phase 1 and Phase 2 studies in our own early stage
manufacturing facilities. We plan to continue to use CMOs to produce the corresponding drug product clinical material.
Longer-term, we expect to use CMOs to produce these product candidates for later-phase clinical studies and eventual
commercialization, if approved.
We require our CMOs to conduct manufacturing activities in compliance with current good manufacturing
practice, or cGMP, requirements. We have assembled a team of experienced employees and consultants to provide the
necessary technical, quality and regulatory oversight of our CMOs. We currently perform process development
internally but are reliant on CMOs for late stage clinical manufacturing, process qualification and validation and
commercial supply. We anticipate that these CMOs will have the capacity to support both clinical supply and
commercial-scale production, but we do not have any formal agreements at this time with any of these CMOs to cover
commercial production. We also may elect to pursue additional CMOs for manufacturing supplies of drug substance and
finished drug product in the future.
Commercial Operations
Our team is experienced in commercial leadership and we intend to expand our capabilities in parallel with the
development path of our product candidates. If the FDA approves rilonacept for recurrent pericarditis, we intend to
market and commercialize rilonacept in the United States and, in anticipation of a potential commercial launch, we are
establishing our own a specialty cardiology salesforce that will be complemented by our current medical affairs and
payor and patient services teams as well as an efficient digital marketing effort by our current marketing team targeting a
subset of cardiologists currently treating pericarditis. For our other product candidates, we intend to establish
commercialization strategies for each as we approach potential marketing approval and, due to the specialization among
physicians treating the indications we are targeting, we expect to be able leverage our then-existing medical affairs,
payor and patient services, and marketing organizations.
Competition
The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense
competition and a strong emphasis on proprietary products. We face potential competition from many different sources,
including pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public
and private research institutions. Any product candidates that we successfully develop and commercialize, including
rilonacept, mavrilimumab, vixarelimab and KPL-404, and any other product candidates that we may develop, may
compete with existing products and new products that may become available in the future.
Our competitors may have significantly greater financial resources, established presence in the market,
expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals
and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting
and retaining qualified scientific, sales, marketing and management personnel, establishing clinical trial sites and patient
registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.
Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies.
26
The key competitive factors affecting the success of rilonacept, mavrilimumab, vixarelimab and KPL-404 and
any other product candidates that we develop, if approved, are likely to be our product candidates, including their
efficacy, safety, convenience, price, the level of generic competition and the availability of reimbursement from
government and other third-party payors. Our commercial opportunity for any of our product candidates could be
reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less
severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors
also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours.
In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to
encourage the use of generic products.
We are aware of the following products currently marketed or in clinical development for the treatment of the
diseases that we are initially targeting:
Rilonacept
Recurrent Pericarditis: We are not aware of any approved therapies in recurrent pericarditis, but are aware of
one program (RPH-104) being developed by R-Pharm International, which inhibits IL-1(cid:533)/IL-1F2-induced signaling and
is in Phase 2 development in recurrent pericarditis subjects in Russia.
Dual IL-1(cid:302) and IL-1(cid:533) Inhibition: Anakinra (KINERET), marketed by Swedish Orphan Biovitrum AB, is
currently approved for use in Rheumatoid Arthritis, CAPS and DIRA. We are not aware of any active, industry
sponsored development programs using anakinra seeking a label for recurrent pericarditis.
IL-1(cid:533) Inhibition Alone: Canakinumab (ILARIS), marketed by Novartis Pharmaceuticals Corporation, is
currently approved for use in CAPS, Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS),
Hyperimmunoglobulin D Syndrome (HIDS), Mevalonate Kinase Deficiency (MKD) and Familial Mediterranean Fever
(FMF), Still’s Disease and Systemic Juvenile Idiopathic Arthritis (SJIA). We are not aware of any active, industry
sponsored development programs using canakinumab seeking a label for recurrent pericarditis. Additionally, Novartis is
also developing gevokizumab for use in oncologic indications.
IL-1(cid:302) Inhibition Alone: There are other therapies which modulate IL-1(cid:302) in preclinical and clinical development
for diseases other than recurrent pericarditis from Johnson & Johnson and XBIOTECH USA, INC. We are not aware of
any active, industry sponsored development programs for these programs seeking a label for recurrent pericarditis.
Mavrilimumab
Giant Cell Arteritis: Tocilizumab (ACTEMRA), produced by Hoffmann—La Roche AG, or Roche, and Chugai
Pharmaceutical Co., Ltd., is an IL-6 inhibitor that is approved by the FDA for the treatment of GCA on top of a
concomitant corticosteroid taper. In addition, Eli Lilly and Company AbbVie, Inc. are conducting clinical trials for oral
janus kinase inhibitors; Novartis International AG, is recruiting a trial with their IL-17 antagonist secukinumab
(Cosentyx) and Janssen Global Services, LLC is in active development with their IL-23 antagonist guselkumab
(Tremfya).
COVID-19: We are also pursuing mavrilimumab development for the treatment of COVID-19 pneumonia and
hyperinflammation. There are currently hundreds of active, industry sponsored clinical trials testing many different
mechanisms of action for the treatment of COVID-19 related therapeutic areas in addition to the approved vaccines, and
the many other clinical trials testing vaccines, for the prevention of COVID-19.
GM-CSF Antagonists: There are also five other programs in clinical development outside of GCA in various
indications that modulate GM-CSF signaling from GlaxoSmithKline plc, or GSK (otilimab), Izana Bioscience Ltd.
(namilumab), I-MAB Biopharma (plonmarlimab), Roivant Sciences Ltd. (gimsilumab) and Humanigen, Inc.
(lenzilumab). All of these competitive programs target the GM-CSF ligand itself versus targeting the GM-CSF receptor.
27
Vixarelimab
We are not aware of any therapies currently approved by the FDA for the treatment of prurigo nodularis and we
are also not aware of any programs in preclinical or clinical development targeting OSMR(cid:533) antagonism.
Prurigo Nodularis: Trevi Therapeutics, Inc., is conducting a Phase 2/3 study with their κ-opioid antagonist,
nalbuphine ER; Galderma SA is conducting a Phase 3 study with their IL-31 specific antagonist nemolizumab; and,
Regeneron / Sanofi SA are conducting a Phase 3 study with their IL-4 antagonist dupilumab (Dupixent).
KPL-404
There are various programs in clinical development antagonizing the CD40 / CD40L signaling pathway that can
be distinguished by the potential to be administered subcutaneously and those programs, that due to their high required
doses or short plasma half-lives, are currently being studied as intravenous only:
Intravenous Administration Only: Astellas Pharma Inc. is developing bleselumab (anti-CD40R); Viela Bio
(currently in the process of being acquired by Horizon Therapeutics plc) is developing the Tn3 fusion protein, VIB4920
(anti-CD40L); Biogen, Inc. and UCB S.A. are developing dapirolizumab pegol (anti-CD40L); and, Eledon
Pharmaceuticals, Inc. (formerly Novus, and also formerly Anelixis) are developing AT-1501 (anti-CD40L).
Potential Subcutaneous Administration: Novartis A.G. is developing CFZ-533, or iscalimab (anti-CD40),
Sanofi S.A./ImmuNext Inc. are developing SAR441344 (anti-CD40L), and Abbvie, Inc. and Boehringer Ingelheim
International GmbH are developing ravagalimab (anti-CD40).
Intellectual Property
Our success depends in part on our ability to obtain and maintain proprietary protection for our drug candidates,
manufacturing and process discoveries, and other know how, to operate without infringing the proprietary rights of
others, and to prevent others from infringing our proprietary rights. We plan to protect our proprietary position using a
variety of methods, which include pursuing U.S. and foreign patent applications related to our proprietary technology,
inventions and improvements, including compositions of matter, drug product formulations, methods of use and methods
of manufacture, that are important to the development and implementation of our business. For example, we or our
licensors have or are pursuing patents covering the composition of matter for each of our product candidates and we
generally pursue patent protection covering methods of use for each clinical program. We also rely on trade secrets,
know how, continuing technological innovation and potential in licensing opportunities to develop and maintain our
proprietary position.
Rilonacept
We have a field specific exclusive license under the Regeneron Agreement to granted patents and pending
applications in the United States and numerous other jurisdictions relating to rilonacept. As of December 31, 2019, the
patent rights in licensed under the Regeneron Agreement relating to our program include one granted patent in the
United States and 47 patents granted in other jurisdictions, including Canada, Australia, Brazil and selected countries in
Europe and Asia. In addition, the patent rights in licensed under the Regeneron Agreement relating to our program
include patent applications that are pending in the United States. A U.S. patent covering rilonacept as a composition of
matter has a statutory expiration date in 2019, not including patent term adjustment, and relevant counterparts outside of
the United States are expected to expire between 2019 and 2023, in each case, not including any patent term extensions.
The FDA granted orphan drug designation for rilonacept for the treatment of pericarditis, which includes recurrent
pericarditis. If we are successful in obtaining regulatory approval of rilonacept for the treatment of recurrent pericarditis,
we would rely on orphan exclusivity, which generally grants seven years of marketing exclusivity in the United States
and, if orphan designation is similarly granted in the European Union, 10 years of marketing exclusivity in Europe. See
“—License agreement with Regeneron” above for additional information on our rights under the Regeneron Agreement.
Mavrilimumab
28
We have an exclusive license under the MedImmune Agreement to granted patents and pending patent
applications in the United States and numerous other jurisdictions relating to mavrilimumab. These patents and patent
applications cover mavrilimumab as a composition of matter and its use. As of December 31, 2020, the patent rights in
licensed under the MedImmune Agreement relating to our program include three granted patents in the United States and
106 patents granted in other jurisdictions, including Canada, Australia and selected countries in Europe and Asia. In
addition, the patent rights in licensed under the MedImmune Agreement relating to our program include patent
applications that are pending in the United States, Europe, Canada, and selected countries in Asia and Latin America.
The composition of matter patents for mavrilimumab generally have statutory expiration dates in 2027, although the
term of some U.S. patents may be longer due to patent term adjustment to compensate for delays during the patent
prosecution process. Patent term extension could extend the expiration date of one patent in the United States and patents
in certain other jurisdictions, each in accordance with applicable law. There can be no assurances that patents will issue
from any pending patent applications. See “—License agreement with MedImmune” above for additional information on
our rights under the MedImmune Agreement.
Vixarelimab
We own, via our acquisition of certain assets from Biogen, granted patents and pending patent applications in
the United States and numerous other jurisdictions relating to vixarelimab. These patents and patent applications cover
vixarelimab as a composition of matter and its use. As of December 31, 2020, the patent rights acquired from Biogen
include four patents granted in the United States and 38 patents granted in other jurisdictions, including Australia,
Mexico, South Africa and selected countries in Europe and Asia. In addition, the patent rights acquired from Biogen
include patent applications pending in the United States, Europe, Canada, and selected countries in Asia and Latin
America. The issued composition of matter patents for vixarelimab have statutory expiration dates in 2034. Patent term
extension could extend the expiration date of one patent in the United States and patents in certain other jurisdictions,
each in accordance with applicable law. There can be no assurance that patents will issue from any of our pending patent
applications. See “—Biogen asset purchase agreement” above for additional information on our rights under the Biogen
Agreement.
KPL-404
We own, via our acquisition of Primatope, granted patents and pending patent applications in the United States
and numerous other jurisdictions relating to KPL 404. We also have an exclusive license with Beth Israel Deaconess
Medical Center to granted patents and pending patent applications in the United States and numerous other jurisdictions
relating to KPL-404. These patents and patent applications cover KPL 404 as a composition of matter and its use. As of
December 31, 2020, the patent rights acquired from Primatope include three patents granted in the United States. In
addition, the patent rights acquired from Primatope include patent applications pending in the United States, Europe,
Canada, and selected countries in Asia. The issued composition of matter patents have statutory expiration dates in 2036.
As of December 31, 2020, the patent rights licensed from Beth Israel Deaconess Medical Center include two patents
granted in the United States and 30 patents granted in other jurisdictions, including Australia and selected countries in
Europe and Asia. In addition, the patent rights licensed from Beth Israel Deaconess Medical Center include patent
applications pending in the United States, Europe, Canada, and selected countries in Asia. The issued composition of
matter patents licensed from Beth Israel Deaconess Medical Center have statutory expiration dates in 2032, not including
any patent term extensions or adjustments. Patent term extension could extend the expiration date of one patent in the
United States and patents in certain other jurisdictions, each in accordance with applicable law. There can be no
assurance that patents will issue from any of our pending patent applications.
The term of individual patents depends upon the legal term for patents in the countries in which they are
obtained. In most countries, including the United States, the patent term is 20 years from the earliest filing date of a non
provisional patent application. In the United States, a patent’s term may be lengthened by patent term adjustment, which
compensates a patentee for administrative delays by the USPTO, in examining and granting a patent, or may be
shortened if a patent is terminally disclaimed over an earlier expiring patent. In certain countries, the term of a patent
that covers a drug product may also be eligible for patent term extension when regulatory approval is granted, provided
the legal requirements are met. In the future, if and when our drug candidates receive approval by the FDA or
29
comparable regulatory authorities in other jurisdictions, provided the legal requirements are met, we expect to apply for
patent term extensions on issued patents covering those drugs, depending upon the length of the clinical trials for each
drug and other factors. There can be no assurance that any of our pending patent applications will issue or that we will
benefit from any patent term extension or favorable adjustment to the term of any of our patents.
Government Regulation
Government authorities in the United States at the federal, state and local level and in other countries and
jurisdictions, including the European Union, extensively regulate, among other things, the research, development,
testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising,
distribution, post-approval monitoring and reporting, marketing and export and import of drug products, such as
rilonacept, mavrilimumab and our other product candidates. Generally, before a new drug can be marketed, considerable
data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory
authority, submitted for review and approved by the regulatory authority.
U.S. Government Regulation of Biological Products
In the United States, the FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act, or FDCA,
and the Public Health Service Act, or PHSA, and their implementing regulations. Products are also subject to other
federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent
compliance with applicable federal, state, local and foreign statutes and regulations requires the expenditure of
substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the
product development process, approval process or after approval, may subject an applicant to a variety of administrative
or judicial sanctions, such as the FDA’s refusal to approve pending biologic license applications, or BLAs, withdrawal
of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial
suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement
of profits or civil or criminal penalties.
The process required by the FDA before a biologic may be marketed in the United States generally involves the
following:
•(cid:3) Completion of extensive preclinical studies and tests in accordance with applicable regulations, including
Good Laboratory Practice, or GLP, regulations and applicable requirements for the humane use of
laboratory animals or other applicable regulations;
•(cid:3) Submission to FDA of an IND which must become effective before human clinical trials may begin;
•(cid:3) Approval by an independent institutional review board, or IRB, or ethics committee at each clinical trial
site before each trial may be initiated;
•(cid:3) Performance of adequate and well-controlled human clinical trials in accordance with applicable IND
regulations, good clinical practices, or GCPs, and other clinical-trial related regulations to evaluate the
safety and efficacy of the investigational product for each proposed indication;
•(cid:3) Submission to FDA of a BLA for marketing approval that includes substantive evidence of safety, purity,
and potency from results of preclinical testing and clinical trials;
•(cid:3) A determination by FDA within 60 days of its receipt of a BLA to accept the filing for review;
•(cid:3) Satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or
facilities where the biologic will be produced to assess compliance with cGMPs to assure that the facilities,
methods and controls used in product manufacture are adequate to preserve the biologic’s identity,
strength, quality and purity;
30
•(cid:3) Potential FDA audit of the preclinical or clinical trial sites that generated the data in support of the BLA;
•(cid:3) Payment of user fees for FDA review of the BLA; and
•(cid:3) FDA review and approval of the BLA, including satisfactory completion of an FDA advisory committee
review, if applicable, prior to any commercial marketing or sale of the product in the United States.
Preclinical Studies and CMC Evaluations
Before testing any biological product candidate, including our product candidates, in humans, the product
candidate must undergo rigorous preclinical testing. The preclinical development stage generally involves laboratory
evaluations of the chemistry, formulation and stability of the product candidate, as well as trials to evaluate toxicity in
animals, which support subsequent clinical testing. The conduct of the preclinical tests must comply with federal
regulations and requirements, including GLP regulations. The sponsor must submit the results of the preclinical studies,
together with chemistry manufacturing and controls, or CMC, information, analytical data, any available clinical data or
literature and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the
FDA to administer an investigational product to humans, and must become effective before human clinical trials may
begin. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective
30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to CMC issues,
preclinical issues, or one or more issues in the proposed clinical trials and places the clinical trial on a clinical hold. In
such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a
result, submission of an IND may not necessarily result in the FDA allowing clinical trials to commence. The FDA also
may place the IND on partial clinical hold, and a proposed study may only be partially executable, including due to FDA
restrictions.
Clinical Trials
The clinical stage of development involves the administration of the investigational product to healthy
volunteers or patients under the supervision of qualified investigators, generally physicians not employed by, or under
control of, the trial sponsor, in accordance with GCPs, which include the requirement that all research subjects provide
their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing,
among other things, the objectives of the clinical trial, dosing procedures, subject selection and inclusion/exclusion
criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent
amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, each clinical trial must be
reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks
to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The
IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal
representative, and must monitor the clinical trial until completed. There also are requirements governing the reporting
of ongoing clinical trials and completed clinical trial results to public registries. Information about most clinical trials in
must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. Information related
to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical
trial is made public as part of the registration of the clinical trial. Sponsors are also obligated to disclose the results of
certain qualifying clinical trials after completion. Disclosure of the results of these trials can be delayed in some cases
for up to two years after the date of completion of the trial. Competitors may use this publicly available information to
gain knowledge regarding the progress of product candidates.
Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:
•(cid:3) Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients
who are initially exposed to a single dose and then multiple doses of the product candidate. The primary
purpose of these clinical trials is to assess the metabolism, pharmacologic action, side effect tolerability and
safety of the drug.
31
•(cid:3) Phase 2 clinical trials involve studies in disease-affected patients to determine the optimal dose required to
produce the desired benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic
information is collected, possible adverse effects and safety risks are identified and a preliminary
evaluation of efficacy is conducted.
•(cid:3) Phase 3 clinical trials generally involve a larger number of patients at multiple sites and are designed to
provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in
use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for
product labeling and approval. These trials may include comparisons with placebo or other comparator
treatments. The duration of treatment is often extended to mimic the actual use of a product during
marketing.
Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing
approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic
indication, particularly for long-term safety follow up. In certain instances, the FDA may mandate the performance of
Phase 4 clinical trials as a condition of approval of a BLA.
Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and
more frequently if serious adverse events occur. The FDA or the sponsor may suspend or terminate a clinical trial at any
time or the FDA may impose a clinical hold on other sanctions on various grounds, including a finding that the research
patients are being exposed to an unacceptable health risk. Similarly, an IRB can refuse, suspend or terminate approval of
a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRBs requirements or if
the drug has been associated with unexpected serious harm to patients.
Concurrently with clinical trials, companies usually complete additional preclinical studies and must also
develop additional information about the physical characteristics of the biological product as well as finalize a process
for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk
of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of
manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be
capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must
develop methods for testing the identity, strength, quality, potency and purity of the final biological product.
Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate
that the biological product candidate does not undergo unacceptable deterioration over its shelf life.
BLA Review and Approval
Assuming successful completion of the required clinical testing, the results of the preclinical studies and
clinical trials, together with detailed information relating to the product’s chemistry, manufacture, controls and proposed
labeling, among other things, are submitted to the FDA as part of a BLA requesting approval to market the product for
one or more indications. The BLA must contain proof of safety, purity, potency and efficacy and may include both
negative and ambiguous results of preclinical studies and clinical trials as well as positive findings. Data may come from
company-sponsored clinical trials intended to test the safety and efficacy of a product’s use or from a number of
alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must
be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction
of the FDA. FDA approval of a BLA must be obtained before a biologic may be marketed in the United States.
In most cases, the submission of a BLA is subject to a substantial application user fee. Under the goals and
policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, for original BLAs, the FDA has ten
months from the filing date in which to complete its initial review of a standard application and respond to the applicant,
and six months from the 60-day filing date for an application with priority review. The FDA does not always meet its
PDUFA goal dates, and the review process is often significantly extended by FDA requests for additional information or
clarification. This review typically takes twelve months from the date the BLA is submitted to the FDA because the
FDA has approximately two months to make a “filing” decision.
32
Before approving a BLA, the FDA will typically conduct a pre-approval inspection of the manufacturing
facilities for the new product to determine whether the manufacturing processes and facilities comply with cGMPs. The
FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance
with cGMP requirements and adequate to assure consistent production of the product within required specifications. The
FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with GCP requirements and
the integrity of the clinical data submitted to the FDA.
Additionally, the FDA may refer applications for novel biologic candidates which present challenges in
interpretation of the safety or efficacy data to an advisory committee, typically a panel that includes clinicians and other
experts, for review, evaluation and a recommendation as to whether the application should be approved and under what
conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such
recommendations when making decisions on approval. The FDA likely will re-analyze the clinical trial data, which
could result in extensive discussions between the FDA and the applicant during the review process. The FDA also may
require submission of a Risk Evaluation and Mitigation Strategy, or REMS, plan if it determines that a REMS is
necessary to ensure that the benefits of the drug outweigh its risks and to assure the safe use of the biological product.
The REMS plan could include medication guides, physician communication plans, assessment plans or elements to
assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA
determines the requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA
concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA
without a REMS, if required.
Under the Pediatric Research Equity Act, or PREA, a BLA or supplement to a BLA must contain data that are
adequate to assess the safety and efficacy of the product candidate for the claimed indications in all relevant pediatric
populations and to support dosing and administration for each pediatric population for which the product is safe and
effective. The FDA may grant deferrals for submission of pediatric data or full or partial waivers. The Food and Drug
Administration Safety and Innovation Act, or FDASIA, amended the FDCA to require that a sponsor who is planning to
submit a marketing application for a product that includes a new active ingredient, new indication, new dosage form,
new dosing regimen or new route of administration submit an initial Pediatric Study Plan, or iPSP, within sixty days of
an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or
Phase 2/3 clinical trial. The initial iPSP must include an outline of the pediatric study or studies that the sponsor plans to
conduct, including trial objectives and design, age groups, relevant endpoints and statistical approach, or a justification
for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial
waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the
sponsor must reach an agreement on the iPSP. A sponsor can submit amendments to an agreed upon initial iPSP at any
time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase
clinical trials or other clinical development programs.
After the FDA evaluates a BLA, it will issue an approval letter or a Complete Response Letter. An approval
letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A
Complete Response Letter indicates that the review cycle of the application is complete and the application will not be
approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the BLA
identified by the FDA. The Complete Response Letter may require additional clinical or other data, additional pivotal
Phase 3 clinical trial(s) or other significant and time-consuming requirements related to clinical trials, preclinical studies
or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of
the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the
FDA may decide that the re-submitted BLA does not satisfy the criteria for approval.
If a product receives regulatory approval, the approval is limited to the conditions of use (e.g., patient
population, indication) described in the label. Further, depending on the specific risk(s) to be addressed, the FDA may
require that contraindications, warnings or precautions be included in the product labeling, require that post-approval
trials, including Phase 4 clinical trials, be conducted to further assess a product’s safety after approval, require testing
and surveillance programs to monitor the product after commercialization, or impose other conditions, including
distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the
potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on
33
the results of post-marketing trials or surveillance programs, or new safety findings after market introduction. After
approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and
additional labeling claims, are subject to further testing requirements and FDA review and approval.
Orphan Drug Designation
Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic product intended to
treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in
the United States or more than 200,000 individuals in the United States and for which there is no reasonable expectation
that the cost of developing and making the product available in the United States for this type of disease or condition will
be recovered from sales of the product. Orphan drug designation must be requested before submitting a BLA. After the
FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed
publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the
regulatory review and approval process. Orphan drug designation entitles a party to financial incentives such as
opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. If a product that has
orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such
designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other
applications to market the same drug for the same indication for seven years from the date of such approval, except in
limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of
greater effectiveness, greater safety, by providing a major contribution to patient care or in instances of drug supply
issues. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor
obtains approval before we do of the same product, as defined by the FDA, for the same indication we are seeking, or if
our product candidate is determined to be contained within the scope of the competitor’s product for the same indication
or disease. If one of our products designated as an orphan drug receives marketing approval for an indication broader
than that which is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the European
Union has similar, but not identical, requirements and benefits.
Expedited Review and Approval
The FDA has various programs, including Fast Track designation, Breakthrough Therapy designation,
accelerated approval and priority review, which are intended to expedite or simplify the process for the development and
FDA review of drugs and biologics that are intended for the treatment of serious or life-threatening diseases or
conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide
important new drugs and biologics to patients earlier than under standard FDA review procedures.
To be eligible for a Fast Track designation, the FDA must determine, based on the request of a sponsor, that a
product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an
unmet medical need. Fast Track designation provides opportunities for more frequent interactions with the FDA review
team to expedite development and review of the product. The FDA may also review sections of the BLA for a Fast
Track product on a rolling basis before the complete application is submitted, if the sponsor and the FDA agree on a
schedule for the submission of the application sections, and the sponsor pays any required user fees upon submission of
the first section of the BLA.
Any product submitted to the FDA for approval, including a product with a Fast Track designation, may also be
eligible for other types of FDA programs intended to expedite development and review, such as priority review and
accelerated approval. A product is eligible for priority review if it is designed to treat a serious condition, and if
approved, would provide a significant improvement in safety or effectiveness compared to marketed products. The FDA
will attempt to direct additional resources to the evaluation of an application for a biologic designated for priority review
in an effort to facilitate the review. The FDA endeavors to review original BLAs with priority review designations
within six months of the filing date as compared to ten months under its standard review goals.
In addition, a product may be eligible for accelerated approval. Drug and biologics intended to treat serious or
life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has
an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be
34
measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible
morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and
the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a
drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials to verify the
predicted clinical benefit. A product that receives accelerated approval may be subject to expedited withdrawal
procedures if the sponsor fails conduct the required post-marketing trials or if such trials fail to verify the predicted
clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of
promotional materials, which could adversely impact the timing of the commercial launch of the product.
In addition, a sponsor can request designation of a product candidate as a “Breakthrough Therapy.” A
Breakthrough Therapy is defined as a drug or biologic that is intended, alone or in combination with one or more other
drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates
that the drug or biologic may demonstrate substantial improvement over existing therapies on one or more clinically
significant endpoints, such as substantial treatment effects observed early in clinical development. The designation
includes all of the Fast Track program features, as well as more intensive FDA interaction and guidance. The
Breakthrough Therapy designation is a distinct status from both accelerated approval and priority review, which can also
be granted to the same drug if relevant criteria are met. If a product is designated as Breakthrough Therapy, the FDA will
expedite the development and review of such drug. All requests for Breakthrough Therapy designation will be reviewed
within 60 days of receipt, and the FDA will either grant or deny the request.
Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no
longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be
shortened. Furthermore, Fast Track designation, Breakthrough Therapy designation, accelerated approval and priority
review do not change the standards for approval and may not ultimately expedite the development or approval process.
Post-approval Requirements
Following approval of a new product, the manufacturer and the approved product are subject to pervasive and
continuing regulation by the FDA, including, among other things, monitoring and recordkeeping activities, reporting of
adverse experiences with the product, product sampling and distribution restrictions, complying with promotion and
advertising requirements, which include restrictions on promoting drugs for unapproved uses or patient populations
(i.e., “off-label use”) and limitations on industry-sponsored scientific and educational activities. Although physicians
may prescribe legally available products for off-label uses, manufacturers may not market or promote such uses. The
FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a
company that is found to have improperly promoted off-label uses may be subject to significant liability. If there are any
modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the
applicant may be required to submit and obtain FDA approval of a new BLA or BLA supplement, which may require the
applicant to develop additional data or conduct additional preclinical studies and clinical trials. The FDA may also place
other conditions on approvals including the requirement for a REMS to assure the safe use of the product. A REMS
could include medication guides, physician communication plans or elements to assure safe use, such as restricted
distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or
marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product
approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial
marketing.
FDA regulations require that products be manufactured in specific approved facilities and in accordance with
cGMPs. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities
of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations that
require, among other things, quality control and quality assurance, the maintenance of records and documentation and
the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the
manufacture and distribution of approved drugs or biologics are required to register their establishments with the FDA
and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for
compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in
the area of production and quality control to maintain cGMP compliance. The discovery of conditions that violate these
35
rules, including failure to conform to cGMPs, could result in enforcement actions, and the discovery of problems with a
product after approval may result in restrictions on a product, manufacturer or holder of an approved BLA, including
voluntary recall.
Once an approval or clearance of a drug is granted, the FDA may withdraw the approval if compliance with
regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later
discovery of previously unknown problems with a product, including adverse events of unanticipated severity or
frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory
revisions to the approved labeling to add new safety information; imposition of post-market or clinical trials to assess
new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences
include, among other things:
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the
market or product recalls;
fines, warning letters or other enforcement-related letters or clinical holds on post-approval clinical trials;
refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or
revocation of product approvals;
product seizure or detention, or refusal to permit the import or export of products;
injunctions or the imposition of civil or criminal penalties; and
consent decrees, corporate integrity agreements, debarment, or exclusion from federal healthcare programs;
or mandated modification of promotional materials and labeling and the issuance of corrective information.
Biosimilars and Exclusivity
An abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an
FDA-licensed reference biological product was created by the Biologics Price Competition and Innovation Act of 2009,
or BPCIA, as part of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education
Reconciliation Act, or the Affordable Care Act. This amendment to the PHSA, in part, attempts to minimize duplicative
testing. A recent federal district court ruling struck down the Affordable Care Act in its entirety. This decision means
numerous reforms enacted as part of the Affordable Care Act, but not specifically related to health insurance, such as the
BPCIA, are invalid as well. While the presidential administration and CMS have both stated that the ruling will have no
immediate effect, it is unclear how this decision, subsequent appeals, if any, and other efforts to repeal and replace the
Affordable Care Act will impact the Affordable Care Act and our business. To date, the FDA has approved a number of
biosimilars, and numerous biosimilars have been approved in Europe. The FDA has issued several guidance documents
outlining its approach to reviewing and approving biosimilars.
Biosimilarity, which requires that the biological product be highly similar to the reference product
notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful
differences between the product and the reference product in terms of safety, purity and potency, must be shown through
analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be
biosimilar to the reference product and that the product can be expected to produce the same clinical results as the
reference product in any given patient and, for products administered multiple times to an individual, that the product
and the reference product may be alternated or switched after one has been previously administered without increasing
safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such
alternation or switch. Complexities associated with the larger, and often more complex, structure of biological products
as compared to small molecule drugs, as well as the processes by which such products are manufactured, pose
significant hurdles to implementation that are still being worked out by the FDA.
36
A reference biological product is granted 12 years of data exclusivity from the time of first licensure of the
product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference
biological product until four years after the date of first licensure of the reference product. “First licensure” typically
means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not
include the date of licensure of (and a new period of exclusivity is not available for) a supplement for the reference
product for a subsequent application filed by the same sponsor or manufacturer of the reference product (or licensor,
predecessor in interest or other related entity) for a change (not including a modification to the structure of the biological
product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery system, delivery
device or strength or for a modification to the structure of the biological product that does not result in a change in
safety, purity or potency. Therefore, one must determine whether a new product includes a modification to the structure
of a previously licensed product that results in a change in safety, purity or potency to assess whether the licensure of the
new product is a first licensure that triggers its own period of exclusivity. Whether a subsequent application, if approved,
warrants exclusivity as the “first licensure” of a biological product is determined on a case-by-case basis with data
submitted by the sponsor.
The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, recent
government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the
BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As
a result, the ultimate impact, implementation and meaning of the BPCIA remain subject to significant uncertainty.
U.S. Patent Term Restoration
Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one
or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and
Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the
European Union. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent
covering an approved product as compensation for effective patent term lost during product development and the FDA
regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail
to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length
of the extension could be less than we request. Only one patent per approved product can be extended, the extension
must be based on the first approval for the product, and the extension cannot extend the total patent term beyond
fourteen years from approval. If we are unable to obtain patent term extension or the term of any such extension is less
than we request, the period during which we can enforce our patent rights for that product will be shortened and our
competitors may obtain approval to market competing products sooner.
European Union Drug Development, Review and Approval
In the European Union, or EU, our product candidates also may be subject to extensive regulatory requirements.
As in the United States, medical products can be marketed only if a marketing authorization from the competent
regulatory agencies has been obtained whether or not product candidates obtain FDA approval for a pharmaceutical
product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we
can start clinical trials or marketing of the products in those countries or jurisdictions. The approval process ultimately
varies between countries and jurisdictions and can involve additional product testing and additional administrative
review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer
than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory
approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively
impact the regulatory process in others.
Similar to the United States, the various phases of preclinical and clinical research in the European Union are
subject to significant regulatory controls.
The EU Clinical Trials Directive 2001/20/EC as well as the Directive 2005/28/EC on good clinical practice as
regards investigational drug products for human use, or GCP, and the related national implementing provisions of the
individual EU Member States govern the system for the approval of clinical trials in the in the European Economic Area,
37
or EEA (27 EU Member States plus Iceland, Norway and Liechtenstein). Under this system, before a clinical trial can be
initiated, an applicant must obtain approval in each EEA Member State in which the clinical trial is to be conducted by
two separate entities: the national competent authority and one or more ethics committees much like the FDA and the
IRB, respectively. In all cases, the clinical studies must be conducted in accordance with GCP. Good Laboratory Practice
standards must also be respected during the conduct of the trials, including the International Council for Harmonization
of Technical Requirements for Pharmaceuticals for Human Use, or ICH, as well as the applicable regulatory
requirements and the ethical principles that have their origin in the Declaration of Helsinki. All suspected unexpected
serious adverse reactions to the investigated drug that occur during the clinical trial have to be reported to the competent
national authority and the ethics committee of the Member State where they occurred. The requirements and process
governing the conduct of clinical studies are to a significant extent harmonized at EU level but could vary from country
to country. During the development of a medicinal product, the European Medicines Agency, or EMA, and national
regulators within the EU provide the opportunity for dialogue and guidance on the development program.
The EU Member States have transposed and applied the provisions of the Clinical Trials Directive in a manner
that is not always uniform. This has led to variations in the rules governing the conduct of clinical trials in the individual
EU Member States. The EU has, therefore, adopted Regulation (EU) No 536/2014 (Clinical Trials Regulation) in
April 2014. The Regulation is expected to come into application in 2022. The Clinical Trials Regulation will be directly
applicable in all the EU Member States, repealing the current Clinical Trials Directive. Conduct of all clinical trials
performed in the European Union will continue to be bound by currently applicable provisions until the new Clinical
Trials Regulation becomes applicable. The extent to which ongoing clinical trials will be governed by the Clinical Trials
Regulation will depend on when the Clinical Trials Regulation becomes applicable and on the duration of the individual
clinical trial. If a clinical trial continues for more than three years from the day on which the Clinical Trials Regulation
becomes applicable the Clinical Trials Regulation will at that time begin to apply to the clinical trial.
The Clinical Trials Regulation harmonizes the assessment and supervision processes for clinical trials
throughout the EU via a Clinical Trials Information System, which will notably contain a centralized EU portal and
database.
To obtain a marketing authorization, or MA, of a drug in the EEA, we may submit marketing authorization
applications, or MAA, either under the so-called centralized (mandatory for biologics) or national authorization
procedures.
Centralized Procedure
The centralized procedure provides for the grant of a single MA by the European Commission following a
favorable opinion by the Committee for Medicinal Products for Human Use, or CHMP, of the EMA, that is valid
throughout the entire territory of the EEA. The centralized procedure is compulsory for certain types of medicines, such
as medicines derived from biotechnological processes, products designated as orphan medicinal products,
advanced-therapy medicines (such as gene-therapy, somatic cell-therapy or tissue-engineered products) and products
with a new active substance indicated for the treatment of specified diseases, such as HIV/AIDS, cancer, diabetes,
neurodegenerative disorders or autoimmune diseases and other immune dysfunctions and viral diseases. The centralized
procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that
represent a significant therapeutic, scientific or technical innovation, or whose authorization would be in the interest of
public health. Under the centralized procedure the maximum timeframe for the evaluation of an MAA by the EMA is
210 days, excluding clock stops, when additional written or oral information is to be provided by the applicant in
response to questions asked by the CHMP.
38
National Authorization Procedures
There are also other possible routes to authorize medicinal products in several EEA countries, which are
available for investigational medicinal products that fall outside the scope of the centralized procedure. National MAs,
are issued by the competent authorities of the Member States of the EEA and only cover their respective territory.
•(cid:3) Decentralized procedure. Using the decentralized procedure, an applicant may apply for simultaneous
authorization in more than one EEA country of medicinal products that have not yet been authorized in any
EU country and that do not fall within the mandatory scope of the centralized procedure.
•(cid:3) Mutual recognition procedure. In the mutual recognition procedure, a medicine is first authorized in one
EEA country, in accordance with the national procedures of that country. Following this, further marketing
authorizations can be sought from other EEA countries in a procedure whereby the countries concerned
agree to recognize the validity of the original, national marketing authorization.
Under the above described procedures, in order to grant the MA, the EMA or the competent authorities of the
Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific
criteria concerning its quality, safety and efficacy.
MAs have an initial duration of five years. After these five years, the authorization may be renewed on the basis
of a reevaluation of the risk-benefit balance.
Innovative products that target an unmet medical need and are expected to be of major public health interest
may be eligible for a number of expedited development and review programs, such as the PRIME scheme, which
provides incentives similar to the breakthrough therapy designation in the U.S. Such products are generally eligible for
accelerated assessment (according to which the timeframe for the evaluation of a MA application is reduced to 150 days,
excluding clock stops) and may also benefit from different types of fast track approvals, such as a conditional marketing
authorization or a marketing authorization under exceptional circumstances granted on the basis of less comprehensive
clinical data than normally required (respectively in the likelihood that the sponsor will provide such data within an
agreed timeframe or when comprehensive data cannot be obtained even after authorization).
European Union Regulatory Exclusivity
In the EEA, new products authorized for marketing (i.e., reference products) qualify for eight years of data
exclusivity and an additional two years of market exclusivity upon MA. The data exclusivity period prevents generic or
biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference
product when applying for a generic or biosimilar marketing authorization in the European Union during a period of
eight years from the date on which the reference product was first authorized in the European Union. The market
exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until
ten years have elapsed from the initial authorization of the reference product in the EU. The overall ten-year market
exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the
marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the
scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with
existing therapies.
European Union Orphan Designation and Exclusivity
The criteria for designating an “orphan medicinal product” in the European Union, are similar in principle to
those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as
orphan if (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating
condition; (2) either (a) such condition affects no more than five in 10,000 persons in the European Union when the
application is made, or (b) the product, without the benefits derived from orphan status, would not generate sufficient
return in the European Union to justify investment; and (3) there exists no satisfactory method of diagnosis, prevention
or treatment of such condition authorized for marketing in the European Union, or if such a method exists, the product
39
will be of significant benefit to those affected by the condition. Orphan medicinal products are eligible for financial
incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years
of market exclusivity for the approved therapeutic indication. The application for orphan drug designation must be
submitted before the application for MA. The applicant will receive a fee reduction for the marketing authorization
application if the orphan designation has been granted, but not if the designation is still pending at the time the MA is
submitted. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review
and approval process.
The ten-year market exclusivity in the European Union may be reduced to six years if, at the end of the fifth
year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is
sufficiently profitable not to justify maintenance of market exclusivity. Additionally, MA may be granted to a similar
product for the same indication at any time if (1) the second applicant can establish that its product, although similar, is
safer, more effective or otherwise clinically superior; (2) the applicant consents to a second orphan medicinal product
application; or (3) the applicant cannot supply enough orphan medicinal product.
Pediatrics Development
In the EEA, MAA for new medicinal products have to include the results of studies conducted in the pediatric
population, in compliance with a PIP agreed with the EMA's Pediatric Committee, or PDCO. The PIP sets out the timing
and measures proposed to generate data to support a pediatric indication of the drug for which MA is being sought. The
PDCO can grant a deferral of the obligation to implement some or all of the measures of the PIP until there are sufficient
data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical
trial data can be waived by the PDCO when these data is not needed or appropriate because the product is likely to be
ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult
populations, or when the product does not represent a significant therapeutic benefit over existing treatments for
pediatric patients. Once the MA is obtained in all Member States of the EU and study results are included in the product
information, even when negative, the product is eligible for six months’ supplementary extension of the protection under
a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan medicinal
products, a two year extension of the orphan market exclusivity is granted.
Post-approval Requirements
Similar to the United States, both marketing authorization holders and manufacturers of medicinal products are
subject to comprehensive regulatory oversight by the EMA, the European Commission and/or the competent regulatory
authorities of the EU Member States. The holder of MA for a medicinal product must also comply with
pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting
pharmacovigilance, or the assessment and monitoring of the safety of medicinal products. Failure to comply with EU
and national laws that apply to the conduct of clinical trials, manufacturing approval, MA of medicinal products and
marketing of such products, both before and after grant of the MA, manufacturing of medicinal products, statutory health
insurance, bribery and anti-corruption or with other applicable regulatory requirements may result in administrative, civil
or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant
MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the marketing
authorization, total or partial suspension of production, distribution, manufacturing or clinical trials, operating
restrictions, injunctions, suspension of licenses, fines and criminal penalties.
In addition, the advertising and promotion of our products is also subject to EU laws concerning promotion of
medicinal products, interactions with physicians, misleading and comparative advertising and unfair commercial
practices. In addition, other national legislation of individual EU Member States may apply to the advertising and
promotion of medicinal products and may differ from one country to another. Violations of the rules governing the
promotion of medicinal products in the European Union could be penalized by administrative measures, fines and
imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general
public and may also impose limitations on its promotional activities with healthcare professionals.
40
Rest of the World Regulation
For other countries outside of the European Union and the United States, such as countries in Eastern Europe,
Latin America, Asia, or Japan, the requirements governing the conduct of clinical trials, product licensing, pricing and
reimbursement vary from jurisdiction to jurisdiction. Additionally, the clinical trials must be conducted in accordance
with cGCP requirements and the applicable regulatory requirements and the ethical principles that have their origin in
the Declaration of Helsinki.
If we fail to comply with applicable regulatory requirements, we may be subject to, among other things, fines,
suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and
criminal prosecution.
Other Healthcare Laws
In addition to FDA restrictions on the marketing of pharmaceutical products, other U.S., federal and state
healthcare regulatory laws restrict business practices in the pharmaceutical industry. These laws include, but are not
limited to, federal and state anti-kickback, false claims, data privacy and security and physician payment and drug
pricing transparency laws. Similar laws exists in foreign jurisdictions, including the EEA, as well.
The U.S. federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and
willfully offering, paying, soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly,
to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of
any good, facility, item or service reimbursable, in whole or in part, under Medicare, Medicaid or other federal
healthcare programs. The term “remuneration” has been broadly interpreted to include anything of value. The
Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical and medical device
manufacturers on the one hand and prescribers, purchasers, formulary managers and beneficiaries on the other hand.
Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from
prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be
alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not
meet the requirements of a statutory or regulatory exception or safe harbor. Failure to meet all of the requirements of a
particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the
U.S. federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis
based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute’s intent
requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal
healthcare covered business, the statute has been violated. In addition, a person or entity does not need to have actual
knowledge of the statute or specific intent to violate it in order to have committed a violation. The majority of states also
have anti-kickback laws, which establish similar prohibitions and in some cases may apply to items or services
reimbursed by any third-party payor, including commercial insurers, or to self-pay patients.
The federal false claims and civil monetary penalties laws, including the civil False Claims Act, prohibit,
among other things, any person or entity from knowingly presenting, or causing to be presented, a false, fictitious or
fraudulent claim for payment to, or approval by, the federal government, knowingly making, using or causing to be
made or used a false record or statement material to a false or fraudulent claim to the federal government, or knowingly
making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. A
claim includes “any request or demand” for money or property presented to the U.S. Government. Moreover, a claim
including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or
fraudulent claim for purposes of the federal civil False Claims Act. Actions under the civil False Claims Act may be
brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Violations
of the civil False Claims Act can result in very significant monetary penalties and treble damages. Several
biopharmaceutical, medical device and other healthcare companies have been prosecuted under these laws for, among
other things, allegedly providing free product to customers with the expectation that the customers would bill federal
programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the
companies’ marketing of products for unapproved (e.g., off-label), and thus non-covered, uses. In addition, the civil
monetary penalties statute imposes penalties against any person who is determined to have presented or caused to be
41
presented a claim to a federal health program that the person knows or should know is for an item or service that was not
provided as claimed or is false or fraudulent. Many states also have similar fraud and abuse statutes or regulations that
apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of
the payor.
Violations of fraud and abuse laws, including federal and state anti-kickback and false claims laws, may be
punishable by criminal and civil sanctions, including fines and civil monetary penalties, the possibility of exclusion from
federal healthcare programs (including Medicare and Medicaid), disgorgement of profits and corporate integrity
agreements, which impose, among other things, rigorous operational and monitoring requirements on companies. Similar
sanctions and penalties, as well as imprisonment, also can be imposed upon executive officers and employees of such
companies. Given the significant size of actual and potential settlements, it is expected that the government authorities
will continue to devote substantial resources to investigating healthcare providers’ and manufacturers’ compliance with
applicable fraud and abuse laws.
The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal
criminal statutes that prohibit, among other actions, knowingly and willfully executing, or attempting to execute, a
scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully
embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare
offense and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false,
fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.
Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed a violation.
In addition, there has been a recent trend of increased federal and state regulation of payments made to
physicians and certain other healthcare providers. The Affordable Care Act imposed, among other things, new annual
reporting requirements through the Physician Payments Sunshine Act for covered manufacturers for certain payments
and “transfers of value” provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and
chiropractors), and additional categories of health care providers in 2022, and teaching hospitals as well as ownership
and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately
and completely the required information for all payments, transfers of value and ownership or investment interests may
result in civil monetary penalties. Covered manufacturers must submit reports by the 90th day of each subsequent
calendar year and the reported information is publicly made available on a searchable website. In addition, certain states
require implementation of compliance programs and compliance with the pharmaceutical industry’s voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions
on marketing practices or require the tracking and reporting of marketing expenditures and pricing information as well as
gifts, compensation and other remuneration or items of value provided to physicians and other healthcare professionals
and entities.
We may also be subject to data privacy and security regulation by both the federal government and the states in
which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical
Health Act, and their respective implementing regulations, impose specified requirements relating to the privacy,
security and transmission of individually identifiable health information held by covered entities and their business
associates, that create, receive, maintain or transmit protected health information in connection with providing a service
for or on behalf of a covered entity, although we believe that we would not be considered a “business associate” in the
normal course of our business. Entities that are found to be in violation of HIPAA, whether as the result of a breach of
unsecured PHI, a complaint about privacy practices, or an audit by HHS, may be subject to significant civil, criminal,
and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a
resolution agreement and corrective action plan with HHS to settle allegations of HIPAA non-compliance. Further,
entities that knowingly receive individually identifiable health information from a HIPAA covered entity in a manner
that is not authorized or permitted by HIPAA may be subject to criminal penalties. Even when HIPAA does not apply,
according to the Federal Trade Commission or the FTC, failing to take appropriate steps to keep consumers’ personal
information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the
Federal Trade Commission Act. The FTC expects a company’s data security measures to be reasonable and appropriate
in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the
42
cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is
considered sensitive data that merits stronger safeguards.
In addition, state laws govern the privacy and security of health information in certain circumstances, many of
which differ from each other in significant ways and may not have the same requirements, thus complicating compliance
efforts. For example, California enacted the California Consumer Privacy Act, or the CCPA, which went into effect on
January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information,
opt out of certain personal information sharing, and receive detailed information about how their personal information is
used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is
expected to increase data breach litigation. Further, the California Privacy Rights Act, or the CPRA, was recently voted
into law by California residents. The CPRA significantly amends the CCPA, and imposes additional data protection
obligations on covered companies doing business in California, including additional consumer rights processes and opt
outs for certain uses of sensitive data. It also creates a new California data protection agency specifically tasked to
enforce the law, which would likely result in increased regulatory scrutiny of California businesses in the areas of data
protection and security. The substantive requirements for businesses subject to the CPRA will go into effect on
January 1, 2023, and become enforceable on July 1, 2023.
Similar laws and regulations in jurisdictions outside of the United States, which may include, for instance,
applicable post-marketing requirements, anti-fraud and abuse laws and implementation of corporate compliance
programs, reporting of payments or other transfers of value to healthcare professionals or data privacy and security laws,
may apply to us to the extent that any of our product candidates, once approved, are sold in a country other than the
United States.
Because of the breadth of these laws and the narrowness of their exceptions and safe harbors, it is possible that
business activities can be subject to challenge under one or more of such laws. The scope and enforcement of each of
these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of
the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their
scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of
investigations, prosecutions, convictions and settlements in the healthcare industry.
Ensuring that business arrangements with third parties comply with applicable healthcare laws and regulations
is costly and time consuming. If business operations are found to be in violation of any of the laws described above or
any other applicable governmental regulations a pharmaceutical manufacturer may be subject to penalties, including
civil, criminal and administrative penalties, damages, fines, disgorgement of profits, individual imprisonment, exclusion
from governmental funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational
harm, diminished profits and future earnings, additional reporting obligations and oversight if subject to a corporate
integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and curtailment or
restructuring of operations, any of which could adversely affect a pharmaceutical manufacturer’s ability to operate its
business and the results of its operations.
Coverage, Pricing and Reimbursement
Significant uncertainty exists as to the coverage and reimbursement status of any biological products for which
we obtain regulatory approval. The United States government, state legislatures and governments outside the United
States have shown significant interest in implementing cost containment programs to limit the growth of
government-paid healthcare costs, including price-controls, restrictions on reimbursement and requirements for
substitution of generic products for branded drug and biologic products. In the United States and markets in other
countries, patients who are prescribed products generally rely on third-party payors to reimburse all or a substantial part
of the associated healthcare costs. Providers and patients are unlikely to use our products unless coverage is provided
and reimbursement is adequate to cover a substantial portion of the cost of our products. For products administered
under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult
because of the higher prices often associated with such drugs. If approved, sales of our product candidates will depend,
in part, on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include
government authorities, managed care plans, private health insurers and other organizations.
43
In the United States, the process for determining whether a third-party payor will provide coverage and the
related coverage criteria for a biological product typically is separate from, but related to, the process for setting the price
of such product or for establishing the level of reimbursement that the payor will pay for the product once coverage is
approved. With respect to biologics, third-party payors may limit coverage to specific products on an approved list, also
known as a formulary, which might not include all of the FDA-approved products for a particular indication, or place
products at certain formulary levels that result in lower reimbursement levels, which results in higher cost-sharing
financial obligation imposed on patients. A decision by a third-party payor not to cover our product candidates, or to
impose coverage criteria the limiting situations in which our product candidates are covered, could reduce physician
utilization of a product. Moreover, a third-party payor’s decision to provide coverage for a product does not imply that
an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable a
manufacturer to maintain price levels sufficient to realize an appropriate return on its investment in product
development. Additionally, coverage, coverage criteria, and reimbursement for products can differ significantly from
payor to payor. One third-party payor’s decision to cover a particular medical product does not ensure that other payors
will also provide coverage for the medical product, or will provide coverage at an adequate reimbursement rate. As a
result, the coverage determination process usually requires manufacturers to provide scientific, clinical and health
economic support for the use of their products to each payor separately, which is a time-consuming process.
As noted above, the marketability of any products for which we receive regulatory approval for commercial
sale may suffer if the government and third-party payors fail to provide coverage and adequate reimbursement. The
increasing emphasis on cost containment measures in the United States has increased and we expect will continue to
increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change at
any time. Even if favorable coverage and reimbursement are attained for one or more products for which we receive
regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.
Third-party payors are increasingly challenging the prices charged for medical products and services, examining the
medical necessity and reviewing the cost-benefit of pharmaceutical products, in addition to questioning safety and
efficacy. If third-party payors do not consider a product to offer a favorable cost-benefit compared to other available
therapies, they may not cover that product after FDA approval or, if they do, the level of payment may not be sufficient
to allow a manufacturer to sell its product at a profit.
In addition, in many countries, the proposed pricing for a drug must be approved before it may be lawfully
marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. In the
EEA, governments influence the price of products through their pricing and reimbursement rules and control of national
healthcare systems that fund a large part of the cost of those products to consumers. Member States are free to restrict
the range of pharmaceutical products for which their national health insurance systems provide reimbursement, and to
control the prices and reimbursement levels of pharmaceutical products for human use. Some jurisdictions operate
positive and negative list systems under which products may only be marketed once a reimbursement price has been
agreed to by the government. Member States may approve a specific price or level of reimbursement for the
pharmaceutical product, or alternatively adopt a system of direct or indirect controls on the profitability of the company
responsible for placing the pharmaceutical product on the market, including volume-based arrangements, caps and
reference pricing mechanisms. To obtain reimbursement or pricing approval, some of these countries may require the
completion of clinical trials that compare the cost effectiveness of a particular product to currently available therapies.
Other Member States allow companies to fix their own prices for medicines, but monitor and control company profits.
There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical
products will allow favorable reimbursement and pricing arrangements for any of our products. The downward pressure
on healthcare costs in general, particularly prescription products, has become very intense. As a result, increasingly high
barriers are being erected to the entry of new products. In addition, in some countries, cross border imports from
low-priced markets exert a commercial pressure on pricing within a country.
Healthcare Reform and Potential Changes to Healthcare Laws
The FDAs and other regulatory authorities’ policies may change and additional government regulations may be
enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, in
December 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is
intended to modernize the regulation of drugs and devices and to spur innovation, but its ultimate implementation is
uncertain. In
44
addition, in August 2017, the FDA Reauthorization Act was signed into law, which reauthorized the FDAs user fee
programs and included additional drug and device provisions that build on the Cures Act. If we are slow or unable to
adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to
maintain regulatory compliance, we may lose any marketing approval that we otherwise may have obtained and we may
not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results
of operations.
A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and
other third-party payors have attempted to control costs by limiting coverage and the level of reimbursement for
particular medical products and services, implementing reductions in Medicare and other healthcare funding and
applying new payment methodologies. For example, in March 2010, the Affordable Care Act was enacted, which,
among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug
Rebate Program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug
Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; extended the Medicaid
Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care plans; imposed
mandatory discounts for certain Medicare Part D beneficiaries as a condition for manufacturers’ outpatient drugs
coverage under Medicare Part D; subjected drug manufacturers to new annual fees based on pharmaceutical companies’
share of sales to federal healthcare programs; imposed a new federal excise tax on the sale of certain medical devices;
created a new Patient Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research; created the Independent Payment Advisory Board,
which, once empaneled, will have authority to recommend certain changes to the Medicare program that could result in
reduced payments for prescription drugs; and established a Center for Medicare Innovation at the CMS to test innovative
payment and service delivery models to lower Medicare and Medicaid spending.
Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable
Care Act. By way of example, the Tax Cuts and Jobs Acts was enacted, which, among other things, removes penalties
for not complying with the individual mandate to carry health insurance. On December 14, 2018, a U.S. District Court
Judge in the Northern District of Texas, ruled that the individual mandate is a critical and inseverable feature of the
Affordable Care Act, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the
Affordable Care Act, such as the BPCIA, are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the
5th Circuit upheld the district court’s decision that the individual mandate was unconstitutional but remanded the case
back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S.
Supreme Court is currently reviewing the case, although it is unclear how the Supreme Court will rule. It is also unclear
how other efforts, if any, to challenge, repeal or replace the Affordable Care Act will impact the law or our business.
In addition, other legislative changes have been proposed and adopted in the United States since the Affordable
Care Act to reduce healthcare expenditures. These changes include the Budget Control Act of 2011, which, among other
things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year and that will remain in
effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021, unless
additional action is taken by Congress; and the American Taxpayer Relief Act of 2012, which, among other things,
further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer
treatment centers and increased the statute of limitations period for the government to recover overpayments to providers
from three to five years. More recently, there has been heightened governmental scrutiny over the manner in which
manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed
and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing,
review the relationship between pricing and manufacturer patient programs and reform government program
reimbursement methodologies for pharmaceutical and biologic products.
Individual states in the United States have become increasingly active in passing legislation and implementing
regulations designed to control biotechnology and pharmaceutical product pricing, including price or patient
reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and
transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.
45
We cannot predict the likelihood, nature or extent of government regulation that may arise from future
legislation or administrative or executive action, either in the United States or abroad. We expect that additional state
and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that
governments and third-party payors will pay for healthcare products and services.
Human Capital
We are intent on cultivating a highly-skilled and passionate team determined to strive to deliver transformative
therapies to the patients who need them most. As of December 31, 2020, we had approximately 168 full-time employees,
of which approximately 164 were located within the United States and 4 employees were located outside of the United
States.
We believe that the success and growth of our business depends in large part on our continued ability to attract,
retain and motivate qualified personnel at all levels of our company. To do that, we employ a number of measures,
including competitive compensation and benefits, fostering an ethical culture that values diversity and inclusion, and
focusing on employee safety and wellness as well as training. These measures help form our human capital management
framework and are advanced through the following:
Competitive Pay and Benefits. We provide our employees with competitive fixed salaries, cash bonus
opportunities designed to incentivize achievement of our goals and individual objectives, equity awards and
opportunities for equity ownership through our employee share purchase plan as well as a robust benefit package
designed to promote well-being across all aspects of our employees’ lives, including comprehensive health insurance,
dental and vision plans, life and other employment related insurance, retirement planning through a 401(k) plan with
partial company match, and paid time off.
Diversity and Inclusion. We value diversity and inclusion at all levels of our company. We believe that our
business benefits from the different perspectives that a diverse workforce brings, and we pride ourselves on having an
inclusive culture based on our shared mission and values.
Health and Safety and our Response to COVID-19. Health and Safety are firmly rooted across our company
through the integration of health and safety processes throughout our business and risk management. To foster a safe and
healthy culture, we have implemented a comprehensive safety program, driving to understand and mitigate against
health and safety incidents. In response to the COVID-19 pandemic and measures introduced by state and federal
governments in the United States, we implemented workplace protocols at our facilities. While the majority of our
employees are able to carry out their responsibilities working outside of our physical locations, for our essential workers
and those choosing to return to our offices to carry out their responsibilities, we implemented additional safety measures,
including occupancy limits, restricting business travel, providing and requiring the use of personal protective equipment,
self-screening prior to accessing our facilities, and others. We continue to monitor the developments, restrictions and
requirements in jurisdictions where we have employees, and update our protocols as applicable.
Our Corporate Information
We are an exempted company incorporated under the laws of Bermuda in July 2015. Our registered office is
located in Bermuda at Clarendon House, 2 Church Street, Hamilton HM11, Bermuda. The telephone number for our
registered office is +44 808-189-6257. Our website address is www.kiniksa.com. The information contained on our
website is not incorporated by reference into this Annual Report, and you should not consider any information contained
on, or that can be accessed through, our website as part of this Annual Report.
Where You Can Find More Information
We are subject to the information requirements of the Securities Exchange Act of 1934, as amended. The SEC
maintains an internet site that contains reports, proxy and information statements, and other information regarding
issuers that file electronically, such as ourselves, with the SEC at http://www.sec.gov.
46
We make available free of charge on our website our Annual Reports on Form 10-K, Quarterly Reports on
Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section
13(a) or 15(d) of the Exchange Act as soon as reasonably possible after we electronically file such material with, or
furnish it to, the SEC. Our website is located at www.kiniksa.com. The reference to our website address does not
constitute incorporation by reference of the information contained at or available through our website, and you should
not consider it to be a part of this Annual Report.
ITEM 1A.
RISK FACTORS.
You should carefully consider the risks described below, as well as the other information in this Annual Report,
including our audited consolidated financial statements and the related notes and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations.” The occurrence of any of the events or developments
described below could adversely affect our business, financial condition, results of operations and growth prospects. In
such an event, the market price of our Class A common shares could decline. Additional risks and uncertainties not
presently known to us or that we currently deem immaterial also may impair our business operations.
Risks Related to Our Financial Position and Capital Needs
We are a biopharmaceutical company and have not generated any revenue from product sales. We have incurred
significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable
future.
Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree
of risk. Typically, it takes many years to develop one new product from the time it is discovered to when it is available
for treating patients, and development may cease for a number of reasons. We have incurred operating losses in each
year since our inception in 2015 and anticipate incurring losses for the foreseeable future. Our future success is
dependent on our ability to develop, obtain regulatory approval for and successfully commercialize one or more of our
product candidates. For example, while the U.S. Food and Drug Administration, or the FDA, accepted the supplemental
Biologics License Application, or sBLA, for rilonacept in recurrent pericarditis with priority review and assigned a
Prescription Drug User Fee Act, or PDUFA, goal date of March 21, 2021, we have not yet demonstrated our ability to
obtain regulatory approvals, manufacture a commercial-scale drug, or conduct sales and marketing activities necessary
for commercialization of rilonacept, if approved. We currently generate no revenue from sales of any products, and we
may never be able to develop or commercialize a marketable product.
We have incurred significant losses related to expenses for research and development and our ongoing
operations. As of December 31, 2020, we had an accumulated deficit of $517.5 million. We expect to continue to incur
losses for the foreseeable future, and anticipate these losses will increase substantially as a result of many factors,
including:
•(cid:3)
•(cid:3)
establishing and expanding sales, marketing and distribution capabilities, infrastructure and organization to
commercialize products for which we may obtain marketing approval, including our lead program,
rilonacept for approved indications in the United States;
our research and preclinical and clinical development of our product candidates, including our global
placebo-controlled Phase 2/3 clinical trial of mavrilimumab in severe coronavirus disease 2019, or
COVID-19, pneumonia and hyperinflammation, Phase 2b dose-ranging study of vixarelimab in prurigo
nodularis, and our Phase 1 clinical trial in healthy volunteers for KPL-404;
•(cid:3) manufacturing our product candidates for clinical or commercial use, and increasing our manufacturing
capabilities or adding additional manufacturers or suppliers;
•(cid:3)
seeking regulatory and marketing approvals for our product candidates that successfully complete clinical
trials, if any;
47
•(cid:3)
initiating potential additional preclinical studies and clinical trials for our product candidates;
•(cid:3) making milestone or other payments under any current or future license, acquisition, collaboration or other
strategic transaction agreements;
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
seeking to identify, assess and study new or expanded indications for our product candidates, new or
alternative dosing levels and frequency for our product candidates, or new or alternative administration of
our product candidates, including method, mode or delivery device;
seeking to identify, assess, acquire or develop additional product candidates;
entering into licensing, acquisition, collaboration or other strategic transaction agreements;
seeking to maintain, protect and expand our intellectual property portfolio;
seeking to attract and retain skilled personnel;
creating additional infrastructure to support our operations as a public company and large accelerated filer,
our product development and planned commercialization efforts; and
experiencing delays or encountering issues with any of the above, including but not limited to the impact of
the COVID-19 pandemic and measures taken in response to the COVID-19 pandemic, failed trials,
complex results, safety issues, regulatory challenges that require longer follow-up of existing trials,
additional major trials, or additional supportive trials in order to pursue marketing approval.
See “Risk Factors — Risks related to product development — The COVID-19 pandemic, and measures taken in
response to the pandemic, could have an adverse impact on our current or planned preclinical studies and clinical trials,
which could be significant.”
Further, the net losses we incur may fluctuate significantly from quarter-to-quarter and year-to-year, such that a
period-to-period comparison of our results of operations may not be a good indication of our future performance. Even if
we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses,
combined with expected future losses, have had and will continue to have an adverse effect on our shareholders’ equity
(deficit) and working capital.
We will require substantial additional financing, and a failure to obtain this necessary capital when needed on
acceptable terms, or at all, will force us to delay, limit, reduce or cease one or more of our product development plans,
research and development programs for our product candidates, or other operations or commercialization efforts.
The development and commercialization of biopharmaceutical products is capital intensive. We are advancing
our product candidates through research, preclinical and clinical development, including our global placebo-controlled
Phase 2/3 clinical trial of mavrilimumab in severe COVID-19 pneumonia and hyperinflammation, our Phase 2b dose-
ranging study of vixarelimab in prurigo nodularis, and our Phase 1 clinical trial with KPL-404 in healthy volunteers.
We expect our expenses to increase in connection with our ongoing activities as we continue the research and
development of our product candidates, establish and expand our sales, marketing and distribution capabilities,
infrastructure and organization, or enter into agreements with third parties to conduct one or more of these
commercialization activities. The FDA accepted the sBLA for rilonacept in recurrent pericarditis with priority review
and assigned a PDUFA goal date of March 21, 2021. Upon approval from the FDA, if any, of the sBLA, we will assume
the sales and distribution of rilonacept for the approved indications in the United States and would evenly split profits on
sales with Regeneron, after deducting certain commercialization expenses subject to specified limits. We expect to incur
significant additional commercialization expenses leading up to and after marketing approval for rilonacept or any of our
other product candidates related to manufacturing, product sales, marketing and distribution. As our product candidates
48
progress through development and towards commercialization, we will need to make milestone payments and, if
successful, eventually make profit-split or royalty payments to the licensors and other third parties from whom we have
acquired our product candidates. Furthermore, we expect to continue to incur costs associated with operating as a public
company, including with respect to increased compliance and disclosure obligations as a result of becoming a large
accelerated filer effective as of December 31, 2020 and no longer being an emerging growth company as of that time or
a smaller reporting company as of January 1, 2021.
Accordingly, we will need to obtain substantial additional funding in connection with our continuing
operations. If we are unable to raise capital when needed on acceptable terms, if at all, we will be forced to delay, limit,
reduce or cease one or more of our product development plans, research and development programs for our product
candidates, or commercialization efforts. We also may not be able to expand our operations or otherwise capitalize on
our business opportunities, or may be required to relinquish rights to our product candidates or products.
The development process for our product candidates is highly uncertain, and we cannot estimate with certainty
the actual amounts necessary to successfully complete the development, regulatory approval process and
commercialization of our product candidates. Our operating plans may change as a result of many factors currently
unknown to us, including delays in or other adverse impacts to our commercialization of rilonacept impacting our ability
to generate projected revenue from rilonacept or delays in commercialization of any of our other product candidates, and
we may need to seek additional funds sooner than expected, through public or private securities offerings, debt
financings or other sources, including government funding or grants. Our future capital requirements will depend on, and
could increase significantly as a result of, many factors, including:
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
our ability to successfully commercialize any of our product candidates, including the cost and timing of
establishing and expanding our sales, marketing and distribution capabilities, infrastructure and
organization or entering into agreements with third parties to conduct one or more of these activities for
rilonacept, if approved, any of our product candidates, if approved or in anticipation of such approval,
including preparations for the potential commercial launch of rilonacept in recurrent pericarditis;
the amount and timing of sales revenues from rilonacept or any of our other product candidates, if
approved, including the sales price and the availability of coverage and adequate third-party
reimbursement;
competitive and potentially competitive products and technologies and patients’ and physicians’ receptivity
to our product candidates and the technology underlying them in light of competitive products and
technologies;
the costs and timing of payments for producing product candidates to support clinical trials as well as the
potential commercial launch of our product candidates such as rilonacept, reserving manufacturing slots, or
transferring manufacturing technology to third-party manufacturers;
the results from, and the time and cost necessary for development of our product candidates, including for
our global placebo-controlled Phase 2/3 clinical trial of mavrilimumab in severe COVID-19 pneumonia
and hyperinflammation, our Phase 2b dose-ranging trial of vixarelimab in prurigo nodularis, and our Phase
1 clinical trial in healthy volunteers for KPL-404;
the costs and timing of establishing and maintaining clinical trial sites for the development of our product
candidates, both in the United States and in jurisdictions outside of the United States, including as a result
of the COVID-19 pandemic and measures taken in response to the pandemic;
the number, size and type of preclinical activities and any additional clinical trials;
the costs, timing and outcomes of seeking and potentially obtaining approvals from the FDA or comparable
regulatory authorities outside of the United States, including the potential for the FDA or such comparable
49
regulatory authorities to require that we conduct more studies than we currently plan to conduct and the
costs of post-marketing studies or risk evaluation and mitigation strategies, or REMS, that could be
required by regulatory authorities;
the timing and amount of milestone and other payments we must make under our agreements with
Regeneron, MedImmune, Limited, or MedImmune, Biogen MA Inc., or Biogen, and the other third parties
from whom we have acquired or in-licensed our product candidates or from whom we may in the future
acquire or in-license product candidates;
the cash requirements for seeking to identify, assess and study new or expanded indications for our product
candidates, new or alternative dosing levels or frequency for our product candidates, or new or alternative
administration of our product candidates, including method, mode or delivery device;
the cash requirements of any future in-license, acquisition, development or discovery of additional product
candidates, including in connection with any licensing, acquisition, collaboration or other strategic
transaction agreements;
the time and cost necessary to respond to technological and market developments;
the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property
rights;
any product liability or other lawsuits related to our product candidates or any related activities;
the costs associated with being a public company, including as a result of becoming a large accelerated filer
as of December 31, 2020 and no longer being an emerging growth company at that time or a smaller
reporting company as of January 1, 2021;
our need and ability to hire and retain skilled personnel; and
the receptivity of the capital markets to financings by biopharmaceutical companies generally and
companies with product candidates and technologies such as ours specifically.
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
Any additional fundraising efforts may divert our management from their day-to-day activities, which may
adversely affect our ability to develop and commercialize our product candidates. The COVID-19 pandemic continues to
adversely impact the global economy with the potential for the continued economic downturn to be severe and
prolonged. A continued severe or prolonged economic downturn could result in a variety of risks to our business,
including disruptions in the financial markets, that may make our ability to raise additional capital when needed,
including through private or public securities offerings and debt financings more difficult to obtain, if at all, and may
have a material adverse effect on our ability to meet our fundraising needs when they arise.
Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If we
are unable to obtain funding when needed, we will be forced to curtail, delay, limit, reduce or cease one or more of our
product development plans, research and development programs for our product candidates, or commercialization efforts
of any product candidate. We may also be unable to expand our operations or otherwise capitalize on our business
opportunities or may be required to relinquish rights to our product candidates or products. Any of these occurrences
could materially affect our business, financial condition and results of operations.
Raising additional capital may cause dilution to our shareholders, restrict our operations or require us to relinquish
rights to our technologies or product candidates.
Until such time as we can generate substantial product revenue, if ever, we expect to finance most of our cash
needs through private or public securities offerings, debt financings, government funding or grants, or other sources,
50
including licensing, collaboration or other strategic transactions or arrangements with third parties and to a lesser extent
through projected revenue from rilonacept if approved in recurrent pericarditis or any of our other product candidates.
The terms of any financing may adversely affect the holdings or the rights of our shareholders and our issuance of
additional securities, whether equity or debt, or the possibility of such issuance, may cause the market price of our
Class A common shares to decline. The sale of additional equity or convertible securities would dilute all of our
shareholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be
required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on
our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely
impact our ability to conduct our business. Obtaining funds through licensing, collaboration or other strategic
transactions or arrangements with third parties may require us to relinquish rights to some of our technologies, product
candidates or future revenue streams, or otherwise agree to terms unfavorable to us, any of which may have a material
adverse effect on our business, operating results and prospects. If we raise funds through research grants, we may be
subject to certain requirements, which may limit our ability to use the funds or require us to share information from our
research and development. Raising additional capital through any of these or other means could adversely affect our
business and the holdings or rights of our shareholders, and may cause the market price of our Class A common shares
to decline.
Risks Related to Product Development
We depend heavily on the success of one or more of our product candidates, which are in various stages of clinical
development. If we are unable to advance our product candidates in clinical development, obtain regulatory approval
and ultimately commercialize one or more of our product candidates, or experience significant delays in doing so, our
business will be significantly harmed.
We do not currently generate any revenue from sales of any products, and we may never be able to develop or
commercialize marketable products. We are not permitted to market or promote any of our product candidates before we
receive regulatory approval from the FDA or comparable regulatory authorities outside of the United States. Our product
candidates in various stages of clinical development. Our assumptions about why our product candidates are worthy of
future development and potential approval in the indications for which we are studying them, or any other indications,
are based in part on indirect data collected by other companies and in part from data collected from our preclinical and
clinical trials. We may not be able to demonstrate that they are safe or effective in the indications for which we are
studying them, and they may not be approved.
Although rilonacept is approved and marketed for human use for the treatment of other indications in the
United States by Regeneron, we studied rilonacept for the treatment of a different indication called recurrent pericarditis,
for which the FDA accepted the sBLA with priority review and assigned a PDUFA goal date of March 21, 2021.
Mavrilimumab was studied in Phase 2 clinical trials conducted by MedImmune outside of the United States for the
treatment of rheumatoid arthritis, or RA. However, we studied mavrilimumab in a global Phase 2 clinical trial for the
treatment of GCA, for which we announced that the trial met both the primary and secondary efficacy endpoints with
statistical significance. Further, we are conducting a global placebo-controlled Phase 2/3 clinical trial of mavrilimumab
in severe COVID-19 pneumonia and hyperinflammation. We have been studying vixarelimab in prurigo nodularis, for
which we released top-line data from our Phase 2a clinical trial, and are enrolling and dosing patients in a Phase 2b dose-
ranging study of vixarelimab in prurigo nodularis. In addition, we are conducting a Phase 1 clinical trial of KPL-404 in
healthy volunteers. Our future preclinical product candidates would need to progress through toxicology studies and
other requirements to enable an Investigational New Drug application, or IND, prior to clinical development.
We cannot be certain that any of our product candidates will be successful in these clinical trials or that
rilonacept, or any of our other product candidates, will receive regulatory approval even after completing a successful
pivotal clinical trial. We may also determine that the potential product and commercial profile of any of our product
candidates may not ultimately be commercially successful or even if they have the potential to ultimately be successful,
we may not have sufficient recourses, which in either case could lead us to discontinue its development, or we may
determine to not support further development of any of our product candidates at any time for any reason. If we do not
receive regulatory approvals for one or more of our product candidates, we may not be able to continue our operations.
51
While our global, pivotal Phase 3 clinical trial, RHAPSODY, of rilonacept in recurrent pericarditis met
statistical significance on its primary and all major secondary efficacy endpoints, we may be required to conduct
additional studies before or after we receive FDA approval of rilonacept in recurrent pericarditis. Each of our other
product candidates require additional preclinical or clinical development and all of our product candidates will require
regulatory approval in one or more jurisdictions, manufacturing capacity and expertise, successful manufacture of
clinical supply, an organization to support commercialization and product launch, and significant marketing efforts
before we will be able to generate any revenue from product sales. The success of our product candidates or potential
future product candidates depends upon several factors, including the following:
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
submission to and acceptance by the FDA of INDs and of clinical trial applications to governmental
authorities outside of the United States for our product candidates to commence planned clinical trials or
future clinical trials;
successful completion of preclinical studies, including toxicology studies, biodistribution studies and
minimally efficacious dose studies in animals, conducted, where applicable, under the FDA’s Good
Laboratory Practice, or GLP, regulations;
successful site activation for, enrollment in, and completion of clinical trials, the design and
implementation of which are agreed to by the applicable regulatory authorities, and the ability of our
contract research organizations, or CROs, to successfully conduct such trials within our planned budget and
timing parameters and without materially adversely impacting our trials;
successful data from our clinical programs that support an acceptable risk-benefit profile of our product
candidates for the targeted indications in the intended populations to the satisfaction of the applicable
regulatory authorities;
timely receipt, if at all, of regulatory approvals from applicable regulatory authorities and maintenance of
any such approvals;
as applicable, pediatric study plans acceptable to the FDA and comparable regulatory authorities outside of
the United States, and follow through of any pediatric study commitments, including development of
pediatric formulations where indicated;
establishment and maintenance of arrangements with third-party manufacturers, as applicable, for
continued clinical supply and commercial manufacturing;
successful development of our manufacturing processes and transfer to third-party facilities to support
future development activities and commercialization that are operated by contract manufacturing
organizations, or CMOs, in a manner compliant with all regulatory requirements;
successful manufacture of sufficient supplies of our product candidates within approved specifications for
purity and efficacy from our facility and from our CMOs or other sole-source manufacturers in order to
meet clinical or commercial demand, as applicable;
establishment and maintenance of patent and trade secret protection or regulatory exclusivity for our
product candidates;
timely and successful commercial launch of our product candidates, including rilonacept if and when
approved;
acceptance of our products, if and when approved, by patients, patient-advocates, the medical community
and third-party payors;
52
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
effective competition with other therapies;
establishment and maintenance of adequate healthcare coverage and reimbursement;
enforcement and defense of intellectual property rights and claims;
continued compliance with any post-marketing requirements imposed by regulatory authorities, including
any required post-marketing clinical trial commitments or REMS; and
•(cid:3) maintenance of a continued acceptable safety profile of our product candidates following approval.
If we do not accomplish one or more of these factors in a timely manner or at all, including as a result of the
COVID-19 pandemic and measures taken in response to the pandemic, we could experience significant delays in, or an
inability to, timely or successfully commercialize our product candidates, which would materially harm our business. If
we do not receive regulatory approvals for one or more of our product candidates, we may not be able to continue our
operations. Even if we successfully obtain regulatory approvals to manufacture and market our product candidates, our
revenues will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval
and have commercial rights, among other things. If the markets for patient subsets that we are targeting are smaller than
we estimate, we may not generate projected revenue levels from sales of such products, if approved.
Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes. We
may encounter substantial delays in our clinical trials, or we may fail to demonstrate safety and efficacy to the
satisfaction of applicable regulatory authorities. We may therefore be unable to obtain required regulatory approvals
and be unable to commercialize our product candidates on a timely basis, if at all.
Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must
conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical
testing is expensive, time consuming and uncertain as to outcome. We are conducting a global, placebo-controlled Phase
2/3 clinical trial of mavrilimumab in severe COVID-19 pneumonia and hyperinflammation, a Phase 2b dose-ranging
study of vixarelimab in prurigo nodularis, for which we are enrolling and dosing patients, and a Phase 1 clinical trial
with KPL-404 in healthy volunteers. Not all of our clinical trials have been conducted as initially planned or completed
on our initial projected schedule, and accordingly, we cannot guarantee that any of our current or potential future clinical
trials will be conducted as initially planned or completed on our initial projected schedule, if at all, including as a result
of the COVID-19 pandemic and measures taken in response to the pandemic.
Commencing a clinical trial is subject to acceptance by the FDA of an IND or IND amendments, acceptance by
European regulatory authorities of a Clinical Trial Application, or CTA, or acceptance by other applicable regulatory
authorities, and finalizing the trial design based on discussions with the FDA, European regulatory authorities or other
applicable regulatory authorities. We have and may in the future receive feedback or guidance from regulatory
authorities on our clinical trial design and protocols and, even after we incorporate such feedback or guidance from these
regulatory authorities, such regulatory authorities may impose other requirements for our clinical trials, could disagree
that we have satisfied their requirements to commence our clinical trials, disagree with our interpretation of data from
the relevant preclinical studies, clinical trials or chemistry, manufacturing and controls, or CMC, data, or disagree or
change their position on the acceptability of our trial designs, including the proposed dosing level or schedule, treatment
duration, our definitions of the patient populations or the clinical endpoints selected, which may require us to complete
additional preclinical studies, clinical trials, CMC development, other studies or impose stricter approval conditions than
we currently expect.
For example, the FDA has provided feedback that the risk-benefit assessment for investigation of
mavrilimumab in a clinical trial may differ depending on the patient population studied. Specifically, the FDA
acknowledged that the risk-benefit assessment for initiation of a clinical trial may be considered favorable in a patient
population with high morbidity and limited effective treatment options. In addition, we anticipate that other potential
indications for mavrilimumab would need to be in serious or life-threatening diseases where the burden of the disease is
sufficient to justify the risk-benefit of mavrilimumab to pursue clinical development in such indications or potentially in
53
indications requiring limited doses where the theoretical risk of PAP is low. Further, based on FDA feedback we
received in connection with its review and approval of an IND for our global Phase 2 clinical trial of mavrilimumab in
GCA, we anticipate that to help inform the risk-benefit profile for the use of mavrilimumab in GCA, we will need to
eventually demonstrate safety and effectiveness of mavrilimumab beyond 26 weeks, as well as evaluate its
pharmacokinetic profile and the effectiveness of mavrilimumab at different doses in GCA.
Commencing our planned clinical trials is also subject to approval by an IRB at each clinical trial site before a
trial may be initiated, which approval could be delayed, rejected or suspended. Further the IRBs of the institutions in
which such trials are being conducted, the Data Safety Monitoring Board for such trial or the FDA or other regulatory
authorities may impose a suspension or termination of our clinical trials even after approval and initiation of trial sites
due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or
our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities,
unforeseen safety issues or adverse side effects that arise in the trial, failure to demonstrate a benefit from using a drug,
any of which could result in the imposition of a clinical hold, as well as changes in governmental regulations or
administrative actions or lack of adequate funding to continue the clinical trial.
Successful completion of our clinical trials is a prerequisite to submitting a Biologics License Application, or
BLA, sBLA or New Drug Applications, or NDA, to the FDA and a marketing authorization application, or MAA, to the
European Medicines Agency, or EMA, or other applicable regulatory authorities in other countries for each product
candidate and, consequently, to obtaining approval and initiating commercial marketing of our current and any future
product candidates. A failure of one or more of our current or future clinical trials can occur at any stage of testing, and
our clinical trials may not be successful. We have and may continue to experience delays in our ongoing clinical trials,
and we do not know whether planned clinical trials will begin on time, be allowed by regulatory authorities, need to be
redesigned, or if we can activate sites or enroll patients on time, or if they will be completed on schedule, if at all. Events
that have and may continue to delay or prevent commencement or successful completion of clinical development of our
product candidates as planned and on schedule, if at all, include but are not limited to:
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the
initiation of human clinical trials;
delays or failure in reaching a consensus with regulatory agencies on trial design or implementation;
delays or failure in establishing the appropriate dosage levels or frequency of dosing or treatment period in
clinical trials;
delays or failure in reaching agreement on acceptable terms with prospective CROs, and clinical trial sites,
the terms of which can be subject to extensive negotiation and may vary significantly among different
CROs and clinical trial sites;
difficulties in obtaining required IRB approval at each clinical trial site;
delays or failure in obtaining regulatory approval to commence a trial, or imposition of a clinical hold by
regulatory authorities, after review of an IND or IND amendment, or equivalent application or amendment,
or an inspection of our clinical trial operations or study sites;
challenges in recruiting and enrolling suitable patients or a sufficient number thereof to participate in our
clinical trials;
amendments to clinical trial protocols impacting study criteria, endpoints or design, including amendments
that either we initiate or are requested by regulatory authorities;
difficulty collaborating with patient groups and investigators;
54
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
failure by our CROs, medical institutions, other third parties we contract with in connection with our
clinical trials, or us to adhere to clinical trial requirements or to perform their obligations in a timely or
compliant manner;
failure to perform in accordance with the FDA’s good clinical practices requirements, or GCPs, or
applicable comparable regulatory guidelines in other countries;
patients not completing participation in a clinical trial or returning for post-treatment follow-up, in either
case including as a result of trial demands on participants as a result of the COVID-19 pandemic and
measures taken in response to the pandemic or otherwise, among other things;
clinical trial sites or patients withdrawing from a clinical trial, including as a result of the COVID-19
pandemic and measures taken in response to the pandemic or otherwise, among other things;
participating patients experiencing serious adverse events or undesirable side effects or being exposed to
unacceptable health risks;
participating patients failing to experience confirmed pre-specified events during the clinical trial within an
expected time-frame, if at all;
safety issues, including occurrence of adverse events associated with the product candidate that are viewed
to outweigh its potential benefits;
difficulty in identifying the patient populations that we are trying to enroll in a particular trial, which may
delay enrollment and reduce the power of a clinical trial to detect statistically significant results;
changes in regulatory requirements, policies and guidance that require amending or submitting new clinical
protocols;
the cost of clinical trials of our product candidates being greater than we anticipate;
clinical trials of our product candidates producing negative, inconclusive or uncompetitive results, which
may result in us deciding, or regulators requiring us, to conduct additional clinical trials or modify or cease
development programs for our product candidates;
suspensions or terminations of our clinical trials by us or the IRBs of the institutions in which our clinical
trials are being conducted, the Data Safety Monitoring Board for such trials or the FDA or comparable
regulatory authorities;
failure of manufacturers, or us, to produce phase-appropriate supplies of our product candidates for use in
our clinical trials in accordance with current good manufacturing practices, or cGMP, requirements and
regulations or applicable comparable regulatory guidelines in other countries;
delays in manufacturing, testing, releasing, validating or importing/exporting sufficient stable quantities of
our product candidates for use in clinical trials or the inability to do any of the foregoing; and
disruptions to our business operations, including our manufacturing operations, and the business operations
of our third-party manufacturers, CROs upon whom we rely to conduct our clinical trials, or other third
parties with whom we conduct business or otherwise engage, as well as disruptions in travel into and
within the countries in which we conduct our clinical trials, our manufacturers produce our product
candidates or we otherwise conduct business or engage with other third parties, now or in the future as a
result of the impact of the COVID-19 pandemic.
55
Delays in the commencement or completion of our planned and ongoing clinical trials of our product candidates
have and may continue to occur. Consequences of delays have or may increase our costs of developing our product
candidates, slow down the development and approval of our product candidates, delay or jeopardize our ability to
commence product sales and generate revenue, if any, from our product candidates and harm their commercial prospects.
Furthermore, disruptions caused by the COVID-19 pandemic have and may continue to increase the likelihood that we
encounter such difficulties or delays in commencing or completing our planned and ongoing clinical trials or other
development. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of
clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates or us deciding to
modify or cease development of our product candidates.
Clinical trial delays could also shorten any periods during which our products have patent protection or shorten
any periods during which we have the exclusive right to commercialize our product candidates and may allow our
competitors to bring products to market before we do, which could impair our ability to obtain orphan exclusivity for our
products that potentially qualify for this designation and to successfully commercialize our product candidates, and may
harm our business and results of operations. Any inability to successfully complete preclinical and clinical development
could result in additional costs to us or impair our ability to generate revenue and harm our business, financial condition
and prospects significantly.
Furthermore, clinical trials must be conducted in accordance with the laws, rules and regulations, guidelines
and other requirements of the FDA, European Union, or EU, and other applicable regulatory authorities outside of those
jurisdictions and are subject to oversight by these regulatory authorities and IRBs at the medical institutions where the
clinical trials are conducted. Further, conducting global clinical trials, as we do for certain of our product candidates,
may require that we coordinate among the legal requirements and guidelines of regulatory authorities across a number of
jurisdictions, including the United States, EU and countries outside of those jurisdictions, which could require that we
amend clinical trial protocols or determine not to conduct a trial in one or more jurisdictions or to run separate trials in
various jurisdictions due to the inability, cost or delay in harmonizing divergent requests from such regulatory
authorities, all of which could increase costs. In addition, clinical trials that are conducted in countries outside the United
States and the EU may subject us to risks associated with the engagement of non-United States and non-EU CROs who
are unknown to the FDA or the EMA, and may have different standards of diagnosis, screening and medical care, as well
as risks associated with further delays and expenses as a result of increased shipment costs (including as a result of local
quality release or in-country testing of a product candidate supply produced in a different jurisdiction for our clinical
trials) and political and economic risks relevant to such countries outside the United States and the EU.
The COVID-19 pandemic, and measures taken in response to the pandemic, could have an adverse impact on our
current or planned preclinical studies and clinical trials, which could be significant.
The COVID-19 pandemic, and measures taken in response to the pandemic, have had and could continue to
have an impact our current or planned preclinical studies and clinical trials. If the COVID-19 pandemic and measures
undertaken in response to the pandemic are prolonged, or the easing of any of such measures has adverse consequences,
we may experience significant disruptions that could materially impact our preclinical studies and clinical trials,
including by:
•(cid:3)
•(cid:3)
impeding, delaying, limiting or preventing the production, delivery or release of our product candidates to
our clinical trial sites or patients, including due to interruptions in the supply of raw materials or global
shipping that may affect the transport of our product candidates or clinical trial materials, or the
reprioritization by third parties or the U.S. government for any products or potential products related to the
treatment or prevention of COVID-19;
impeding, delaying, limiting or preventing the production, delivery or release of the potential commercial
supply of rilonacept, including due to disruptions at Regeneron’s manufacturing facilities that produce
rilonacept, staffing shortages or reprioritizations, production slowdowns or stoppages or interruptions in
global shipping;
56
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
impeding, delaying, limiting or preventing clinical trial investigators, other critical staff, or patients from
traveling to our clinical trial sites or visiting nurses traveling to patients;
impeding, delaying, limiting or preventing key clinical trial activities, including clinical trial site
monitoring, patient dosing, study procedures (such as biopsies, which may be deemed non-essential),
collection of clinical data and samples as well as cleaning and verification of clinical data, which could
affect the integrity of clinical trial data;
diverting healthcare resources away from the conduct of clinical trials or a reprioritizing of the focus of
such resources on clinical trials for product candidates with the potential for treatment or prevention of
COVID-19 related conditions;
impeding, delaying, limiting or preventing clinical trial site initiation, including difficulties in recruiting
clinical site investigators and clinical site staff, and enrollment or retention of patients in our clinical trials;
increasing the risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical
trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of
observed adverse events;
interrupting or delaying preclinical studies due to restricted or limited operations at our research and
development laboratory facility;
causing interruptions or delays at the FDA, or other regulatory authorities, which could result in delays in
review and approval of our submissions and applications, including INDs, clinical trial protocols and BLAs
for our product candidates;
resulting in the refusal of the FDA to accept data from clinical trials in affected geographies;
prompting changes in local regulations as part of a response to the COVID-19 pandemic which may require
us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or
cause us to pause or discontinue one or more of our current or planned clinical trials altogether;
delaying necessary interactions with local regulators, ethics committees and other important agencies and
contractors due to limitations in employee resources or forced furlough of government employees; and
limiting employee resources that would otherwise be focused on the conduct of our clinical trials, including
because of sickness of employees or their families or the desire or requirement of employees to avoid
contact with large groups of people.
Any one of the foregoing could significantly impede, delay, limit or prevent the clinical development of our
product candidates and ultimately lead to the delay or denial of regulatory approval of our product candidates. For
example, the large number of competitive studies for the treatment of conditions associated with COVID-19 and the
evolving standard of care with overall improvement in the quality of care for patients diagnosed with COVID-19 initially
had an impact on the number of eligible patients for our global placebo-controlled Phase 2/3 clinical trial of
mavrilimumab in severe COVID-19 pneumonia and hyperinflammation. While we continuously look to identify
business-critical activities and to develop contingencies and mitigation strategies for those activities to potentially
minimize the impact of the COVID-19 pandemic on our business and operations, there can be no assurance that we will
be able to identify all such activities or that any identified contingencies and mitigation strategies will be effective. If the
clinical development of our product candidates is significantly impeded, delayed, limited or is prevented, it could
ultimately lead to the delay or denial of regulatory approval of our product candidates which would materially adversely
affect our business and operations, including our ability to generate revenue.
57
We may find it difficult to enroll patients in our clinical trials in a timely manner given the limited number of patients
who have the diseases for which our product candidates are being studied, our particular enrollment criteria or
competing clinical studies in the same patient population, including patients with COVID-19, or due to the impact of
the COVID-19 pandemic. Difficulty in enrolling patients could delay or prevent completion of our clinical trials of
our product candidates, and our research and development efforts could be adversely affected.
Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our
success. The timing of our clinical trials depends in part on the speed at which we can recruit a sufficient number of
patients to participate in testing our product candidates, including for the treatment of conditions associated with
COVID-19, particularly given that many of the conditions for which we are evaluating our current product candidates or
may evaluate them in the future are in small disease populations. In addition, the eligibility criteria of our clinical trials
will further limit the pool of available trial participants, as we will require patients to have specific characteristics that
we can evaluate based on the primary and secondary endpoints of the study. Further, our product candidates modulate
the immune system and carry risks associated with immunosuppression, including the risk of serious infections and other
potential serious health risks.
Our clinical trials have and may continue to compete with other clinical trials for product candidates that are in
the same therapeutic areas as our product candidates, and this competition may further reduce the number and types of
patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a
trial being conducted by one of our competitors. For example, the large number of competitive studies for the treatment
of conditions associated with COVID-19 and the evolving standard of care with overall improvement in the quality of
care for patients diagnosed with COVID-19 initially had an impact on the number of eligible patients for our global
placebo-controlled Phase 2/3 clinical trial of mavrilimumab in severe COVID-19 pneumonia and hyperinflammation.
Since the number of qualified clinical investigators is limited, we may conduct some of our clinical trials at the same
clinical trial sites that some of our competitors use, which would reduce the number of patients who are available for our
clinical trials at such clinical trial site.
In addition, disruptions to our business operations and the business operations of our CROs or other third
parties with whom we conduct business, as well as disruptions in travel into and within the countries in which we
conduct our clinical trials, now or in the future, as a result of the impact of the COVID-19 pandemic, may delay or
prevent patient enrollment. For example, our CRO for the Phase 1 clinical trial of KPL-404 notified us that, after a
temporary pause due to the impact of the COVID-19 pandemic, they resumed certain clinical trial activities, but we also
engaged an additional CRO to conduct additional portions of the trial at another clinical trial site.
Accordingly, when we encounter these or other difficulties in enrollment we have and may continue to
experience delays or we may be prevented from completing our clinical trials. Patient enrollment depends on many
factors, including:
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
the size and nature of the patient population;
the severity of the disease being studied;
patient referral practices of physicians;
patient eligibility criteria for the clinical trial and evolving standards of care;
the proximity of patients to clinical sites;
the complexity of the design and nature of the clinical protocol and trial;
the availability and nature of competing clinical trials;
58
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
the availability of standard of care or new drugs approved for the indication the clinical trial is
investigating;
failure to obtain and maintain or timely amend patient consents;
our ability to recruit clinical trial investigators with applicable competencies and experience;
the risk that patients enrolled in clinical trials will withdraw from the trials before completion of their
treatment or follow-up period (in either case including as a result of trial demands on participants among
other things);
clinicians’ and patients’ perceptions as to the safety and potential advantages of the product candidate
being studied in relation to other available therapies; and
the occurrence of adverse events, or AEs, or undesirable side effects attributable to our product candidates.
The process of finding and enrolling patients may prove costly, especially since we are looking to identify a
subset of the patients eligible for our studies from a relatively small patient population for many of the diseases we are
studying, including for the treatment of conditions associated with COVID-19. If patients are unable or unwilling to
participate in our clinical trials for any reason, or we experience difficulties in patient enrollment for any other reasons,
such as due to the COVID-19 pandemic, our costs may significantly increase and the timeline for recruiting patients,
conducting trials and obtaining regulatory approval of our product candidates may be significantly delayed or prevented,
the commercial prospects of our product candidates may be harmed, and our ability to commence product sales and
generate product revenue from any of these product candidates could be delayed or prevented. Any of these occurrences
may harm our business, financial condition, and prospects significantly.
Our product candidates may cause undesirable side effects or have other safety risks that could delay or prevent their
regulatory approval, limit the commercial profile of an approved label or result in significant negative consequences,
including withdrawal of approval, following any potential marketing approval.
Treatment with our product candidates may produce undesirable side effects or adverse reactions or events.
Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or
halt clinical trials and could result in more restrictive labels or the delay or denial of regulatory approvals by the FDA or
other comparable regulatory authorities outside of the United States.
Our product candidates modulate the immune system and carry risks associated with immunosuppression,
including the risk of serious infections and other potential serious health risks. For example, some common side effects
of rilonacept include, cold symptoms, nausea, stomach pain, diarrhea, numbness or tingly feeling and injection-site
reaction. IL-1 blockade may interfere with immune response to or delay symptomatology and diagnosis of infections.
Serious, life-threatening infections have been reported in patients taking rilonacept. In our open-label Phase 2 proof-of-
concept clinical trial of rilonacept for recurrent pericarditis, the most common AEs were gastrointestinal disorders and
injection site reactions and there was one treatment-related serious AE which resulted in discontinuation: a skin abscess
which responded to medical treatment. In our global, pivotal Phase 3 clinical trial, RHAPSODY, the most common AEs
were injection site reactions and upper respiratory tract infections and there were four serious AEs on rilonacept, none of
which were treatment-related.
For mavrilimumab, there is a theoretical risk for the development of pulmonary alveolar proteinosis, or PAP.
PAP is a rare lung disorder in which surfactant-derived lipoproteins accumulate excessively within pulmonary alveoli
due to loss of granulocyte macrophage colony stimulating factor, or GM-CSF, function. The disease can range in
severity from a sub-clinical reduction in diffusion capacity to significant dyspnea during mild exertion. In preclinical
studies conducted by MedImmune, certain effects were observed in the lungs of non-human primates, which led the
FDA to issue a clinical hold with respect to MedImmune’s proposed clinical trial in RA. Preclinical data generated to-
59
date suggest mavrilimumab does not reach the lungs in sufficient quantities to induce PAP at clinically relevant doses
and human trials thus far have not shown a clinical effect on pulmonary function tests attributable to mavrilimumab.
However, if the results of our clinical trials reveal an unacceptable severity and prevalence of these or other side
effects, the FDA or applicable regulatory authority outside of the United States may suspend or terminate our clinical
trials, or not authorize us to initiate further trials. In addition, if other anti-GM-CSF molecules in development by third
parties show these or similar side effects, it could have an impact on the entire class of anti-GM-CSF molecules in
development and the applicable regulatory agency may suspend or terminate our clinical trials, or not authorize us to
initiate further trials. The FDA or comparable regulatory authorities outside of the United States could order us to cease
further development of, or deny or withdraw any approval of, any of our product candidates for any or all targeted
indications.
In addition, subsequent to MedImmune’s original IND submission for RA and the availability of additional
clinical safety data that MedImmune generated in human clinical trials conducted outside of the United States for RA,
the FDA provided feedback that the risk-benefit assessment for investigation of mavrilimumab in a clinical trial may
differ depending on the patient population studied. Specifically, the FDA acknowledged that the risk-benefit assessment
for initiation of a clinical trial may be considered favorable in a patient population with high morbidity and limited
effective treatment options. Further, we anticipate that other potential indications for mavrilimumab would need to be in
serious or life-threatening diseases where the burden of the disease is sufficient to justify the risk-benefit of
mavrilimumab to be studied in such indications or potentially in indications requiring limited doses where the theoretical
risk of PAP is low. In addition, based on FDA feedback we received in connection with its review and authorization of
an IND for our global Phase 2 clinical trial of mavrilimumab in GCA, we anticipate that to help inform the risk-benefit
profile for the use of mavrilimumab in GCA, we will need to eventually demonstrate the safety and effectiveness of
mavrilimumab beyond 26 weeks as well as evaluate its pharmacokinetic profile and the effectiveness of mavrilimumab
at different doses in GCA.
In our repeated-single-dose Phase 1b clinical trial of vixarelimab, there were no serious AEs, however, there
were more atopic dermatitis flares in the vixarelimab-treated population versus placebo (47.6% versus 4.5%) through the
12-week treatment period; all subjects who experienced a flare were successfully managed with topical corticosteroids.
In addition, the development of any of our product candidates in other potential indications could increase the
possibility of identification of adverse safety results that impact our development of such product candidates. For
example, the development of mavrilimumab in other potential indications, such as COVID-19 pneumonia and
hyperinflammation, could increase the possibility of identification of adverse safety results that impact our development
of mavrilimumab for GCA or any other indication.
Further, clinical trials by their nature utilize a sample of the potential patient population. Certain rare and severe
side effects associated with our product candidates may only be uncovered with a significantly larger number of patients
exposed to the product candidates. If one or more of our product candidates receives marketing approval, and we or
others later identify undesirable side effects caused by the product, a number of potentially significant negative
consequences could result, including but not limited to:
•(cid:3)
•(cid:3)
regulatory authorities may withdraw approvals of such product and require us to take it off the market;
regulatory authorities may require the addition of labeling statements, specific warnings, contraindications
or field alerts to physicians and pharmacies;
•(cid:3) we may be required to create a registry or a REMS plan, which could include a medication guide outlining
the risks of such side effects for distribution to patients, a communication plan for healthcare providers or
other elements to assure safe use;
•(cid:3) we may be required to change the way the product is administered, conduct additional clinical trials or
change the labeling of the product;
60
•(cid:3) we may be subject to limitations on how we promote the product, or sales of the product may decrease
significantly;
•(cid:3) we could be sued and held liable for harm caused to patients;
•(cid:3)
•(cid:3)
the product may become less competitive; and
our reputation may suffer.
Any of these events could prevent us from achieving or maintaining market acceptance of the particular product
candidate, if approved, and could significantly harm our business, results of operations and prospects.
If we cannot replicate positive results from earlier preclinical studies and clinical trials conducted by us or third
parties, including the companies from whom we have licensed or acquired or may in the future license or acquire our
product candidates, in our later clinical trials, we may be unable to successfully develop, obtain regulatory approval
for and commercialize our product candidates.
Positive results from our preclinical studies and any positive results we may obtain from our earlier clinical
trials of our product candidates, or from the clinical trials conducted by third parties, including investigator-initiated
studies or the companies from whom we in-licensed or acquired or may in the future in-license or acquire our product
candidates, may not be predictive of the results from any required later preclinical studies and clinical trials. Similarly,
the positive results from the preclinical studies and earlier clinical trials or investigator initiated studies of our product
candidates may not be replicated in our subsequent preclinical studies and clinical trial or investigator initiated study
results. The mechanisms of action of our product candidates may not prove to be safe or effective to treat the diseases we
are studying. Further, the safety and efficacy of our product candidates have not been determined for the indications in
which we are developing them, and we cannot provide any assurance that their development will be successful. For
example, although rilonacept is FDA approved for the treatment of CAPS and DIRA, and we announced that our global,
pivotal Phase 3 clinical trial, RHAPSODY, with rilonacept in recurrent pericarditis met statistical significance on its
primary and all major secondary efficacy endpoints, and mavrilimumab has been studied in Phase 2 clinical trials for the
treatment of RA by MedImmune, and we announced that our global Phase 2 clinical trial for the treatment of GCA met
achieved statistical significance on both its primary and secondary efficacy endpoints, their safety and efficacy have not
been determined in the indications we are pursuing, and each may fail to receive regulatory approval for those
indications.
Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in
later-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that we
will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while
clinical trials were underway or safety or efficacy observations made in preclinical studies and clinical trials, including
AEs previously unreported in earlier studies and trials and favorable safety and efficacy observed in earlier studies and
trials not replicated in later studies or trials. Further, such setbacks may be caused by manufacturing or formulation
changes to product candidates or changes in manufacturers or manufacturing processes to produce products as compared
to the process or manufacturing methods used in prior preclinical studies and clinical trials. Moreover, preclinical and
clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product
candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or EMA
approval. Furthermore, the approval policies or regulations of the FDA or the applicable regulatory authorities outside of
the United States may significantly change in a manner rendering our clinical data insufficient for approval, which may
lead to the FDA or such other regulatory authorities delaying, limiting or denying approval of our product candidates.
Interim, preliminary, and “top-line” data from our clinical trials that we announce or publish from time to time may
change as more patient data become available following the interim data; preliminary data are subject to audit and
verification procedures, and deeper analysis of the data beyond the topline data may provide more color and context
to the data, all of which could result in material or other changes in the final data.
61
From time to time, we may disclose interim data from our preclinical studies and clinical trials, which are based
on an interim analysis of then-available data from ongoing studies or trials. Interim data from our preclinical studies and
clinical trials that we may complete are subject to the risk that one or more of the clinical observations may materially
change as patient enrollment continues and more patient data become available from the particular study or trial. As a
result, interim data should be viewed with caution until final data are available. Adverse differences between interim
data and final data could significantly harm the development of our product candidate and our business prospects with
respect thereto.
Further, from time to time we may announce or publish preliminary data from our pre-clinical studies or
clinical trials, which are based on a preliminary analysis of final data. Preliminary data from our preclinical studies and
clinical trials are subject to change following a more comprehensive review of the data from the particular preclinical
study or trial. We also make assumptions, estimations, calculations and conclusions as part of our preliminary analyses
of the data, and we may not have received, or had the opportunity to fully and carefully evaluate, all of the data. As a
result, preliminary data remain subject to audit and verification procedures that may result in the final data being
different from the preliminary data we previously announced or published.
From time to time, we may also announce or publish topline data from our preclinical studies and clinical trials,
which are a subset of the total data intended to provide the important results from the study or trial. As a result, deeper
analysis of the data beyond the topline data may provide more color and context to the results. Any adverse color and
context provided by the broader data to the topline data could significantly harm the development of our product
candidate and our business prospects with respect thereto.
Further, third parties, including regulatory agencies, may not accept or agree with our assumptions, estimates,
calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact
the value of the particular program, the approvability or commercialization of the particular product candidate and our
business prospects. In addition, the information we announce or publish regarding a particular preclinical study or
clinical trial may represent only a portion of extensive information generated from that study or trial, and our
shareholders or other third parties may not agree with what we determine is material, important or otherwise appropriate
information to include in our disclosure.
If the interim, preliminary, or topline data that we report differ materially from final results, or if third parties,
including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and
commercialize, our product candidates may be harmed, which could harm our business prospects, operating results or
financial condition. Further, announcement of preliminary, interim or top-line data by us or differences between that data
and the final data could result in volatility in the price of our Class A common shares.
Risks Related to Marketing Approval and Regulatory Matters
Regulatory approval processes are lengthy, time consuming and inherently unpredictable. If we are not able to
obtain, or if there are delays in obtaining, required regulatory approvals for our product candidates or we fail or
otherwise cease to advance their development, we will be delayed in commercializing or will not be able to
commercialize, our product candidates and our ability to generate revenue will be materially impaired.
Our product candidates and the activities associated with their development and commercialization, including
their trial design, testing, manufacture, safety, efficacy, record-keeping, labeling, storage, approval, advertising,
promotion, pricing, sale, distribution, import and export are subject to comprehensive regulation by the FDA and other
regulatory agencies in the United States and by comparable authorities in other countries. Before we can commercialize
any of our product candidates, we must obtain marketing approval. We have not received approval or clearance to
market any of our product candidates from regulatory authorities in any jurisdiction and it is possible that none of our
product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval
or clearance. We have limited experience in filing and supporting the applications necessary to gain regulatory approvals
and may need to rely on third-party CROs and regulatory consultants to assist us in this process. Securing regulatory
approval requires the submission of extensive preclinical and clinical data and supporting information to the various
regulatory authorities for each therapeutic indication to establish the product candidate’s safety and efficacy. Securing
62
regulatory approval also requires the submission of information about the biologic manufacturing process to, and
inspection of manufacturing facilities by, the relevant regulatory authorities. Our product candidates may not be
effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or
other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. The FDA
and other regulatory authorities have substantial discretion in the approval process, and determining when or whether
regulatory approval will be obtained for a product candidate. Even if we believe the data collected from clinical trials are
promising, such data may not be sufficient to support approval by the FDA or any other regulatory authority. In addition
to the United States, we may seek regulatory approval to commercialize our product candidates in other jurisdictions.
While the scope of regulatory approval is similar in many countries, to obtain separate regulatory approval in multiple
countries will require us to comply with numerous and varying regulatory requirements of each such country or
jurisdiction regarding safety and efficacy and governing, among other things, clinical trials and commercial sales,
pricing and distribution, and we cannot predict success in any such jurisdictions.
The process of obtaining regulatory approvals, both in the United States and in other countries, is time
consuming, expensive, may take many years, if approval is obtained at all, and can vary substantially based upon a
variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing
approval policies during the development period, changes in or the enactment of additional statutes or regulations, or
changes in regulatory review for each submitted BLA, or equivalent application types, may cause delays in the approval
or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the
approval process and may refuse to accept any application or may decide that our data are insufficient for approval and
require additional preclinical, clinical or other trials, including with respect to approval for the commercial marketing of
rilonacept in the United States for recurrent pericarditis.
The FDA accepted the sBLA for rilonacept in recurrent pericarditis with priority review and assigned a PDUFA
goal date of March 21, 2021. Upon approval from the FDA, if any, of the sBLA, we will assume the sales and
distribution of rilonacept for the approved indications in the United States. However, we must continue to coordinate
numerous activities with Regeneron in order for us to take over certain responsibilities and obligations with respect to
owning the BLA for CAPS and DIRA. The activities and obligations are complex and resource intensive, and we may
not have anticipated all such activities to be coordinated or responsibilities and obligations to be assumed. Further, if
Regeneron or we do not perform in accordance with our expectations, or we are not ready to assume the responsibilities
and obligations on a timely basis, or either we or Regeneron have critical or major observations during the FDA’s
potential inspection with respect to our and Regeneron’s ability to manufacture rilonacept to the requisite level of quality
standards and controls could delay FDA approval or our commercialization of rilonacept, and our ability to generate
revenue from rilonacept could be materially impaired. Approval by the FDA in the United States, if obtained, does not
ensure approval by regulatory authorities in other countries or jurisdictions. Our product candidates could be delayed in
receiving, or fail to receive, regulatory approval or we may fail or cease to advance their development for many reasons,
including the following:
•(cid:3)
the FDA or comparable regulatory authorities in other jurisdictions may disagree with the number, design
or implementation of our clinical trials to support further development or approval;
•(cid:3) we may be unable to demonstrate to the satisfaction of the FDA or comparable regulatory authorities in
other jurisdictions that a product candidate is safe and effective for its proposed indication;
•(cid:3)
the FDA or comparable regulatory authorities in other jurisdictions could require us to collect additional
data or conduct additional clinical trials; for example, based on FDA feedback, we anticipate that to help
inform the risk-benefit profile for the use of mavrilimumab in GCA, we will need to eventually
demonstrate the safety and effectiveness of mavrilimumab beyond 26 weeks, as well as evaluate its
pharmacokinetic profile and the effectiveness of mavrilimumab at different doses;
•(cid:3) we may be unable to demonstrate to the satisfaction of the FDA or comparable regulatory authorities in
other jurisdictions that we or our CMOs can manufacture clinical trial material that is deemed to be
comparable to the material used in previous clinical trials of our product candidates;
63
•(cid:3)
•(cid:3)
the results of clinical trials may produce negative, inconclusive or uncompetitive results, which may result
in us deciding, or regulators requiring us, to conduct additional clinical trials or to modify or cease
development programs for our product candidates;
the results of clinical trials may not meet the primary or secondary endpoints of the applicable study or the
level of statistical significance required by the FDA or comparable regulatory authorities in other
jurisdictions;
•(cid:3) we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety
risks;
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
the FDA or comparable regulatory authorities in other jurisdictions may disagree with our interpretation of
data from preclinical studies or clinical trials;
the FDA or comparable regulatory authorities in other jurisdictions may disagree that we have provided
sufficient safety data or adequately demonstrated clinical benefit in a patient population or subpopulation
studied in the clinical trial;
the data collected from clinical trials of our product candidates may not be sufficient to support the
submission of a BLA, sBLA or other submission or to obtain regulatory approval in the United States or
elsewhere;
the FDA or comparable regulatory authorities in other jurisdictions could require us to conduct additional
clinical trials to compare our product candidates to other therapies for the treatment of the same indication;
the number of patients required for clinical trials of our product candidates may be larger than we
anticipate, enrollment in these clinical trials may be slower than we anticipate, participants may drop out of
these clinical trials at a higher rate than we anticipate or we may fail to recruit suitable patients to
participate in a trial;
our third-party contractors may fail to comply with regulatory requirements or meet their contractual
obligations to us in a timely manner, or at all;
the FDA or comparable regulatory authorities in other jurisdictions may not believe that we have
sufficiently demonstrated our ability to manufacture the products to the requisite level of quality standards,
or they may fail to approve our manufacturing processes or facilities, or the manufacturing processes or
facilities of third-party manufacturers with which we contract for clinical and commercial supplies;
the FDA or comparable regulatory authorities in other jurisdictions may not believe that their on-site
inspections and data audits have sufficiently demonstrated the quality and integrity of the clinical trial
conduct and of data submitted to the FDA or comparable regulatory authorities in other jurisdictions in
support of our new product approvals and marketing applications;
the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our
product candidates may be insufficient or inadequate;
our product candidates may have undesirable side effects, toxicities or other unexpected characteristics,
causing us or our investigators, regulators or IRBs to reject, suspend or terminate the clinical trials; and
the approval policies or regulations of the FDA or comparable regulatory authorities in other jurisdictions
may significantly change in a manner rendering our clinical data, biologic manufacturing process and other
supporting information insufficient for approval.
64
In addition, even if we were to obtain approval for one or more of our product candidates, regulatory authorities
may approve any of our product candidates for fewer or more limited indications than we request. For example, in
connection with our vixarelimab program, regulatory authorities may recognize a narrower patient population as having
prurigo nodularis or define the disease differently than we do. Furthermore, regulatory authorities may not approve the
price we intend to charge, may grant approval contingent on the performance of costly post-marketing clinical trials,
may impose certain post-marketing requirements that impose limits on our marketing and distribution activities, or may
approve a product candidate with a label that does not include the labeling claims necessary or desirable for the
successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the
commercial prospects for our product candidates.
If we experience delays in obtaining approval or if we fail to obtain approval of or to advance our product
candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will
be materially impaired.
Our current product candidates and any of our future product candidates regulated as biologics in the United States
may face biosimilar competition sooner than anticipated.
In the United States, the Biologics Price Competition and Innovation Act of 2009, or BPCIA, created an
abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed
reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA
until four years following the date that the reference product was first approved under a BLA by the FDA. In addition,
the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the
reference product was first licensed. During this 12-year period of exclusivity, another company may still market a
competing version of the reference product for the same therapeutic indication if the FDA approves a full BLA for the
competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical
trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and
implemented by the FDA. As a result, its ultimate impact, implementation and meaning are subject to uncertainty. While
it is uncertain when processes intended to implement the BPCIA may be fully adopted by the FDA, any such processes
could have a material adverse effect on the future commercial prospects of our product candidates.
For example, although rilonacept was approved as a biological product under a BLA for the treatment of CAPS
in February 2008, and we believe it qualified for the 12-year period of exclusivity against any biosimilars, such 12-year
period of exclusivity has lapsed. The FDA accepted the sBLA for rilonacept in recurrent pericarditis with priority review
and assigned a PDUFA goal date of March 21, 2021. Upon approval from the FDA, if any, of the sBLA, we will assume
the sales and distribution of rilonacept for the approved indications in the United States. However, the 12-year
exclusivity period does not attach to the approval of an sBLA, potentially creating the opportunity for biosimilar
competition, subject to any orphan drug exclusivity under the U.S. Orphan Drug Act (see “Risks Related to Marketing
Approval and Regulatory Matters(cid:4416)We received orphan drug designation in the United States for rilonacept for the
treatment of pericarditis and for mavrilimumab for the treatment of GCA and may seek orphan drug designation for
some of our other product candidates in the United States, as well as for any of our product candidates in the EU, and we
may be unsuccessful, or may be unable to maintain the benefits associated with orphan drug designation, including the
potential for market exclusivity, for any product candidate for which we obtain orphan drug designation”). If we obtain
FDA approval for any of our other biological product candidates, we expect any such product candidates to qualify for
the 12-year period of exclusivity under the BPCIA. However, there is a risk that this exclusivity could be shortened due
to Congressional action or otherwise, or that the FDA will not consider any such approved product candidates, to be
reference products for competing products, potentially creating the opportunity for generic competition sooner than
anticipated.
Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the
subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for a reference
product in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will
depend on a number of marketplace and regulatory factors that are still developing.
65
Even if we obtain marketing authorization of our product candidates in a major pharmaceutical market such as the
United States or the EU, we may not seek or obtain approval or commercialize our product candidates in other
markets, which would limit our ability to realize their full market potential.
In order to market any products in a country or territory, we must establish and comply with numerous and
varying regulatory requirements of such country or territory regarding safety and efficacy. Regulatory requirements can
vary widely from country to country, and clinical trials conducted in one country may not be accepted by regulatory
authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be
obtained in any other country. Approval procedures vary among countries and can involve additional product testing and
validation, additional administrative review periods, and additional preclinical studies or clinical trials, which would be
costly and time consuming and could delay or prevent the introduction of our product candidates in those countries.
Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated
delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the
process for regulatory approval in other countries.
We may seek orphan drug designation for our other product candidates in the United States, as well as for any of our
product candidates in the EU, and we may be unsuccessful, or may be unable to maintain the benefits associated with
orphan drug designation, including the potential for market exclusivity, for any product candidate for which we
obtain orphan drug designation.
We received orphan drug designations in the United States for rilonacept for the treatment of pericarditis, which
includes recurrent pericarditis and for mavrilimumab for the treatment of GCA, and we may seek orphan drug
designation for certain of our other product candidates in the United States as well as for any of our product candidates
in the EU. We may be unsuccessful in obtaining such designation for any of our other product candidates or unable to
maintain the associated benefits for rilonacept or mavrilimumab or any of our other product candidates that are granted
orphan drug designation, if any. Regulatory authorities in some jurisdictions, including the United States and Europe,
may designate drugs or biologics intended to treat relatively small patient populations as orphan drug products. Under
the U.S. Orphan Drug Act, the FDA may designate a drug or biologic as an orphan drug if it is intended to treat a rare
disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United
States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the
cost of developing the drug will be recovered from sales in the United States.
In the EU, the European Commission grants orphan drug designation after receiving the opinion of the EMA’s
Committee for Orphan Medicinal Products on an Orphan Drug Designation application. In the EU, orphan drug
designation is intended to promote the development of drugs that are intended for the diagnosis, prevention or treatment
of life-threatening or chronically debilitating conditions affecting not more than five in 10,000 persons in the EU and for
which no satisfactory method of diagnosis, prevention, or treatment has been authorized (or the product would be a
significant benefit to those affected). Additionally, orphan drug designation is granted for drugs intended for the
diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition when,
without incentives, it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment
in developing the drug. In the EU, orphan drug designation entitles a party to financial incentives such as reduction of
fees or fee waivers, as well as potential marketing exclusivity.
In addition, if a drug or biologic with an orphan drug designation subsequently receives the first marketing
approval for the indication for which it has such designation, the drug or biologic is entitled to a period of marketing
exclusivity, which precludes the FDA from approving another marketing application for the same drug and indication for
that time period, except in limited circumstances. If our competitors are able to obtain orphan drug exclusivity prior to
us, for products that constitute the “same drug” and treat the same indications as our product candidates, we may not be
able to have competing products approved by the applicable regulatory authority for a significant period of time. The
applicable period is seven years in the United States and ten years in the EU. The EU exclusivity period can be reduced
to six years if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so
that market exclusivity is no longer justified.
66
Even if we obtain orphan drug exclusivity for any of our product candidates, that exclusivity may not
effectively protect those product candidates from competition because different drugs can be approved for the same
condition, and orphan drug exclusivity does not prevent the FDA from approving the same or a different drug in another
indication. Even after an orphan drug is approved, the FDA can subsequently approve a later application for the same
drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer in
a substantial portion of the target populations, more effective or makes a major contribution to patient care. In addition, a
designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the
indication for which it received orphan designation. Moreover, orphan-drug-exclusive marketing rights in the United
States may be lost if the FDA later determines that the request for designation was materially defective or if we are
unable to manufacture sufficient quantities of the product to meet the needs of patients with the rare disease or condition.
Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug
any advantage in the regulatory review or approval process. While we received orphan drug designations in the United
States for rilonacept for the treatment of pericarditis and for mavrilimumab for the treatment of GCA, and we may seek
orphan drug designation for certain of our product candidates, we may never receive such designation for such other
product candidates. Even though we received such designation for rilonacept and mavrilimumab and may receive such
designation for any of our other product candidates, there is no guarantee that we will enjoy the benefits of such
designations.
We may seek Breakthrough Therapy designation or Fast Track designation by the FDA for one or more of our
product candidates, which we may not receive. Such designation may not lead to a faster development or regulatory
review or approval process and does not increase the likelihood that our product candidates will receive marketing
approval.
We received Breakthrough Therapy designation for rilonacept for the treatment of recurrent pericarditis, and we
may seek Breakthrough Therapy or Fast Track designation for some of our other product candidates. A Breakthrough
Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs or biologics, to treat
a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as
substantial treatment effects observed early in clinical development. In addition, if a product candidate is intended for the
treatment of a serious or life-threatening condition and clinical or preclinical data demonstrate the potential to address
unmet medical needs for this condition, the sponsor may apply for Fast Track designation.
The FDA has broad discretion whether or not to grant Fast Track and Breakthrough Therapy designations, and
even if we believe a particular product candidate is eligible for this designation, we cannot be certain that the FDA
would decide to grant it. Even if we obtain such designations for one or more of our product candidates, we may not
experience a faster development process, review or approval compared to non-expedited FDA review procedures. In
addition, the FDA may withdraw Fast Track or Breakthrough Therapy designations if it believes that such designations
are no longer supported. Although products receiving Fast Track and Breakthrough Therapy designation are generally
eligible for the FDA’s priority review procedures, receiving such designations does not guarantee that the BLA for such
products will receive priority review.
Whether to grant Breakthrough Therapy or Fast Track designation is within the discretion of the FDA.
Accordingly, even if we believe one of our product candidates meets the criteria for these designations, the FDA may
disagree and instead determine not to make such designation. In any event, the receipt of either of these designations for
a product candidate may not result in a faster development process, review or approval compared to product candidates
considered for approval under non-expedited FDA review procedures and does not assure ultimate approval by the FDA.
In addition, even if one or more of our product candidates qualify for either of these designations, the FDA may later
decide that the product candidate no longer meets the conditions for qualification.
67
We have never obtained marketing approval for any product candidate, and we may be unable to successfully do so
for any of our product candidates. Failure to successfully complete a pivotal clinical trial or obtain marketing
approval in a timely manner for any of our product candidates could have a material adverse impact on our business
and financial performance.
Conducting pivotal clinical trials and preparing, and obtaining marketing approval for, a product candidate is a
complicated process. Although members of our management team have participated in our global, pivotal Phase 3
clinical trial, RHAPSODY, for rilonacept in recurrent pericarditis and members of our management team have obtained
marketing approvals for product candidates in the past while employed at other companies, we as a company have not
obtained marketing approvals for any of our product candidates. As a result, such activities may require more time than
we anticipate. Failure to successfully complete, or delays in, any of our eventual other pivotal trials or related regulatory
submissions would prevent us from, or delay us in, obtaining regulatory approval for, or clearance of, our product
candidates. It is possible that the FDA or other government agencies may refuse to accept for substantive review any
regulatory submissions that we submit for our product candidates or may conclude after review of our applications for
rilonacept or any of our other product candidates that the submissions are insufficient to obtain marketing approval or
clearance of rilonacept or any of our other product candidates. While the FDA accepted the sBLA for rilonacept in
recurrent pericarditis with priority review and assigned a PDUFA goal date of March 21, 2021, if the FDA or other
government agencies do not accept our applications for our other product candidates, if any, or the FDA delays or does
not issue marketing authorizations for rilonacept or any of our other our product candidates, the FDA or other regulatory
authorities may require that we conduct additional clinical, preclinical or manufacturing validation trials and submit that
data before they will reconsider our applications. Depending on the extent of these or any other required trials, approval
or receipt of any marketing authorization may be delayed by several years or may require us to expend more resources
than we have available. It is also possible that additional trials, if performed and completed, may not be considered
sufficient by the FDA or other government agencies to approve or grant marketing authorizations. Any delay in
obtaining, or an inability to obtain, marketing approvals would delay or prevent us from commercializing rilonacept or
any of our other product candidates, generating revenues and achieving and sustaining profitability. If any of these
outcomes occur, we may be forced to modify or cease our development efforts for one or more of our product
candidates, which could significantly harm our business.
Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could
hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified
products from being developed, approved or commercialized in a timely manner or at all, which could negatively
impact our business.
The ability of the FDA to review and approve new products can be affected by a variety of factors, including
government budget and funding levels, statutory, regulatory, and policy changes, the FDA’s ability to hire and retain key
personnel and accept the payment of user fees, and other events that may otherwise affect the FDA’s ability to perform
routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government
funding of other government agencies that fund research and development activities is subject to the political process,
which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary
for new drugs and biologics or modifications to approved drugs or biologics to be reviewed and/or approved by
necessary government agencies, which would adversely affect our business. For example, over the last several years,
including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain
regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.
Separately, in response to the COVID-19 pandemic, on March 10, 2020 the FDA announced its intention to
postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed
routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020 the FDA
announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based
prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory
activity that can occur within a given geographic area, ranging from mission-critical inspections to resumption of all
regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy
measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health
concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews,
68
or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely
review and process our regulatory submissions, which could have a material adverse effect on our business.
Risks Related to Manufacturing and Our Reliance on Third Parties
We contract with third parties for manufacturing our product candidates and for certain research and other
preclinical and clinical development and expect to continue to do so for our commercial supply. This reliance on third
parties increases the risk that we may not have sufficient quantities of our product candidates or such quantities at an
acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
We do not currently own or operate any late-stage manufacturing facilities. Although we have built a
development and manufacturing facility to produce drug substance to support certain research, preclinical and other
clinical development for our product candidates, we rely, and expect to continue to rely, on third parties for the
manufacture of our late-stage product candidates and certain of our early-stage product candidates for the majority of our
clinical development efforts, as well as for the potential commercial manufacture of our product candidates, if approved,
as well as label and packaging activities. We rely on these third parties to produce our product candidates at sufficient
quality and quantity to support our development and commercialization efforts. Our reliance increases the risk that we
will have insufficient quantities of our product candidates or that our product candidates are not produced at an
acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.
For example, Regeneron is the sole manufacturer of rilonacept and we have a contract with Regeneron to
produce rilonacept on an exclusive basis for a period of time. Regeneron, in turn, relies upon a third-party CMO to
conduct fill/finish operations for rilonacept. Under certain circumstances, we or Regeneron could initiate a technology
transfer to either us or another CMO to manufacture rilonacept. Finding new CMOs or third-party suppliers to produce
rilonacept would add additional cost and require significant time and focus of our management team. The CMO would
need to produce rilonacept at a different manufacturing site and potentially using a different process or at a different
scale. We cannot provide any assurance that the technology transfer from Regeneron to us or another CMO will be
successful in producing rilonacept in sufficient quantities or of acceptable quality, if at all, or that we or another CMO
will produce a comparable product to the satisfaction of the FDA or other comparable regulatory authorities, which
could delay, prevent or impair the development or commercialization of rilonacept. In addition, there is typically a
transition period when a new CMO commences work. Any significant delay or interruption in the supply of rilonacept
by Regeneron or otherwise could considerably impact our ability to meet commercial or clinical demand for the product
and our ability to generate revenue from rilonacept could be materially impaired.
We also have CMOs manufacture vixarelimab drug substance and drug product and entered into an agreement
with a CMO to produce mavrilimumab beyond our current inventory. While we have built a manufacturing facility to
support early development for our product candidates, we and our CMOs may not be able to produce sufficient
quantities of our product candidates or produce them at an acceptable quality, including as a result of the COVID-19
pandemic, which could delay, prevent or impair our development or commercialization efforts and increase costs.
As a result of the COVID-19 pandemic, existing and any new third-party CMOs or suppliers may be unable to
produce or supply our product candidates or the raw materials needed to produce or supply our product candidates or
may experience delays, restrictions or limitations in the production, delivery or release of the supply of our product
candidates or the raw materials needed to produce our product candidates, including due to disruptions at the respective
facilities that produce our product candidates or the raw materials needed to produce our product candidates, staffing
shortages or reprioritizations, production slowdowns, stoppages or reprioritizations, including as a result of
reprioritization by third parties or the U.S. government for any products or potential products related to the treatment or
prevention of COVID-19, or interruptions in global shipping. In addition, there is typically a transition period when a
new CMO commences work. Finding new CMOs or third-party suppliers involves additional cost and requires our
management’s time and focus. Any significant delay in the supply of our product candidates or the raw materials needed
to produce our product candidates, could considerably delay conducting our clinical trials and potential regulatory
approval of our product candidates. Our current and anticipated future dependence upon others for the manufacture of
our product candidates may adversely affect our future profit margins and our ability to commercialize any products that
receive marketing approval on a timely and competitive basis.
69
If we make manufacturing or formulation changes to our product candidates or change manufacturers or
manufacturing processes, we may be unsuccessful in producing products comparable to those used in prior clinical trials.
Therefore, we may need to conduct additional process development or additional clinical trials to bridge our prior
clinical results to those resulting from the new manufacturing process, which could impact the timing and subsequent
success of our planned clinical trials. In addition, as we plan to produce clinical trial and potential commercial material
at a CMO, the CMO may be required to adopt different manufacturing protocols or processes. For example, although
Regeneron has produced rilonacept for commercial use for over ten years, the FDA or other applicable regulatory
authorities in other jurisdictions may reevaluate rilonacept’s current manufacturing processes or route of administration
in connection with evaluating whether to approve rilonacept for a new indication, such as recurrent pericarditis.
The facilities used by our CMOs to manufacture our product candidates may be inspected by the FDA and other
comparable regulatory authorities in connection with the submission of our marketing applications to, and review by, the
FDA or other comparable regulatory authorities or based on their work for other clinical trial sponsors. While we
provide oversight of manufacturing activities, we do not and will not control the manufacturing process of, and will be
completely dependent on, our CMOs for compliance with cGMPs and other regulatory requirements in connection with
the manufacture of our product candidates. If our CMOs cannot successfully manufacture material that conforms to our
specifications and the strict regulatory requirements of the FDA or other applicable regulatory authorities in other
jurisdictions, they will not be able to secure or maintain regulatory approval for their manufacturing facilities. While we
may review the compliance history and performance of our CMOs, we have no control over the ability of our CMOs to
maintain adequate quality control, quality assurance and qualified personnel. If the FDA or comparable regulatory
authorities in other jurisdictions does not approve these facilities for the manufacture of our product candidates or if it
withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would
significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.
Further, our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in
sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or
withdrawal of approvals, license revocation, seizures or recalls of product candidates, if approved, operating restrictions
and criminal prosecutions, any of which could significantly and adversely affect our business and supplies of our product
candidates.
Although we have entered into certain agreements for the manufacture of clinical material for our product
candidates, we may be unable to establish new agreements on acceptable terms, if at all, with third-party manufacturers
for those product candidates. Even if we are able to establish agreements with third-party manufacturers, reliance on
third-party manufacturers entails additional risks, including:
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
reliance on the third party for regulatory compliance and quality assurance;
the possible breach of the manufacturing agreement by the third party;
the possible misappropriation of our proprietary information, including our trade secrets and know-how;
and
the possible termination or nonrenewal of the agreement by the third party at a time that is costly or
inconvenient for us.
Our product candidates may compete with other product candidates and approved products for access to
manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that
might be capable of manufacturing for us. Furthermore, given the limited number of available manufacturing slots and
the long lead times needed to reserve them, manufacturers require monetary commitments in connection with such
reservations as well as fees for changes or cancellations in the reserved manufacturing slots. As a result, we may wait to
reserve manufacturing slots until we can be informed by data from the clinical trials of our product candidates, which
may be several months from the time we request manufacturing slots. Any significant delay in the supply of clinical
materials for our product candidates could considerably delay conducting our clinical trials and potential regulatory
approval of our product candidates. Alternatively, we may project when we may need additional clinical material for our
product candidates and reserve manufacturing time-slots “at-risk” prior to our product candidates having generated data
70
from their then current clinical trials. Such projections involve risks and uncertainties and may result in additional costs
or delays in manufacturing clinical materials for our product candidates when and if we actually need them.
Any performance failure on the part of our existing or future manufacturers could delay clinical development or
marketing approval. If our current CMOs cannot perform as agreed, we may be required to replace such manufacturers.
Although we believe that there are several potential alternative manufacturers who could manufacture our product
candidates, we may incur added costs and delays in identifying and qualifying any such replacement. Further, Regeneron
has an exclusive right to produce rilonacept for a period of time, which could impact our ability to find a replacement
manufacturer for rilonacept in a short-period of time if needed.
Our business involves the use of hazardous materials, and we and our third-party manufacturers and suppliers must
comply with environmental laws and regulations, which can be expensive and restrict how we do business.
Our research and development activities and our third-party manufacturers’ and suppliers’ activities involve the
controlled storage, use and disposal of hazardous materials owned by us, including the components of our product
candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations
governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these
hazardous materials and various wastes resulting from their use are stored at our and our manufacturers’ and suppliers’
facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an
interruption of our commercialization efforts, research and development efforts and business operations, environmental
damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage,
handling and disposal of these materials and specified waste products. Although we believe that the safety procedures
utilized by our third-party manufacturers and suppliers for handling and disposing of these materials generally comply
with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk
of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting
damages and such liability could exceed our resources, and state or federal or other applicable authorities may curtail our
use of certain materials or interrupt our business operations. Furthermore, environmental laws and regulations are
complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes
and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance
coverage.
Manufacturing issues at our facility and the facilities of our third-party service providers, including as a result of the
COVID-19 pandemic, could cause product shortages, disrupt or delay our clinical trials or regulatory approvals,
delay or stop commercialization of our product candidates, and adversely affect our business.
The manufacture of our product candidates is highly regulated, complex and difficult, requiring a multi-step and
controlled process, and even minor problems or deviations could result in the product candidates being out-of-spec,
failed batches or other failures, such as defective products or manufacturing failures. We have limited experience
overseeing the manufacturing processes of mavrilimumab, vixarelimab, and KPL-404 and no experience overseeing the
manufacturing process of rilonacept. Due to the highly technical requirements of manufacturing our product candidates
and the strict quality and control specifications, we and our third-party providers may be unable to manufacture or
supply our product candidates despite our and their efforts. Failure to produce sufficient quantities of our product
candidates could delay their development, result in supply shortages for our patients, result in lost revenue, if any, and
diminish our potential profitability, which may lead to lawsuits or could delay the introduction of our product candidates
to the market.
The manufacture of our product candidates is at high risk of product loss due to contamination, equipment
malfunctions, human error or raw material shortages. Deviations from established manufacturing processes could result
in reduced production yields, failed batches and other supply disruptions. If microbial, viral or other contaminations are
discovered in our product candidates or manufacturing facilities, any related production lot could be lost and the relevant
manufacturing facilities may need to close for an extended period of time to investigate and remediate the contaminant.
Many additional factors could cause production interruptions at our facilities or at the facilities of our
third-party providers, as well as disruptions in travel, shipping or delivery capabilities into and within the countries in
71
which we or our manufacturers produce our product candidates or disruptions to production capabilities, including due to
the impact of natural disasters, accidents, boycotts, labor disputes, political and economic instability, including acts of
terrorism or war, and an epidemic or pandemic or other outbreak of disease, including the COVID-19 pandemic. The
occurrence of any such event could adversely affect our ability to satisfy the required supply for any of our product
candidates or successfully complete preclinical and clinical development, which would result in additional costs to us or
impair our ability to generate revenue and would harm our business, financial condition and prospects significantly.
We and our third-party providers are required to maintain compliance with cGMP and other stringent
requirements and are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm such
compliance. If we or any of our third-party providers are not able to establish and maintain procedures and processes
sufficient to satisfy cGMP standards, we could experience a delay, interruption or other issues in our manufacture,
fill-finish, packaging, storage or delivery of our product candidates, and any related failure of the facilities or operations
of third parties to pass any regulatory agency inspection could significantly impair our ability to supply our products and
product candidates. Significant noncompliance could also result in the imposition of monetary penalties or other civil or
criminal sanctions and damage our reputation.
Any adverse developments affecting the operations of our third-party providers, such as any impact due to the
COVID-19 pandemic including shortages or reprioritizations of raw materials, including reprioritization by third parties
or the U.S. government for any products or potential products related to the treatment or prevention of COVID-19, could
result in a shortage of clinical products or impose commercial product requirements, cause withdrawal of our product
candidates or any approved products, shipment delays, lot failures or recalls. We may also have to write off inventory
and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or
seek more costly manufacturing alternatives. Such manufacturing issues could increase our cost of goods, cause us to
lose potential revenue, reduce our potential profitability or damage our reputation.
The third parties upon whom we rely for the supply of the drug substance and drug product used in our product
candidates are our sole source of supply, and the loss of any of these suppliers could significantly harm our business.
The drug substance and drug product used in rilonacept, mavrilimumab and vixarelimab are supplied to us from
single-source suppliers. Regeneron has a contractual right to be our sole source manufacturer of rilonacept unless they
have a persistent failure to satisfy our supply needs. Our ability to successfully develop our product candidates, and to
ultimately supply our commercial products in quantities sufficient to meet the market demand, depends in part on our
ability to obtain the drug substance and drug product for these product candidates in accordance with regulatory
requirements and in sufficient quantities for commercialization and clinical testing. We do not currently have
arrangements in place for a redundant or second-source supply of any such drug substance and drug product in the event
any of our current suppliers of such drug substance and drug product cease their operations or stop offering us sufficient
quantities of these materials for any reason.
We are not certain that our single-source suppliers will be able to meet our demand for their products, either
because of the nature of our agreements with those suppliers, our limited experience with those suppliers or our relative
importance as a customer to those suppliers. It may be difficult for us to assess their ability to timely meet our demand in
the future based on past performance. While our suppliers have generally met our demand on a timely basis in the past,
they may subordinate our needs in the future to their other customers.
In addition, to manufacturing rilonacept, mavrilimumab and vixarelimab in the quantities that we believe would
be required to meet anticipated market demand, our third-party manufacturers may need to increase manufacturing
capacity and, in some cases, alternative sources of commercial supply may need to be secured, which could involve
significant challenges and may require additional regulatory approvals. In addition, the development of
commercial-scale manufacturing capabilities may require us and our third-party manufacturers to invest substantial
additional funds and hire and retain the technical personnel who have the necessary manufacturing experience. Neither
we nor our third-party manufacturers may successfully complete any required increase to existing manufacturing
capacity in a timely manner, or at all.
72
Moreover, if there is a disruption to our manufacturing operations or one or more of our third-party
manufacturers’ or suppliers’ relevant operations, such as due to the impact of the COVID-19 pandemic, including due to
staffing shortages or reprioritizations, production slowdowns or stoppages or interruptions in global shipping, the supply
of the related product candidate will be delayed until we or such manufacturer or supplier restores the affected facilities
or we or they procure alternative manufacturing facilities or sources of supply. Our ability to progress our preclinical and
clinical programs could be materially and adversely impacted if any of the third-party suppliers upon which we rely for
preclinical and clinical stage product candidate supply were to experience a significant business challenge, disruption or
failure due to issues such as financial difficulties or bankruptcy, issues relating to other customers such as regulatory or
quality compliance issues, or other financial, legal, regulatory or reputational issues. Additionally, any damage to or
destruction of our third-party manufacturers’ or suppliers’ facilities or equipment may significantly impair our ability to
manufacture our product candidates on a timely basis.
Establishing additional or replacement suppliers for the drug substance and drug product used in our product
candidates, if required, is unlikely to be accomplished quickly and can take several years, if at all. Furthermore, despite
our efforts, we may be unable to procure a replacement supplier or do so on commercially reasonable terms, which could
have a material adverse impact upon our business. If we are able to find a replacement supplier, such replacement
supplier would need to be qualified and may require additional regulatory approval, which could result in further delay.
While we seek to maintain adequate inventory of the drug substance and drug product used in our product candidates,
any interruption or delay in the supply of components or materials, or our inability to obtain such drug substance and
drug product from alternate sources of comparable quality at acceptable prices in a timely manner could impede, delay,
limit or prevent our development efforts, which could harm our business, results of operations, financial condition and
prospects.
Certain of the materials required in the manufacture and the formulation of our product candidates are derived
from biological sources. Such materials are difficult to procure and may be subject to contamination or recall. Access to
and supply of sufficient quantities of raw materials which meet the technical specifications for the production process is
challenging, and often limited to single-source suppliers. Finding an alternative supplier could take a significant amount
of time and involve significant expense due to the nature of the products and the need to obtain regulatory approvals. If
we or our manufacturers are unable to purchase the materials necessary for the manufacture of our product candidates on
acceptable terms, in a timely manner, at sufficient quality levels, or in adequate quantities, if at all, our ability to produce
sufficient quantities of our products for clinical or commercial requirements would be negatively impacted. A material
shortage, contamination, recall or restriction on the use of certain biologically derived substances or any other material
used in the manufacture of our product candidates could adversely impact or disrupt manufacturing, which would impair
our ability to generate revenues from the sale of such product candidates, if approved.
We rely, and expect to continue to rely, on third parties, including independent investigators and CROs, to activate
sites, conduct and otherwise support our research activities, preclinical studies, clinical trials and other trials for our
product candidates. If these third parties do not successfully carry out their contractual duties, comply with
regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or
commercialize our product candidates, and our business could be substantially harmed.
We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as
CROs, to activate sites, conduct or otherwise support our GLP-compliant preclinical studies and GCP-compliant clinical
trials for our product candidates properly and on time. We also rely on third parties to conduct other research related to
our product candidates. We expect to rely heavily on these parties for such site activation, execution of and otherwise
supporting clinical trials for our product candidates. While we have agreements governing their activities, we control
only certain aspects of these parties’ activities and have limited influence over their actual performance. The third parties
with whom we contract for execution of our GLP-compliant preclinical studies and our GCP-compliant clinical trials
play a significant role in the conduct of these trials and the subsequent collection and analysis of data. These third parties
are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited
ability to control the amount or timing of resources that they devote to our programs. Although we rely on these third
parties to conduct our GLP-compliant preclinical studies and GCP-compliant clinical trials, we remain responsible for
ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal and regulatory
requirements and scientific standards, and our reliance on these third parties does not and will not relieve us of our
73
regulatory responsibilities. For any violations of laws and regulations during the conduct of our preclinical studies or
clinical trials, we could be subject to warning letters or enforcement actions that may include civil penalties and criminal
prosecution.
We and our CROs are required to comply with regulations, including GCPs, for conducting, monitoring,
recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and
accurate, and that the trial patients are adequately informed of the potential risks of participating in clinical trials and
their rights are protected. These regulations are enforced by the FDA, the Competent Authorities of the Member States
of the European Economic Area, or EEA, and comparable regulatory authorities in other jurisdictions for any products in
clinical development. The FDA enforces GCP regulations through periodic inspections of clinical trial sponsors,
principal investigators and trial sites. If we or our CROs fail to comply with applicable GCPs, the clinical data generated
in our clinical trials may be deemed unreliable, and the FDA or comparable regulatory authorities in other jurisdictions
may require us to perform additional clinical trials before approving our marketing applications. We cannot ensure that,
upon inspection, the FDA or comparable regulatory authorities in other jurisdictions will determine that any of our future
clinical trials will comply with GCPs. In addition, our clinical trials must be conducted with product candidates produced
under cGMPs regulations. Our failure or the failure of our CROs to comply with these regulations may require us to
repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action.
We also are required to register certain clinical trials and post the results of completed clinical trials on a
government-sponsored database within certain timeframes. Failure to do so when required can result in fines, adverse
publicity and civil and criminal sanctions.
Although we have and intend to continue to design the clinical trials for our product candidates, CROs will
activate sites and conduct and oversee all of the clinical trials together with the various clinical trial sites that we engage
to conduct the studies. As a result, many important aspects of our development programs for our product candidates,
including their conduct and timing, will be outside of our direct control. Our reliance on third parties to activate sites and
conduct future clinical trials will also result in less direct control over the management of data developed through
clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties
can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties
may:
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
have staffing difficulties;
have disruptions to their business and operations, including as a result of the impact from an epidemic or
pandemic disease outbreak, including COVID-19 (see “Risk Factors — Risks related to product
development — The COVID-19 pandemic, and measures taken in response to the pandemic, could have an
adverse impact on our current or planned preclinical studies and clinical trials, which could be
significant.”);
fail to comply with contractual obligations;
have difficulty with or controlling the performance of their subcontractors;
experience regulatory compliance issues;
undergo changes in priorities or become financially distressed; or
form relationships with other entities, some of which may be our competitors.
These factors may materially adversely affect the willingness or ability of third parties to activate sites and
conduct and oversee our clinical trials and may subject us to unexpected cost increases that are beyond our control. If the
CROs, their subcontractors or the clinical trial sites do not perform clinical trials in a satisfactory manner, breach their
obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and
commercialization of our product candidates may be delayed, we may not be able to obtain regulatory approval and
74
commercialize our product candidates, or our development program may be materially and irreversibly harmed. If we
are unable to rely on clinical data collected by our CROs, their subcontractors or the clinical trial sites, we could be
required to repeat, extend the duration of or increase the size of any clinical trials we conduct and this could significantly
delay commercialization and require significantly greater expenditures.
These third parties are not our employees, and we are not able to control, other than by contract, the amount of
resources, including time, which they devote to our clinical trials. If our CROs, their subcontractors or the clinical trial
sites fail to devote sufficient resources to the development of our product candidates, or if their performance is
substandard, it may delay or compromise the prospects for approval and commercialization of our product candidates. In
addition, the use of third-party service providers requires us to disclose our proprietary information to these parties,
which could increase the risk that this information is misappropriated.
If the third parties conducting our preclinical studies or our clinical trials do not perform their contractual duties
or obligations, experience significant business challenges, disruptions or failures, such as due to the impact of the
COVID-19 pandemic, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if
the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GCPs,
or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be
difficult, costly or impossible, and our preclinical studies or clinical trials may need to be extended, delayed, terminated
or repeated. As a result, we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable
product candidate, our financial results and the commercial prospects for our product candidates would be harmed, our
costs could increase, and our ability to generate revenues could be delayed.
If any of our relationships with these third-party CROs are suspended or terminate, we may not be able to enter
into arrangements with alternative third-party service providers at all or on commercially reasonable terms. If CROs,
their subcontractors or the clinical trial sites do not successfully carry out their contractual duties or obligations or meet
expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is
compromised due to their failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any
clinical trials such CROs, subcontractors or clinical trial sites are associated with may be extended, delayed or
terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product
candidates. As a result, our financial results and the commercial prospects for our product candidates in the subject
indication would be harmed, our costs could increase and our ability to generate revenue could be delayed.
Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor
will discover them or that our trade secrets will be misappropriated or disclosed.
Because we rely on third parties to develop and manufacture our product candidates, we must, at times, share
trade secrets with them. We seek to protect our proprietary technology in part by entering into confidentiality agreements
and, if applicable, invention assignment agreements, material transfer agreements, collaborative research agreements,
consulting agreements or other similar agreements with our collaborators, advisors, employees, independent contractors
and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the
rights of the third parties to use or disclose our confidential information, such as trade secrets. Despite the contractual
provisions employed when working with third parties, the need to share trade secrets and other confidential information
increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the
technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is
based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade secrets or other unauthorized
use or disclosure would impair our competitive position and may harm our business. To the extent that we share trade
secrets of third parties that are licensed to us, unauthorized use or disclosure could expose us to liability.
Risks Related to Commercialization
We have no experience as a company commercializing a therapeutic and limited experience establishing sales,
marketing, distribution and general infrastructure either directly and/or through agreements with third parties. As a
company we have not obtained marketing approvals for any of our product candidates and have never sold, marketed
or distributed any therapeutic products. As a result we may not be successful in commercializing rilonacept in
75
recurrent pericarditis, if approved, or any future approved product candidates, thus potentially impairing commercial
potential for rilonacept and our other product candidates to generate any revenue.
The FDA accepted the sBLA for rilonacept in recurrent pericarditis with priority review and assigned a PDUFA
goal date of March 21, 2021. If approved by the FDA, we will assume the sales and distribution of rilonacept for the
approved indications in the United States. While members of our management team have obtained marketing approvals
for product candidates in the past while employed at other companies, we as a company have not obtained marketing
approvals for any of our product candidates and have never sold, marketed or distributed any therapeutic products. To
achieve commercial success for rilonacept, if approved, or any future approved product candidate, we have been
establishing and expanding our internal capabilities, including but not limited to, sales, marketing, distribution, access
and patient support services as well as making arrangements with third parties to perform certain services. We are
recruiting and training a specialty cardiology sales force of approximately 30 representatives who will call on high-
volume accounts and specialists. We have hired other customer facing teams, including for our medical affairs, payor
and patient support services teams to complement the efforts of the sales force, as well as the development of an efficient
digital marketing campaign. Our internal capabilities are augmented through contracts with third parties for distribution
services, price reporting and aspects of our patient services programs. We are currently undertaking these efforts in order
to commercialize rilonacept in the United States in anticipation of a potential approval. Each aspect of
commercialization on its own can be complex, expensive and time consuming, and collectively the required effort for
coordination is intensive. For example, recruiting and training a sales force and establishing marketing, payor and patient
support service capabilities is expensive and time consuming and if not completed as planned could delay or reduce the
effectiveness of the launch of our product candidates.
Factors that may inhibit our efforts to timely and successfully commercialize rilonacept, if approved, or any of
our other future product candidates, include:
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
our inability to recruit, train and retain adequate numbers of effective sales, marketing, access, and payor
and patient support personnel;
the inability of sales personnel to obtain access, especially within the restrictions of the ongoing COVID-19
pandemic, to physicians and accounts as well as for an adequate number of physicians or accounts to
prescribe rilonacept or any of our future products, including rilonacept, if approved;
the lack of complementary products to be supported by sales personnel, which may put us at a competitive
disadvantage relative to companies with more extensive product lines;
our inability to develop strong scientific-based relationships to drive disease awareness and education;
our inability to establish the unmet medical need for the disease, and, with respect to rilonacept, our
inability to enable it to be viewed as the product of choice within the indication in which it is approved, if
any;
our inability or delay in gaining reimbursement and broad patient access at a price that reflects the value of
rilonacept or any of our other future products;
our inability to equip customer-facing personnel with effective materials, including medical and sales
literature to help them educate physicians and other healthcare providers regarding applicable diseases
relevant to our future products;
our inability to effectively distribute products in a timely manner;
our inability to provide physicians and patients adequate support and training to build comfort around
reconstitution and self-administration process to initiate and continue to use our products;
76
•(cid:3)
•(cid:3)
•(cid:3)
our inability to develop robust patient support programs to optimize the patient and customer experience
with rilonacept or any of our other future products as well as with the Company;
our inability to develop or obtain sufficient operational functions and infrastructure to support our
commercial activities; and
unforeseen costs and expenses associated with creating a sales, marketing, and access organization.
In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such
difficulties, delays or unforeseen costs. If we have not established effective commercialization infrastructure and
capabilities as planned in advance of our anticipated commercial launch of rilonacept in recurrent pericarditis, if
approved, either on our own or through arrangements with third parties, or if we experience any of the factors that may
inhibit our efforts to commercialize rilonacept or any of our other product candidates, if approved, we will not be
successful in commercializing rilonacept or any such future product candidates. Further, our business, results of
operations, financial condition and prospects will be materially adversely affected.
The impact of the COVID-19 pandemic and measures taken in response to the COVID-19 pandemic has resulted in
limitations on certain commercial activities, which, if prolonged, may impede the effective commercialization of our
product candidates and result in lower than anticipated future revenue.
As part of our commercial strategy for rilonacept, if approved for the treatment of recurrent pericarditis, we
expect to have a focused and targeted launch effort, with a specialty cardiology salesforce of approximately 30
representatives calling on high-volume accounts and high-volume specialists to help ensure that decision-makers view
recurrent pericarditis as a serious, debilitating disease with a significant unmet need and view rilonacept as the product
of choice for the treatment and prevention of recurrent pericarditis.
The COVID-19 pandemic and measures taken in response to the COVID-19 pandemic, including business and
travel restrictions and social-distancing to halt the spread of the pandemic, has had an impact on businesses, healthcare
systems, regulatory authorities and other organizations and conferences. These measures may result in limitations on
certain aspects of our commercialization strategy, including our specialty cardiology salesforce not being able, or having
limited access, to physician offices and other high-volume accounts in person, which if prolonged, may impede the
effective commercialization of rilonacept and result in lower than anticipated future revenue.
Our current or future product candidates may not gain market acceptance by physicians, patients, or third-party
payors (e.g., governments and private health insurers), in which case our ability to generate product revenues will be
impaired.
Even if the FDA or any other regulatory authority approves the marketing of rilonacept or any of our other
product candidates (whether developed on our own or with a collaborator), physicians, healthcare providers, patients, the
medical community or third-party payors may not accept or use rilonacept or any of our other product candidates, or
may effectively block or limit their use in the case of third-party payors. For example, the FDA accepted the sBLA for
rilonacept in recurrent pericarditis with priority review and assigned a PDUFA goal date of March 21, 2021. Upon
approval from the FDA, if any, of the sBLA, we will assume the sales and distribution of rilonacept for the approved
indications in the United States and would evenly split profits on sales with Regeneron, after deducting certain
commercialization expenses subject to specified limits. If rilonacept in recurrent pericarditis or any of our other product
candidates do not achieve an adequate level of acceptance, we may not generate the projected level of product revenue
or profits from operations, if at all. The degree of market acceptance of rilonacept, if approved, or any of our other
product candidates will depend on a variety of factors, including:
•(cid:3)
•(cid:3)
the timing of market introduction;
disease awareness, including understanding the severity and epidemiology of the disease;
77
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
the number and clinical profile of competing products, whether regulatory approved or not;
the potential and perceived advantages or disadvantages of our product candidates relative to alternative
treatments;
our ability to provide acceptable evidence of safety and efficacy;
the prevalence and severity of any side effects;
product labeling or product insert requirements of the FDA or other regulatory authorities;
limitations or warnings contained in the labeling approved by the FDA or other regulatory authorities;
convenience and ease of administration, including relative to alternative therapies;
pricing (including patient out-of-pocket costs), budget impact, affordability and cost effectiveness,
particularly in relation to alternative treatments;
the effectiveness of our sales, marketing and distribution activities;
availability of adequate coverage, reimbursement and payment from health maintenance organizations and
other insurers, both public and private, and the timing thereof; and
other potential advantages over alternative treatment methods.
If rilonacept in recurrent pericarditis or any of our other product candidates fail to gain market acceptance, our
ability to generate revenue will be adversely affected. Even if rilonacept or any of our other product candidates achieve
market acceptance, the relevant market may prove not to be large enough to allow us to generate significant revenue.
The successful commercialization of our product candidates will depend in part on the extent to which third-party
payors, including governmental authorities and private health insurers, provide funding, establish favorable coverage
and pricing policies and set adequate reimbursement levels. Failure to obtain or maintain coverage and adequate
reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease
our ability to generate revenue.
Our ability to commercialize rilonacept in recurrent pericarditis or any of our other product candidates
successfully, particularly in orphan or rare disease indications, will depend in part on the availability of favorable
coverage and the adequacy of reimbursement for the product candidate and alternative treatments from third-party
payors (e.g., governmental authorities, private health insurers and other organizations). Although rilonacept is approved
and marketed for human use for the treatment of CAPS and DIRA in the United States by Regeneron, if rilonacept is
approved by the FDA for recurrent pericarditis we would need to seek favorable coverage and reimbursement for this
indication from third-party payors. Obtaining coverage and adequate reimbursement is contingent on our ability to:
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
obtain clinical data that supports payor value/benefit assessments;
execute formal payor value/benefit assessment processes;
obtain coverage that enables use in populations reflected in any product candidate’s approved product
label; and
effectively negotiate favorable pricing and reimbursement terms.
78
While in some markets, there is a single payor, in other markets there are multiple payors that can have
different ways of assessing prescription drugs and therapeutics. To commercialize rilonacept in recurrent pericarditis, if
approved, or any of our other product candidates successfully, we will be required to have sufficient expertise, internally
or through a third party, and sufficient resources to execute on the respective product candidate’s coverage and
reimbursement strategy. We cannot be certain we will be able to effectively execute our coverage and reimbursement
strategy in the markets we pursue, which could limit the commercial potential of rilonacept in recurrent pericarditis or
any of our other product candidates. As a result, our ability to generate projected revenue from rilonacept or any of our
other product candidates could be negatively impacted.
Governmental authorities, private health insurers and other third-party payors have attempted to control costs
by delaying the time to reimbursement, and by restricting the breadth of coverage and limiting the amount of
reimbursement for particular products in terms of lower pricing and increasing the proportion of the cost for which the
patient is responsible. There may be significant delays in obtaining reimbursement for newly approved products or
product indications, coverage may be limited to a subset of the patient population for which the treatment is approved by
the FDA or similar regulatory authorities outside the United States, and reimbursement rates may vary according to the
use of the product and the clinical setting in which it is used. Coverage and reimbursement barriers by payors may
materially impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If
coverage and reimbursement are not available, or available only at limited levels, or if such coverage will require patient
out-of-pocket costs that are unacceptably high, we may not be able to successfully commercialize product candidates for
which we obtain marketing approval. Moreover, any coverage or reimbursement that may be obtained may be decreased
or eliminated in the future.
Third-party payors continue to introduce new tactics to contain costs, including more rigorous value/benefit
assessment processes and criteria. For example, it is possible that third-party payors will select low-cost clinical
comparators that serve as benchmarks for determining relative value, including generics, biosimilars and lower costs
brands with or without the same approved indication. The result of such a change would be a more challenging
value/benefit assessment caused by a more challenging basis for comparison and the potential for a worse relative
outcome. Third-party payors may determine that we have failed to generate sufficient evidence to demonstrate the
relative benefits of our product candidates and refuse to provide coverage and reimbursement entirely, or many find the
evidence not sufficiently compelling to support the desired pricing and reimbursement. Similarly payors may implement
coverage criteria that seeks to limit the use of our product candidates to situations where a patient must be proven to not
adequately respond to the lower-cost comparator. The potential of third-party payors to introduce more rigorous
value/benefit assessment processes and criteria could have a negative impact on our ability to commercialize our product
candidates successfully.
Third-party payors are also introducing more challenging price negotiation methodologies, including in re-
visiting established coverage and reimbursement parameters when new competitors, including brands, generics and
biosimilars enter the market. It is possible that a third-party payor may consider our product candidates as substitutable
and only be willing to cover the cost of the alternative product. Even if we show improved efficacy, safety or improved
convenience of administration with our product candidates, pricing of competitive products may limit the amount we
will be able to charge for our product candidates. Third-party payors may deny or revoke the reimbursement status of a
given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize
an appropriate return on our investment in our product candidates. In some cases, when new competitor generic and
biosimilar products enter the market, there are mandatory price reductions for the innovator compound, in other cases,
payors employ “therapeutic category” price referencing and seek to lower the reimbursement levels for all treatment in
the respective therapeutic category. In other cases, new competitor brand drugs can trigger therapeutic category reviews
in the interest of modifying coverage and or reimbursement levels. The potential of third-party payors to introduce more
challenging price negotiation methodologies could have a negative impact on our ability to commercialize our product
candidates successfully.
79
The incidence and prevalence for target patient populations of our product candidates have not been established with
precision. If the market opportunities for our product candidates are smaller than we estimate, or if any approval that
we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability
may be materially adversely affected.
The precise incidence and prevalence for all the conditions we aim to address with our programs are not known
with specificity, including with respect to COVID-19 pneumonia and hyperinflammation. Our projections of both the
number of people who have these diseases, as well as the subset of people with these diseases who have the potential to
benefit from treatment with our product candidates, are based largely on our extrapolation from available population
studies and estimates. These estimates have been derived from a variety of sources, including scientific literature,
surveys of clinics, patient foundations, pharmacy claims analyses, large national surveillance databases or market
research, and may prove to be incorrect. Further, new trials and therapeutic options may lead to changes in the estimated
incidence or prevalence of these diseases, or relevant subpopulations thereof, including the introduction of a vaccine for
the prevention of COVID-19 with respect to COVID-19 pneumonia and hyperinflammation. As a result, the number of
patients who may benefit from our product candidates may turn out to be lower than expected.
The total addressable market for any of our product candidates will ultimately depend upon, among other
things, the diagnostic criteria and applicable patient population included in the final label for the product candidate
approved for sale for its indication, the efficacy, safety and tolerability demonstrated by the product candidate in our
clinical trials, acceptance by the medical community and patients, pricing, access and reimbursement. The number of
addressable patients in the United States and other major markets outside of the United States may turn out to be lower
than expected, patients may not be otherwise amenable to treatment with our products or new patients may become
increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our
business. Further, even if we obtain significant market share for our product candidates, because the potential target
populations are very small, we may never achieve profitability despite obtaining significant market share.
Evolving health policy and associated legislative changes related to coverage and reimbursement aimed at lowering
healthcare expenditure could impact the commercialization of our product candidates. Pharmaceutical pricing has
been, and likely will continue to be, a central component of these efforts.
The regulations that govern regulatory approvals, pricing and reimbursement for new pharmaceutical products
vary widely from country to country. In markets of some of the countries we may pursue outside of the United States for
any of our product candidates, the products may be subject to extensive governmental price control or other price
regulations. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the
pricing review period begins after marketing approval is granted. In some markets, prescription pharmaceutical pricing
remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain
marketing approval for a product candidate in a particular country, but then be subject to price negotiations that delay
our commercial launch of the product candidate in that country, possibly for lengthy time periods, which may negatively
impact the revenues we are able to generate from the sale of the product candidate in that country. Adverse pricing and
reimbursement limitations may hinder our ability to recoup our investment in one or more product candidates, even if
our product candidates obtain marketing approval.
Net prices for products may be reduced by mandatory discounts or legislated rebates that must be paid in order
to participate in government healthcare programs or paid to other third-party payors. Mandatory discounts can be
legislated at any time in any market. Similarly, some markets currently have pricing legislation that sets the price of a
pharmaceutical product in their market by referencing the price of that product in other markets, known as international
reference pricing. International reference pricing has the potential to impact price cut decisions in individual countries
and the countries that reference the pricing of certain other individual countries. Expansion of mandatory discounts and
international reference pricing, including into the United States, presents a material risk to our ability to achieve
favorable pricing and adequate reimbursement.
Drug importation and cross-border trade, both sanctioned and unsanctioned, occurs when a pharmaceutical
product from a market where the official price is set lower is shipped and made commercially available in a market
where the official price is set higher. Any future relaxation of laws that presently restrict or limit drug importation or
80
cross-border trade, including in the United States, could have a material negative impact on our ability to commercialize
our product candidates, if approved.
We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend
toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative
changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and
surgical procedures and other treatments, has become intense. As a result, we may not be able to achieve or sustain
favorable pricing for our product candidates and adequate reimbursement.
If, in the future, we are unable to maintain our sales, marketing and distribution capabilities, infrastructure and
organization directly and/or through agreements with third parties to sell and market rilonacept in recurrent
pericarditis or any future product candidates, if approved, the commercial potential for rilonacept and our other
product candidates to generate any revenue may be impaired.
There are risks involved with both establishing our own sales and marketing capabilities and entering into
arrangements with third parties to perform these services. For example, recruiting and training a sales force is expensive
and time-consuming and could delay any drug launch. If the commercial launch of a drug candidate for which we recruit
a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have
prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would
be lost if we cannot retain or reposition our sales and marketing personnel.
If we enter into arrangements with third parties to perform sales, marketing, distribution and other commercial
support services, our product revenues or the profitability of these revenues to us are likely to be lower than if we were
to market and sell any approved product candidates ourselves. In addition, we may not be successful in entering into
arrangements with third parties to market and sell our approved product candidates, if any, or may be unable to do so on
terms that are favorable to us. Further, we will likely have little control over such third parties, and any of them may fail
to devote the necessary resources and attention to sell and market our approved product candidates effectively. However,
developing a sales, marketing and access organization requires significant investment, is time consuming and if not
completed as planned could delay the launch of our approved product candidates. Furthermore, we may not be able to
adequately establish an effective sales, marketing, distribution and access organization in the EU or other key markets in
which we have obtained approval for the commercial marketing of our product candidates outside of the United States. If
we are unable to maintain or reestablish sales, marketing and distribution capabilities successfully, either on our own or
in collaboration with third parties, we will not be successful in commercializing our approved product candidates, if any,
and approved product candidates ability to generate any revenue may be impaired. Furthermore, our business, results of
operations, financial condition and prospects will be materially adversely affected.
Our future growth may depend, in part, on our ability to penetrate markets outside of the United States, where we
would be subject to additional regulatory burdens and other risks and uncertainties.
Our future profitability may depend, in part, on our ability to commercialize our product candidates in markets
outside of the United States for which we may rely on collaborations with third parties.
Although we do not have immediate plans to pursue the commercialization of rilonacept for recurrent
pericarditis or any other approved indication outside of the United States, we are evaluating the opportunities for the
development and commercialization of our product candidates in certain markets outside of the United States. We are
not permitted to market or promote any of our product candidates before we receive regulatory approval from the
applicable regulatory authority in that market, and we may never receive such regulatory approval for any of our product
candidates. To obtain separate regulatory approval in many other countries we must comply with numerous and varying
regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical
trials, manufacturing and commercial sales, pricing and distribution of our product candidates, and we cannot predict
success in these jurisdictions. If we obtain approval of our product candidates and ultimately commercialize our product
candidates in markets outside of the United States, we would be subject to additional risks and uncertainties, including:
•(cid:3)
our ability to obtain reimbursement for our product candidates in such markets;
81
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
our inability to directly control commercial activities because we are relying on third parties;
the burden of complying with complex and changing regulatory, tax, accounting and legal requirements of
such countries;
different medical practices and customs in such countries affecting acceptance in the marketplace;
import or export licensing requirements;
longer accounts receivable collection times;
longer lead times for shipping;
language barriers for technical training and the need for language translations;
reduced protection of intellectual property rights in such countries;
the existence of additional potentially relevant third-party intellectual property rights;
foreign currency exchange rate fluctuations; and
the interpretation of contractual provisions governed by laws of such country in the event of a contract
dispute.
Sales of our product candidates outside of the United States could also be adversely affected by the imposition
of governmental controls, political and economic instability, trade restrictions and changes in tariffs.
In some countries, particularly the countries in Europe, the pricing of prescription pharmaceuticals is subject to
governmental control. In these countries, price negotiations with governmental authorities can take considerable time
after the receipt of marketing approval for a drug. To obtain adequate reimbursement or favorable pricing approval in
some countries, we may be required to conduct a clinical trial that compares our product candidate to other available
therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at
unsatisfactory levels, our business could be harmed, possibly materially.
The United Kingdom’s withdrawal from the European Union may have a negative effect on global economic
conditions, financial markets and our business.
Following a national referendum and enactment of legislation by the government of the United Kingdom, the
United Kingdom formally withdrew from the European Union and ratified a trade and cooperation agreement governing
its future relationship with the European Union. The agreement, which is being applied provisionally from January 1,
2021 until it is ratified by the European Parliament and the Council of the European Union, addresses trade, economic
arrangements, law enforcement, judicial cooperation and a governance framework including procedures for dispute
resolution, among other things. Because the agreement merely sets forth a framework in many respects and will require
complex additional bilateral negotiations between the United Kingdom and the European Union as both parties continue
to work on the rules for implementation, significant political and economic uncertainty remains about how the precise
terms of the relationship between the parties will differ from the terms before withdrawal.
These developments, or the perception that any related developments could occur, have had and may continue
to have a material adverse effect on global economic conditions and the financial markets, and may significantly reduce
global market liquidity, restrict the ability of key market participants to operate in certain financial markets or restrict our
access to capital. Any of these factors could have a material adverse effect on our business, financial condition and
results of operations and reduce the price of our shares.
82
We are currently subject to ongoing obligations, regulatory requirements, and review, and if we receive regulatory
approval for any of our product candidates, will be subject to additional ongoing obligations and continued
regulatory review, which may result in significant additional expense. Additionally, our product candidates, if
approved, could be subject to labeling and other restrictions and market withdrawal, and we may be subject to
penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.
If the FDA or a comparable regulatory authorities outside of the United States approves any of our product
candidates, we will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, distribution,
storage, advertising, promotion, sampling, record-keeping, AE reporting, conduct of post-marketing trials and
submission of safety, efficacy and other post-market information for our approved product candidates, including both
federal and state requirements in the United States and requirements of comparable regulatory authorities outside of the
United States. For example, the FDA accepted the sBLA for rilonacept in recurrent pericarditis with priority review and
assigned a PDUFA goal date of March 21, 2021. While we hold the BLA for rilonacept in CAPS, we will only assume
the sales and distribution of rilonacept for approved indications in the United States upon approval from the FDA, if any,
of the sBLA for the commercial marketing of rilonacept in the United States for recurrent pericarditis, at which time we
would evenly split profits on sales with Regeneron, after deducting certain commercialization expenses subject to
specified limits. As we assume the sales and distribution responsibilities of rilonacept for the approved indications in the
United States and begin commercializing rilonacept for the treatment of recurrent pericarditis or any of our other product
candidates, if approved, we will be subject to additional ongoing obligations and continued regulatory review, which
may result in significant additional expense.
Manufacturers and their facilities are required to comply with extensive requirements of the FDA and
comparable regulatory authorities outside of the United States, including ensuring that quality control and manufacturing
procedures conform to cGMP regulations. As such, we and our CMOs will be subject to user fees and continual review
and inspections to assess compliance with cGMP and adherence to commitments made in any BLA or MAA.
Accordingly, we and our CMOs and others with whom we work must continue to expend time, money and effort in all
areas of regulatory compliance, including manufacturing, production and quality control.
Any regulatory approvals that we receive for our product candidates may be subject to limitations on the
approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements
for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and
efficacy of the product candidate. We will be required to report certain adverse reactions and production problems, if
any, to the FDA and comparable regulatory authorities outside of the United States. Any new legislation addressing drug
safety issues could result in delays in product development or commercialization, or increased costs to assure
compliance.
While our current clinical and medical affairs activities are subject to certain ongoing regulatory requirements
concerning appropriate exchange of medical and scientific information, if the FDA or a comparable regulatory authority
outside of the United States approves any of our product candidates we will have to comply with additional requirements
concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs
and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in
the product’s approved label. As such, we may not promote our products for indications or uses for which they do not
have approval.
The holder of an approved BLA or MAA must submit new or supplemental applications and obtain approval
for certain changes to the approved product, product labeling or manufacturing process. We could also be asked to
conduct post-marketing clinical trials to verify the safety and efficacy of our products in general or in specific patient
subsets. If original marketing approval were obtained via the accelerated approval pathway, we could be required to
conduct a successful post-marketing clinical trial to confirm clinical benefit for our products. An unsuccessful
post-marketing trial or failure to complete such a trial could result in the withdrawal of marketing approval. The FDA
also may place other conditions on approvals including the requirement for a REMS, to assure the safe use of the
product. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS before it can
obtain approval. A REMS could include medication guides, physician communication plans or elements to assure safe
use, such as restricted distribution methods, patient registries and other risk minimization tools.
83
If a regulatory agency discovers previously unknown problems with our product, such as AEs of unanticipated
severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion,
marketing or labeling of a product, such regulatory agency may impose restrictions on that product or us, including
requiring withdrawal of the product from the market. If we discover previously unknown problems with a product
candidate, including AEs of unanticipated severity or frequency, or with our manufacturing processes, or fail to comply
with regulatory requirements, a regulatory agency or enforcement authority may, among other things:
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
issue warning letters;
impose civil or criminal penalties;
suspend or withdraw regulatory approval;
suspend any of our ongoing clinical trials;
refuse to approve pending applications or supplements to approved applications submitted by us;
impose restrictions on our operations, including closing our CMOs’ facilities; or
seize or detain products, or require a product recall.
Any government investigation of alleged violations of law could require us to expend significant time and
resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory
requirements may significantly and adversely affect our ability to commercialize and generate revenue from our
products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our
operating results will be adversely affected.
If there are changes in the application of legislation or regulatory policies, or if problems are discovered with a
product or the manufacture of a product, or if we or one of our distributors, licensees, co-marketers or other third-parties
operating on our behalf fails to comply with regulatory requirements, the regulatory authorities could take various
actions. These include imposing fines on us, imposing restrictions on our product or its manufacture and requiring us to
recall or remove the product from the market. The regulatory authorities could also suspend or withdraw our marketing
authorizations, or require us to conduct additional clinical trials, change our product labeling or submit additional
applications for marketing authorization. If any of these events occurs, our ability to sell our product may be impaired,
and we may incur substantial additional expense to comply with regulatory requirements.
The policies of the FDA and other regulatory authorities may change and additional government regulations
may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the
likelihood, nature or extent of government regulation that may arise from future legislation or administrative or
executive action, either in the United States, Europe or in other jurisdictions. For example, the previous U.S. presidential
administration took several executive actions, including the issuance of a number of Executive Orders, that could impose
significant burdens on, or otherwise materially delay, the FDA’s ability to engage in routine oversight activities such as
implementing statutes through rulemaking, issuance of guidance and review and approval of marketing applications. It is
difficult to predict whether or how these Executive Orders will be implemented by the current U.S. presidential
administration, if at all, and the extent to which they may impact the FDA’s ability to exercise its regulatory authority. If
these executive actions impose restrictions on the FDA’s ability to engage in oversight and implementation activities in
the normal course, our business may be negatively impacted. Further, the policies and priorities of the new
administration are unknown and could materially impact the regulations governing our product candidates. In addition, if
we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if
we are not able to maintain regulatory compliance, we may be subject to enforcement actions and we may not achieve or
sustain profitability.
84
Our business operations and current and future relationships with investigators, healthcare professionals,
consultants, customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse, physician
and other healthcare provider payment and price transparency, and other healthcare laws and regulations, which
could expose us to criminal sanctions, civil penalties, exclusion from government healthcare programs, contractual
damages, reputational harm and diminished profits and future earnings.
Although we do not currently have any products in the market, the FDA accepted the sBLA for rilonacept in
recurrent pericarditis with priority review and assigned a PDUFA goal date of March 21, 2021. Upon receipt of FDA
approval, if any, of the sBLA, we will assume the sales and distribution of rilonacept for the approved indications in the
United States and would evenly split profits on sales with Regeneron, after deducting certain commercialization
expenses subject to specified limits. As we assume the sales and distribution responsibilities of rilonacept for the
approved indications in the United States and begin commercializing rilonacept for the treatment or recurrent pericarditis
or any of our other product candidates, if approved, we will be subject to additional healthcare statutory and regulatory
requirements and enforcement by the United States federal and state governments and the governments of other
countries or jurisdictions in which we conduct our business.
Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and
prescription of any product candidates for which we obtain marketing approval. Our future arrangements with
third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and
regulations that may constrain the business or financial arrangements and relationships through which we market, sell
and distribute our product candidates for which we obtain marketing approval.
Restrictions under applicable federal and state healthcare laws and regulations, include the following:
•(cid:3)
•(cid:3)
•(cid:3)
the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and
willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind,
to induce or reward either the referral of an individual for, or the purchase, order or recommendation of,
any good or service, for which payment may be made under federal and state healthcare programs such as
Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or
specific intent to violate it in order to have committed a violation. The U.S. federal Anti-Kickback Statute
has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and
prescribers, purchasers and formulary managers on the other hand;
the U.S. federal False Claims Act and civil monetary penalties laws, which, among other things, impose
criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or
entities for knowingly presenting, or causing to be presented, to the federal government, claims for
payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation
to pay money to the federal government. As a result of a modification made by the Fraud Enforcement and
Recovery Act of 2009, a claim includes “any request or demand” for money or property presented to the
federal government. In addition, manufacturers can be held liable under the False Claims Act even when
they do not submit claims directly to government payors if they are deemed to “cause” the submission of
false or fraudulent claims. Moreover, the government may assert that a claim including items and services
resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for
purposes of the False Claims Act;
the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes
criminal and civil liability for executing a scheme to defraud any healthcare benefit program or obtain, by
means of false or fraudulent pretenses, representations or promises, any of the money or property owned
by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public
or private) and knowingly and willfully falsifying, concealing or covering up a material fact or making any
materially false statement in connection with the delivery of or payment for healthcare benefits, items or
service. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual
knowledge of the statute or specific intent to violate it in order to have committed a violation;
85
•(cid:3)
•(cid:3)
the U.S. federal physician payment transparency requirements, sometimes referred to as the “Sunshine
Act” created under Section 6002 of the Patient Protection and Affordable Care Act, as amended by the
Health Care and Education Reconciliation Act, or the Affordable Care Act, which requires manufacturers
of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the
Children’s Health Insurance Program to report to the Department of Health and Human Services
information related to certain financial interactions with physicians (defined to include doctors, dentists,
optometrists, podiatrists and chiropractors), additional categories of healthcare practitioners beginning in
2022, and teaching hospitals, as well as the ownership and investment interests of physicians and their
immediate family members; and
analogous state laws and regulations, such as state anti-kickback and false claims laws that may apply to
sales or marketing arrangements and claims involving healthcare items or services reimbursed by
non-governmental third-party payors, including private insurers; and some state laws require
pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines
and the relevant compliance guidance promulgated by the federal government in addition to requiring drug
manufacturers to report information related to payments to physicians and other healthcare providers or
marketing expenditures and pricing information.
These laws and regulations, among other things, may constrain our business, marketing and other promotional
activities by limiting the kinds of financial arrangements we may have with hospitals, prescribers or other potential
purchasers of our product candidates, if approved. We have entered into consulting and advisory board agreements with
physicians, some of whom are paid in the form of shares or options to acquire our common shares. We could be
adversely affected if regulatory agencies determine our financial relationships with such prescribers to be in violation of
applicable laws or the appearance of a conflict of interest. For example, principal investigators for our clinical trials may
serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such
services. The FDA or other regulatory authorities may conclude that a financial relationship between us and a principal
investigator or a clinical trial site has created a conflict of interest or otherwise affected interpretation of a study. The
FDA or other regulatory authorities may therefore question the integrity of the data generated at the applicable clinical
trial site and the utility of the clinical trial itself may be jeopardized, which could result in a delay in approval, or
rejection, of our marketing applications by the FDA or other regulatory authorities and may ultimately lead to the denial
of marketing approval of our product candidates. Furthermore, investigators for our clinical trials may become debarred
by FDA or other regulatory authorities, which may impact the integrity of our studies and the utility of the clinical trial
itself may be jeopardized. Because of the breadth of these laws and the narrowness of the statutory exceptions and
regulatory safe harbors available under such laws, it is possible that some of our business activities could be subject to
challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to
rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and
regulations.
Interactions between biopharmaceutical companies and healthcare professionals are also governed by strict
laws, regulations, industry self-regulation codes of conduct and healthcare professionals’ codes of professional conduct
in the individual EU member states. The provision of any inducements to healthcare professionals to prescribe,
recommend, endorse, order, purchase, supply, use or administer a drug product is prohibited. A number of EU member
states have established additional rules requiring pharmaceutical companies to publicly disclose their interactions with
physicians and other healthcare professionals and to obtain approval from employers, professional organizations or
competent authorities before entering into agreements with healthcare professionals.
Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and
regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business
practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or
other healthcare laws and regulations. If our operations, including anticipated activities to be conducted by our sales
team, were to be found to be in violation of any of these laws or any other governmental regulations that may apply to
us, we may be subject to the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary
fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual
imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting
86
requirements or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve
allegations of non-compliance with these laws, and curtailment or restructuring of our operations, any of which could
adversely affect our ability to operate our business and our results of operations. Further, defending against any such
actions can be costly, time consuming and may require significant personnel resources. Therefore, even if we are
successful in defending against any such actions that may be brought against us, our business may be impaired.
Risks Related to Competition, Executing our Strategy, Retaining Key Employees and Managing Growth
We face substantial competition, which may result in others discovering, developing or commercializing drugs before
or more successfully than we do.
The development and commercialization of new drugs and biologics is highly competitive. We face
competition with respect to our current product candidates, and will face competition with respect to any product
candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty
pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and
biotechnology companies that currently market and sell drugs or biologics or are pursuing the development of therapies
in the fields in which we are interested. Some of these competitive products and therapies are based on scientific
approaches that are the same as or similar to our approach, and others are based on entirely different approaches.
Potential competitors also include academic institutions, government agencies and other public and private research
organizations that conduct research, seek patent protection and establish collaborative arrangements for research,
development, manufacturing and commercialization.
While we are not aware of any therapies currently approved or actively continuing clinical trials in recurrent
pericarditis, there is one product that modulates the signaling of IL-1(cid:302) and IL-1(cid:533), anakinra (KINERET), marketed by
Swedish Orphan Biovitrum AB, and one product that modulates the signaling of IL-1(cid:533), canakinumab (ILARIS),
marketed by Novartis Pharmaceuticals Corporation. There are other therapies which modulates IL-1(cid:302) in preclinical and
clinical development for diseases other than recurrent pericarditis from Johnson & Johnson and XBIOTECH USA, INC.
We expect mavrilimumab, if approved for the treatment of GCA, to experience competitive pressure from
tocilizumab (ACTEMRA), marketed by Genentech USA, Inc., which was approved in 2017 for use in GCA as an
adjunct to steroid taper. Additional competition may be experienced from Eli Lilly and Company and AbbVie Inc.,
which are conducting clinical trials for oral janus kinase inhibitors, Sanofi S.A. and Regeneron, which are recruiting a
Phase 3 clinical trial with their anti-IL-6 program, Novartis International AG, which is recruiting a trial with its IL-17
antagonist secukinumab (Cosentyx) and Janssen Biotech, Inc., which is testing ustekinumab (STELARA) in two small
studies for GCA. There are multiple other programs targeting GM-CSF antagonism not currently pursuing GCA in
clinical trials that could decide in the future to engage in development of therapies for GCA, including GlaxoSmithKline
plc, Izana Bioscience, Roivant Sciences Ltd., I-Mab Biopharma Co., Ltd., and Humanigen, Inc.
We are also pursuing mavrilimumab development for the treatment of COVID-19 pneumonia and
hyperinflammation. There are currently hundreds of active, industry sponsored clinical trials testing many different
mechanisms of action for the treatment of COVID-19 related therapeutic areas in addition to the approved vaccines, and
the many other clinical trials testing vaccines for the prevention of COVID-19.
Multiple therapies are in development for prurigo nodularis, and any that receive FDA approval for this
indication will be likely competitors to vixarelimab. These products include nemolizumab, dupilumab and nalbuphine
ER. There are multiple agents targeting antagonism of the CD40/CD40L interaction across a variety of clinical uses
including, Novartis International AG, Biogen Inc., or Biogen, and UCB, Inc., C.H. Boehringer Sohn AG & Ko. KG and
AbbVie Inc., Annelixis Therapeutics LLC, ImmuNext Inc. and Sanofi S.A., Viela Bio and Astellas Pharma Inc.
Further, the results of clinical trials for our product candidates may produce negative, inconclusive or
uncompetitive results compared to those produced by any of these or other companies in the indications we are studying,
which may result in us deciding, or regulators requiring us, to conduct additional clinical trials or modify or cease
development programs for our product candidates. We may also determine that the potential product and commercial
profile of any of our product candidates may not ultimately be commercially successful or even if they have the potential
87
to ultimately be successful, we may not have sufficient recourses, which in either case could lead us to discontinue its
development, or we may determine to not support further development of any of our product candidates at any time for
any reason.
Many of the companies against which we are competing or against which we may compete in the future have
significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing,
conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and
acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being
concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be
significant competitors, particularly through collaborative arrangements with large and established companies. These
competitors also compete with us in recruiting and retaining qualified scientific and management personnel and
establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies
complementary to, or necessary for, our programs.
Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize
products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive
than any drugs that we may develop. Our competitors also may obtain FDA or other regulatory approval for their
products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong
market position before we are able to enter the market. The key competitive factors affecting the success of all of our
product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the effectiveness of companion
diagnostics in guiding the use of related products, market acceptance by physicians and patients, the level of generic
competition and the availability of reimbursement from government and other third-party payors.
We may not be successful in executing our growth strategy to identify, discover, develop, in-license or acquire
additional product candidates or technologies, and our growth strategy may not deliver the anticipated results or we
may refine or otherwise alter our growth strategy. We may seek to acquire businesses or undertake business
combinations, collaborations or other strategic transactions which may not be successful or on favorable terms, if at
all, and we may not realize the intended benefits of such transactions.
We have acquired or in-licensed our existing product candidates, and as part of our strategy we plan to identify
new product candidates or technologies that we believe are complementary to our existing product candidates. We may
do this through our internal discovery program, or by acquiring the rights to product candidates and technologies through
a variety of transaction types, including in-licensing, strategic transactions, mergers or acquisitions. If we are unable to
identify, discover, develop, in-license or otherwise acquire and integrate product candidates, or their related companies,
in accordance with this strategy, our ability to pursue this component of our growth strategy would be limited and we
may need to refine or otherwise alter this strategy. We cannot be certain that we will be successful in such efforts, and
even if we are successful in such efforts, we cannot be certain that such discovery or transaction will be on favorable
terms, or that, following any such discovery or transaction, we will be able to realize the intended benefits of it.
Research programs and business development efforts to identify new product candidates and technologies
require substantial technical, financial and human resources. We may focus our efforts and resources on potential
product candidates, technologies or businesses that ultimately prove to be unsuccessful. In-licensing and acquisitions of
product candidates, technology or businesses often require significant payments and expenses and consume additional
resources. We will need to continue to devote a substantial amount of time and personnel to research, develop and
commercialize any such in-licensed or acquired product candidate or technology, or integrate any new business, and we
may decide to reprioritize our efforts even after having expended resources on a particular prospect. Our research
programs and business development efforts, including businesses or technology acquisitions, collaborations or licensing
attempts, may fail to yield additional complementary or successful product candidates for clinical development and
commercialization or successful business combinations for a number of reasons, including, but not limited to, the
following:
•(cid:3)
our research or business development methodology or search criteria and process may be unsuccessful in
identifying potential product candidates or businesses with a high probability of success for development
progression;
88
•(cid:3) we may not be able or willing to assemble sufficient resources or expertise to in-license, acquire or
discover additional product candidates or acquire businesses or undertake business combinations,
collaborations, or other strategic transactions;
•(cid:3)
for product candidates we seek to in-license or acquire or for businesses we seek to acquire or undertake
business combinations, collaborations or other strategic transactions with, we may not be able to agree to
acceptable terms with the licensor or owner of those product candidates or businesses;
•(cid:3) we may not succeed in formulation or process development;
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
any product candidates to which we acquire the rights or that we discover may not succeed in preclinical
studies or clinical trials or may be shown to have harmful side effects or may have other characteristics that
may make the products unmarketable or unlikely to receive regulatory approval;
competitors may develop alternatives that render any product candidates or technologies to which we
acquire the rights or that we discover, obsolete or less attractive;
any product candidates or technologies to which we acquire the rights may be covered by third-party
patents or other exclusive rights;
any product candidates or technologies to which we acquire the rights or that we discover may not allow us
to leverage our expertise and our development and commercial infrastructure as currently expected;
any product candidates or technologies to which we acquire the rights or that we discover will take
substantial additional financial resources to develop and commercialize and we may not have sufficient
funds to do so;
the market for any product candidates or technologies to which we acquire the rights or that we discover
may change during our program so that such a product or technology may become unreasonable to
continue to develop;
any product candidate to which we acquire the rights or that we discover may not be capable of being
produced in commercial quantities at an acceptable cost, or at all; and
any product candidate to which we acquire the rights or that we discover may not be accepted as safe and
effective by patients, the medical community or third-party payors.
If any of these events occurs, we may not be successful in executing our growth strategy to identify, discover,
develop, in-license or acquire additional product candidates or technologies or to acquire businesses or undertake
business combinations, collaborations, or other strategic transactions, or our growth strategy or strategic transactions
may not deliver the anticipated results or we may refine or otherwise alter this strategy.
The consummation or performance of any acquisition, business combination, collaboration or other strategic
transaction we may undertake in furtherance of our growth strategy or any refined or otherwise altered strategy, may
involve additional risks, such as difficulties in assimilating different cultures, retaining personnel and integrating
operations, which may be geographically dispersed, increased costs, exposure to liabilities, incurrence of indebtedness,
or use a substantial portion of our available cash for all or a portion of the consideration or cause dilution to our existing
shareholders if we issue equity securities for all or a portion of the consideration. If any of these events occurs or we are
unable to meet our strategic objectives for any such transaction, we may not be able to achieve the expected benefits
from the transaction and our business may be materially harmed.
We may seek to enter into collaboration, licensing or other strategic transactions or arrangements to further develop,
commercialize or otherwise attempt to realize value from one or more of our product candidates, and any such
89
transactions or arrangements that we may enter into may not be successful or be on favorable terms, which could
adversely affect our ability to develop, commercialize or attempt to realize value from our product candidates.
We may seek to enter into collaboration, licensing or other strategic transactions or arrangements to further
develop, commercialize or otherwise attempt to realize value from one or more of our product candidates depending on
the merits of retaining rights to develop or commercialize the product candidates ourselves as compared to entering into
such transactions or arrangements. In addition, we may seek to jointly develop, commercialize or otherwise exploit one
or more of our product candidates with a third party. To the extent that we decide to enter into such transactions or
arrangements, we will face significant competition in seeking appropriate collaborators, licensees or other strategic
parties. Moreover, these transactions and arrangements are complex and time consuming to negotiate, document,
implement and to close or maintain. We may not be successful in our efforts to establish collaborations, licenses or other
strategic transactions or arrangements should we so chose to do so. The terms of any such transactions or arrangements
that we may establish may have unfavorable tax consequences for our shareholders in the United States. In addition, our
right to grant a sublicense of intellectual property licensed to us under certain of our current agreements requires the
consent of the applicable licensor.
Any current or future collaborations, licenses or other strategic transactions or arrangements that we enter into
may not be successful. The success of these potential collaboration, license arrangements and other strategic transactions
or arrangements may depend heavily on the efforts and activities of our collaborators, sublicensees or other strategic
parties. For example, in December 2019, we entered into a clinical collaboration with Kite to initiate a Phase 2 clinical
trial evaluating the combination of Yescarta (axicabtagene ciloleucel) and mavrilimumab in relapsed or refractory large
B-Cell lymphoma. Kite was to be the sponsor of this study and responsible for its conduct, but Kite later informed us
that our clinical collaboration was discontinued due to a portfolio strategy review that impacted our trial as it had not
started recruiting. Collaborations, licenses or other strategic transactions or arrangements are subject to numerous risks,
which may include risks that the collaborator, licensee or other strategic party, as applicable:
•(cid:3) may have significant discretion in determining the efforts and resources that they will apply;
•(cid:3) may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out its activities;
•(cid:3) may not properly maintain or defend our intellectual property rights or may use our intellectual property or
proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or
invalidate our intellectual property or proprietary information or expose us to potential liability;
•(cid:3) may own or co-own intellectual property covering products that results from our arrangement with them,
and in such cases, we would not have the exclusive right to develop or commercialize such intellectual
property, and even if we are able to license such exclusive rights, we may have to enter into a license
agreement that include obligations to make milestone, royalty or other payments under such agreement;
and
•(cid:3) may conduct sales and marketing activities or other operations that may not be in compliance with
applicable laws, resulting in civil or criminal proceedings.
In addition, disputes may arise with respect to the ownership of any intellectual property developed pursuant to
these arrangements. These arrangements may also be terminated, and, if terminated, may result in a need for additional
capital to pursue further development or commercialization of the applicable product candidates.
Our future success depends on our ability to retain key executives and senior management as well as to attract, retain
and motivate qualified personnel.
We are highly dependent on the research and development, clinical, regulatory, manufacturing, commercial and
business development expertise of members of our executive and senior management teams, as well as the other
members of our management, scientific and clinical teams. Although we have entered into employment agreements with
our executive officers and certain members of senior management, each of them or we may terminate their employment
90
with us at any time. We do not maintain “key person” insurance for any of our executives, senior management or other
employees. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in
formulating our research and development and commercialization strategy. Our consultants and advisors may be
employed by employers other than us and may have commitments under consulting or advisory contracts with other
entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our
ability to pursue our growth strategy will be limited.
Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel is also
critical to our success. The failure to recruit, or the loss of the services of our executive officers, senior management or
other key employees could impede the achievement of our research, development and commercialization objectives,
including with respect to our establishing and expanding sales, marketing and distribution capabilities, infrastructure and
organization to commercialize products for which we may obtain marketing approval, including our lead program,
rilonacept in recurrent pericarditis, if approved and for its other approved indications in the United States, which would
seriously harm our ability to successfully implement our business strategy and potential commercial launch of
rilonacept. Furthermore, replacing executive officers, senior management and key employees may be difficult and may
take an extended period of time because of the limited number of individuals in our industry with the breadth of skills
and experience required to successfully develop, gain regulatory approval of and commercialize products. For example,
our Senior Vice President, Operations and Chief Commercial Officer departed the Company in January 2021, and we
may not seek to find a replacement or may experience difficulties or delays in identifying a qualified replacement if we
do seek to do so. This or other changes in our senior management may be disruptive to our business, and, if we are
unable to manage an orderly transition of responsibilities, our business may be adversely affected. Competition to hire
from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on
acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar
personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and
research institutions. Failure to succeed in clinical trials may make it more challenging to recruit and retain qualified
scientific and clinical personnel. If we are not able to continue to attract and retain, on acceptable terms, the qualified
personnel necessary for the continued development of our business, we may not be able to sustain our operations or
growth.
We need to continue to develop our company and expand our scope of operations, and we may encounter difficulties
in managing this development and expansion, which could disrupt our operations.
We expect to continue to develop our company and expand the scope of our operations. To manage our
anticipated development and expansion, we must continue to implement and improve our managerial, operational and
financial systems and infrastructure, expand our facilities over time and continue to recruit and train qualified personnel.
Also, our executive and senior management teams have and may continue to divert a disproportionate amount of their
attention away from their day-to-day activities and devote a substantial amount of time to managing these development
and expansion activities. For example in January 2021, we implemented select components of a new ERP system that
will enable the organization to more efficiently manage the complexity of operating a commercial organization. As with
any implementation this new system will require specific skills and expertise to setup, maintain and utilize the system.
We may not be able to develop these skills internally or in sufficient time and capacity, which could require us to expend
additional resources to acquire them. Due to our limited resources, certain employees have and may continue to perform
activities that are beyond their regular scope of work, and we may not be able to effectively manage the development of
our company, expansion of our operations or recruit and train qualified personnel. This may result in weaknesses of our
systems and infrastructure, give rise to managerial, operational and financial mistakes, loss of business opportunities,
loss of employees and reduced productivity among remaining employees. The development of our company and
expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as
the development of one or more of our product candidates. If our executive and senior management teams are unable to
effectively manage our anticipated development and expansion, our expenses may increase more than expected, our
ability to generate revenue could be reduced and we may not be able to implement our business strategy as planned,
including with respect to our commercial launch of rilonacept in recurrent pericarditis, if approved. Our future financial
performance and our ability to commercialize our product candidates, if approved, and to compete effectively will
depend, in part, on our ability to effectively manage the future development of our company and expansion of our
operations.
91
Risks Related to Intellectual Property
If we are unable to adequately protect our proprietary technology or obtain and maintain patent protection for our
technology and products, if the scope of the patent protection obtained is not sufficiently broad, or if the terms of our
patents are insufficient to protect our product candidates for an adequate amount of time, our competitors could
develop and commercialize technology and products similar or identical to ours, and our ability to successfully
commercialize our technology and products may be materially impaired.
Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual
property protection in the United States and other countries for our product candidates, including rilonacept,
mavrilimumab and vixarelimab. We seek to protect our proprietary and intellectual property position by, among other
methods, filing patent applications in the United States and abroad related to our proprietary technology, inventions and
improvements that are important to the development and implementation of our business. We also rely on trade secrets,
know-how and continuing technological innovation to develop and maintain our proprietary and intellectual property
position.
We acquire, in-license and file patent applications directed to our product candidates in an effort to establish
intellectual property positions directed to their compositions of matter and manufacture as well as uses of these product
candidates in the treatment of diseases. Our intellectual property includes patents and patent applications that we own as
well as patents and patent applications that we in-license. For example, we have a field-specific exclusive license under a
license agreement with Regeneron to patent applications and patents relating to rilonacept, an exclusive license under a
license agreement with MedImmune, or the MedImmune Agreement, to patent applications and patents relating to
mavrilimumab, and an exclusive license under our license agreement with Beth Israel Deaconess Medical Center to
patent applications and patents related to KPL-404.
Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The
resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant
intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of which
could have a material adverse effect on our business, financial condition, results of operations and prospects.
We or our licensors have not pursued or maintained, and may not pursue or maintain in the future, patent
protection for our products in every country or territory in which we may sell our products. In addition, we cannot be
sure that any of our pending patent applications or pending trademark applications will issue or that, if issued, they have
or will issue in a form that will be advantageous to us. The United States Patent and Trademark Office, or the USPTO,
international patent offices or judicial bodies may deny or significantly narrow claims made under our patent
applications and our issued patents may be successfully challenged, may be designed around or may otherwise be of
insufficient scope to provide us with protection for our commercial products. Further, the USPTO, international
trademark offices or judicial bodies may deny our trademark applications and, even if published or registered, these
trademarks may not effectively protect our brand and goodwill. Like patents, trademarks also may be successfully
opposed or challenged.
The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves
complex legal and factual questions and has in recent years been the subject of much litigation. The degree of patent
protection we require to successfully commercialize our product candidates may be unavailable or severely limited in
some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot
provide any assurances that any of our owned or in-licensed patents have, or that any of our owned or in-licensed
pending patent applications that mature into issued patents will have, claims with a scope sufficient to protect rilonacept,
mavrilimumab, vixarelimab, KPL-404 or our other product candidates. In addition, the laws of other countries may not
protect our rights to the same extent as the laws of the United States. Furthermore, patents have a limited lifespan. In the
United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions and adjustments
may be available; however, the life of a patent, and the protection it affords, is limited. The actual protection afforded by
a patent varies on a product-by-product basis, from country to country and depends upon many factors, including the
type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal
remedies in a particular country and the validity and enforceability of the patent.
92
Patents may be eligible for limited patent term extension in the United States under the Drug Price Competition
and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. Similar patent extensions exist in the
EU and Japan, subject to the applicable laws in those jurisdictions. We may not receive an extension if we fail to apply
within applicable deadlines or fail to apply prior to expiration of relevant patents. For example, no patent term extension
was obtained in the United States following the FDA’s approval of rilonacept for the treatment of CAPS in 2008, and the
deadline for applying for such extension has passed. Accordingly, patent term extension in the United States based on
the FDA’s approval of rilonacept for CAPS, or any other indication for which the FDA may grant approval in the future,
is unavailable. Further, while patent term extension was awarded for relevant patents in certain European countries
following the EMA’s approval of rilonacept for the treatment of CAPS, in 2012 the marketing authorization for CAPs
was withdrawn. Patent term extensions may no longer be in effect or available, subject to the applicable laws in those
countries as well as other factors, such as whether a marketing approval for rilonacept is reissued and whether such
reissuance is prior to the expiration of the patent’s natural 20-year patent term. Moreover, the length of the extension
could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less
than we request, the period during which we can enforce our patent rights for that product will be shortened and our
competitors may obtain approval to market competing products sooner, impacting our revenue.
Given the amount of time required for the development, testing and regulatory review of new product
candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized,
thereby limiting protection such patent would afford the respective product and any competitive advantage such patent
may provide. In some cases, an in-licensed patent portfolio may have undergone a considerable loss of patent term prior
to our initiation of development and commercialization of the product candidate. For example, the patents in the United
States covering rilonacept as a composition of matter have expired, and patents covering rilonacept as a composition of
matter in Europe have a term that expires in 2023, not including any patent term extensions, and the patents covering
mavrilimumab as a composition of matter have a term that expires in 2027 in the United States, not including any patent
term adjustments (an adjustment to the term of the U.S. patent to compensate the patentee for delays caused by the
USPTO during the examination process) or patent term extensions, and in 2027 in Europe, not including any patent term
extensions. As a result, our owned and in-licensed patent portfolio may not provide us with adequate and continuing
patent protection sufficient to exclude others from commercializing products similar or identical to our product
candidates. In such cases, we expect to rely on regulatory exclusivity for our product candidates, such as orphan drug
exclusivity, which generally grants seven years of marketing exclusivity under the Federal Food, Drug, and Cosmetic
Act, and up to ten years of marketing exclusivity in Europe. While, we obtained orphan drug designations from the FDA
for rilonacept for the treatment of pericarditis, which includes the treatment of recurrent pericarditis, and for
mavrilimumab for the treatment of GCA, we may pursue orphan drug designation for our other product candidates in the
United States and we may not be successful in obtaining such designation, or we may not be able to maintain the
benefits of the designation for rilonacept or mavrilimumab or any of our other product candidates. Even if we obtain
orphan drug exclusivity for any of our product candidates, that exclusivity may not effectively protect those product
candidates from competition because different drugs can be approved for the same condition, and orphan drug
exclusivity does not prevent the FDA from approving the same or a different drug in another indication. Even after an
orphan drug is approved, the FDA can subsequently approve a later application for the same drug for the same condition
if the FDA concludes that the later drug is clinically superior in that it is shown to be safer in a substantial portion of the
target populations, more effective or makes a major contribution to patient care. In addition, a designated orphan drug
may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it
received orphan designation. See “Risk Factors — Risks related to marketing approval and regulatory matters.”
Other parties may have developed or may develop technologies that may be related or competitive to our own,
and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming
inventions that may overlap or conflict with those claimed in our patent applications or issued patents, with respect to
either the same methods or formulations or the same subject matter, in either case, that we may rely upon to dominate
our patent position in the market. Publications of discoveries in the scientific literature often lag behind the actual
discoveries, and patent applications in the United States and other jurisdictions are typically not published until
18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we or our licensors
were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we
or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity,
enforceability and commercial value of our patent rights cannot be predicted with any certainty.
93
In addition, the patent prosecution process is expensive and time consuming, and we may not be able to file and
prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. Patent prosecution is a
lengthy process, during which the scope of the claims initially submitted for examination by the USPTO is often
significantly narrowed by the time they issue, if at all. The claims of our issued patents or patent applications when
issued may not cover our product candidates, proposed commercial technologies or the future products that we develop,
or even if such patents provide coverage, the coverage obtained may not provide any competitive advantage. Further, it
is possible that we will fail to identify patentable aspects of our research and development output before it is too late to
obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and
prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties.
Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best
interests of our business. In the case of our field-limited license from Regeneron, another licensee may have the right to
enforce patents covering the product in their field. As a result, we may need to coordinate enforcement with another
party, and the other party could enforce the patents in a manner adverse to our interests or otherwise put the patents at
risk of invalidation.
The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific
questions and can be uncertain. The patent applications that we own or license may fail to result in issued patents in the
United States or in other countries. Even if we acquire patent protection that we expect should enable us to maintain a
competitive advantage, third parties may challenge the validity, enforceability or scope thereof, which may result in such
patents being narrowed, invalidated or held unenforceable. The issuance of a patent is not conclusive as to its
inventorship, scope, validity, enforceability or term, and our owned and licensed patents may be challenged in the courts
or patent offices in the United States and abroad. For example, we may be subject to a third-party submission of prior art
to the USPTO challenging the priority of an invention claimed within one of our patents, which submissions may also be
made prior to a patent’s issuance, precluding the granting of any of our pending patent applications. We may become
involved in contested proceedings challenging our patent rights or the patent rights of others from whom we have
obtained licenses to such rights. For example, patents granted by the USPTO may be subject to third-party challenges
such as (without limitation) derivation, re-examination, interference, post-grant review or inter partes review
proceedings, and patents granted by the European Patent Office may be challenged by any person in an opposition
proceeding within nine months from the publication of the grant. Similar proceedings are available in other jurisdictions,
and in some jurisdictions third parties can raise questions of validity with a patent office even before a patent has
granted. Competitors may claim that they invented the inventions claimed in our issued patents or patent applications
prior to us, or may file patent applications before we do. In such case, we may have to participate in interference or
derivation proceedings in the USPTO, to determine which party is entitled to a patent on the disputed invention. We may
also become involved in similar opposition proceedings in the European Patent Office or similar offices in other
jurisdictions regarding our intellectual property rights with respect to our products and technology.
Such proceedings can be expensive, time consuming and may divert the efforts of our technical and managerial
personnel, which could in turn harm our business, whether or not we receive a determination favorable to us. We may
not be able to correctly estimate or control our future operating expenses in relation to such proceedings, which could
affect operating expenses. Our operating expenses may fluctuate significantly in the future as a result of a variety of
factors, including the costs of such proceedings.
Since patent applications are confidential for a period of time after filing, we cannot be certain that we or our
licensors were the first to file any patent application related to our product candidates. Competitors may also contest our
patents, if issued, by showing the patent examiner that the invention was not original, was not novel or was obvious. In
litigation, a competitor could claim that our patents, if issued, are not valid or enforceable for a number of reasons. If a
court agrees, rights to those challenged patents may be diminished or lost.
In addition, we may in the future be subject to claims by our or our licensors’ former employees or consultants
asserting an ownership right in our patents or patent applications, as a result of the work they performed on our or their
behalf, respectively. Although we generally require all of our employees and consultants and any other partners or
collaborators who have access to our proprietary know-how, information or technology to assign or grant similar rights
to their inventions to us, we cannot be certain that we or our licensors have executed such agreements with all parties
who may have contributed to our intellectual property, nor can we be certain that our agreements with such parties will
94
be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate
remedy.
An adverse determination in any such submission or proceeding may result in loss of exclusivity or freedom to
operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our
ability to stop others from using or commercializing similar or identical technology and products, without payment to us,
or could limit the duration of the patent protection covering our technology and product candidates. Such challenges may
also result in our inability to manufacture or commercialize our product candidates without infringing third-party patent
rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it
could dissuade companies from collaborating with us to license, develop or commercialize current or future product
candidates.
Even if they are unchallenged, our issued patents and our pending patent applications, if issued, may not
provide us with any meaningful protection or prevent competitors from designing around our patent claims to
circumvent our owned or licensed patents by developing similar or alternative technologies or products in a
non-infringing manner. For example, a third party may develop a competitive drug that provides benefits similar to one
or more of our product candidates but that has a different composition that falls outside the scope of our patent
protection. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our
product candidates is not sufficiently broad to impede such competition, or if the breadth, strength or term (including any
extensions or adjustments) of protection provided by the patents and patent applications we hold or pursue with respect
to our product candidates or any future product candidates is successfully challenged, our ability to successfully
commercialize our product candidates could be negatively affected, which would harm our business. Further, if we
encounter delays in our clinical trials, the period of time during which we could market our product candidates or any
future product candidates under patent protection would be reduced.
Licensing of intellectual property is of critical importance to our business and involves complex legal, business and
scientific issues. If we breach any of the agreements related to our product candidates, we could lose the ability to
continue the development and commercialization of the related product. Additionally, our current licensing and
acquisition agreements contain limitations and restrictions that could limit or adversely affect our ability to develop
and commercialize other products in the future.
We entered into agreements to acquire the rights to develop or commercialize our product candidates,
rilonacept, mavrilimumab, vixarelimab and KPL-404. In September 2017, we entered into a license agreement with
Regeneron to obtain an exclusive license under certain intellectual property rights controlled by Regeneron to develop
and commercialize rilonacept. In December 2017, we entered into the MedImmune Agreement to obtain exclusive
worldwide rights to research, develop, manufacture, market and sell mavrilimumab and any other products covered by
the licensed patent rights. In September 2016, pursuant to an asset purchase agreement with Biogen, or the Biogen
Agreement, we acquired all of Biogen’s right, title and interest in and to certain assets used in or relating to vixarelimab,
including patents and other intellectual property rights, clinical data, know-how and inventory. In connection with our
acquisition of Primatope Therapeutics, Inc., or Primatope, in March 2019, we acquired an exclusive world-wide license
with Beth Israel Deaconess Medical Center for certain patent applications and patents related to KPL-404. Each of these
agreements requires us to use commercially reasonable efforts to develop and commercialize the related product
candidates, make timely milestone and other payments, provide certain information regarding our activities with respect
to such product candidates and indemnify the other party with respect to our development and commercialization
activities under the terms of the agreements. These agreements and any future such agreements that we enter into impose
a variety of obligations and related consequences.
We are a party to license and acquisition agreements of importance to our business and to our current product
candidates, and we expect to be subject to additional such agreements in the future. Disputes may arise between us and
any of these counterparties regarding intellectual property subject to and each parties’ obligations under such
agreements, including:
•(cid:3)
our diligence obligations with respect to the use of the licensed technology in relation to our development
and commercialization of our product candidates, and what activities satisfy those diligence obligations;
95
•(cid:3)
•(cid:3)
the scope of rights granted under the agreement and other interpretation-related issues;
our obligations to make milestone, royalty or other payments under those agreements;
•(cid:3) whether and the extent to which our technology and processes infringe on intellectual property of the
licensor that is not subject to the agreement;
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
our right to sublicense patent and other rights to third parties;
the ownership of inventions and know-how resulting from the joint creation or use of intellectual property
by our licensors and us and our partners;
our right to transfer or assign the license; and
the effects of termination.
These or other disputes over our obligations or intellectual property that we have licensed or acquired may
prevent or impair our ability to maintain our current arrangements on acceptable terms, or may impair the value of the
arrangement to us. Any such dispute could have an adverse effect on our business.
If we fail to meet our obligations under these agreements in a material respect, the respective licensor/seller
would have the right to terminate the respective agreement and upon the effective date of such termination, have the
right to re-obtain the related technology as well as aspects of any intellectual property controlled by us and developed
during the period the agreement was in force that relate to the applicable technology. This means that the licensor/seller
to each of these agreements could effectively take control of the development and commercialization of our product
candidates after an uncured, material breach of the agreement by us. This would also be the case if we voluntarily
elected to terminate the relevant agreement, which we have the right to do under each of these agreements. While we
would expect to exercise our rights and remedies available to us in the event we fail to meet our obligations under these
agreements in any material respect, including seeking to cure any breach by us, and otherwise seek to preserve our rights
under the technology licensed to or acquired by us, we may not be able to do so in a timely manner, at an acceptable cost
or at all. Any uncured, material breach under the license could result in our loss of exclusive rights and may lead to a
complete termination of our product development and any commercialization efforts for each of our product candidates.
Termination of one of these agreements for any reason, and the related discontinuation of the development or
commercialization of a product candidate could impair our ability to raise additional capital, generate revenue and may
significantly harm our business, financial condition and prospects.
Regeneron has rights to develop rilonacept in its retained fields of local administration to the eye and ear,
oncology, deficiency of the IL-1 receptor, and CAPS, as well as for the treatment of Deficiency of the Interleukin-1
Receptor Antagonist, or DIRA, which was recently approved by the FDA. Regeneron may also develop rilonacept in
fields to which we have licensed the rights, but we retain the commercial benefit related to that development upon
approval of rilonacept in any field that we have licensed. We and Regeneron communicate with each other concerning
our related development activities, and we have approval rights over Regeneron’s development in the fields that we have
licensed, including pericarditis. The FDA accepted the sBLA for rilonacept in recurrent pericarditis with priority review
and assigned a PDUFA goal date of March 21, 2021. Upon receipt of FDA approval for rilonacept in recurrent
pericarditis, if any, we would assume the sales and distribution of rilonacept for the other approved indications in the
United States and would evenly split profits on sales with Regeneron, after deducting certain commercialization
expenses subject to specified limits. We must continue to coordinate numerous activities with Regeneron in order for us
to take over certain responsibilities and obligations with respect to owning the BLA. Outside of the United States and
Japan, Regeneron has granted a third-party licensee the right to develop and commercialize rilonacept in CAPS and
certain periodic fever syndromes. The development of rilonacept in other fields could increase the possibility of
identification of adverse safety results that impact our development of rilonacept for recurrent pericarditis. In addition, if
approved, commercialization of rilonacept in other fields could result in an increased threat of off-label use to compete
96
with the sale of rilonacept to treat these indications, which may diminish sales of rilonacept in fields licensed exclusively
to us.
Certain of our agreements may limit or delay our ability to consummate certain transactions, may impact the
value of those transactions, or may limit our ability to pursue certain activities. For example, under the MedImmune
Agreement, we cannot sublicense the rights licensed or sublicensed to us without the consent of MedImmune and certain
applicable third-party licensors, if required by agreements between MedImmune and such third-party licensors. Under
the Biogen Agreement, Biogen has a right of first negotiation under certain circumstances to purchase the assets we
acquired from Biogen or to obtain a license to exploit the applicable products. This right of first negotiation remains in
effect until the earlier of 12 years from the date of the agreement or the first commercial sale of a product under the
agreement, and applies to a variety of transactions, including licensing transactions and the sale of our company. In
addition, under the Biogen Agreement, we are subject to an exclusivity obligation, pursuant to which we may not
conduct any activity alone or through a third party related to a product that modulates the oncostatin M receptor (other
than for the development and commercialization of products that are the subject of the Biogen Agreement). This
exclusivity obligation runs from the earlier of the eighth anniversary of the agreement or the first commercial sale of a
product that is the subject of the Biogen Agreement.
Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the
outcome of which would be uncertain and could have a material adverse effect on the success of our business.
Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture,
market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights and
intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and
frequent litigation regarding patents and other intellectual property rights. We cannot assure you that our product
candidates or any future product candidates, including methods of making or using these product candidates, will not
infringe existing or future third-party patents. We may in the future become party to, or threatened with, adversarial
proceedings or litigation regarding intellectual property rights with respect to our product candidates and technology,
including contested proceedings before the USPTO. Our competitors or other third parties may assert infringement
claims against us, alleging that our products are covered by their patents.
Given the vast number of patents in our field of technology, we cannot be certain that we do not infringe
existing patents or that we will not infringe patents that may be granted in the future. Many companies have filed, and
continue to file, patent applications related to immunomodulation. Some of these patent applications have already been
allowed or issued, and others may issue in the future. For example, we are aware of third-party patents that contain
claims potentially relevant to mavrilimumab and vixarelimab. If the claims of any of these patents are asserted against
us, we do not believe our proposed activities related to mavrilimumab and vixarelimab would be found to infringe any
valid claim of these patents. While we may decide to initiate proceedings to challenge the validity of these or other
patents in the future, we may be unsuccessful, and courts or patent offices in the United States and abroad could uphold
the validity of any such patent. If we were to challenge the validity of any issued U.S. patent in court, we would need to
overcome a statutory presumption of validity that attaches to every U.S. patent. This means that in order to prevail, we
would have to present clear and convincing evidence as to the invalidity of the patent’s claims. In order to avoid
infringing these or any other third-party patents, we may find it necessary or prudent to obtain licenses to such patents
from such third-party intellectual property holders. However, we may be unable to secure such licenses or otherwise
acquire or in-license any compositions, methods of use processes or other intellectual property rights from third parties
that we identify as necessary for our current or future product candidates. The licensing or acquisition of third-party
intellectual property rights is a competitive area, and several more established companies may also pursue strategies to
license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established
companies may have a competitive advantage over us due to their size, capital resources and greater clinical
development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be
unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property
rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to
successfully obtain rights to required third-party intellectual property or maintain the existing intellectual property rights
we have, we may have to cease development of the relevant program or product candidate, which could have a material
adverse effect on our business, financial condition, results of operations and prospects.
97
Since our product candidates are being developed for use in fields that are competitive and of strong interest to
pharmaceutical and biotechnology companies, we will likely seek to file additional patent applications and may have
additional patents granted in the future, based on our future research and development efforts. Furthermore, because
patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because
pending patent claims can be revised before issuance, there may be applications now pending which may later result in
issued patents that may be infringed by the manufacture, use or sale of our product candidates. Regardless of when filed,
we may fail to identify relevant third-party patents or patent applications, or we may incorrectly conclude that a
third-party patent is invalid or not infringed by our product candidates or activities. If a patent holder believes our
product candidate infringes its patent, the patent holder may sue us even if we have received patent protection for our
technology. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant drug
revenue and against whom our own patent portfolio may thus have no deterrent effect. If a patent infringement suit were
threatened or brought against us, we could be forced to stop or delay research, development, manufacturing or sales of
the product candidate that is the subject of the actual or threatened suit.
If we are found to infringe a third-party’s intellectual property rights, we could be required to obtain a license
from such third party to continue developing and marketing our product candidates and technology. Under any such
license, we would most likely be required to pay various types of fees, milestones, royalties or other amounts. However,
we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to
obtain such a license, it could be granted on non-exclusive terms, thereby providing our competitors and other third
parties access to the same technologies licensed to us. Without such a license, we could be forced, including by court
order, to cease developing and commercializing the infringing technology or product candidate, or forced to redesign it,
or to cease some aspect of our business operations. In addition, we could be found liable for monetary damages,
including treble damages and attorneys’ fees if we are found to have willfully infringed such third-party patent rights.
We may be required to indemnify collaborators or contractors against such claims. A finding of infringement could
prevent us from commercializing our product candidates or force us to cease some of our business operations, which
could materially harm our business. Even if we are successful in defending against such claims, litigation can be
expensive and time consuming and would divert management’s attention from our core business. Any of these events
could harm our business significantly.
We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which
could be expensive, time consuming and unsuccessful.
Competitors and other third parties may infringe, misappropriate or otherwise violate our patents and other
intellectual property rights, whether owned or in-licensed. To counter infringement or unauthorized use, we or our
current or future collaborators may be required to file infringement claims against these infringers. A court may disagree
with our allegations, however, and may refuse to stop the other party from using the technology at issue on the grounds
that our patents do not cover the third-party technology in question. Further, such third parties could counterclaim that
we infringe their intellectual property or that a patent we have asserted against them is invalid or unenforceable. In
patent litigation in the United States, defendant counterclaims challenging the validity, enforceability or scope of
asserted patents are commonplace. In addition, third parties may initiate legal proceedings against us to assert such
challenges to our intellectual property rights. The outcome of any such proceeding is generally unpredictable. Grounds
for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of
novelty, obviousness or non-enablement. Patents may be unenforceable if someone connected with prosecution of the
patent withheld relevant information from the USPTO or made a misleading statement during prosecution. It is possible
that prior art of which we or our licensors and the patent examiner were unaware during prosecution exists, which could
render our patents invalid. Moreover, it is also possible that prior art may exist that we are aware of but do not believe is
relevant to our current or future patents, but that could nevertheless be determined to render our patents invalid.
Some of our competitors may be able to devote significantly more resources to intellectual property litigation,
and may have significantly broader patent portfolios to assert against us if we assert our rights against them. Further,
because of the substantial discovery required in connection with intellectual property litigation, there is a risk that some
of our confidential information could be disclosed or otherwise compromised during litigation.
98
An adverse result in any litigation proceeding could put one or more of our patents, whether owned or
in-licensed, at risk of being invalidated or interpreted narrowly. If a defendant were to prevail on a legal assertion of
invalidity or unenforceability of our patents covering one of our product candidates, we would lose at least part, and
perhaps all, of the patent protection covering such product candidate. Competing products may also be sold in other
countries in which our patent coverage might not exist or be as strong. If we lose a patent lawsuit outside of the United
States, alleging our infringement of a competitor’s patents, we could be prevented from marketing our products in one or
more such countries. Any of these outcomes would have a materially adverse effect on our business.
Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their
normal responsibilities.
Litigation or other legal proceedings relating to intellectual property claims, with or without merit, is
unpredictable and generally expensive and time consuming and is likely to divert significant resources from our core
business, including distracting our technical and management personnel from their normal responsibilities. Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk
that some of our confidential information could be compromised by disclosure during this type of litigation. In addition,
there could be public announcements of the results of hearings, motions or other interim proceedings or developments
and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on
the price of our Class A common shares. Such litigation or proceedings could substantially increase our operating losses
and reduce the resources available for development activities or any future sales, marketing or distribution activities.
We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings.
Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can
because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly,
despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from
successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of
patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.
Obtaining and maintaining patent protection depends on compliance with various procedural, document submission,
fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be
reduced or eliminated for non-compliance with these requirements.
The USPTO and various governmental patent agencies outside of the United States require compliance with a
number of procedural, documentary, fee payment and other similar provisions during the patent application process. In
addition, periodic maintenance fees on issued patents often must be paid to the USPTO and patent agencies outside of
the United States over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of
a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can
result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in
the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent
application include, but are not limited to, failure to respond to official actions within prescribed time limits,
non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain
the patents and patent applications covering our products or technologies, we may not be able to stop a competitor from
marketing products that are the same as or similar to our product candidates, which would have a material adverse effect
on our business. In addition, if we fail to apply for applicable patent term extensions or adjustments, we will have a more
limited time during which we can enforce our granted patents. In addition, if we are responsible for patent prosecution
and maintenance of patent rights in-licensed to us, any of the foregoing could expose us to liability to the applicable
patent owner.
We may not be able to effectively enforce our intellectual property rights throughout the world.
Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would
be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly in developing
countries. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by
unforeseen changes in intellectual property laws outside of the United States. In addition, the patent laws of some such
99
countries do not afford intellectual property protection to the same extent as the laws of the United States. Many
companies have encountered significant problems in protecting and defending intellectual property rights in certain
jurisdictions outside of the United States. Varying filing dates in international countries may also permit intervening
third parties to allege priority to patent applications claiming certain technology. The legal systems of some countries,
particularly developing countries, do not favor the enforcement of patents and other intellectual property rights. This
could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual
property rights. For example, many countries outside of the United States have compulsory licensing laws under which a
patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against
certain parties, including government agencies or government contractors. Consequently, we may not be able to prevent
third parties from practicing our inventions in all countries outside the United States. Competitors may use our
technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further,
may export otherwise infringing products to territories where we have patent protection, if our ability to enforce our
patents to stop infringing activities is inadequate. These products may compete with our product candidates, and our
patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
Proceedings to enforce our patent rights, whether owned or in-licensed, in jurisdictions outside of the United
States, whether or not successful, could result in substantial costs and divert our efforts and resources from other aspects
of our business. Furthermore, while we intend to pursue protection for our intellectual property rights in the major
markets for our product candidates, we cannot ensure that we will be able to initiate or maintain similar efforts in all
jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual
property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the
United States and other countries may affect our ability to obtain and enforce adequate intellectual property protection
for our technology.
Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general,
thereby impairing our ability to protect our product candidates.
As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual
property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both
technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Patent reform
legislation in the United States and other countries, including the Leahy-Smith America Invents Act, or Leahy-Smith
Act, signed into law on September 16, 2011, could increase those uncertainties and costs. The Leahy-Smith Act includes
a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are
prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the
validity of patents. In addition, the Leahy-Smith Act has transformed the U.S. patent system into a first-to-file system.
The first-to-file provisions, however, only became effective on March 16, 2013. Accordingly, it is not yet clear what, if
any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its
implementation could make it more difficult to obtain patent protection for our inventions, whether owned or
in-licensed, and increase the uncertainties and costs surrounding the prosecution of our patent applications and the
enforcement or defense of our issued patents, in each case whether owned or in-licensed, all of which could harm our
business, results of operations and financial condition.
Among some of the other changes introduced by the Leahy-Smith Act are changes that limit where a patentee
may file a patent infringement suit and provide new opportunities for third parties to challenge issued patents in the
USPTO. We may be subject to the risk of third-party prior art submissions on pending applications or become a party to
opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our
patents. There is a lower standard of evidence necessary to invalidate a patent claim in a USPTO proceeding relative to
the standard in U.S. district or federal court. This could lead third parties to challenge and successfully invalidate our
patents that would not otherwise be invalidated if challenged through the court system.
The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent
protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition,
there have been recent proposals for additional changes to the patent laws of the United States and other countries that, if
adopted, could impact our ability to obtain or maintain patent protection for our proprietary technology or our ability to
100
enforce our proprietary technology. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and
the relevant law-making bodies in other countries, the laws and regulations governing patents could change in
unpredictable ways that would weaken our ability to obtain new patents; enforce or shorten the term of our existing
patents and patents that we might obtain in the future; shorten the term that has been lengthened by patent term
adjustment of our existing patents or patents that we might obtain in the future; or challenge the validity or enforceability
of our patents that may be asserted against us by our competitors or other third parties. Any of these outcomes could
have a material adverse effect on our business.
If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be
harmed.
In addition to the protection afforded by patents, we may rely upon unpatented trade secret protection,
unpatented know-how and continuing technological innovation to develop and maintain our competitive position.
Although we seek to protect our proprietary technology and processes, in part, by entering into confidentiality
agreements with our collaborators, scientific advisors, contractors, employees, independent contractors and consultants,
and invention assignment agreements with our independent contractors, consultants, scientific advisors and employees,
we may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the
parties to these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party
that may have or have had access to our confidential information or proprietary technology and processes. Monitoring
unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our
proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, contractors and
consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not
have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Moreover, if
confidential information that is licensed or disclosed to us by our partners, collaborators or others is inadvertently
disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information.
Enforcing a claim that a third party illegally obtained and is using our trade secrets, like patent litigation, is expensive
and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less
willing to protect trade secrets.
We cannot be certain that the steps we have taken will prevent unauthorized use or unauthorized reverse
engineering of our technology. Monitoring unauthorized use of our intellectual property is difficult and costly. We may
not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. The steps
we have taken to protect our proprietary rights may not be adequate to prevent misappropriation of our intellectual
property.
We also seek to preserve the integrity and confidentiality of our data and other confidential information by
maintaining physical security of our premises and physical and electronic security of our information technology
systems. While we have confidence in these individuals, organizations and systems, agreements or security measures
may be breached. Detecting the disclosure or misappropriation of confidential information and enforcing a claim that a
party illegally disclosed or misappropriated confidential information is difficult, expensive and time consuming, and the
outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. In addition, our
confidential information may otherwise become known or be independently discovered by competitors, in which case
we would have no right to prevent them, or those to whom they communicate it, from using that technology or
information to compete with us. We may in the future rely on trade secret protection, which would be subject to the risks
identified above with respect to confidential information.
Our trade secrets could otherwise become known or be independently discovered by our competitors.
Competitors could purchase our product candidates and attempt to replicate some or all of the competitive advantages
we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected
technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of
our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to
prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If
our trade secrets are not adequately protected so as to protect our market against competitors’ products, our competitive
position could be adversely affected, as could our business.
101
If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition
in our markets of interest and our business may be adversely affected.
Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or
declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these
trademarks and trade names in the United States or jurisdictions outside of the United States, which we need to build
name recognition among potential partners or customers in our markets of interest. At times, competitors or other third
parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and
possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims
brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or
unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our
trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.
Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or
other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could
adversely affect our business, financial condition, results of operations and prospects.
We have not yet registered trademarks for a commercial trade name for our product candidates in the United States
or jurisdictions outside of the United States and failure to secure such registrations could adversely affect our
business.
We have not yet registered trademarks for a commercial trade name for some of our product candidates in the
United States or any jurisdiction outside of the United States. During trademark registration proceedings, we may
receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome
such rejections. In addition, in the USPTO and in comparable agencies in many jurisdictions outside of the United
States, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered
trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not
survive such proceedings. Moreover, any name we propose to use with our product candidates in the United States must
be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA
typically conducts a review of proposed product names, including an evaluation of potential for confusion with other
product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend
significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable
trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.
Other Risks Related to Our Business
The COVID-19 pandemic, and measures taken in response to the pandemic or the easing of such measures, could
have an adverse impact that is significant on our business and operations as well as the business or operations of our
manufacturers, CROs and other third parties with whom we conduct business or otherwise engage, including the
FDA and other regulatory authorities, and has impacted and could continue to impact the global economy, which
may have a material adverse effect on our business, operations and financial position.
The COVID-19 pandemic, and measures taken in response to the pandemic or the easing of such measures,
could cause significant disruption in our business and operations and could cause significant disruption the business and
operations of our manufacturers, CROs upon whom we rely to conduct our clinical trials, and other third parties with
whom we conduct business or otherwise engage, including the FDA and other regulatory authorities. For example, our
CRO for the Phase 1 clinical trial of KPL-404 notified us that, after a temporary pause due to the impact of the
COVID-19 pandemic, they resumed certain clinical trial activities, but we also engaged an additional CRO to conduct
additional portions of the trial at another clinical trial site.
The federal and state governments in the United States and the governments of other countries around the globe
have implemented various measures in response to the COVID-19 pandemic, including significant restrictions on
businesses as well as travel into and within the countries in which our manufacturers produce our product candidates or
where we conduct our clinical trials or otherwise conduct business or engage with other third parties. In response to the
COVID-19 pandemic and measures introduced by state and federal governments in the United States, we implemented
102
workplace protocols at our facilities. While the majority of our employees are able to carry out their responsibilities
working outside of our physical locations, for our essential workers and those choosing to return to our offices to carry
out their responsibilities, we implemented additional safety measures, including occupancy limits, restricting business
travel, providing and requiring the use of personal protective equipment, self-screening prior to accessing our facilities,
and others. We continue to monitor the developments, restrictions and requirements in jurisdictions where we have
offices, and plan to update the protocols for our offices as applicable. If the COVID-19 pandemic and measures
undertaken in response to the pandemic are prolonged, or the easing of any of such measures has significant adverse
consequences, we may experience and our manufacturers, CROs or other third parties with whom we conduct business
or otherwise engage, may experience or continue to experience staffing shortages or reprioritizations, production
slowdowns or stoppages, and disruptions in delivery systems now or in the future. For example, the COVID-19
pandemic and measures taken in response to the pandemic, including business and travel restrictions and social-
distancing to halt the spread of the pandemic, has had an impact on certain aspects of our commercialization strategy,
including interacting with third-party payors, physicians and patient advocacy groups to build disease awareness, and
conducting in-person market research as well as recruiting qualified candidates to enhance our commercial operations
and support commercialization, which, if prolonged, may impede the effective commercialization of our product
candidates and result in lower than anticipated future revenue.
The COVID-19 pandemic may also have a significant adverse impact our preclinical studies and clinical trials,
which could significantly impede, delay, limit or prevent the clinical development of our product candidates and
ultimately lead to the delay or denial of regulatory approval of our product candidates, which would materially adversely
affect our business and operations, including our ability to generate revenue. See “Risk Factors — Risks related to
product development — The COVID-19 pandemic, and measures taken in response to the pandemic, could have an
adverse impact our current or planned preclinical studies and clinical trials, which could be significant.”
Moreover, the COVID-19 pandemic is impacting the global economy, and the U.S. economy in particular, with
the potential for the economic downturn to be severe and prolonged. A severe or prolonged economic downturn could
result in a variety of risks to our business, including disruptions in the financial markets. For example, the trading prices
of biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. These disruptions
could adversely impact our ability to raise additional capital when needed or on acceptable terms, if at all.
The COVID-19 pandemic and measures undertaken in response to the pandemic continue to rapidly evolve.
There is uncertainty relating to the potential effect of COVID-19 on our business and operations. The extent of the
impact on our business and operations will depend on future developments, which are highly uncertain and cannot be
predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, business
and travel restrictions, quarantines, shelter-in-place orders and social distancing in the United States and other countries,
business closures or business disruptions, the availability and efficacy of vaccines, the effectiveness of other actions
taken in the United States and other countries to contain and treat the disease, and the impact of any easing of such
measures.
Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization
of any product candidates that we may develop.
We face an inherent risk of product liability exposure related to the testing of our product candidates in human
clinical trials and will face an even greater risk if we commercially sell any product candidates that we may develop. If
we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur
substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:
•(cid:3)
•(cid:3)
•(cid:3)
decreased demand for any product candidates that we may develop;
injury to our reputation and significant negative media attention;
regulatory investigations that could require costly recalls or product modifications;
•(cid:3) withdrawal of clinical trial participants;
103
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
significant costs to defend the related litigation;
substantial monetary awards to trial participants or patients;
loss of potential revenue;
the diversion of management’s attention away from managing our business; and
the inability to commercialize any product candidates that we may develop.
Although we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that
we may incur and is subject to deductibles and coverage limitations. We anticipate that we will need to increase our
insurance coverage when and if we successfully commercialize any product candidate. Insurance coverage is
increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount
adequate to satisfy any liability that may arise. If we are unable to obtain insurance at acceptable cost or otherwise
protect against potential product liability claims, we will be exposed to significant liabilities, which may materially and
adversely affect our business and financial position. These liabilities could prevent or interfere with our
commercialization efforts.
Enacted and future healthcare legislation may have a material adverse effect on our business and results of
operations.
In the United States, EU and other jurisdictions, there have been and we expect there will continue to be a
number of legislative and regulatory initiatives and proposed changes to the healthcare system that could affect our
future operations. For example, in the United States, the Affordable Care Act substantially changes the way healthcare is
financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The
Affordable Care Act, among other things, subjects biologic products to potential competition by lower-cost biosimilars,
addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are
calculated for drugs and biologics that are inhaled, infused, instilled, implanted or injected, increases the minimum
Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to
individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of
certain branded prescription drugs and biologics, and a new Medicare Part D coverage gap discount program, in which
manufacturers must agree to offer 50% point-of-sale discounts which, through subsequent legislative amendments, was
increased to 70%, off negotiated prices of applicable brand drugs and biologics to eligible beneficiaries during their
coverage gap period, as a condition for the manufacturer’s outpatient products to be covered under Medicare Part D.
Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable
Care Act. For example, the Tax Cuts and Jobs Act was enacted, which, among other things, removes penalties for not
complying with the Affordable Care Act’s individual mandate to carry health insurance. On December 14, 2018, a U.S.
District Court Judge in Texas ruled that the Affordable Care Act is unconstitutional in its entirety because the
“individual mandate” was repealed by Congress as part of the Tax Act. On December 18, 2019, the U.S. Court of
Appeals for the 5th Circuit upheld the district court’s decision that the individual mandate was unconstitutional but
remanded the case back to the District Court to determine whether the remaining provisions of the Affordable Care Act
are invalid as well. The U.S. Supreme Court is currently reviewing the case, although it is unclear when a decision will
be made or how the Supreme Court will rule. In addition, there may be other efforts to challenge, repeal or replace the
ACA, or portions thereof, which will affect our business. It is possible that the ACA, as currently enacted or as it may be
amended in the future, and other healthcare reform measures that may be adopted in the future, could have a material
adverse effect on our industry generally and on our ability to successfully commercialize our product candidates, if
approved.
In addition, other legislative changes have been proposed and adopted in the United States since the Affordable
Care Act was enacted. The Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare
payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent
legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension
104
from May 1, 2020 through March 31, 2021, unless additional Congressional action is taken. The American Taxpayer
Relief Act of 2012, among other things, further reduced Medicare payments to several types of providers.
Additionally, there has been increasing legislative and enforcement interest in the United States with respect to
specialty drug pricing practices. Specifically, there have been several recent Congressional inquiries and proposed and
enacted federal and state legislation designed to, among other things, bring more transparency to drug and biologic
pricing, reduce the cost of prescription drugs and biologics under Medicare, review the relationship between pricing and
manufacturer patient programs and reform government program reimbursement methodologies for drugs and biologics.
For example, in September 2018, CMS announced that it will allow Medicare Advantage Plans the option to use step
therapy for Part B drugs beginning January 1, 2019. Moreover, payment methodologies may be subject to changes in
healthcare legislation and regulatory initiatives. We expect that additional U.S. federal healthcare reform measures will
be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare
products and services, which could result in reduced demand for our product candidates or additional pricing pressures.
Individual states and municipalities in the United States have also become increasingly active in passing
legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including
price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost
disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and
bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could
harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities
and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which
suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate
demand for our product candidates, if approved, or put pressure on our product pricing.
In the EU, similar political, economic and regulatory developments may affect our ability to profitably
commercialize our product candidates, if approved. In addition to continuing pressure on prices and cost containment
measures, legislative developments at the EU or member state level may result in significant additional requirements or
obstacles that may increase our operating costs. The delivery of healthcare in the EU, including the establishment and
operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national,
rather than EU, law and policy. National governments and health service providers have different priorities and
approaches to the delivery of health care and the pricing and reimbursement of products in that context. In general,
however, the healthcare budgetary constraints in most EU member states have resulted in restrictions on the pricing and
reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national
regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of
our product candidates, restrict or regulate post-approval activities and affect our ability to commercialize our product
candidates, if approved.
In markets outside of the United States and the EU, reimbursement and healthcare payment systems vary
significantly by country, and many countries have instituted price ceilings on specific products and therapies.
We cannot predict the likelihood, nature or extent of government regulation that may arise from future
legislation or administrative action, either in the United States, the EU or elsewhere. For example, the new presidential
administration may change governmental policies and regulations that affect our operations and business, including our
clinical trials, regulatory approval, pharmaceutical pricing and reimbursement. If we or any third party we may engage
are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we
or such third party are not able to maintain regulatory compliance, our product candidates may lose any regulatory
approval that may have been obtained and we may not achieve or sustain profitability.
Unfavorable global economic or operational conditions could adversely affect our business, financial condition or
results of operations.
Our results of operations could be adversely affected by general conditions in the global economy and in the
global financial markets. For example, the COVID-19 pandemic is impacting the global economy with the potential for
the economic downturn to be severe and prolonged. A severe or prolonged economic downturn caused by the economic
105
impact from the COVID-19 pandemic could result in a variety of risks to our business, such as disruptions to our
operations and the operations of our manufacturers, CROs or other third parties with whom we conduct business or
engage, including as a result of disruptions in travel into and within the countries in which we conduct our clinical trials
or our manufacturers produce our product candidates or we conduct business or otherwise engage with such other third
parties. These disruptions could adversely affect our ability to satisfy the required supply for any of our product
candidates or successfully complete preclinical and clinical development of our product candidates, which could require
us to incur additional costs, and impair our ability to obtain regulatory approval of our product candidates and generate
revenue. A severe or prolonged economic downturn could also impair our ability to raise additional capital when needed
or on acceptable terms, if at all. Doing business internationally involves a number of other risks, including but not
limited to:
•(cid:3) multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and
import restrictions;
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
employment laws, regulatory requirements and other governmental approvals, permits and licenses;
failure by us to obtain and maintain regulatory approvals for the use of our products in various countries;
additional potentially relevant third-party patent rights;
complexities and difficulties in obtaining protection and enforcing our intellectual property;
difficulties in staffing and managing operations outside of the United States;
complexities associated with managing multiple payor reimbursement regimes, government payors or
patient self-pay systems;
limits in our ability to penetrate international markets;
financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local
and regional financial crises on demand and payment for our products and exposure to foreign currency
exchange rate fluctuations;
natural disasters, political and economic instability, including wars, terrorism, political unrest, outbreak of
disease and boycotts;
curtailment of trade, and other business restrictions;
certain expenses including, among others, expenses for travel, translation and insurance; and
regulatory and compliance risks that relate to maintaining accurate information and control over sales and
activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records
provisions or its anti-bribery provisions.
Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current
economic climate and financial market conditions could adversely impact our business.
106
Our internal technology systems, or those of our third-party CMOs, CROs or other contractors, consultants and
service providers, may fail or suffer cyber-attacks or security breaches, which could result in a material disruption of
our or such third-party’s business or operations and our development programs for our product candidates’ or loss of
other assets, including funds.
Despite the implementation of security measures and cyber-security insurance, our internal technology systems
and those of our third-party CMOs, CROs and other contractors, consultants and service providers as well as employees
that are working outside of our facilities are vulnerable to damage from viruses, unauthorized access and attacks, theft,
natural disasters, terrorism, war and telecommunication and electrical failures. As a result of the COVID-19 pandemic,
we may experience increased cybersecurity risks due to the impacts from prolonged remote work arrangements. Attacks
upon information technology systems are increasing in their frequency, levels of persistence, sophistication and
intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives
and expertise. As a result of the COVID-19 pandemic, we may also face increased cybersecurity risks due to our reliance
on internet technology and the number of our employees who are working remotely, which may create additional
opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain
unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a
target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also
experience security breaches that may remain undetected for an extended period. If such an event were to occur and
cause interruptions in our business and operations or those of our third-party CMOs, CROs and other contractors,
consultants and service providers as well as employees that are working outside of our facilities, it could result in a
material disruption of our or such third-party’s business or operations and our development programs of our product
candidates’ or loss of other assets, including funds. For example, the loss of clinical trial data for our product candidates
could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the
data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or
other data or applications relating to our technology or product candidates, or inappropriate disclosure or theft of
confidential or proprietary information, we could incur liabilities not covered by our cyber-security insurance and the
further development of our product candidates could be delayed.
Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations,
standards and other requirements could adversely affect our business, results of operations, and financial condition.
Most healthcare providers, including research institutions from which we obtain patient health information, are
subject to privacy and security regulations promulgated under HIPAA, as amended. We are not currently acting as a
covered entity or business associate under HIPAA and thus are not subject to its requirements or penalties. However, any
person may be prosecuted under HIPAA’s criminal provisions either directly or under aiding-and-abetting or conspiracy
principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we
knowingly receive individually identifiable health information from a HIPAA-covered healthcare provider or research
institution that has not satisfied HIPAA’s requirements for disclosure of individually identifiable health information. In
addition, we may maintain sensitive personally identifiable information, including health information, that we receive
throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their
healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring
notification of affected individuals and state regulators in the event of a breach of personal information, which is a
broader class of information than the health information protected by HIPAA.
In addition, certain state laws govern the privacy and security of health information in certain circumstances,
some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may
not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can
result in the imposition of significant civil and/or criminal penalties and private litigation. For example, California
enacted the California Consumer Privacy Act, or the CCPA, on June 28, 2018, which went into effect on January 1,
2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of
certain personal information sharing and receive detailed information about how their personal information is used. The
CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to
increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Further, the
California Privacy Rights Act, or CPRA, recently passed in California. The CPRA will impose additional data protection
107
obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit
requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data
protection agency authorized to issue substantive regulations and could result in increased privacy and information
security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance
investment and potential business process changes may be required.
Our clinical trial programs outside the United States may implicate international data protection laws, including
the EU General Data Protection Regulation and legislation of the EU member states implementing it, or GDPR, and
legislation of the EU and EEA member states implementing it. The GDPR went into effect in May 2018 and imposes
strict requirements for processing the personal data of individuals within the EEA. Companies that must comply with the
GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection
requirements and potential fines for noncompliance of up to €20 million or 4% of the annual global revenues of the
noncompliant company, whichever is greater. Further from January 1, 2021, we may be subject to the GDPR and also
the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law.
The UK GDPR mirrors the fines under the GDPR, e.g. fines up to the greater of €20 million (£17.5 million) or 4% of
global turnover. The relationship between the United Kingdom and the European Union in relation to certain aspects of
data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the
medium to longer term, and how data transfers to and from the United Kingdom will be regulated in the long term.
Currently there is a four to six-month grace period agreed in the EU and UK Trade and Cooperation Agreement, ending
June 30, 2021 at the latest, whilst the parties discuss an adequacy decision. However, it is not clear whether (and when)
an adequacy decision may be granted by the European Commission enabling data transfers from EU member states to
the United Kingdom long term without additional measures. These changes will lead to additional costs and increase our
overall risk exposure. Our activities outside the United States impose additional compliance requirements and generate
additional risks of enforcement for noncompliance. Failure by our CROs and other third-party contractors to comply
with the strict rules on the transfer of personal data outside of the EU into the United States may result in the imposition
of criminal and administrative sanctions on such collaborators, which could adversely affect our business.
Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws and genetic
testing laws may apply directly to our operations or those of our collaborators and may impose restrictions on our
collection, use and dissemination of individuals’ health information. Moreover, patients about whom we or our
collaborators obtain health information, as well as the providers who share this information with us, may have statutory
or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant
capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we
have violated individuals’ privacy rights or breached our contractual obligations, even if we are not found liable, could
be expensive and time consuming to defend and could result in adverse publicity that could harm our business.
If we or third-party CMOs, CROs or other contractors or consultants fail to comply with applicable regulatory
requirements, we could be subject to a range of regulatory actions that could affect our or our contractors’ ability to
develop and commercialize our product candidates and could harm or prevent sales of any affected products that we are
able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and
marketing our products. Any threatened or actual government enforcement action could also generate adverse publicity
and require that we devote substantial resources that could otherwise be used in other aspects of our business.
Securities class action and derivative lawsuits and other legal proceedings are often brought against companies,
which could result in substantial costs and divert management's attention.
Securities class action and derivative lawsuits and other legal proceedings are often brought against companies
following a decline in the market price of their securities. There can be significant fluctuations in market price for the
securities of early-stage biotechnology companies, such as us. As a result, we may be more susceptible to these types of
lawsuits and legal proceedings than other companies with more stable security prices. In connection with any litigation
or other legal proceedings, we could incur substantial costs, and such costs and any related settlements or judgments may
not be covered by insurance. We could also suffer an adverse impact on our reputation and a diversion of management’s
attention and resources, which could have a material adverse effect on our business.
108
Although we maintain director and officer liability insurance coverage, it may not be adequate to cover all
liabilities that we may incur and is subject to deductibles and coverage limitations. Insurance coverage is increasingly
expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy
any liability that may arise. If we are unable to obtain insurance at acceptable cost or otherwise protect against potential
class action and derivative lawsuits and other legal proceedings or claims often brought against companies following a
decline in the market price of their securities, we will be exposed to significant liabilities, which may materially and
adversely affect our business and financial position.
We and our employees and third parties with whom we contract are increasingly utilizing social media tools as a
means of communication both internally and externally, and noncompliance with applicable requirements, policies
or contracts due to social media use or negative posts or comments could have an adverse effect on our business.
Despite our efforts to monitor evolving social media communication guidelines and comply with applicable
rules, there is risk that the use of social media by us or our employees to communicate about our product candidates or
business may cause us to be found in violation of applicable requirements. In addition, our employees or third parties
with whom we contract, such as our CROs or CMOs, may knowingly or inadvertently make use of social media in ways
that may not comply with our social media policy or other legal or contractual requirements, which may give rise to
liability, lead to the loss of trade secrets or other intellectual property or result in public exposure of personal information
of our employees, clinical trial patients, customers and others or information regarding our product candidates or clinical
trials. Clinical trial patients may also knowingly or inadvertently make use of social media in ways that may not comply
with legal or contractual requirements for participation in a clinical trial, including with respect to any AEs they may
experience, which may give rise to liability and regulatory risk. Furthermore, negative posts or comments about us or our
product candidates in social media could seriously damage our reputation, brand image and goodwill. Any of these
events could have a material adverse effect on our business, prospects, operating results and financial condition and
could adversely affect the price of our Class A common shares.
Our employees, principal investigators, CROs, consultants and other third-party service providers may engage in
misconduct or other improper activities, including noncompliance with regulatory standards and requirements and
insider trading.
We are exposed to the risk that our employees, principal investigators, CROs, consultants and other third-party
service providers may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include
intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the
FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate
information to such authorities; healthcare fraud and abuse laws and regulations in the United States and abroad; or laws
that require the reporting of financial information or data accurately.
In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive
laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These
laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, including
off-label promotion, sales commission, customer incentive programs and other business arrangements. Activities subject
to these laws also involve the improper use of information obtained in the course of clinical trials or creating fraudulent
data in our preclinical studies or clinical trials, which could result in regulatory sanctions and cause serious harm to our
reputation.
It is not always possible to identify and deter misconduct by employees and other third parties. The precautions
we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or
in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with
these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other
misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending
ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition
of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in
Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits
109
and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our
business and our results of operations.
Risks Related to Our Common Shares
The concentration of ownership of our Class B common shares, which are held primarily by our executive officers
and certain other members of our senior management, and the conversion rights of the holders of our Class A1
common shares, which shares are held primarily by entities affiliated with certain of our directors, and Class B1
common shares, all of which shares are held by entities affiliated with certain of our directors means that such
persons are, and such entities may in the future be, able to influence certain matters submitted to our shareholders
for approval; and such concentration and conversion rights and resulting concentration of control may have an
adverse effect on the price of our Class A common shares and may result in our Class A common shares being
undervalued.
Each Class A common share is entitled to one vote per Class A common share and each Class B common share
is entitled to ten votes per Class B common share. Our Class A1 common shares and Class B1 common shares have no
voting rights. As a result, all matters submitted to our shareholders are decided by the vote of holders of our Class A
common shares and Class B common shares. As a result of the multi-class voting structure of our common shares, the
holders of our Class B common shares, which consist primarily of our executive officers and certain other members of
our senior management, collectively control over a majority of the combined voting power of our common shares and
therefore are able to control the outcome of certain matters submitted to our shareholders for approval. As of January 31,
2021, the holders of Class A common shares accounted for approximately 59% of our aggregate voting power and the
holders of Class B common shares accounted for approximately 41% of our aggregate voting power. Our executive
officers and certain other members of our senior management hold Class A common shares and Class B common shares
representing approximately 37% of our aggregate voting power as of January 31, 2021 and may have the ability to
influence the outcome of certain matters submitted to our shareholders for approval.
However, this percentage may change depending on any conversion of our Class B common shares, Class A1
common shares or Class B1 common shares. Each holder of our Class B common shares has the ability to convert any
portion of its Class B common shares into Class B1 common shares or Class A common shares at any time with advance
notice to us. Each holder of our Class B1 common shares has the ability to convert any portion of its Class B1 common
shares into Class A common shares or Class B common shares at any time with advance notice to us, and each holder of
our Class A1 common shares has the ability to convert any portion of its Class A1 common shares into Class A common
shares at any time with advance notice to us. Our Class A1 common shares and Class B1 common shares cannot be
converted if, immediately prior to or following such conversion, the holder and its affiliates beneficially own, or would
beneficially own, more than 4.99% of our issued and outstanding Class A common shares unless such holder provides us
with 61-days’ prior notice that it intends to increase, decrease or waive such threshold upon conversion. As of
January 31, 2021, entities affiliated with certain members of our directors could convert their Class A1 common shares
and Class B1 common shares upon 61-days’ prior written notice into Class A common shares and Class B common
shares, respectively, which in the aggregate would result in such entities holding approximately 77% of our aggregate
voting power and having the ability to control the outcome of certain matters submitted to our shareholders for approval.
Due to these conversion rights, holders of our Class A1 common shares and our Class B1 common shares
could, at any time with appropriate advance notice to us, significantly increase their voting control of us, which could
result in their ability to significantly influence or control matters submitted to our shareholders for approval and would
decrease the ability of the current holders of our Class A common shares and Class B common shares to influence or
control matters submitted to our shareholders for approval. In addition, the conversion of Class B common shares to
Class A or Class B1 common shares will have the effect of increasing the relative voting power of the holders of Class B
common shares who retain their shares in the long term.
These conversion rights as well as concentrated control that limit certain shareholders’ ability to influence
corporate matters may have an adverse effect on the price of our Class A common shares, including our Class A
common shares being undervalued. Holders of our Class B common shares collectively control our management and
affairs and are able to influence or control the outcome of certain matters submitted to our shareholders for approval,
110
including the election of directors. Due to the conversion rights of the holders of our Class A1 and B1 common shares,
entities affiliated with certain of our directors could significantly increase their voting control of us, which could result in
their ability to significantly influence or control matters submitted to our shareholders for approval. As of January 31,
2021, entities affiliated with certain of our directors held 71% of our Class A1 common shares and 100% of our Class
B1 common shares. Upon 61-days’ prior written notice, these entities could convert their Class A1 common shares and
Class B1 common shares into Class A common shares and Class B common shares, which in the aggregate would result
in such entities holding approximately 77% of the voting power of our outstanding share capital. In addition, this
concentration of control might adversely affect certain corporate actions that some of our shareholders may view as
beneficial, for example, by:
•(cid:3)
•(cid:3)
•(cid:3)
delaying, deferring or preventing a change of control of us;
impeding a merger, consolidation, takeover or other business combination involving us; or
discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of
us.
The price of our Class A common shares is likely to continue to be volatile and fluctuate substantially, which could
result in substantial losses for holders of our Class A common shares.
Our share price is likely to continue to be volatile. The stock market in general and the market for
biopharmaceutical companies in particular have experienced extreme volatility, including as a result of the COVID-19
pandemic, that has often been unrelated to the operating performance of particular companies. As a result of this
volatility, our shareholders may not be able to sell their Class A common shares at or above the price they paid for their
shares. The market price for our Class A common shares may be influenced by many factors, including:
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
the results of clinical trials for our product candidates;
delays in the commencement, enrollment and the ultimate completion of clinical trials;
delays in approvals of our product candidates from the PDUFA goal date or failures in obtaining approval
of our product candidates;
the results and potential impact of competitive products or technologies;
our ability to manufacture and successfully produce our product candidates;
our ability to commercialize our product candidates, if approved;
the size of the market for our product candidates;
actual or anticipated changes in estimates as to financial results, capitalization, development timelines or
recommendations by securities analysts;
the level of expenses related to any of our product candidates or clinical development programs;
variations in our financial results or those of companies that are perceived to be similar to us;
financing or other corporate transactions, or our inability to obtain additional funding;
failure to meet or exceed the expectations of the investment community;
111
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
regulatory or legal developments in the United States and other countries;
the recruitment or departure of key personnel;
developments or disputes concerning patent applications, issued patents or other proprietary rights;
the results of our efforts to discover, develop, acquire or in-license additional product candidates or from
our entering into entering collaborations or other strategic transaction agreements;
changes in the structure of healthcare payment systems;
•(cid:3) market conditions in the pharmaceutical and biotechnology sectors;
•(cid:3)
•(cid:3)
•(cid:3)
general economic, industry and market conditions, including as a result of the COVID-19 pandemic and
measures taken in response to the pandemic;
changes in voting control of, or sales of our shares by, our executive officers and certain other members of
our senior management or entities affiliated with certain of our directors that hold our shares; and
the other factors described in this “Risk Factors” section.
In addition, given the limited trading history of our Class A common shares, there is a risk that an active trading
market for our shares will not be sustained, which could put downward pressure on the market price of our common
shares and thereby affect the ability of our shareholders to sell their shares. An inactive trading market may also impair
our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire other
companies or technologies by using our shares as consideration.
Additionally, the trading prices of biopharmaceutical companies have been highly volatile as a result of the
COVID-19 pandemic. The COVID-19 outbreak continues to rapidly evolve. The extent to which the outbreak may
impact our business in the future, including our preclinical studies and clinical trials, results of operations and financial
condition will depend on future developments, which are highly uncertain and cannot be predicted with confidence.
Such factors include but are not limited to the ultimate geographic spread of the disease, the duration of the pandemic,
business and travel restrictions, quarantines, shelter-in-place orders and social distancing in the United States and other
countries, business closures or business disruptions, the availability and efficacy of vaccines, the effectiveness of other
actions taken in the United States and other countries to contain and treat the disease and the impact of any easing of
such measures.
If securities or industry analysts cease publishing or publish unfavorable research or reports about us, our business
or our market, our shares price and trading volume could decline.
The trading market for our Class A common shares is influenced by the research and reports that equity
research analysts publish about us and our business. We do not have any control over the analysts or the content and
opinions included in their reports. The price of our Class A common shares could decline if one or more equity research
analysts downgrades our shares or issues other unfavorable commentary or research. If one or more equity research
analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our Class A common
shares could decrease, which in turn could cause the price of our Class A common shares or its trading volume to
decline.
Sales of a number of our Class A common shares in the public market, including Class A common shares issuable
upon conversion of our Class B, Class A1 and Class B1 common shares, could cause the share price of our Class A
common shares to fall.
112
A significant number of our Class A common shares are issuable upon conversion of our Class B, Class A1,
and Class B1 common shares. Our Class B and Class B1 common shares automatically convert into Class A common
shares upon transfer by a holder of such shares to persons or entities not affiliated with such holder. In addition, each
holder of our Class B common shares has the ability to convert any portion of its Class B common shares into Class B1
common shares or Class A common shares at any time with advance notice to us, each holder of our Class B1 common
shares has the ability to convert any portion of its Class B1 common shares into Class A common shares or Class B
common shares at any time with advance notice to us and each holder of our Class A1 common shares has the ability to
convert any portion of its Class A1 common shares into Class A common shares at any time with advance notice to us.
However, our Class A1 common shares and Class B1 common shares cannot be converted if, immediately prior to or
following such conversion, the holder and its affiliates beneficially own, or would beneficially own, more than 4.99% of
our issued and outstanding Class A common shares unless such holder provides us with 61-days’ prior notice that it
intends to increase, decrease or waive such threshold upon conversion.
As of January 31, 2021 upon conversions of our Class B, Class A1, and Class B1 common shares,
approximately 2.3 million of additional Class A common shares were issuable and eligible for resale in the public market
to the extent permitted by the provisions of Rule 144 promulgated under the Securities Act of 1933, as amended, or the
Securities Act, and such rule, Rule 144. In addition, as of January 31, 2021, there were approximately 10.2 million
Class A common shares subject to outstanding share options and restricted share units under our equity incentive plans
that may become eligible for sale in the public market to the extent permitted by the provisions of applicable vesting
schedules and Rule 144 and Rule 701 under the Securities Act.
Over a majority of our common shares are held by our executive officers and other members of our senior
management together with entities affiliated with certain of our directors. As of January 31, 2021, on an as-converted to
Class A common shares basis, these shareholders collectively held approximately 34.4 million of our Class A common
shares. If any of these shareholders sell, convert or transfer, or indicate an intention to sell, convert or transfer, a
substantial amount of their common shares (after certain restrictions on conversion or resale lapse), the market price of
our Class A common shares could decline.
Pursuant to our amended and restated investor rights agreement, or our investors rights agreement, certain
shareholders are entitled to certain registration rights with respect our Class A common shares, including Class A
common shares issuable upon conversions of our Class B, Class A1, and Class B1 common shares and upon the exercise
of certain rights to acquire Class A common shares, or collectively registerable securities, under the Securities Act. As of
January 31, 2021, on an as-converted to Class A common shares basis, we have registered approximately 31.8 million
Class A common shares held by certain holders affiliated with certain of our directors as well as certain other
shareholders pursuant to our investor rights agreement, which are freely tradable without restriction under the Securities
Act, to the extent permitted by Rule 144. Further, pursuant to the investors rights agreement (a) the holders affiliated
with certain of our directors are entitled to certain registration rights under the Securities Act with respect to registrable
securities they may own now or in the future and (b) our executive officers are also entitled to certain registration rights
under the Securities Act with respect to registrable securities they may own now or in the future, including, on an as-
converted to Class A common shares basis, the approximately 1.9 million Class A common shares held by our executive
officers as of January 31, 2021. If any of these Class A common shares are sold, or if it is perceived that they will be
sold, in the public market, the market price of our Class A common shares could decline.
Future sales or issuances of our common shares or rights to purchase common shares, including under our shelf
registration statement or pursuant to our equity incentive plans, could result in additional dilution of the percentage
ownership of our shareholders and could cause our Class A common share price to fall.
We will need additional capital in the future to continue our planned operations. To the extent we raise
additional capital by issuing additional Class A common shares, Class B common shares, Class A1 common shares,
Class B1 common shares or other equity securities, our shareholders may experience substantial dilution. We may sell
common shares, convertible securities or other equity securities in one or more transactions at prices and in a manner we
determine from time to time under our shelf registration statement or otherwise. If we sell common shares, convertible
securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent
113
sales. These sales may also result in material dilution to our existing shareholders, and new investors could gain rights
superior to our existing shareholders.
In addition, the consummation or performance of any acquisition, business combination, collaboration or other
strategic transaction we may undertake in furtherance of our growth strategy may cause dilution to our existing
shareholders if we issue equity securities for all or a portion of the consideration. For example, we acquired the
outstanding securities of Primatope in exchange for (a) upfront consideration of $10.0 million paid at closing in
March 2019 as well as milestone payments of $5.0 million that had been achieved and was also paid at closing and (b) a
milestone payment of $3.0 million that had been achieved after the closing and was paid in June 2019, all of which paid
in a combination of cash and our Class A common shares (inclusive of escrow and holdback share amounts) in
accordance with the terms and conditions of our stock purchase option agreement with Primatope, or the Primatope
Agreement. In June 2020, we released the escrow and in June and September of 2020 we issued all of the shares held
back in connection with the acquisition.
We will continue to incur increased costs as a result of operating as a public company, including in connection with
becoming a large accelerated filer, and our management will be required to devote substantial time to new
compliance initiatives.
As a public company, we incur significant legal, accounting and other expenses. In addition, the
Sarbanes-Oxley Act of 2002 and rules subsequently implemented by the SEC and The Nasdaq Global Select Market, or
Nasdaq, where our Class A common shares are listed, impose various requirements on public companies, including
establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our
management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these
rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming
and costly, which we expect to increase in connection with our becoming a large accelerated filer and no longer
qualifying as an emerging growth company effective December 31, 2020 and smaller reporting company effective
January 1, 2021. In addition, we expect our costs to increase as we comply with requirements that we were previously
exempt from as an emerging growth company and smaller reporting company and cause management and other
personnel to divert attention from operational and other business matters to devote substantial time to public company
reporting requirements. However, for this Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and
the executive compensation disclosure in our proxy statement for our 2021 annual meeting of shareholders, we are
permitted to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies.
We may choose to take advantage of some, but not all, of the available exemptions for smaller reporting companies.
Pursuant to Section 404, we are required to furnish a report by our management on our internal control over
financial reporting, including an attestation report on internal control over financial reporting issued by our independent
registered public accounting firm. To maintain compliance with Section 404, we engage in a process to document and
evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need
to continue to dedicate internal resources, engage outside consultants and refine and revise a detailed work plan to assess
and document the adequacy of internal control over financial reporting, continue steps to improve control processes as
appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting
and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we
nor our independent registered public accounting firm will be able to conclude that our internal control over financial
reporting is effective as required by Section 404. This could result in an adverse reaction in the financial markets due to
a loss of confidence in the reliability of our financial statements.
We have anti-takeover provisions in our amended and restated bye-laws that may discourage a change of control.
Our amended and restated bye-laws contain provisions that could make it more difficult for a third party to
acquire us. These provisions provide for:
•(cid:3)
•(cid:3)
a classified board of directors with staggered three-year terms;
directors only to be removed for cause;
114
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
an affirmative vote of 66 2/3% of the voting power of our voting shares for certain “business combination”
transactions that have not been approved by our board of directors;
our multi-class common share structure, which provides our holders of Class B common shares with the
ability to significantly influence the outcome of matters requiring shareholder approval, even if they own
less than a majority of our outstanding Class A common shares;
restrictions on the time period in which directors may be nominated; and
our board of directors to determine the powers, preferences and rights of our preferred shares and to issue
the preferred shares without shareholder approval.
These anti-takeover defenses could discourage, delay or prevent a transaction involving a change in control of
our company and may prevent our shareholders from receiving the benefit from any premium to the market price of our
Class A common shares offered by a bidder in a takeover context. Even in the absence of a takeover attempt, the
existence of these provisions may adversely affect the prevailing market price of our Class A common shares if the
provisions are viewed as discouraging takeover attempts in the future. These provisions could also discourage proxy
contests, make it more difficult for our shareholders to elect directors of their choosing and cause us to take corporate
actions other than those our shareholders desire.
Because we do not anticipate paying any cash dividends on our shares in the foreseeable future, capital appreciation,
if any, will be the sole source of gain for our shareholders.
We have never declared or paid cash dividends on our shares. We currently intend to retain all of our future
earnings, if any, to finance the growth and development of our business. Additionally, the proposal to pay future
dividends to shareholders will effectively be at the sole discretion of our board of directors after taking into account
various factors our board of directors deems relevant, including our business prospects, capital requirements, financial
performance and new product development. As a result, capital appreciation, if any, of our Class A common shares will
be the sole source of gain for our shareholders for the foreseeable future.
Risks Related to Owning Shares in a Bermuda Exempted Company and Certain Tax Risks
We are a Bermuda company and it may be difficult for our shareholders to enforce judgments against us or our
directors and executive officers.
We are a Bermuda exempted company. As a result, the rights of holders of our Class A common shares will be
governed by Bermuda law and our memorandum of association and amended and restated bye-laws. The rights of
shareholders under Bermuda law may differ from the rights of shareholders of companies incorporated in other
jurisdictions. It may be difficult for investors to enforce in the United States judgments obtained in U.S. courts against us
based on the civil liability provisions of the U.S. securities laws. It is doubtful whether courts in Bermuda will enforce
judgments obtained in other jurisdictions, including the United States, against us or our directors or officers under the
securities laws of those jurisdictions or entertain actions in Bermuda against us or our directors or officers under the
securities laws of other jurisdictions.
Our amended and restated bye-laws designate the Supreme Court of Bermuda as the choice of jurisdiction for
disputes that arise concerning the Bermuda Companies Act 1981, as amended, or the Companies Act, or out of or in
connection with our amended and restated bye-laws, which could limit our shareholders’ ability to choose the judicial
forum for disputes with us or our directors or officers.
Our amended and restated bye-laws provide that, unless we consent in writing to the selection of an alternative
jurisdiction, any dispute that arises concerning the Companies Act, or out of or in connection with our amended and
restated bye-laws, including any question regarding the existence and scope of any bye-law or whether there has been a
breach of the Companies Act or the amended and restated bye-laws by any of our officers or directors (whether or not
115
such a claim is brought in the name of a shareholder or in the name of our company) shall be subject to the jurisdiction
of the Supreme Court of Bermuda.
Any person or entity purchasing or otherwise acquiring any interest in any of our shares shall be deemed to
have notice of and consented to this provision. This choice of jurisdiction provision may limit a shareholder’s ability to
bring a claim in a judicial forum of its choosing for disputes with us or our directors or officers, which may discourage
lawsuits against us and our directors and officers. If a court were to find either choice of jurisdiction provision in our
amended and restated bye-laws to be inapplicable or unenforceable in an action, we may incur additional costs
associated with resolving the dispute in other jurisdictions, which could harm our results of operations.
Bermuda law differs from the laws in effect in the United States and may afford less protection to our shareholders.
We are organized under the laws of Bermuda. As a result, our corporate affairs are governed by the Companies
Act, which differs in some material respects from laws typically applicable to U.S. corporations and shareholders,
including the provisions relating to interested directors, amalgamations, mergers and acquisitions, takeovers, shareholder
lawsuits and indemnification of directors. Generally, the duties of directors and officers of a Bermuda company are owed
to the company only. Shareholders of Bermuda companies typically do not have rights to take action against directors or
officers of the company and may only do so in limited circumstances. Shareholder class actions are not available under
Bermuda law. The circumstances in which shareholder derivative actions may be available under Bermuda law are
substantially more proscribed and less clear than they would be to shareholders of U.S. corporations. The Bermuda
courts, however, would ordinarily be expected to permit a shareholder to commence an action in the name of a company
to remedy a wrong to the company where the act complained of is alleged to be beyond the corporate power of the
company or illegal, or would result in the violation of the company’s memorandum of association or bye-laws.
Furthermore, consideration would be given by a Bermuda court to acts that are alleged to constitute a fraud against the
minority shareholders or, for instance, where an act requires the approval of a greater percentage of the company’s
shareholders than those who actually approved it.
When the affairs of a company are being conducted in a manner that is oppressive or prejudicial to the interests
of some shareholders, one or more shareholders may apply to the Supreme Court of Bermuda, which may make such
order as it sees fit, including an order regulating the conduct of the company’s affairs in the future or ordering the
purchase of the shares of any shareholders by other shareholders or by the company. Additionally, under our amended
and restated bye-laws and as permitted by Bermuda law, each shareholder has waived any claim or right of action
against our directors or officers for any action taken by directors or officers in the performance of their duties, except for
actions involving fraud or dishonesty. In addition, the rights of our shareholders and the fiduciary responsibilities of our
directors under Bermuda law are not as clearly established as under statutes or judicial precedent in existence in
jurisdictions in the United States, particularly the State of Delaware. Therefore, our shareholders may have more
difficulty protecting their interests than would shareholders of a corporation incorporated in a jurisdiction within the
United States.
There are regulatory limitations on the ownership and transfer of our common shares.
Common shares may be offered or sold in Bermuda only in compliance with the provisions of the Companies
Act and the Bermuda Investment Business Act 2003, as amended, which regulates the sale of securities in Bermuda. In
addition, the Bermuda Monetary Authority must approve all issues and transfers of shares of a Bermuda exempted
company. However, the Bermuda Monetary Authority has, pursuant to its statement of June 1, 2005, given its general
permission under the Exchange Control Act 1972 and related regulations for the issue and free transfer of our common
shares to and among persons who are non-residents of Bermuda for exchange control purposes as long as the shares are
listed on an appointed shares exchange, which includes Nasdaq. This general permission would cease to apply if we
were to cease to be listed on Nasdaq.
We may become subject to unanticipated tax liabilities.
Although we are incorporated under the laws of Bermuda, we may become subject to income, withholding or
other taxes in certain other jurisdictions by reason of our activities and operations, and it is also possible that taxing
116
authorities in any such jurisdictions could assert that we are subject to greater taxation than we currently anticipate. Any
such non-Bermudan tax liability could materially adversely affect our results of operations.
Taxing authorities could reallocate our taxable income among our subsidiaries, which could increase our overall tax
liability.
We are incorporated under the laws of Bermuda and currently have subsidiaries in the United States, the United
Kingdom, Germany, Switzerland and France. If we succeed in growing our business, we expect to conduct increased
operations through our subsidiaries in various tax jurisdictions subject to transfer pricing arrangements between us and
such subsidiaries. If two or more affiliated companies are located in different countries, the tax laws or regulations of
each country generally will require that transfer prices be the same as those between unrelated companies dealing at
arms’ length and that appropriate documentation is maintained to support the transfer prices. While we believe that we
operate in compliance with applicable transfer pricing laws and intend to continue to do so, our transfer pricing
procedures are not binding on applicable tax authorities.
If tax authorities in any of these countries were to successfully challenge our transfer prices as not reflecting
arms’ length transactions, they could require us to adjust our transfer prices and thereby reallocate our income to reflect
these revised transfer prices, which could result in a higher tax liability to us. In addition, if the country from which the
income is reallocated does not agree with the reallocation, both countries could tax the same income, resulting in double
taxation. If tax authorities were to allocate income to a higher tax jurisdiction, subject our income to double taxation or
assess interest and penalties, it would increase our consolidated tax liability, which could adversely affect our financial
condition, results of operations and cash flows.
Changes in laws related to tax practices and substance requirements in Bermuda and other jurisdictions could
adversely affect our operations.
Our tax position could be adversely impacted by changes in tax rates, tax laws, tax practice, tax treaties or tax
regulations or changes in the interpretation thereof by the tax authorities in Europe (including the United Kingdom), the
United States, Bermuda and other jurisdictions, as well as being affected by certain changes currently proposed by the
Organization for Economic Co-operation and Development and their action plan on Base Erosion and Profit Shifting.
Such changes may become more likely as a result of recent economic trends in the jurisdictions in which we operate,
particularly if such trends continue. If such a situation was to arise, it could adversely impact our tax position and our
effective tax rate. Failure to manage the risks associated with such changes, or misinterpretation of the laws providing
such changes, could result in costly audits, interest, penalties and reputational damage, which could adversely affect our
business, results of operations and our financial condition. Our actual effective tax rate may vary from our expectation
and that variance may be material. A number of factors may increase our future effective tax rates, including:
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
the jurisdictions in which profits are determined to be earned and taxed;
the resolution of issues arising from any future tax audits with various tax authorities;
changes in the valuation of our deferred tax assets and liabilities;
changes to and increases in expenses not deductible for tax purposes, including transaction costs and
impairments of goodwill in connection with acquisitions;
changes in the taxation of share-based compensation;
changes in tax laws or the interpretation of such tax laws, and changes in generally accepted accounting
principles; and
challenges to the transfer pricing policies related to our structure.
117
In late 2017, the EU Economic and Financial Affairs Council, or ECOFIN, released a list of non-cooperative
jurisdictions for tax purposes. The stated aim of this list, and accompanying report, was to promote the EU’s view for
good governance worldwide in order to maximize efforts to prevent tax fraud and tax evasion. While Bermuda was not
on the original EU list of non-cooperative jurisdictions, it committed to address EU concerns relating to economic
substance by December 31, 2018. In accordance with that commitment, Bermuda enacted the Economic Substance Act
2018, which was amended as recently as December 24, 2019, or the Substance Act, and issued Economic Substance
Regulations in 2018, which were amended as recently as December 24, 2019). Pursuant to the Substance Act and
Economic Substance Regulations, certain entities in Bermuda engaged in “relevant activities” are required to maintain
physical presence in Bermuda and to satisfy economic substance requirements commencing as of January 1, 2019, with a
six-month transition period until July 1, 2019. The list of “relevant activities” includes carrying on as a business in any
one or more of the following categories: banking, insurance, fund management, financing, leasing, headquarters,
shipping, distribution and service center, intellectual property and holding entities. Under the Substance Act, any
relevant entity must satisfy economic substance requirements locally or face financial penalties, restriction or regulation
of its business activities or may be struck off as a registered entity from the Bermuda Registrar of Companies. Because
we do not report gross revenue attributable to any such relevant activity, under Section 6 of the Revised Final Guidance
Notes issued on September 18, 2020, we believe that we are not obliged to meet the economic substance requirements.
We will continue to monitor our status with respect to the Substance Act based on our results of operations, and may
become subject to the Substance Act in future.
We believe we may be classified as a passive foreign investment company for U.S. federal income tax purposes for the
year ended December 31, 2020, which could result in adverse U.S. federal income tax consequences to U.S. investors
in our common shares.
Because our sole source of income has been and currently is interest on bank accounts held by us, we believe
we may be classified as a “passive foreign investment company,” or PFIC, for the taxable year ended December 31,
2020. We believe that none of our subsidiaries will be classified as a PFIC for the year ended December 31, 2020. A
non-U.S. company will be considered a PFIC for any taxable year if (i) at least 75% of its gross income is passive
(including interest income), or (ii) at least 50% of the value of its assets (based on an average of the quarterly values of
the assets during a taxable year) is attributable to assets that produce or are held for the production of passive income. If
we are classified as a PFIC in any year with respect to which a U.S. Holder owns our Class A common shares, we will
continue to be treated as a PFIC with respect to such U.S. Holder in all succeeding years during which the U.S. Holder
owns the Class A common shares, regardless of whether we continue to meet the PFIC test described above, unless we
cease to be a PFIC and (i) the U.S. Holder made a “qualified electing fund” election or “mark-to-market” election for the
first taxable year the U.S. Holder was treated as owning our shares while we were a PFIC or (ii) the U.S. Holder made a
“deemed sale” election or was qualified to and made a “deemed dividend” election. A “U.S. Holder” is a beneficial
owner of our Class A common shares that, for U.S. federal income tax purposes, is or is treated as any of the following:
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
an individual who is a citizen or resident of the United States;
a corporation created or organized under the laws of the United States, any state thereof, or the District of
Columbia;
an estate, the income of which is subject to U.S. federal income tax regardless of its source; or
a trust that (i) is subject to the supervision of a U.S. court and all substantial decisions of which are subject
to the control of one or more “United States persons” (within the meaning of Section 7701(a)(30) of the
U.S. Internal Revenue Code of 1986, as amended), or (ii) has a valid election in effect to be treated as a
United States person for U.S. federal income tax purposes.
If we are classified as a PFIC for any taxable year during which a U.S. Holder holds our Class A common
shares, certain adverse U.S. federal income tax consequences could apply to such U.S. Holder, including (i) the
treatment as ordinary income of all or a portion of any gain realized on a disposition of our shares and on the receipt of
distributions on our shares to the extent such gain or distribution is treated as an “excess distribution”, (ii) the application
118
of a deferred interest charge on the tax on such gain and distributions and (iii) the obligation to comply with certain
reporting requirements.
If a U.S. Holder is treated as owning at least 10% of our shares, by vote or by value, such holder may be subject to
adverse U.S. federal income tax consequences.
We believe we will likely be classified as a controlled foreign corporation for the taxable year ended
December 31, 2020. Even if we were not classified as a controlled foreign corporation, certain of our non-U.S.
subsidiaries could be treated as controlled foreign corporations because our group includes one or more U.S.
subsidiaries. If a U.S. Holder is treated as owning (directly, indirectly or constructively) at least 10% of the value or
voting power of our shares, such U.S. Holder may be treated as a “United States shareholder” with respect to us (if we
are classified as a controlled foreign corporation) and each controlled foreign corporation in our group (if any). A United
States shareholder of a controlled foreign corporation may be required to annually report and include in its U.S. taxable
income its pro rata share of “Subpart F income,” “global intangible low-taxed income,” or GILTI, and investments in
U.S. property by such controlled foreign corporation, regardless of whether such corporation makes any distributions.
An individual that is a United States shareholder with respect to a controlled foreign corporation generally would not be
allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S.
corporation. Failure to comply with these reporting obligations may subject such shareholder to significant monetary
penalties and may prevent the statute of limitations with respect to such shareholder’s U.S. federal income tax return for
the year for which reporting was due from starting. We cannot provide any assurances that we will assist investors in
determining whether such investor is treated as a United States shareholder with respect to us or any of our non-U.S.
subsidiaries. Further, we cannot provide any assurances that we will furnish to any United States shareholders
information that may be necessary to comply with the reporting and tax paying obligations discussed above. U.S.
Holders should consult their tax advisors regarding the potential application of these rules to any investment in our Class
A common shares.
ITEM 1B. UNRESOLVED STAFF COMMENTS.
None.
ITEM 2. PROPERTIES.
Our U.S. headquarters are located in Lexington, Massachusetts, where Kiniksa US has leased approximately
55,924 square feet of office and laboratory space, under a lease which expires in August 2023. Kiniksa US has also
leased approximately 4,400 square feet of office space in San Diego, California which expires in January 2022. Further,
Kiniksa UK has leased approximately 164 square meters of office space in London, UK which expires in
November 2025 with an option for early termination in November 2023. We believe that our offices are sufficient to
meet our current needs and that suitable additional space will be available as and when needed.
ITEM 3. LEGAL PROCEEDINGS.
We are not party to any material legal proceedings.
ITEM 4. MINE SAFETY DISCLOSURES.
Not applicable.
119
EXECUTIVE OFFICER AND DIRECTOR BIOGRAPHIES
Directors of the Registrant
Sanj K. Patel has served as our Chief Executive Officer and Chairman of our Board of Directors since our
formation in July 2015. In June 2008, Mr. Patel formed Synageva BioPharma Corp., or Synageva, a biotechnology
company focused on rare diseases, where he served as President and Chief Executive Officer and was a member of its
board of directors until Synageva’s sale to Alexion Pharmaceuticals, Inc., or Alexion, in June 2015. Prior to Synageva,
Mr. Patel held various roles at Genzyme Corporation, or Genzyme, from 1999 to 2008, most recently as head of U.S.
Sales, Marketing and Commercial Operations for the Genzyme Therapeutics franchise. Mr. Patel previously served as a
member of the boards of directors of Syros Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc., and Intercept
Pharmaceuticals, Inc. He is also the founder and director of the Sanj K. Patel and Family Foundation, a philanthropic
organization that supports charities for patients with rare and devastating diseases. Mr. Patel holds a B.Sc. with Honors
from the University of the South Bank, London and completed his management and business studies at Ealing College,
London and his Pharmacology research program at the Wellcome Foundation.
Felix J. Baker, Ph.D., has served as our Lead Independent Director and on our Board of Directors since
October 2015. Dr. Baker is a Managing Member of Baker Bros. Advisors LP, a registered investment adviser focused on
long-term investments in life-sciences companies, or Baker Bros. Advisors. Dr. Baker founded Baker Bros. Advisors.,
together with his brother Julian Baker, in 2000. Dr. Baker currently serves on the boards of directors of Alexion, Seagen,
Inc., and Kodiak Sciences Inc., or Kodiak Sciences, and previously served on the boards of directors of Genomic Health,
Inc., or Genomic Health, Seattle Genetics, Inc., and Synageva. Dr. Baker holds a B.S. and a Ph.D. in Immunology from
Stanford University, where he also completed two years of medical school.
Stephen R. Biggar, M.D., Ph.D., has served as a member of our Board of Directors since October 2015.
Dr. Biggar is a Partner at Baker Bros. Advisors. Dr. Biggar joined Baker Bros. Advisors in 2000. Dr. Biggar is currently
chairman of the board of directors of ACADIA Pharmaceuticals Inc. and previously served on the board of directors of
Synageva. Dr. Biggar received an M.D. and a Ph.D. in Immunology from Stanford University and a B.S. in Genetics
from the University of Rochester.
G. Bradley Cole has served as a member of our Board of Directors since July 2020. He served as Executive
Advisor of Exact Sciences Corporation, or Exact Sciences, from April 2020 to September 2020, and from
November 2019 until April 2020 he served as its GM, Precision Oncology. Prior to that, Mr. Cole served as Chief
Financial Officer of Genomic Health, Inc., or Genomic Health, a molecular diagnostics company, from July 2014 to
November 2019 and from July 2004 to January 2011, and as Chief Operating Officer of Genomic Health from
January 2009 until March 2018, which was acquired by Exact Sciences. Mr. Cole served as Secretary of Genomic Health
from February 2005 until July 2012. From December 1997 to May 2004, he served in various roles at Guidant
Corporation, a medical device company, most recently serving as Vice President, Finance and Business Development for
the Endovascular Solutions Group. From January 2001 until May 2004 he served as Vice President, Finance and Chief
Financial Officer of Endovascular Technologies, Inc., a medical device company that was acquired by Guidant
Corporation. Previously, Mr. Cole served as Vice President, Finance and Chief Financial Officer of Applied Biosystems
Incorporated, a life sciences systems company. Mr. Cole currently serves on the board of directors of Castle Biosciences,
a skin cancer diagnostics company. He also serves on the Genomic Life, Inc., or Genomic Life, board of directors, a
private company, and as Vice Chairman of the Board of Trustees of Biola University. Mr. Cole holds a B.S. in Business
from Biola University and an M.B.A. from San Jose State University.
Richard S. Levy, M.D. has served on our Board of Directors since March 2019. Dr. Levy served as a Senior
Advisor at Baker Bros. Advisors from December 2016 to May 2019. Prior to that, Dr. Levy served as Executive Vice
President and Chief Drug Development Officer at lncyte Corporation, a biopharmaceutical company, from January 2009
until June 2016, and as Senior Vice President of Drug Development from August 2003 to January 2009. Dr. Levy
currently serves on the boards of directors of Madrigal Pharmaceuticals, Inc., Protara Therapeutics, Inc. (f/k/a ArTara
Therapeutics, Inc.), Constellation Pharmaceuticals Inc. and Kodiak Sciences, and previously served on the board of
directors of Aquinox Pharmaceuticals, Inc. Dr. Levy is Board Certified in Internal Medicine and Gastroenterology and
holds an A.B. in Biology from Brown University and an M.D. from the University of Pennsylvania School of Medicine,
120
and completed his training in Internal Medicine at the Hospital of the University of Pennsylvania and a fellowship in
Gastroenterology and Hepatology at UCLA.
Thomas R. Malley has served as a member of our Board of Directors since December 2016. Since May 2007,
Mr. Malley has served as the President of Mossrock Capital, LLC, a private investment firm. Mr. Malley serves on the
boards of directors of BeiGene, Ltd. and Kura Oncology, Inc., and previously served on the boards of directors of
OvaScience, Inc., Cougar Biotechnology, Inc., Puma Biotechnology, Inc. and Synageva. Mr. Malley holds a B.S. degree
in Biology from Stanford University. Mr. Malley is also a Chartered Financial Analyst.
Tracey L. McCain has served as a member of our Board of Directors since February 2018. Since
September 2016, Ms. McCain has served as Executive Vice President and Chief Legal and Compliance Officer of
Blueprint Medicine Corporation, or Blueprint, a biotechnology company. Prior to Blueprint, from January 2016 to
September 2016, Ms. McCain was Senior Vice President and Head of Legal for Sanofi Genzyme, a global business unit
of Sanofi S.A., or Sanofi. From May 1997 to September 2016, Ms. McCain held various roles at Genzyme, including as
General Counsel following Genzyme’s acquisition by Sanofi in 2011. Ms. McCain holds a J.D. from Columbia
University School of Law and a B.A. from the University of Pennsylvania.
Kimberly J. Popovits has served as a member of our Board of Directors since February 2018. Ms. Popovits
served as Genomic Health’s Chairman of the Board from 2012 through 2019, and Chief Executive Officer and President
from 2009 through 2019. She was President and Chief Operating Officer upon joining the company in 2002. Prior to
leading Genomic Health, Ms. Popovits served as Senior Vice President, Marketing and Sales at Genentech, Inc. During
her 15 years at Genentech, Ms. Popovits led the successful commercialization of 14 new therapies, including Herceptin.
Ms. Popovits currently serves on the board of directors of 10x Genomics, Inc. and previously served on the boards of
directors of MyoKardia, Inc. and ZS Pharma, Inc. She also serves on the boards of directors of the Coalition for 21st
Century Medicine, the Personalized Medicine Coalition, Talis Inc., Wamberg Genomic Advisors, and Genomic Life.
She also serves as an Executive Advisor to Blackstone Life Sciences and is an Advisor to the Healthcare
Businesswomen’s Association (HBA). Ms. Popovits holds a Bachelor of Arts degree in Business from Michigan State
University.
Barry D. Quart, Pharm.D., has served as a member of our Board of Directors since October 2015. Since 2013,
Dr. Quart has served as the Chief Executive Officer and a member of the board of directors of Heron Therapeutics, Inc.,
a biotechnology company. In 2006, Dr. Quart co-founded Ardea Biosciences, Inc., a biotechnology company, and served
as its President and Chief Executive Officer, and on its board of directors, from its inception through May 2013.
Dr. Quart previously served on the board of directors of Synageva. Dr. Quart holds a Pharm.D. degree from the
University of California, San Francisco.
Executive Officers of the Registrant
Sanj K. Patel has served as our Chief Executive Officer and Chairman of our Board of Directors since our
formation in July 2015. See “—Directors of the Registrant” for Mr. Patel’s biography.
Thomas Beetham has served as our Executive Vice President, Corporate Development and Operations, Chief
Legal Officer and Secretary since November 2019. Previously, Mr. Beetham served as our Executive Vice President,
Corporate Development, Chief Legal Officer and Secretary since December 2015, and previously as Senior Vice
President in the same roles since our formation in July 2015. Prior to that, Mr. Beetham held various roles at Synageva
from October 2013 to June 2015, most recently serving as the Chief Legal Officer and Senior Vice President of
Corporate Development, where he led the legal department and was responsible for business development activities.
Prior to joining Synageva, from 2011 to 2013, Mr. Beetham was the General Legal Counsel for New England Biolabs,
Inc., or Biolabs, where he was responsible for all legal matters and was a member of Biolabs’ global business
development team. Before Biolabs, Mr. Beetham held various roles at Genzyme, most recently as the lead corporate
attorney responsible for Genzyme’s hematology/oncology and multiple sclerosis products, and before that was a
business and transactional attorney with the law firm of Palmer & Dodge, LLP. Mr. Beetham holds a J.D. from Boston
College Law School, an M.B.A. from Boston College’s Carroll School of Management, and a B.A. from the University
of Rochester.
121
Mark Ragosa has served as our Vice President and Interim Chief Financial Officer since December 2020, at
which point he also assumed the role of principal financial officer. As our Interim Chief Financial Officer, Mr. Ragosa
oversees our Finance and Investor Relations organizations. Prior to that, Mr. Ragosa served as our Vice President,
Investor Relations and Finance since May 2020 having served as our Vice President, Investor Relations since
May 2018. In these roles Mr. Ragosa oversaw the development and execution of our strategic investor-relations plan
aligned with our long-term goals and contributed to our capital raise strategy. Prior to that, Mr. Ragosa served as
Director, Investor Relations from February 2018 to May 2018 and Associate Director from September 2016 to
February 2018 at Ironwood Pharmaceuticals Inc, a biotechnology company, or Ironwood, where he managed
relationships with investors and analysts and served as an external spokesperson. Prior to joining Ironwood, Mr. Ragosa
served as a Vice President within the equities division at Goldman Sachs Group, Inc. from March 2012 to June 2016
where, among other things, he facilitated capital raises for private and public companies and conducted financial
analyses. Prior to that Mr. Ragosa held roles within the equities divisions at Morgan Stanley and Bank of America
Securities. Mr. Ragosa received his bachelor’s degree in History and Government at Bowdoin College and is a Chartered
Financial Analyst.
John F. Paolini, M.D., Ph.D., has served as our Chief Medical Officer since August 2016. From August 2015 to
August 2016, Dr. Paolini was Clinical Research Head of the Cardiovascular and Metabolic Diseases Research Unit at
Pfizer Inc., a pharmaceutical company, or Pfizer, where he was responsible for bringing forward programs from pre-
clinical through early clinical development and proof of concept. Prior to Pfizer, from August 2011 to July 2015,
Dr. Paolini served as Chief Medical Officer of Cerenis Therapeutics, a biotechnology company focused on
cardiovascular and metabolic diseases, where he was responsible for designing and executing clinical trials and
regulatory strategy for a portfolio of products. Dr. Paolini holds an M.D. and a Ph.D. from Duke University School of
Medicine, a B.A. and a B.S. from Tulane University, and completed his internship, residency and fellowship in Internal
Medicine and Cardiology at Brigham and Women’s Hospital, Boston.
122
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS
AND ISSUER PURCHASES OF EQUITY SECURITIES.
Principal Market
Our Class A common shares are listed on The Nasdaq Global Select Market under the symbol “KNSA.”
Holders
As of January 31, 2021, there were 16 holders of record of our Class A common shares, five holders of record
of our Class B common shares, four holders of record of our Class A1 common shares and two holders of record of our
Class B1 common shares. The actual number of shareholders is greater than this number of record holders, and includes
shareholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. The
number of holders of record also does not include shareholders whose shares may be held in trust by other entities.
Dividends Policy
We have never declared or paid any cash dividends on our common shares. We intend to retain all of our future
earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends
in the foreseeable future. Any future determination to declare and pay dividends to holders of our common shares will be
made at the discretion of our board of directors, which may take into account several factors, including general economic
conditions, our financial condition and results of operations, available cash and current and anticipated cash needs,
capital requirements, contractual, legal, tax and regulatory restrictions, the implications of the payment of dividends by
us to our shareholders and any other factors that our board of directors may deem relevant. In addition, pursuant to the
Bermuda Companies Act 1981, as amended, a company may not declare or pay dividends if there are reasonable
grounds for believing that (1) the company is, or would after the payment be, unable to pay its liabilities as they become
due or (2) that the realizable value of its assets would thereby be less than its liabilities. Under our amended and restated
bye-laws, each of our common shares is entitled to dividends if, as and when dividends are declared by our board of
directors, subject to any preferred dividend right of the holders of any preferred shares.
Recent Sales of Unregistered Securities
On May 18, 2020, we issued and sold an aggregate of 1,600,000 Class A1 common shares to existing investors
at price of $18.25 per share, resulting in aggregate gross proceeds to us of approximately $29.2 million. These securities
were issued under Section 4(a)(2) of the Securities Act in a transaction not involving a public offering.
On June 6, 2020, we issued an aggregate of 59,469 Class A common shares to the former shareholders of
Primatope, having an aggregate value of approximately less than $0.1 million, in connection with the release and
issuance of the shares held back at the closing of the acquisition of Primatope, in accordance with the Primatope
Agreement. These securities were issued under Section 4(a)(2) and Rule 506 of the Securities Act in a transaction not
involving a public offering.
On July 24, 2020, we issued and sold an aggregate of 1,428,572 Class A1 common shares to existing investors
at a price of $21.00 per share, resulting in aggregate gross proceeds to us of approximately $30.0 million. These
securities were issued under Section 4(a)(2) of the Securities Act in a transaction not involving a public offering.
123
On September 4, 2020, we issued an aggregate of 16,634 Class A common shares to the former shareholders of
Primatope, having an aggregate value of approximately $0.3 million, as payment, in part, for the achievement of a
milestone in accordance with the Primatope Agreement. These securities were issued under Section 4(a)(2) and Rule 506
of the Securities Act in a transaction not involving a public offering.
Use of Proceeds from Registered Securities
On May 29, 2018, we issued and sold 8,477,777 Class A common shares to the underwriters in our initial
public offering, or IPO, and on June 22, 2018, we issued and sold an additional 1,006,425 Class A common shares
pursuant to the exercise by the underwriters of their over-allotment option to purchase additional shares. Our Class A
common shares were sold at a price to the public of $18.00 per share. We received aggregate gross proceeds from the
IPO inclusive of the underwriters’ over-allotment option of approximately $170.7 million and aggregate net proceeds of
approximately $155.5 million after deducting underwriting discounts and commissions of approximately $12.0 million
and other offering expenses. The offer and sale of all of the shares in our IPO inclusive of the underwriters’ over-
allotment option were registered under the Securities Act pursuant to a registration statement on Form S-1 (File
No. 333-224488), which was declared effective by the Securities and Exchange Commission, or SEC, on May 23, 2018,
and a registration statement on Form S-1 to register additional shares (File No. 333-225159), which was automatically
effective upon filing with the SEC on May 23, 2018. There has been no material change in our planned use of the net
proceeds from the IPO as described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act with
the SEC on May 24, 2018. As of December 31, 2020, we had used all of the net proceeds from our initial public
offering.
ITEM 6. SELECTED CONSOLIDATED FINANCIAL DATA.
You should read the following selected consolidated financial data together with our consolidated financial
statements and the related notes included elsewhere in this Annual Report and the “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” section of this Annual Report. We have derived the
consolidated statement of operations data for the years ended December 31, 2020, 2019 and 2018 and the consolidated
balance sheet data as of December 31, 2020 and 2019 from our audited consolidated financial statements included
elsewhere in this Annual Report. Our historical results are not necessarily indicative of results that may be expected in
any future period.
Consolidated Statement of Operations Data:
Operating expenses:
Research and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Selling, general and administrative . . . . . . . . . . . . . . . . . . . . . . .
Total operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Loss from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Interest income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Loss before (provision) benefit for income taxes . . . . . . . . . . . . .
(Provision) benefit for income taxes . . . . . . . . . . . . . . . . . . . . . . .
Net loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Net loss per share attributable to common shareholders—basic
and diluted(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Weighted average common shares outstanding—basic and
Years Ended
December 31,
2020
2019
2018
(in thousands, except share and per share data)
112,042 $
45,321
157,363
(157,363)
1,134
(156,229)
(5,152)
(161,381) $
135,001 $
34,962
169,963
(169,963)
6,049
(163,914)
2,047
(161,867) $
86,597
21,563
108,160
(108,160)
4,719
(103,441)
214
(103,227)
(2.61) $
(2.99) $
(3.49)
diluted(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
61,842,722
54,049,477
29,547,427
(1)
See Note 12 to our consolidated financial statements included elsewhere in this Annual Report for further details on the calculation of basic and
diluted net loss per share attributable to common shareholders.
124
As of
December 31,
2020
As of
December 31,
2019
(in thousands)
As of
December 31,
2018
Consolidated Balance Sheet Data:
Cash, cash equivalents and short-term investments . . . . . . . . . . . . . . $
Working capital(1) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accumulated deficit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total shareholders’ equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
323,482 $
301,403
349,464
(517,473)
311,935
233,380 $
213,797
254,534
(356,092)
225,423
307,304
271,196
321,965
(194,225)
279,267
(1) We define working capital as current assets less current liabilities.
125
ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS.
The following discussion and analysis of our financial condition and results of operations should be read in
conjunction with our consolidated financial statements and related notes included elsewhere in this Annual Report on
Form 10-K, or Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere
in this Annual Report, including information with respect to our plans and strategy for our business, includes forward-
looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act,
and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve risks and
uncertainties. As a result of many factors, including those factors set forth in the risks identified in Part I-Item 1A “Risk
Factors’’ section of this Annual Report and our other filings with the Securities and Exchange Commission, or SEC, our
actual results could differ materially from the results, performance or achievements expressed in or implied by these
forward-looking statements.
Overview
We are a biopharmaceutical company focused on discovering, acquiring, developing and commercializing
therapeutic medicines for patients with significant unmet medical need. Our product candidates, rilonacept,
mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target
underserved conditions and offer the potential for differentiation. This pipeline of product candidates are designed to
modulate immunological pathways across a spectrum of diseases.
Rilonacept is a protein cytokine trap for inhibiting interleukin-1alpha, or IL-1(cid:302), and interleukin-1beta, or IL-1(cid:533).
Cytokines are small proteins that play a role in cell signaling. Rilonacept was discovered and developed by Regeneron
Pharmaceuticals, Inc., or Regeneron, and is approved by the U.S. Food and Drug Administration, or FDA, under the
brand name ARCALYST for the treatment of CAPS, specifically familial cold autoinflammatory syndrome and muckle-
wells syndrome, and for the treatment of deficiency of IL-1 receptor antagonist, or DIRA. We licensed rilonacept from
Regeneron in 2017.
We are initially developing rilonacept for the potential treatment of recurrent pericarditis, a painful
inflammatory cardiovascular disease with an estimated U.S. prevalent population of approximately 40,000 patients
seeking and receiving medical treatment. Currently there is no FDA-approved therapy for the treatment of recurrent
pericarditis. We received Breakthrough Therapy designation from the FDA for rilonacept for the treatment of recurrent
pericarditis in 2019 and Orphan Drug designation from the FDA for rilonacept for the treatment of pericarditis, which
includes the treatment of recurrent pericarditis, in 2020. In June 2020, we reported final results from RHAPSODY, our
global, double-blind, placebo-controlled, randomized-withdrawal design, pivotal Phase 3 clinical trial of rilonacept in
subjects with recurrent pericarditis. RHAPSODY met its prescribed primary and all major secondary efficacy endpoints
with statistical significance, showing that rilonacept improved clinically meaningful outcomes associated with unmet
medical need in recurrent pericarditis. RHAPSODY data were also published in The New England Journal of Medicine
simultaneously with a late-breaking scientific presentation at the American Heart Association’s Scientific Sessions 2020.
The FDA accepted the supplemental Biologics License Application, or sBLA, for rilonacept in recurrent
pericarditis and assigned a Prescription Drug User Fee Act, or PDUFA, goal date of March 21, 2021 with priority
review. If approved by the FDA for recurrent pericarditis, we expect the potential commercial launch of rilonacept in
recurrent pericarditis in the first half of 2021 and consequently would take responsibility for sales and distribution of
rilonacept for all approved indications in the United States and evenly split profits on sales with Regeneron, after
deducting certain commercialization expenses subject to specified limits.
Mavrilimumab is a fully-human monoclonal antibody that antagonizes granulocyte-macrophage colony
stimulating factor, or GM-CSF. We licensed mavrilimumab from MedImmune Limited, or MedImmune, in 2017.
We are evaluating mavrilimumab for the potential treatment of giant cell arteritis, or GCA, a chronic
inflammatory disease of the medium-to-large arteries with an estimated U.S. prevalence of approximately 75,000 to
150,000 patients. There is only one FDA-approved therapy for GCA, which is an adjunct to corticosteroid therapy, and
126
we believe that an unmet need persists. We received Orphan Drug designation from the FDA for mavrilimumab for the
treatment of GCA in 2020. In November 2020, we presented results from our randomized, double-blind,
placebo-controlled, global Phase 2 proof-of-concept trial of mavrilimumab in subjects with GCA at the late-breaking
abstracts session during the American College of Rheumatology Convergence 2020. The Phase 2 trial met both its
prescribed primary and secondary efficacy endpoints with statistical significance. In addition, while the trial was not
powered for individual disease cohorts, there was a consistent trend of efficacy across the new onset and
relapsing/refractory cohorts. Mavrilimumab was well-tolerated in the Phase 2 trial; there were no drug-related serious
adverse events, and the rates of drug-related treatment-emergent adverse events between mavrilimumab recipients and
placebo recipients were similar. Data from the Phase 2a trial were presented at the European Academy of Dermatology
and Venereology Virtual Congress in 2020.
We are also evaluating mavrilimumab for the potential treatment of severe coronavirus 2019 disease, or
COVID-19, pneumonia and hyperinflammation. In June 2020, we announced 28-day clinical outcomes from an open-
label investigator-initiated treatment protocol with mavrilimumab conducted in Italy in 13 non-mechanically ventilated
patients with severe COVID-19 pneumonia and hyperinflammation. Mavrilimumab-treated patients experienced earlier
and improved clinical outcomes compared to control-group patients, including earlier weaning from supplemental
oxygen, shorter hospitalizations, and no deaths. These data were published in The Lancet Rheumatology. In
December 2020, we reported results from a randomized, double-blind, placebo-controlled investigator-initiated study in
the same patient population across a consortium of academic sites in the United States showing encouraging trends of
reduced mortality and duration of mechanical ventilation in patients treated with mavrilimumab on top of standard of
care therapy. There was no difference in serious adverse events between the mavrilimumab arm and the placebo arm in
the investigator-initiated study. We are conducting a global, randomized, double-blind, placebo-controlled Phase 2/3
clinical trial of mavrilimumab in severe COVID-19 pneumonia and hyperinflammation. We expect to provide data from
the Phase 2 portion of the trial in the first half of 2021. We expect to provide next steps for mavrilimumab, including in
GCA, in the first half of 2021.
Vixarelimab is a fully-human monoclonal antibody that simultaneously inhibits the signaling of the cytokines
interleukin 31 and oncostatin M by targeting their common receptor subunit, oncostatin M receptor beta. We believe
vixarelimab is the only monoclonal antibody in development that simultaneously targets both pathways. We licensed
vixarelimab from Biogen MA, Inc., or Biogen, in 2016.
We are evaluating vixarelimab for the potential treatment of prurigo nodularis, a chronic inflammatory skin
condition with an estimated U.S. prevalence of approximately 300,000 patients. We received Breakthrough Therapy
designation for vixarelimab for the treatment of pruritus associated with prurigo nodularis in 2020. In April 2020, we
reported results from our randomized, double-blind, placebo-controlled Phase 2a trial of vixarelimab in prurigo
nodularis. The Phase 2a trial met its primary efficacy endpoint, as there was a statistically significant reduction in
weekly-average Worst-Itch Numeric Rating Scale, or WI-NRS, from baseline at Week 8 in vixarelimab recipients
compared to placebo recipients. In addition, the majority of vixarelimab recipients showed a clinically meaningful
greater-than-or-equal-to 4-point weekly-average WI-NRS reduction at Week 8 and a statistically significant percentage
of vixarelimab recipients achieved a prurigo nodularis-investigator’s global assessment score of 0/1 at Week 8 compared
to placebo recipients. We are conducting a randomized, double-blind, placebo-controlled Phase 2b dose ranging study
designed to investigate the efficacy, safety, and pharmacokinetics of vixarelimab in patients with prurigo nodularis.
KPL-404 is a humanized monoclonal antibody that is designed to inhibit the CD40-CD40 ligand, or CD40L,
interaction, a central control node of T-cell-dependent, B-cell-mediated humoral adaptive immunity. We believe that
disrupting the CD40-CD40L interaction is an attractive approach for multiple autoimmune disease pathologies such as
rheumatoid arthritis, Sjogren’s syndrome, Graves’ disease, systemic lupus erythematosus and solid organ transplant graft
rejection. We acquired all of the outstanding securities of Primatope Therapeutics, Inc., or Primatope, the company that
owned or controlled the intellectual property related to KPL-404 in 2019.
We are conducting a randomized, double-blind, placebo-controlled single-ascending-dose Phase 1 clinical trial
of KPL-404 in healthy volunteers to evaluate the safety and tolerability of KPL-404 as well as to pharmacokinetics,
CD40 receptor occupancy, the immune response to the novel test antigen keyhole limpet hemocyanin, or KLH, in
clinically relevant dose cohorts, and T-cell dependent antibody response, or TDAR, in these subjects. The study is
127
divided into two parts: a single dose of KPL-404 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg or 10 mg/kg intravenously,
or IV, and a single dose of KPL-404 1 mg/kg or 5 mg/kg subcutaneously, or SC. In November 2020, we reported
preliminary data from the Phase 1 trial. All dose escalations occurred as per protocol with no dose limiting safety
findings. All 6 subjects dosed with KPL-404 3 mg/kg IV showed full receptor occupancy through Day 29, which
corresponded with complete suppression of TDAR to KLH through Day 29. Consistent dose relatedness was shown in
the lower dose level cohorts, including 0.03 mg/kg, 0.3 mg/kg, 1 mg/kg IV and 1 mg/kg SC. We believe that these data
support subsequent study in patients, including potential IV or SC monthly administration. Further, we expect final data
and safety follow-up from all cohorts of the Phase 1 trial in the first half of 2021.
Our future success is dependent on our ability to develop, obtain regulatory approval for and successfully
commercialize one or more of our product candidates. The FDA accepted the sBLA for rilonacept in recurrent
pericarditis with priority review and assigned a PDUFA goal date of March 21, 2021. Upon approval from the FDA, if
any, of the commercial marketing of rilonacept in the United States for recurrent pericarditis, we will assume the sales
and distribution of rilonacept for the approved indications in the United States and would evenly split profits on sales
with Regeneron, after deducting certain commercialization expenses subject to specified limits. However, we have not
yet demonstrated our ability to successfully obtain regulatory approvals, manufacture a commercial scale drug, or
conduct sales and marketing activities. We currently generate no revenue from sales of any products, and we may never
be able to develop or commercialize a marketable product.
On February 4, 2019, we completed a follow-on offering of 2,654,984 Class A common shares and concurrent
private placement of 2,000,000 Class A1 common shares, both at $18.26 per share for aggregate gross proceeds of $85.0
million. In addition, on March 1, 2019, we completed the sale of 161,126 Class A common shares to the underwriters of
the follow-on offering following the exercise in part of their option to purchase additional shares at $18.26 per share for
gross proceeds of $2.9 million. The aggregate net proceeds to us from the follow-on offering and concurrent private
placement, inclusive of the option exercise, was $83.0 million after deducting underwriting discounts and commissions,
placement agent fees and other offering costs.
On May 18, 2020, we completed a follow-on offering of 2,760,000 Class A common shares, inclusive of the
exercise of the underwriters’ option to purchase additional shares at a public offering price of $18.25 and a concurrent
private placement of 1,600,000 Class A1 common shares at an offering price of $18.25 per share for aggregate gross
proceeds of $79.6 million. The aggregate net proceeds to us from the follow-on offering and concurrent private
placement, inclusive of the option exercise, was $74.5 million after deducting underwriting discounts and commissions,
placement agent fees and other offering costs.
On July 24, 2020, we completed a follow-on offering of 5,952,381 Class A common shares, at a public offering
price of $21.00 and a concurrent private placement of 1,428,572 Class A1 common shares at an offering price of $21.00
per share for aggregate gross proceeds of $155.0 million. The aggregate net proceeds to us from the follow-on offering
and concurrent private placement was $146.0 million after deducting underwriting discounts and commissions,
placement agent fees and other offering costs.
We have incurred significant operating losses since inception. Our ability to generate product revenue sufficient
to achieve profitability will depend heavily on the successful development and eventual commercialization of one or
more of our current or future product candidates. Our net losses were $161.4 million and $161.9 million for the years
ended December 31, 2020 and 2019, respectively. As of December 31, 2020, we had an accumulated deficit of
$517.5 million. We expect to continue to incur significant operating losses for at least the next several years as we
advance our product candidates through preclinical and clinical development, manufacture our product candidates for
clinical or commercial use, and, ultimately, seek regulatory approval. In addition, if we obtain marketing approval for
any of our product candidates, including rilonacept, we expect to continue to incur significant commercialization
expenses related to product manufacturing, marketing, sales and distribution. We may also incur expenses in connection
with the in-licensing or acquisition of additional product candidates.
As a result, until such time as we can generate significant revenue from product sales, if ever, we expect to
finance our operations through public or private securities offerings, debt financings or other sources, which may include
licensing, collaborations or other strategic transactions or arrangements, and a lesser extent through projected revenue
128
from rilonacept if approved in recurrent pericarditis or any of our other product candidates . We may be unable to raise
additional funds or enter into such other transactions or arrangements when needed on favorable terms, or at all. If we
fail to raise capital or enter into such transactions or arrangements as and when needed, we may have to significantly
delay, scale back or discontinue the development and commercialization of one or more of our product candidates or
delay our pursuit of potential in-licenses or acquisitions.
Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree
of risk. Typically, it takes many years to develop one new product from the time it is discovered to when it is available
for treating patients, and development may cease for a number of reasons. Because of the numerous risks and
uncertainties associated with product development, including any impact from the COVID-19 pandemic, we are unable
to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability.
Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are
unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and
be forced to reduce or terminate our operations.
As of December 31, 2020, we had cash, cash equivalents and short-term investments of $323.5 million. We
believe that our existing cash, cash equivalents and short-term investments will enable us to fund our operating expenses
and capital expenditure requirements for at least the next 12 months from the date of issuance of the consolidated
financial statements included in this Annual Report. We have based this estimate on assumptions that may prove to be
wrong, and we could exhaust our available capital resources sooner than we expect. See “— Liquidity and Capital
Resources.” Our future viability beyond that point is dependent on our ability to raise additional capital to finance our
operations.
Components of Our Results of Operations
Revenue
To date, we have not generated any revenue from any products, and may never be able to develop and
commercialize a marketable product. If our development efforts for our product candidates are successful and result in
regulatory approval, we may generate revenue in the future from product sales. The FDA accepted the sBLA for
rilonacept in recurrent pericarditis with priority review and assigned a PDUFA goal date of March 21, 2021. Upon
approval from the FDA, if any, of the sBLA, we will assume the sales and distribution of rilonacept for the approved
indications in the United States and would evenly split profits on sales with Regeneron, after deducting certain
commercialization expenses subject to specified limits.
Operating Expenses
Research and Development Expenses
Research and development expenses consist primarily of costs incurred in connection with the research and
development of our product candidates. We expense research and development costs as incurred. These expenses may
include:
•(cid:3)
•(cid:3)
•(cid:3)
expenses incurred to conduct the necessary preclinical studies and clinical trials required to obtain
regulatory approval;
expenses incurred under agreements with contract research organizations, or CROs, that are primarily
engaged in the oversight and conduct of our clinical trials and contract manufacturing organizations, or
CMOs, that are primarily engaged to provide preclinical and clinical drug substance and product for our
research and development programs for our product candidates;
other costs related to acquiring and manufacturing preclinical and clinical trial materials, including
manufacturing validation batches, as well as investigative sites and consultants that conduct our clinical
trials, preclinical studies and other scientific development services;
129
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
payments made in cash or equity securities under third-party licensing, acquisition and other similar
agreements;
employee-related expenses, including salaries and benefits, travel and share-based compensation expense
for employees engaged in research and development functions;
costs related to compliance with regulatory requirements; and
allocated facilities-related costs, depreciation and other expenses, which include rent and utilities.
We recognize external development costs based on an evaluation of the progress to completion of specific tasks
using information provided to us by our service providers. This process involves reviewing open contracts and purchase
orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the
level of service performed and the associated cost incurred for the service when we have not yet been invoiced or
otherwise notified of actual costs. Nonrefundable advance payments for goods or services to be received in the future for
use in research and development activities are recorded as prepaid expenses. Such amounts are recognized as an expense
as the goods are delivered or the related services are performed, or until it is no longer expected that the goods will be
delivered or the services rendered.
Our direct research and development expenses are tracked on a program-by-program basis for our product
candidates and consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and research
laboratories in connection with our preclinical development, process development, manufacturing and clinical
development activities. Our direct research and development expenses by program also include fees incurred under
license, acquisition and other similar agreements. We do not allocate employee costs or facility expenses, including
depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and,
as such, are not separately classified. We use internal resources primarily to conduct our research and discovery
activities as well as for managing our preclinical and clinical development, process development and manufacturing
activities.
130
The table below summarizes our research and development expenses incurred by program:
2020
Years Ended
December 31,
2019
(in thousands)
2018
Rilonacept (1) . . . . . . . . . . . . . . . $ 25,729 $ 25,677 $ 13,446 $
Mavrilimumab (2) . . . . . . . . . . . .
Vixarelimab (3) . . . . . . . . . . . . . .
KPL-404 (4) . . . . . . . . . . . . . . . .
Unallocated research and
15,260
25,562
5,967
25,862
8,796
3,738
13,840
28,772
22,848
2020/2019
Comparison
Increase/(Decrease)
%
$
2019/2018
Comparison
Increase/(Decrease)
%
$
(in thousands, except percentages)
52
12,022
(19,976)
(19,110)
0% $ 12,231
(1,420)
87%
3,210
(69)%
16,881
(84)%
91%
(9)%
13%
283%
development expenses . . . . . .
Total research and
47,917
43,864
26,362
4,053
9%
17,502
66%
development expenses . . . . . $ 112,042 $ 135,001 $ 86,597
$ (22,959)
(17)% $ 48,404
56%
(1)
The amount for the year ended December 31, 2020 includes $7.5 million related to a milestone payment for the achievement of a specified
regulatory milestone event due under the Regeneron License Agreement.
(2) The amount for the year ended December 31, 2018 includes $5.0 million related to a pass-through payment due upon the achievement of a
specified clinical milestone event due under our license agreement with MedImmune.
(3)
The amount for the year ended December 31, 2019 includes expense of $10.0 million related to an accrued milestone under our asset purchase
agreement with Biogen associated with the achievement of a specified clinical milestone event.
(4) The amount for the year ended December 31, 2019 includes expense of $18.0 million related to our acquisition of outstanding securities of
Primatope and milestone achievements, paid in a combination of cash and Class A common shares (inclusive of escrow and holdback share
amounts) in accordance with the stock purchase option agreement with Primatope, or the Primatope Agreement. The amount for the year ended
December 31, 2018 includes expense of $0.8 million related to the extension of the option period under the Primatope Agreement.
Research and development activities are central to our business. Product candidates in later stages of clinical
development generally have higher costs than those in earlier stages of clinical development, primarily due to the
increased size and duration of later-stage clinical trials. As a result, we expect that our research and development
expenses will be substantial over the next several years as we conduct our ongoing and/or planned clinical trials for
rilonacept, mavrilimumab, vixarelimab and KPL-404, as well as conduct other preclinical and clinical development, and
make regulatory filings for our product candidates. As a result, our related personnel costs will increase, including costs
associated with share-based compensation. We also expect to incur additional expenses related to milestone and royalty
payments payable to third parties with whom we have entered into license, acquisition and other similar agreements to
acquire the rights to our product candidates.
The FDA accepted the sBLA for rilonacept in recurrent pericarditis with priority review and assigned a PDUFA
goal date of March 21, 2021. Upon approval from the FDA, if any, of the sBLA, we will assume the sales and
distribution of rilonacept for the approved indications in the United States and would evenly split profits on sales with
Regeneron, after deducting certain commercialization expenses subject to specified limits. However, we have not yet
demonstrated our ability to successfully obtain regulatory approvals, manufacture a commercial scale drug, or conduct
sales and marketing activities. As such, the successful development and commercialization of rilonacept and our other
product candidates is highly uncertain. At this time, we cannot reasonably estimate or know the nature, timing and costs
of the efforts that will be necessary to complete the clinical development our product candidates or when, if ever,
material net cash inflows may commence from any of our product candidates, including rilonacept if approved. This
uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization,
including the uncertainty of:
•(cid:3)
•(cid:3)
the potential impact of the COVID-19 pandemic on our business, including our preclinical studies, clinical
trials, regulatory actions, commercials launch activities and operations;
the scope, progress, outcome and costs of our research and preclinical development activities, clinical trials
and other development activities;
131
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
establishing an appropriate safety and efficacy profile with IND enabling and clinical studies;
the successful enrollment and initiation, performance and completion of preclinical studies and clinical
trials;
the timing, receipt and terms of any marketing approvals from applicable regulatory authorities, including
the FDA;
the extent of any required post-marketing approval commitments to applicable regulatory authorities;
increasing clinical and commercial manufacturing capabilities or making arrangements with additional
third-party manufacturers to successfully manufacture our product candidates;
development and timely delivery of clinical-grade and commercial-grade drug formulations that can be
used in our clinical trials and for commercial launch;
establishing a sales, marketing and distribution infrastructure to commercialize products for which we may
obtain marketing approval;
launching commercial sales of our product candidates, if and when approved, whether alone or in
collaboration with others;
•(cid:3) making milestone or other payments under any current or future license, acquisition, collaboration or other
strategic transaction agreements;
•(cid:3)
•(cid:3)
obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;
significant and changing government regulation; and
•(cid:3) maintaining a continued acceptable safety profile of our product candidates following approval, if any, of
our product candidates.
Selling, General and Administrative Expenses
Selling, general and administrative expenses consist primarily of salaries and benefits, travel and share-based
compensation expense for personnel in executive, business development, finance, human resources, legal,
pre-commercial and support personnel functions. Selling, general and administrative expenses also include insurance and
professional fees for legal, patent, consulting, accounting and audit services.
We expect that our selling, general and administrative expenses will continue to increase in the future as we
continue to prepare for potential commercialization activities and increase our headcount to support our business
objectives. We also anticipate that we will continue to incur significant costs associated with being a public company,
including accounting, audit, legal, compliance and director and officer insurance costs as well as investor and public
relations expenses, and that such costs will increase over time especially as we are a large accelerated filer and are no
longer permitted to rely on exemptions from certain requirements that are applicable to public companies that are not
emerging growth companies or smaller reporting companies.
Interest Income
Interest income consists of income recognized from investments in money market funds and U.S. Treasury
notes.
132
Income Taxes
As an exempted company incorporated under the laws of Bermuda, we are principally subject to taxation in
Bermuda. Under the current laws of Bermuda, tax on a company’s income is assessed at a zero percent tax rate. As a
result, we have not recorded any income tax benefits from our losses incurred in Bermuda during each reporting period,
and no net operating loss carryforwards are currently available to us for those losses, while our assets remain in
Bermuda. Our wholly owned U.S. subsidiaries, Kiniksa Pharmaceuticals Corp., or Kiniksa U.S., and Primatope are
subject to federal and state income taxes in the United States. Our wholly owned subsidiary Kiniksa Pharmaceuticals
(UK), Ltd., and its wholly owned subsidiaries, Kiniksa Pharmaceuticals (Germany) GmbH, Kiniksa Pharmaceuticals
(France) SARL, and Kiniksa Pharmaceuticals GmbH are subject to taxation in their respective countries. Our provision
for income taxes relates mainly to U.S. taxable income, generated by our wholly owned subsidiary Kiniksa US. If
rilonacept is approved by the FDA for the treatment of recurrent pericarditis in the United States, the commercial launch
will be made out of Kiniksa UK. In connection with its launch readiness activities, the Company transferred all of its
rights, title and interest in, among other things, certain contracts (including the Regeneron Agreement), intellectual
property rights, product filings and approvals and other information, plans and materials owned or controlled by the
Company insofar as they related exclusively or primarily to rilonacept to Kiniksa UK in January 2021 pursuant to an
asset transfer agreement between the Company and Kiniksa UK for the consideration described therein.
As of December 31, 2020 and 2019, we had federal research and development tax credit carryforwards of
approximately $1.4 million and $0.2 million respectively, available to reduce future tax liabilities, which begin to expire
in 2040. As of December 31, 2020 and 2019, we had state research and development tax credit carryforwards of
approximately $0.8 million and $0.3 million respectively, available to reduce future tax liabilities, which begin to expire
in 2035.
Results of Operations
Comparison of the Years Ended December 31, 2020, 2019 and 2018
The following table summarizes our results of operations for the years ended December 31, 2020, 2019 and
2018:
2020
Years Ended
December 31,
2019
(in thousands)
2018
2020/2019
Comparison
Increase/(Decrease)
%
$
2019/2018
Comparison
Increase/(Decrease)
%
$
(in thousands, except percentages)
Operating expenses:
Research and development . . $ 112,042 $ 135,001 $
Selling, general and
86,597 $ (22,959)
(17)% $ 48,404
56%
administrative . . . . . . . . . . .
Total operating expenses . .
Loss from operations . . . . . . . .
Interest income . . . . . . . . . . . .
Loss before (provision)
45,321
157,363
(157,363)
1,134
34,962
169,963
(169,963)
6,049
21,563
108,160
(108,160)
4,719
10,359
(12,600)
12,600
(4,915)
30%
(7)%
(7)%
(81)%
13,399
61,803
(61,803)
1,330
62%
57%
57%
28%
benefit for income taxes . . . .
(156,229)
(163,914)
(103,441)
7,685
(5)%
(60,473)
58%
(Provision) benefit for
income taxes . . . . . . . . . . . . .
(5,152)
2,047
214
Net loss . . . . . . . . . . . . . . . . . . . $ (161,381) $ (161,867) $ (103,227) $
(7,199)
486
(352)%
1,833
0% $ (58,640)
857%
57%
133
Research and Development Expenses
Direct research and development
Years Ended
December 31,
2019
2020
2018
2020/2019
Comparison
Increase/(Decrease)
%
$
2019/2018
Comparison
Increase/(Decrease)
$
%
expenses by program:
Rilonacept . . . . . . . . . . . . . . . . . $ 25,729 $ 25,677 $ 13,446 $
Mavrilimumab . . . . . . . . . . . . . .
Vixarelimab . . . . . . . . . . . . . . .
KPL-404 . . . . . . . . . . . . . . . . . .
25,862
8,796
3,738
15,260
25,562
5,967
13,840
28,772
22,848
52
12,022
(19,976)
(19,110)
0% $ 12,231
(1,420)
87%
3,210
(69)%
16,881
(84)%
91%
(9)%
13%
283%
Unallocated research and
development expenses:
Personnel related (including
share-based compensation) .
Other . . . . . . . . . . . . . . . . . . . .
33,489
14,428
29,019
14,845
15,032
11,330
4,470
(417)
15%
(3)%
13,987
3,515
93%
31%
Total research and
development expenses . . . $ 112,042 $ 135,001 $ 86,597 $ (22,959)
(17)% $ 48,404
56%
Research and development expenses were $112.0 million for the year ended December 31, 2020, compared to
$135.0 million for the year ended December 31, 2019, or a decrease of $23.0 million.
During the year ended December 31, 2020, the research and development expenses incurred related to external
spend with respect to our product candidates of $64.1 million, including $32.4 million of costs related to our clinical
trials, $15.6 million of costs related to the manufacturing of our clinical drug supply, and $7.5 million for the
achievement of a specified regulatory milestone event under the Regeneron Agreement which was achieved in the fourth
quarter of 2020. In addition, we incurred unallocated research and development expenses of $47.9 million, including
$33.5 million of personnel costs and $14.4 million of other operating costs including costs associated with our laboratory
including costs related to preclinical and discovery research.
During the year ended December 31, 2019, expenses incurred related to the acquisition of all of the outstanding
securities of Primatope for aggregate upfront and contingent payments of $18.0 million, paid in a combination of cash
and Class A common shares (inclusive of escrow and holdback share amounts) in accordance with the Primatope
Agreement, $10.0 million for an accrued milestone under the Biogen Agreement, associated with the achievement of a
specified clinical milestone event, and expenses for external spend with respect to our product candidates of $63.2
million, including $34.1 million of costs related to our clinical trials and $19.2 million of costs related to the
manufacturing of our clinical drug supply. In addition, we incurred unallocated research and development expenses of
$43.9 million, including, $29.0 million of personnel costs and $14.8 million of other operating costs including costs
associated with our laboratory and other facility costs including costs related to preclinical and discovery research.
During the year ended December 31, 2018, the research and development expenses incurred related to external
spend with respect to our product candidates of $60.2 million, including $26.7 million of costs related to our preclinical
and clinical trials and $20.7 million of costs related to manufacturing of our clinical drug supply. In addition, we
incurred unallocated research and development expenses of $26.4 million, including $15.0 million of personnel costs
and $11.3 million of other operating costs including costs associated with the first year of operations of our laboratory
and costs related to preclinical studies and discovery research.
Direct costs for our rilonacept program were $25.7 million, $25.7 million and $13.4 million for the years ended
December 31, 2020, 2019 and 2018, respectively. During the year ended December 31, 2020, expenses incurred
primarily related to conducting RHAPSODY, our global, pivotal Phase 3 clinical trial in recurrent pericarditis, including
the long-term extension, a milestone payment of $7.5 million for the achievement of a specified regulatory milestone
event under the Regeneron Agreement, and supply chain costs. During the year ended December 31, 2019, expenses
incurred primarily related to our clinical research and development for RHAPSODY, including $6.6 million related to
134
purchases of drug materials under our clinical supply agreement with Regeneron, as well as for our open-label Phase 2
proof-of-concept clinical trial. During the year ended December 31, 2018, expenses incurred primarily related to clinical
research and development for our Phase 2 open-label clinical trial and the initiation of RHAPSODY.
Direct costs of our mavrilimumab program were $25.9 million, $13.8 million and $15.3 million for the years
ended December 31, 2020, 2019 and 2018, respectively. During the year ended December 31, 2020, expenses incurred
primarily related to conducting our global Phase 2 clinical trial in GCA, including manufacturing costs for our clinical
drug supply, and initiation of our Phase 2/3 clinical trial in COVID-19 pneumonia and hyperinflammation. During the
year ended December 31, 2019, expenses incurred primarily related to costs related to our global Phase 2 clinical trial in
GCA. During the year ended December 31, 2018, expenses incurred primarily related to a $5.0 million pass-through
payment due upon the achievement of a specified clinical milestone event due under our license agreement with
MedImmune as well as expenses related to preparation for our planned global Phase 2 clinical trial in GCA and
manufacturing process development expenses.
Direct costs for our vixarelimab program were $8.8 million, $28.8 million and $25.6 million for the year ended
December 31, 2020, 2019 and 2018, respectively. During the year ended December 31, 2020, expenses incurred related
primarily related to conducting our Phase 2a clinical trial in prurigo nodularis and our exploratory Phase 2 clinical trial
in diseases characterized by chronic pruritus, which concluded earlier in the year. During the year ended December 31,
2019, expenses incurred primarily related to a milestone payment of $10.0 million under the Biogen Agreement
associated with the achievement of a specified clinical milestone event as well as expenses incurred for our Phase 2a
clinical trial in prurigo nodularis, our exploratory Phase 2 clinical trial in diseases characterized by chronic pruritus and
our Phase 1b clinical trial, as well as approximately $2.1 million of manufacturing and development costs for our clinical
drug supply. During the year ended December 31, 2018 expenses incurred related to manufacturing and development
costs for our clinical drug supply, our Phase 1a/1b clinical trial, and our LOTUS-PN observational study.
Direct costs for our KPL-404 program were $3.7 million, $22.8 million and $6.0 million for the years ended
December 31, 2020, 2019 and 2018, respectively. During the year ended December 31, 2020, expenses incurred
primarily related to preclinical and clinical trial costs for our Phase 1 trial of KPL-404 in healthy volunteers, including
toxicology costs. During the year ended December 31, 2019, expenses incurred primarily related to the acquisition of all
of the outstanding securities of Primatope for aggregate upfront and contingent payments of $18.0 million paid in a
combination of cash and Class A common shares (inclusive of escrow and holdback share amounts) in accordance with
the Primatope Agreement. The Primatope acquisition was accounted for as an asset acquisition in 2019 as it did not meet
the definition of a business. We recorded the upfront payment, milestone payments and the accrued milestone as
research and development expense in the consolidated statement of operations and comprehensive loss because the
acquired technology represented in-process research and development and had no alternative future use. During the year
ended December 31, 2018, expenses incurred primarily related to pre-clinical research and development, including
manufacturing development costs as well as $0.8 million related to the extension of the option period under our stock
purchase option agreement with Primatope.
Unallocated research and development expenses were $47.9 million, $43.9 million and $26.4 million for the
years ended December 31, 2020, 2019 and 2018, respectively. The increase of $4.0 million in unallocated research and
development expenses in 2020 from 2019 was due to increases of $2.9 million in operating costs of our laboratory and
$4.5 million in personnel-related costs primarily related to share-based compensation and additional personnel in our
research and development functions to support our ongoing clinical trials, partially offset by decreases of $2.0 million
related to the cessation of our development of a pre-clinical product candidate and $1.4 million in other operating
expenses including costs related to our internal lab and costs related to preclinical studies and discovery research. The
increase of $17.5 million in unallocated research and development expenses in 2019 from 2018 was due to an increase of
$13.9 million in personnel-related costs, including share-based compensation, and an increase of $3.5 million in other
operating expenses, including costs related to our laboratory and to preclinical studies and discovery research. The
increase in personnel-related costs was primarily due to additional personnel in our research and development functions
to support our ongoing clinical trials, including development and manufacture of clinical supply and regulatory filings.
Personnel-related costs for the years ended December 31, 2020, 2019 and 2018 included share-based compensation of
$8.9 million, $5.7 million and $2.3 million, respectively.
135
Selling, General and Administrative Expenses
Selling, general and administrative expenses were $45.3 million, $35.0 million and $21.6 million for the years
ended December 31, 2020, 2019 and 2018. The increase of $10.3 million in 2020 from 2019 was primarily due to
increases of $5.2 million in personnel-related costs and $6.7 million in marketing costs associated with the pre-
commercialization of our rilonacept program partially offset by a decrease $1.6 million of other expenses primarily due
to a decrease in travel costs due to the travel restrictions associated with the COVID-19 pandemic and other
miscellaneous professional fees. The increase of $13.4 million in 2019 from 2018 was primarily due to increases of
$11.7 million in personnel-related costs and $2.1 million in professional fees, partially offset by a decrease of $0.4
million in other general expenses. The increase in personnel-related costs was due to additional personnel, primarily in
our commercial and corporate departments, including legal, finance and human resources. In 2019, expenses related to
professional fees increased due to costs related to commercial preparations, including market research as well as legal
costs incurred in connection with maintaining and registering worldwide patents and costs associated with our ongoing
business operations, as well as expenses for higher recruiting, accounting and other costs incurred as a public company
for a full fiscal year. Personnel-related costs for the years ended December 30, 2020, 2019 and 2018 included share-
based compensation of $12.0 million, $9.3 million and $3.4 million, respectively.
Interest Income
Interest income was $1.1 million for the year ended December 31, 2020 compared to $6.0 million for the year
ended December 31, 2019. The decrease was primarily due to lower interest rates on U.S. Treasury notes.
Interest income was $6.0 million for the year ended December 31, 2019 compared to $4.7 million for the year
ended December 31, 2018. The increase was largely due to higher average invested balances during the year ended
December 31, 2019.
(Provision) Benefit for Income Taxes
For the year ended December 31, 2020, we recorded a provision for income taxes of $5.2 million relating
primarily to the recognition of the valuation allowance and the current year tax expense. The current year expense is
reduced by the favorable impact of the Foreign Derived Intangible Income, or FDII, deduction, equity compensation and
U.S. federal and state research and development tax credit utilization. For the year ended December 31, 2019, we
recorded a $2.0 million benefit for income taxes relating primarily to the impact of the FDII deduction, and U.S. federal
and state research and development tax credits. For the year ended December 31, 2018, we recorded an insignificant
benefit for income taxes.
Liquidity and Capital Resources
Since our inception, we have not generated any revenue from any sources, including from product sales, and
have incurred significant operating losses and negative cash flows from our operations.
On February 4, 2019, we completed a follow-on offering of 2,654,984 Class A common shares at a public
offering price of $18.26 per share and concurrent private placement of 2,000,000 Class A1 common shares at an offering
price of $18.26 per share for aggregate gross proceeds of $85.0 million. In addition, on March 1, 2019, we completed the
sale of 161,126 Class A common shares to the underwriters of the follow-on offering following the exercise in part of
their option to purchase additional shares at a public offering price of $18.26 per share for gross proceeds of $2.9
million. The aggregate net proceeds to us from the follow-on offering and concurrent private placement, inclusive of the
option exercise, was $83.0 million after deducting underwriting discounts and commissions, placement agent fees and
other offering costs.
On May 18, 2020, we completed a follow-on offering of 2,760,000 Class A common shares, inclusive of the
exercise of the underwriters’ overallotment option at a public offering price of $18.25 per share and a concurrent private
placement of 1,600,000 Class A1 common shares at an offering price of $18.25 per share for aggregate gross proceeds of
$79.6 million. The aggregate net proceeds to us from the follow-on offering and concurrent private placement, inclusive
136
of the option exercise, was $74.5 million after deducting underwriting discounts and commissions, placement agent fees
and other offering costs.
On July 24, 2020, we completed a follow-on offering of 5,952,381 Class A common shares, at a public offering
price of $21.00 and a concurrent private placement of 1,428,572 Class A1 common shares at an offering price of $21.00
per share for aggregate gross proceeds of $155.0 million. The estimated aggregate net proceeds to us from the follow-on
offering and concurrent private placement was $146.0 million after deducting underwriting discounts and commissions,
placement agent fees and other offering costs.
As of December 31, 2020, we had cash, cash equivalents and short-term investments of $323.5 million.
Cash Flows
The following table summarizes our cash flows for each of the periods presented:
2020
Years Ended
December 31,
2019
(in thousands)
2018
Net cash used in operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ (136,532) $ (158,369) $ (81,012)
(239,198)
Net cash (used in) provided by investing activities . . . . . . . . . . . . . . . . . . . . . .
346,736
Net cash provided by financing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
26,526
Net increase (decrease) in cash and cash equivalents and restricted cash . . $
67,110 $ (25,048) $
(23,444)
227,086
49,214
84,107
Operating Activities
During the year ended December 31, 2020, operating activities used $136.5 million of cash, primarily resulting
from our net loss of $161.4 million and net cash used in our operating assets and liabilities of $4.3 million, partially
offset by non-cash charges of $29.2 million. Net cash used in our operating assets and liabilities for the year ended
December 31, 2020 consisted of a $5.0 million decrease in accounts payable primarily due to the timing of vendor
invoicing and payments, a $8.8 million increase in accrued expenses and other liabilities primarily due to increases in the
accrued costs for our clinical trials and pre-commercialization activities for our rilonacept program, a $0.5 million
increase in other long-term liabilities, a $1.7 million decrease in operating lease liabilities due to monthly payments for
our right-of-use assets, a $5.6 million increase in other long term assets due to payments associated with minimum
balance requirements of our clinical trials which are not expected to be completed within a year, and $1.3 million
increase in prepaid expenses and other current assets.
During the year ended December 31, 2019, operating activities used $158.4 million of cash, primarily resulting
from our net loss of $161.9 million and net cash used by changes in our operating assets and liabilities of $17.0 million
partially offset by non-cash charges of $20.5 million. Net cash used by changes in our operating assets and liabilities for
the year ended December 31, 2019 consisted of a $15.0 million decrease in accrued milestones, a $4.7 million decrease
in accounts payable, and a $1.3 million decrease in operating lease liabilities partially offset by a $1.0 million increase in
prepaid expenses and other current assets, a $0.3 million increase in other long-term liabilities and a $4.6 million
increase in accrued expenses. The decrease in accrued milestones resulted from the payment of outstanding milestones
for which the expense was recognized in prior years. The decrease in accounts payable was primarily due to the timing
of vendor invoicing and payments. The increase in prepaid expenses and other current assets was due to increases in
prepaid insurance expenses and prepaid expenses to CROs related to our clinical trials. The decrease in operating lease
liabilities is due to monthly payments for our right-of-use assets.
During the year ended December 31, 2018, operating activities used $81.0 million of cash, primarily resulting
from our net loss of $103.2 million, partially offset by net non-cash charges of $3.9 million and net cash provided by
changes in our operating assets and liabilities of $18.3 million. Net cash provided by changes in our operating assets and
liabilities for the year ended December 31, 2018 consisted of a $14.3 million increase in accrued expenses and other
137
liabilities and a $8.8 million increase in accounts payable, partially offset by a $4.8 million increase in prepaid expenses
and other current assets. The increase in accrued expenses was primarily due to our increased level of operating activities
and the timing of vendor invoicing and payments, an increase in accrued milestones as well as an increase in accrued
employee compensation expense. The increase in accounts payable was primarily due to increased operating activities as
well as the timing of vendor invoicing and payments. The increase in prepaid expenses and other current assets was due
to increases in prepaid insurance expenses, interest receivable and prepaid expenses to CMOs related to manufacturing
development and CROs related to our clinical trials.
Investing Activities
During the year ended December 31, 2020 investing activities used $23.4 million of cash, consisting of $430.2
million of purchases of short-term investments and $0.3 million of purchases of property and equipment, partially offset
by $407.1 million from proceeds of maturities of short-term investments.
During the year ended December 31, 2019, investing activities provided $49.2 million of cash, consisting of
$541.2 million from proceeds of maturities of short-term investments partially offset by $488.8 million of purchases of
short-term investments and $3.2 million of purchases of property and equipment.
During the year ended December 31, 2018, investing activities used $239.2 million of cash, consisting of $5.3
million of purchases of property and equipment and $402.0 million of purchases of short-term investments partially
offset by $168.1 million from proceeds of maturities of short-term investments.
Financing Activities
During the year ended December 31, 2020, net cash provided by financing activities was $227.1 million,
consisting of net proceeds of $220.5 million in aggregate from our issuance and sale of Class A common shares in two
follow-on public offerings, inclusive of the exercise of the underwriters’ option to purchase additional Class A common
shares, as applicable, and the concurrent issuances and sales of Class A1 common shares in two private placements, after
the deduction of underwriting discounts and commissions, placement agent fees and other offering costs, and $6.6
million of proceeds primarily from the exercise of share options and our employee share purchase plan.
During the year ended December 31, 2019, net cash provided by financing activities was $84.1 million,
consisting of net proceeds of $83.0 million from our issuance and sale of Class A common shares in a follow-on public
offering, inclusive of the concurrent issuance and sale of Class A1 common shares in a private placement, and exercise
in part of the underwriters’ option to purchase additional Class A common shares after the deduction of underwriting
discounts and commissions, placement agent fees and other offering costs.
During the year ended December 31, 2018, net cash provided by financing activities was $346.7 million,
primarily consisting of net proceeds of $159.2 million from our issuance and sale of Class A common shares, after the
deduction of underwriting discounts and commissions , inclusive of the over-allotment option exercise, and $190.8
million in net proceeds from our issuance and sale of Series C preferred shares, partially offset by $3.7 million of
payments of other offering costs associated with our IPO.
Funding Requirements
We expect to incur significant expenses in connection with our ongoing and planned activities as we advance
our product candidates through preclinical and clinical development, seek regulatory approval and prepare for
commercial operations. In addition, if we obtain marketing approval for any of our product candidates, including
rilonacept, we expect to continue to incur significant commercialization expenses related to product manufacturing,
marketing, sales and distribution. We may also incur expenses in connection with the in-licensing or acquisition of
additional product candidates. As a result, our related personnel costs will increase, including costs associated with
share-based compensation. We also expect to incur additional expenses related to milestone and royalty payments
payable to third parties with whom we have entered into license, acquisition and other similar agreements to acquire the
rights to our product candidates. For example, under the Regeneron Agreement, we are obligated to make payments to
138
Regeneron of $20.0 million upon the achievement of a specified regulatory milestone which may be met in the first
quarter of 2021. Additionally, we expect to continue to incur costs associated with operating as a public company,
including significant legal, accounting, investor relations and other expenses. We expect to incur expenses as we:
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
conduct our current and planned clinical trials for mavrilimumab, vixarelimab and KPL-404, as applicable;
increase clinical and commercial manufacturing capabilities or make arrangements with additional third
party manufacturers to successfully manufacture our product candidates;
develop and timely deliver clinical grade and commercial grade product formulations that can be used in
our clinical trials and for commercial launch;
seek regulatory approvals for any product candidates that successfully complete clinical trials;
establish and expand a sales, marketing, medical affairs and distribution capabilities and infrastructure to
commercialize any product candidates, including rilonacept, for which we may obtain marketing approval
and intend to commercialize on our own;
launch commercial sales of our product candidates, if and when approved, whether alone or in
collaboration with others;
•(cid:3) make milestone or other payments under any current or future license, acquisition, collaboration or other
strategic transaction agreements;
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
hire additional sales, marketing, clinical, quality and research and development personnel;
expand our operational, financial and management systems and increase personnel globally to support our
clinical development, manufacturing and commercialization efforts and our operations as a public
company;
maintain, expand and protect our intellectual property portfolio; and
in-license or acquire other product candidates and technologies or their related businesses, if we determine
to do so.
We believe that our existing cash, cash equivalents and short-term investments will enable us to fund our
operating expenses and capital expenditure requirements for at least the next 12 months. We have based these estimates
on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect.
We anticipate that we may require additional capital if we choose to pursue in-licenses or acquisitions of other product
candidates and technologies or their related businesses. If we receive regulatory approval for rilonacept or our other
product candidates or pursue additional indications for our existing product candidates, we expect to incur significant
commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we
choose to commercialize.
Because of the numerous risks and uncertainties associated with research, development and commercialization
of biologic products, we are unable to estimate the exact amount of our working capital requirements. Our future funding
requirements will depend on and could increase significantly as a result of many factors, including:
•(cid:3)
•(cid:3)
any impact of the COVID-19 pandemic on our business, including our preclinical studies and clinical trials,
regulatory actions, commercials launch activities and operations;
the scope, progress, results and costs of researching and developing our product candidates, and conducting
preclinical and clinical trials;
139
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
•(cid:3)
the costs, timing and outcome of regulatory review of our product candidates;
the costs, timing and ability to manufacture our product candidates to supply our clinical and preclinical
development efforts and our clinical trials;
the costs of future activities, including product sales, medical affairs, marketing, manufacturing, pricing
and reimbursement, distribution and compliance, for any of our product candidates for which we receive
marketing approval;
the costs of manufacturing commercial-grade product and necessary inventory to support commercial
launch;
the ability to receive additional non-dilutive funding;
the revenue, if any, received from commercial sale of our products, should any of our product candidates
receive marketing approval;
the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual
property rights and defending intellectual property-related claims;
our ability to establish and maintain licensing, collaboration or other strategic transactions and
arrangements on favorable terms, if at all;
the extent to which we acquire or in-license other product candidates, technologies and their related
businesses; and
the timing, receipt and amount of sales of, or milestone payments related to or royalties on, our current or
future product candidates, if any.
Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs
through a combination of public or private equity offerings, debt financings, or other sources, including, licensing,
collaboration, marketing, distribution or other strategic transactions or arrangements with third parties and to a lesser
extent through projected revenue from rilonacept if approved in recurrent pericarditis or any of our other product
candidates. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our
shareholders’ ownership interest may be materially diluted, and the terms of such securities could include liquidation or
other preferences that adversely affect our shareholders’ rights as a common shareholder. Debt financing and preferred
equity financing, if available, may involve agreements that include restrictive covenants that limit our ability to take
specified actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, debt
financing would result in fixed payment obligations.
If we raise funds through licensing, collaboration, marketing, distribution or other strategic transactions or
arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates or
future revenue streams, or otherwise agree to terms that may not be favorable to us. If we are unable to obtain funding,
we could be forced to delay, reduce or eliminate some or all of our research and development programs for product
candidates, product portfolio expansion or commercialization efforts, which could adversely affect our business
prospects, or we may be unable to continue operations.
Contractual Obligations and Commitments
The following table summarizes our contractual obligations as of December 31, 2020 and the effects that such
obligations are expected to have on our liquidity and cash flows in future periods:
140
Less than
1 year
1 to 3
years
Payments Due by Period
4 to 5
years
(in thousands)
More than
5 years
Total
Manufacturing commitments (1) . . . . . . $
Operating lease commitments (2) . . . . . .
Rilonacept long-term incentive plan (3) .
Total . . . . . . . . . . . . . . . . . . . . . . . . . . $
16,178
2,419
2,013
20,610
$
$
—
5,120
—
5,120
$
$
—
—
—
—
$
$
—
—
—
—
$
$
16,178
7,539
2,013
25,730
(1) Amounts in the table reflect commitments for costs associated with our external CMOs, which we have engaged to manufacture clinical trial
materials and forecasted purchases under the Regeneron clinical supply agreement. Manufacturing commitments include agreements that are
enforceable and legally binding on us and that specify all significant terms, including fixed or minimum quantities to be purchased; fixed,
minimum or variable price provisions; and the approximate timing of the transaction. For obligations with cancellation provisions, the amounts
included in the preceding table are limited to the non-cancelable portion of the agreement terms or the minimum cancellation fee.
(2) Amounts in the table reflect minimum payments due under operating lease agreements entered into by our wholly owned U.S. subsidiary Kiniksa
US for office and laboratory space in Lexington, Massachusetts, which expires in 2023, office space in San Diego, California, which expires in
2022, and office space in London UK, which expires in 2025 with an option to terminate in 2023.
(3) Amounts in the table reflect the cash awards granted to employees under the Rilonacept Long-Term Incentive Plan, or RLTIP, which become
payable in such amounts if the performance goals defined in the RLTIP are achieved at target.
Our contracts with CMOs, CROs and other third parties for the manufacture of our product candidates and to
support clinical trials and preclinical research studies and testing are generally cancelable by us upon prior notice.
Payments due upon cancellation consisting only of payments for services provided or expenses incurred, including
noncancelable obligations of our service providers, up to the date of cancellation are not included in the preceding table
as the amount and timing of such payments are not known.
Under various agreements with third parties, we have agreed to make milestone payments, pay royalties, annual
maintenance fees and to meet due diligence requirements based upon specified milestones. We generally have not
included any contingent payment obligations, such as milestones, royalties or due diligence, in the table above as the
amount, timing and likelihood of such payments are not known. We have not included any of the annual maintenance fee
payments in the above table, as although the amount and timing are known, we cannot currently determine the final
termination dates of the agreements and, as a result, we cannot determine the total amounts of such payments we will be
required to make under the agreements.
Under our license agreement with Regeneron, we are obligated to make future regulatory milestone payments
of $20.0 million which may be met in the first quarter of 2021. Upon approval from the FDA, if any, of rilonacept in
recurrent pericarditis, we will assume the sales and distribution of rilonacept for the approved indications in the United
States and, under the license agreement, we have agreed to evenly split profits on our sales of rilonacept with Regeneron
after deducting certain commercialization expenses subject to specified limits.
Under our license agreement with MedImmune, we are obligated to make future clinical, regulatory and initial
sales milestone payments of up to $57.5 million in aggregate for the first two indications we develop. In addition, we are
obligated to make clinical and regulatory milestone payments of up to $15.0 million in the aggregate for each subsequent
indication. In third quarter of 2020, we entered into an amendment to the MedImmune Agreement to establish a new
coronavirus field and defer the payment of certain development and regulatory milestones as applied to the new
coronavirus field. We are also obligated to make milestone payments to MedImmune of up to $85.0 million upon the
achievement of annual net sales thresholds of up to, but excluding, $1.0 billion in annual net sales as well as additional
milestone payments aggregating up to $1.1 billion upon the achievement of additional specified annual net sales
thresholds starting at $1.0 billion and higher. Commencing on the first commercial sale of licensed products, we are
obligated to pay tiered royalties on escalating tiers of annual net sales of licensed products starting in the low
double-digit percentages and ending at twenty percent. We must pay such royalties on a product-by-product and
141
country-by-country basis until the latest to occur of the expiration of licensed patents, the expiration of regulatory
exclusivity or the tenth anniversary of the first commercial sale of such product in such country.
Under our asset purchase agreement with Biogen, we are obligated to make future milestone payments of up to
$315.0 million upon the achievement of specified clinical and regulatory milestones as well as upon the achievement of
annual net sales thresholds. We have also agreed to pay certain obligations under third-party contracts retained by
Biogen that relate to vixarelimab. Additionally, we are obligated to pay tiered royalties on escalating tiers of annual net
sales of licensed products starting in the high single-digit percentages and ending below the teens.
Critical Accounting Policies and Significant Judgments and Estimates
Our consolidated financial statements are prepared in accordance with generally accepted accounting principles
in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make
estimates and judgments that affect the reported amounts of assets, liabilities, revenue, costs and expenses, and the
disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience,
known trends and events and various other factors that we believe are reasonable under the circumstances, the results of
which form the basis for making judgments about the carrying values of assets and liabilities that are not readily
apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may
differ from these estimates under different assumptions or conditions.
While our significant accounting policies are described in more detail in Note 2 to our consolidated financial
statements included elsewhere in this Annual Report, we believe that the following accounting policies are those most
critical to the judgments and estimates used in the preparation of our consolidated financial statements.
Accrued Research and Development Expenses
As part of the process of preparing our consolidated financial statements, we are required to estimate our
accrued research and development expenses. This process involves reviewing open contracts and purchase orders,
communicating with our personnel to identify services that have been performed on our behalf and estimating the level
of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise
notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a
pre-determined schedule or when contractual milestones are met; however, some require advanced payments. We make
estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts
and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service
providers and make adjustments if necessary. Examples of estimated accrued research and development expenses
include fees paid to:
•(cid:3)
vendors, including research laboratories, in connection with preclinical development activities;
•(cid:3) CROs and investigative sites in connection with preclinical studies and clinical trials;
•(cid:3)
third parties in the connection with the achievement of milestones due under license acquisition and other
similar agreements; and
•(cid:3) CMOs in connection with drug substance and drug product formulation and manufacturing of materials.
We base our expenses related to preclinical studies and clinical trials on our estimates of the services received
and efforts expended pursuant to quotes and contracts with multiple research institutions and CROs that conduct and
manage preclinical studies and clinical trials on our behalf. The financial terms of these agreements are subject to
negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which
payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense.
Payments under some of these contracts depend on factors such as the successful enrollment of patients and the
completion of clinical trial milestones. Non-refundable prepayments determined to be used within one year for goods or
services that will be used or rendered for future research and development activities are recorded as prepaid expenses.
142
Non-refundable prepayments or minimum balance requirements associated to clinical trials determined to not be used
within one year are classified as other long-term assets. In accruing service fees, we estimate the time period over which
services will be performed and the level of effort to be expended in each period. If the actual timing of the performance
of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses
accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our
understanding of the status and timing of services performed relative to the actual status and timing of services
performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date,
there have not been any material adjustments to our prior estimates of accrued research and development expenses.
Share-Based Compensation
We measure all share-based awards granted to employees and directors based on their fair value on the date of
the grant and recognize compensation expense for those awards over the requisite service period. Forfeitures are
accounted for as they occur. We issue share-based awards with both service-based vesting conditions and performance-
based vesting conditions. Expense for awards with service-based vesting is recorded using the straight-line method, and
expense for awards with performance-based vesting conditions is recognized using the accelerated-attribution method.
For share-based awards granted to consultants and non-employees, compensation expense is recognized over
the vesting period of the awards, which is generally the period during which services are rendered by such consultants
and non-employees until completed.
We classified share-based compensation expense in the consolidated statements of operations and
comprehensive loss in the same manner in which the award recipient's payroll costs are classified or in which the award
recipient's service payments are classified.
The fair value of each restricted share award was estimated on the date of grant based on the fair value of the
Company’s Class A common shares or Class B common shares on that same date.
The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing
model, which requires inputs based on certain subjective assumptions, including the expected share price volatility, the
expected term of the award, the risk-free interest rate, and expected dividends (see Note 9). Prior to May 2018, we were
a private company and, accordingly, lacked company-specific historical and implied volatility information. Therefore,
we estimate our expected share price volatility based on the historical volatility of publicly traded peer companies and
expect to continue to do so until such time as we have adequate historical data regarding the volatility of our traded share
price. The expected term of our share options has been determined utilizing the “simplified” method for awards that
qualify as “plain-vanilla” share options. The expected term of share options granted to non-employees is equal to the
contractual term of the share option award. The risk-free interest rate is determined by reference to the U.S. Treasury
yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the
award. Expected dividend yield is based on the fact that we have never paid cash dividends and do not expect to pay any
cash dividends in the foreseeable future.
The fair value of each restricted share unit award is based on the closing price of our Class A common shares
on the date of grant. Restricted share unit awards with an associated performance condition are evaluated on a regular
basis for probability of achievement, to determine the timing of recording share-based compensation expense to include
in our consolidated statements of operations and comprehensive loss.
Off-Balance Sheet Arrangements
We did not have during the periods presented, and we do not currently have, any off-balance sheet
arrangements, as defined in the rules and regulations of the SEC.
143
Recently Issued Accounting Pronouncements
A description of recently issued accounting pronouncements that may potentially impact our financial position
and results of operations is disclosed in Note 2 to our annual consolidated financial statements included elsewhere in this
Annual Report.
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
Interest Rate Risk
We are exposed to market risk related to changes in interest rates. As of December 31, 2020, our cash, cash
equivalents and short-term investments consisted of money market funds and U.S. Treasury notes. Our primary exposure
to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates.
Further, the COVID-19 pandemic has adversely impacted the U.S. and global economy and financial markets, and any
prolonged impact may have an impact on market interest rates. However, because of the short-term nature of the
instruments in our portfolio, an immediate 10% change in market interest rates would not have a material impact on the
fair market value of our investment portfolio or on our financial position or results of operations.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
The financial statements required to be filed pursuant to this Item 8 are appended to this report. An index of
those financial statements is found in Item 15.
ITEM 9.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE.
None.
ITEM 9A. CONTROLS AND PROCEDURES.
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Interim Chief Financial Officer,
evaluated, as of the end of the period covered by this Annual Report, the effectiveness of our disclosure controls and
procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the
Exchange Act. Based on that evaluation, our Chief Executive Officer and Interim Chief Financial Officer concluded that
our disclosure controls and procedures were effective at the reasonable assurance level as of December 31, 2020.
In designing and evaluating our disclosure controls and procedures (as defined in Rules 13a-15(e) and
15d-15(e) under the Exchange Act), management recognizes that any controls and procedures, no matter how well
designed and operated, can provide only reasonable assurance of achieving the desired control objectives.
Management’s Report on Internal Control over Financial Reporting for the Fiscal Year Ended December 31, 2020.
Our management is responsible for establishing and maintaining adequate internal control over our financial
reporting, as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended.
Our management conducted an assessment of the effectiveness of our internal control over financial reporting
based on the criteria set forth in “Internal Control – Integrated Framework (2013)” issued by the Committee of
Sponsoring Organizations of the Treadway Commission.
144
Based on this assessment, our management concluded that, as of December 31, 2020, our internal control over
financial reporting was effective.
The effectiveness of our internal control over financial reporting as of December 31, 2020 has been audited by
PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which is
included in Item 15 in this Annual Report on Form 10-K.
Changes in Internal Control over Financial Reporting
There was no change in our internal control over financial reporting, (as defined in Rules 13a-15(f) and
15d-15(f) under the Exchange Act) during the fourth quarter of the year ended December 31, 2020 that has materially
affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Report of Independent Public Accounting Firm
The effectiveness of our internal control over financial reporting as of December 31, 2020 has been audited by
PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which is
included in Item 15 in this Annual Report on Form 10-K.
ITEM 9B. OTHER INFORMATION.
None
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.
Except to the extent provided below, the information required to be disclosed by this Item will be set forth in
our proxy statement for our 2021 Annual Meeting to be filed with the SEC within 120 days of December 31, 2020, and
is incorporated into this Annual Report by reference.
We have adopted a written code of business conduct and ethics that applies to all of our directors, officers and
employees, including our principal executive officer, principal financial officer, principal accounting officer and
controller, or persons performing similar functions. Our code of business conduct and ethics is available in the
“Investors & Media” section of our website at www.kiniksa.com under “Corporate Governance”. We intend to post on
our website all disclosures that are required by law or the Nasdaq rules concerning any amendments to, or waivers from,
any provision of the code. The reference to our website address does not constitute incorporation by reference of the
information contained at or available through our website, and you should not consider it to be a part of this Annual
Report.
ITEM 11. EXECUTIVE COMPENSATION.
The information required to be disclosed by this Item will be set forth in our proxy statement for our 2021
Annual Meeting to be filed with the SEC within 120 days of December 31, 2020, and is incorporated into this Annual
Report by reference.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED SHAREHOLDER MATTERS.
The information required to be disclosed by this Item will be set forth in our proxy statement for our 2021
Annual Meeting to be filed with the SEC within 120 days of December 31, 2020, and is incorporated into this Annual
Report by reference.
145
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE.
The information required to be disclosed by this Item will be set forth in our proxy statement for our 2021
Annual Meeting to be filed with the SEC within 120 days of December 31, 2020, and is incorporated into this Annual
Report by reference.
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.
The information required to be disclosed by this Item will be set forth in our proxy statement for our 2021
Annual Meeting to be filed with the SEC within 120 days of December 31, 2020, and is incorporated into this Annual
Report by reference.
146
ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES.
(a)(1) Financial Statements.
PART IV
See the “Index to Consolidated Financial Statements” on page F-1 below for the list of financial statements
filed as part of this report.
(a)(2) Financial Statement Schedules.
All schedules have been omitted because they are not required or because the required information is given
in the Consolidated Financial Statements or Notes thereto set forth below beginning on page F-1.
(a)(3) Exhibits. See Exhibit Index.
147
EXHIBIT INDEX
Exhibit
Number
Exhibit Description
Form
File No.
Exhibit
Filing
Date
Filed/
Furnished
Herewith
Incorporated by Reference
3.1
Memorandum of Association of Kiniksa
Pharmaceuticals, Ltd.
S-1
333-224488 3.1
4/27/18
3.2
Amended and Restated Bye-Laws of Kiniksa
Pharmaceuticals, Ltd.
8-K
001-38492 3.1
5/29/18
4.1
Specimen Share Certificate evidencing the Class A
common shares
S-1/A 333-224488 4.1
5/14/18
4.2
Second Amended and Restated Investors’ Rights
Agreement, dated as of February 9, 2018
S-1
333-224488 4.2
4/27/18
4.3
Description of Kiniksa Pharmaceuticals, Ltd. Securities
10-K 001-38492 4.3
3/5/20
10.1
10.2
10.3
Amended and Restated Employment Agreement, dated as
of May 29, 2018, by and between Kiniksa Pharmaceuticals
Corp. and Sanj K. Patel
Amended and Restated Employment Agreement, dated as
of May 29, 2018, by and between Kiniksa Pharmaceuticals
Corp. and Stephen Mahoney
Amended and Restated Employment Agreement, dated as
of May 29, 2018, by and between Kiniksa Pharmaceuticals
Corp. and John F. Paolini
10.4†
Asset Purchase Agreement, dated September 7, 2016, by
and between the Registrant and Biogen MA Inc., as
amended
10.5†
License Agreement, dated September 25, 2017, by and
between the Registrant and Regeneron
Pharmaceuticals, Inc.
10-Q 001-38492 10.7 8/6/18
10-Q 001-38492 10.8 8/6/18
10-Q 001-38492 10.9 8/6/18
S-1
333-224488 10.6 4/27/18
S-1
333-224488 10.7 4/27/18
10.6†
License Agreement, dated as of December 21, 2017, by and
between the Registrant and MedImmune, Limited
S-1
333-224488 10.8 4/27/18
10.7†
Amendment No. 1 to the License Agreement, effective as
of July 9, 2020, by and between Kiniksa Pharmaceuticals,
Ltd. and MedImmune Limited
10.8
10.9
Clinical Supply Agreement, dated as of September 27,
2017, by and between the Registrant and Regeneron
Pharmaceuticals, Inc.
Sublease Agreement, dated as of March 13, 2018, by and
between Kiniksa Pharmaceuticals Corp. and Shire Human
Genetic Therapies, Inc.
8-K
001-38492 10.1 7/15/20
S-1
333-224488 10.9 4/27/18
S-1
333-224488 10.10 4/27/18
148
10.10
First and Second Amendment to Sublease Agreement,
dated as of June 26, 2018 and July 17, 2018, respectively,
by and between Kiniksa Pharmaceuticals Corp. and Shire
Human Genetic Therapies, Inc.
10.11
Third Amendment to Sublease Agreement, dated as of
November 7, 2018, by and between Kiniksa
Pharmaceuticals Corp. and Shire Human Genetic
Therapies, Inc.
10.12
Recognition and Attornment Agreement and Amendment
of Sublease by and between Kiniksa Pharmaceuticals Corp.
and 92 Hayden Avenue Trust dated as of November 6,
2020
10.13
Form of Indemnification Agreement for
Non-Fund-Designated Directors
10-Q 001-38492 10.10 8/6/18
8-K
001-38492 10.1 11/13/18
8-K
001-38492 10.1 11/10/20
S-1
333-224488 10.11 4/27/18
10.14
Form of Indemnification Agreement for Fund-Designated
Directors
S-1
333-224488 10.12 4/27/18
10.15
Form of Indemnification Agreement for Officers
S-1
333-224488 10.13 4/27/18
10.16
2015 Equity Incentive Plan, as amended, and form of share
option grant notice and option agreement thereunder
S-1
333-224488 10.1 4/27/18
10.17
2018 Incentive Award Plan, and the form of share option
grant notice and option agreement, form of restricted share
grant notice and restricted share agreement, and form of
restricted share unit grant notice and restricted share unit
agreement thereunder
10.18
2018 Incentive Award Plan; Sub-Plan for UK Employees,
and the form of share option grant notice for UK
participants
10.19
10.20
Form of Restricted Share Unit Grant Notice and Restricted
Share Unit Agreement Thereunder for UK Participants
under the 2018 Incentive Award plan; Sub-Plan for UK
Employees
2018 Incentive Award Plan forms of share option grant
notice and share option agreement for German participants,
restricted share grant notice and restricted share agreement
for German participants, and restricted share unit grant
notice and restricted share unit agreement for German
participants
10-Q 001-38492 10.3 5/4/20
S-1
333-229394 10.23 1/28/19
S-8
333-237589 99.3 4/7/20
10-K 001-38492 10.27 3/12/19
10.21
2018 Employee Share Purchase Plan
S-1/A 333-224488 10.14 5/14/18
10.22
10.23
10.24†
Offering Document under the 2018 Employee Share
Purchase Plan (effective July 1, 2019)
Offering Document under the 2018 Employee Share
Purchase Plan (effective January 1, 2021)
*
*
Kiniksa Pharmaceuticals, Ltd. Rilonacept Long-Term
Incentive Plan
8-K
001-38492 10.1 12/16/19
149
10.25
10.26
10.27
Form of U.S. Performance Restricted Share Unit and
Performance Cash Award Grant Notice and Agreement
under the Rilonacept Long-Term Incentive Plan
8-K
001-38492 10.2 12/16/19
Form of U.S. Restricted Share Unit Grant Notice and
Agreement under the Rilonacept Long-Term Incentive Plan
8-K
001-38492 10.3 12/16/19
Forms of Performance Restricted Share Unit and
Performance Cash Award Grant Notice and Performance
Restricted Share Unit and Performance Cash Award
Agreement thereunder and Restricted Share Unit Grant
Notice and Restricted Share Unit Agreement thereunder for
UK participants and German participants under the
Rilonacept Long-Term Incentive Plan
S-8
333-237589 99.8 4/7/2020
10.28
Non-Employee Director Compensation Program
10-Q 001-38492 10.1 11/5/19
10.29
Restricted Share Agreement, dated as of September 16,
2015, by and between the Registrant and Sanj K. Patel
S-1
333-229394 10.25 1/28/19
10.30
Restricted Share Agreement, dated as of September 18,
2015, by and between the Registrant and Stephen Mahoney
S-1
333-229394 10.26 1/28/19
10.31
10.32
10.33
10.34
Letter Agreement, dated November 13, 2019, between
Kiniksa Pharmaceuticals, Ltd. and Stephen Mahoney
10-K 001-38492 10.24 3/5/2020
Employment agreement, dated August 20, 2018, by and
between Kiniksa Pharmaceuticals Corp. and Qasim Rizvi
10-K 001-38492 10.25 3/5/2020
Amended and Restated Employment Agreement, dated as
of May 29, 2018, by and between Kiniksa Pharmaceuticals
Corp. and Thomas Beetham
Restricted Share Agreement, dated as of September 18,
2015, by and between Kiniksa Pharmaceuticals, Ltd. and
Thomas Beetham
21.1
Subsidiaries of the Registrant
23.1
Consent of PricewaterhouseCoopers LLP, independent
registered public accounting firm
31.1
Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive
Officer
31.2
Rule 13a-14(a) / 15d-14(a) Certification of Interim Chief
Financial Officer
32.1
Section 1350 Certification of Chief Executive Officer
32.2
Section 1350 Certification of Interim Chief Financial
Officer
101.INS Inline XBRL Instance Document
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase
Document
101.DEF Inline XBRL Extension Definition Linkbase Document
150
*
*
*
*
*
*
**
**
***
***
***
***
101.LAB Inline XBRL Taxonomy Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase
Document
104
Cover Page Interactive Data File (formatted as Inline
XBRL and contained in Exhibit 101).
***
***
* Filed herewith
** Furnished herewith
*** Submitted electronically herewith
† Confidential treatments of certain provisions has been granted by the SEC pursuant to Rule 406 under the Securities
Act of 1933, as amended
151
ITEM 16. FORM 10-K SUMMARY
None.
152
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SIGNATURES
Date: February 25, 2021
KINIKSA PHARMACEUTICALS, LTD.
By:/s/ Sanj K. Patel
Sanj K. Patel
Chief Executive Officer and Chairman of the Board of
Directors
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the
following persons on behalf of the registrant and in the capacities and on the dates indicated.
Signature
Title
Date
/s/ Sanj K. Patel
Sanj K. Patel
Chief Executive Officer and Chairman of
the Board of Directors (principal
executive officer)
February 25, 2021
/s/ Mark Ragosa
financial officer)
February 25, 2021
Interim Chief Financial Officer (principal
Mark Ragosa
/s/ Michael R. Megna
Michael R. Megna
VP, Finance and Chief Accounting
Officer (principal accounting officer)
February 25, 2021
/s/ Felix J. Baker
Lead Independent Director
February 25, 2021
Felix J. Baker
/s/ Stephen R. Biggar
Director
Stephen R. Biggar
/s/ G. Bradley Cole
Director
G. Bradley Cole
/s/ Richard S. Levy
Director
Richard S. Levy
/s/ Thomas R. Malley
Director
Thomas R. Malley
/s/ Tracey L. McCain
Director
Tracey L. McCain
/s/ Kimberly J. Popovits
Director
Kimberly J. Popovits
/s/ Barry D. Quart
Director
Barry D. Quart
153
February 25, 2021
February 25, 2021
February 25, 2021
February 25, 2021
February 25, 2021
February 25, 2021
February 25, 2021
(cid:3)
(cid:3)
(cid:3)
(cid:3)
(cid:3)
(cid:3)
(cid:3)
(cid:3)
(cid:3)
(cid:3)
(cid:3)
(cid:3)
(cid:3)
(cid:3)
(cid:3)
(cid:3)
(cid:3)
INTENTIONALLY LEFT BLANK(cid:3)
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Report of Independent Registered Public Accounting Firm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Consolidated Balance Sheets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Consolidated Statements of Operations and Comprehensive Loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Consolidated Statements of Convertible Preferred Shares and Shareholders’ Equity (Deficit) . . . . . . . . . . . . . . . .
Consolidated Statements of Cash Flows . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Notes to Consolidated Financial Statements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Page
F-2
F-5
F-6
F-7
F-8
F-9
F-1
Report of Independent Registered Public Accounting Firm
To the Board of Directors and Shareholders of Kiniksa Pharmaceuticals, Ltd.
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of Kiniksa Pharmaceuticals, Ltd. and its subsidiaries
(the “Company”) as of December 31, 2020 and 2019, and the related consolidated statements of operations and
comprehensive loss, of convertible preferred shares and shareholders' equity (deficit) and of cash flows for each of the
three years in the period ended December 31, 2020, including the related notes (collectively referred to as the
“consolidated financial statements”). We also have audited the Company's internal control over financial reporting as of
December 31, 2020, based on criteria established in Internal Control - Integrated Framework (2013) issued by the
Committee of Sponsoring Organizations of the Treadway Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the
financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows
for each of the three years in the period ended December 31, 2020 in conformity with accounting principles generally
accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects,
effective internal control over financial reporting as of December 31, 2020, based on criteria established in Internal
Control - Integrated Framework (2013) issued by the COSO.
Change in Accounting Principle
As discussed in Note 2 to the consolidated financial statements, the Company changed the manner in which it accounts
for leases in 2019.
Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective internal
control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting,
included in Management’s Report on Internal Control over Financial Reporting appearing under Item 9A. Our
responsibility is to express opinions on the Company’s consolidated financial statements and on the Company's internal
control over financial reporting based on our audits. We are a public accounting firm registered with the Public
Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities
and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and
perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of
material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was
maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material
misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the consolidated
financial statements. Our audit of internal control over financial reporting included obtaining an understanding of
internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the
design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing
such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable
basis for our opinions.
F-2
Emphasis of Matter
As discussed in Note 1 to the consolidated financial statements, the Company will require additional financing to fund
future operations. Management’s evaluation of the events and conditions and management’s plans to mitigate this matter
is also described in Note 1.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding
the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with
generally accepted accounting principles. A company’s internal control over financial reporting includes those policies
and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the
transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are
recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of
management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the
financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.
Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become
inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may
deteriorate.
Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated
financial statements that was communicated or required to be communicated to the audit committee and that (i) relates to
accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially
challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way
our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical
audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it
relates.
Accrued Research and Development Costs
As described in Notes 2 and 6 to the consolidated financial statements, the Company has entered into various research
and development contracts with companies both inside and outside of the United States. When billing terms under these
contracts do not coincide with the timing of when the work is performed, management is required to make estimates of
outstanding obligations to those third parties as of the end of the reporting period. Within accrued expenses, total
accrued research and development expenses amounted to $16.9 million as of December 31, 2020, which include accruals
for these estimated research and development obligations. Accrual estimates are based on a number of factors, including
management’s assessment of progress towards completion of the research and development activities, invoicing to date
under the contracts, communication from the research institution or other companies of any actual costs incurred during
the period that have not yet been invoiced, and the costs included in the contracts. Significant judgments and estimates
are made in determining the accrued balances at the end of any reporting period.
The principal considerations for our determination that performing procedures relating to accrued research and
development costs is a critical audit matter are (i) the significant judgment by management in determining the accrued
costs, which in turn led to (ii) significant auditor judgment, subjectivity and effort in performing procedures and
evaluating audit evidence for these accrued costs and the factors related to management’s assessment of progress
towards completion of the research and development activities, invoicing to date under the contracts and communication
from the research institution or other companies of any actual costs incurred during the period that have not yet been
invoiced.
F-3
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our
overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls
relating to accrued research and development costs, including controls over the review of contracts, accumulating
information on actual costs incurred during the period, and assessment of progress towards completion of the research
and development activities. These procedures also included, among others (i) testing management’s process for
estimating accrued research and development costs, (ii) evaluating the appropriateness of the methodology used by
management to determine the estimate, (iii) evaluating the reasonableness of the factors related to management’s
assessment of progress towards completion of the research and development activities, invoicing to date under the
contracts and communication from the research institution or other companies of any actual costs incurred during the
period that have not yet been invoiced by testing specific tasks and the associated cost incurred for services the Company
has not yet been invoiced for or otherwise notified of the actual cost at period end, and (iv) testing the completeness and
accuracy of the data inputs to the estimate, including total costs included within executed contracts and actual billed
expenses under these contracts.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 25, 2021
We have served as the Company’s auditor since 2016.
F-4
KINIKSA PHARMACEUTICALS, LTD.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
December 31,
December 31,
2020
2019
Assets
Current assets:
Cash and cash equivalents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Short-term investments. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Restricted cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Prepaid expenses and other current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total current assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Property and equipment, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating lease right-of-use assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-current restricted cash . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other long-term assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred tax assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
114,038 $
209,444
210
9,557
333,249
4,051
6,566
—
5,588
10
349,464 $
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Accrued expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating lease liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total current liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-current liabilities:
Non-current operating lease liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other long-term liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
503 $
29,199
2,107
37
31,846
4,878
805
37,529
Commitments and contingencies (Note 13)
Shareholders’ equity:
Class A common shares, par value of $0.000273235 per share; 31,777,420 shares and
19,245,201 shares issued and outstanding as of December 31, 2020
and 2019, respectively . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Class B common shares, par value of $0.000273235 per share; 2,355,458 shares and
4,638,855 shares issued and outstanding as of December 31, 2020 and 2019, respectively .
Class A1 common shares, $0.000273235 par value; 18,024,526 shares and 14,995,954
issued and outstanding as of December 31, 2020 and 2019, respectively . . . . . . . . . . . . . . .
Class B1 common shares, $0.000273235 par value; 16,057,618 shares issued and
8
1
5
46,928
186,452
—
8,247
241,627
6,398
1,927
210
—
4,372
254,534
5,693
20,415
1,697
25
27,830
955
326
29,111
6
1
4
outstanding as of December 31, 2020 and 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Additional paid-in capital . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accumulated other comprehensive income (loss) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accumulated deficit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total shareholders’ equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total liabilities and shareholders’ equity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
4
829,424
(34)
(517,473)
311,935
349,464 $
4
581,467
33
(356,092)
225,423
254,534
The accompanying notes are an integral part of these consolidated financial statements.
F-5
(3.49)
29,547,427
KINIKSA PHARMACEUTICALS, LTD.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share amounts)
Years Ended
December 31,
2019
2020
2018
Operating expenses:
(cid:3)
86,597
Research and development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
21,563
Selling, general and administrative . . . . . . . . . . . . . . . . . . . . . . . . . . . .
108,160
Total operating expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(108,160)
Loss from operations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4,719
Interest income . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(103,441)
Loss before (provision) benefit for income taxes . . . . . . . . . . . . . . . . . . .
(Provision) benefit for income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
214
Net loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ (161,381) $ (161,867) $ (103,227)
Net loss per share attributable to common shareholders—basic and
(cid:3)(cid:3)(cid:3)(cid:3)
112,042 $
45,321
157,363
(157,363)
1,134
(156,229)
(5,152)
(cid:3)(cid:3)(cid:3)(cid:3)
135,001 $
34,962
169,963
(169,963)
6,049
(163,914)
2,047
diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
(2.61) $
(2.99) $
Weighted average common shares outstanding—basic and diluted . . . .
Comprehensive loss:
Net loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ (161,381) $ (161,867) $ (103,227)
Other comprehensive income (loss):
61,842,722
54,049,477
Unrealized gain (loss) on short-term investments and currency
translation adjustments, net of tax . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total other comprehensive income (loss) . . . . . . . . . . . . . . . . . . . . . . . . .
(4)
(4)
Total comprehensive loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ (161,448) $ (161,830) $ (103,231)
(67)
(67)
37
37
The accompanying notes are an integral part of these consolidated financial statements.
F-6
)
T
I
C
I
F
E
D
(
)
s
t
n
u
o
m
a
e
r
a
h
s
t
p
e
c
x
e
,
s
d
n
a
s
u
o
h
t
n
I
(
.
D
T
L
,
S
L
A
C
I
T
U
E
C
A
M
R
A
H
P
A
S
K
I
N
I
K
Y
T
I
U
Q
E
’
S
R
E
D
L
O
H
E
R
A
H
S
D
N
A
S
E
R
A
H
S
D
E
R
R
E
F
E
R
P
E
L
B
I
T
R
E
V
N
O
C
F
O
S
T
N
E
M
E
T
A
T
S
D
E
T
A
D
I
L
O
S
N
O
C
$
)
8
9
9
,
0
9
(
$
)
t
i
c
i
f
e
D
(
y
t
i
u
q
E
t
i
c
i
f
e
D
)
s
s
o
L
(
e
m
o
c
n
I
'
s
r
e
d
l
o
h
e
r
a
h
S
d
e
t
a
l
u
m
u
c
c
A
e
v
i
s
n
e
h
e
r
p
m
o
C
r
e
h
t
O
n
I
-
d
i
a
P
l
a
t
i
p
a
C
t
n
u
o
m
A
s
e
r
a
h
S
)
1
B
d
n
a
1
A
,
B
,
A
s
s
a
l
C
(
l
a
t
o
T
d
e
t
a
l
u
m
u
c
c
A
l
a
n
o
i
t
i
d
d
A
s
e
r
a
h
S
n
o
m
m
o
C
)
8
0
7
,
9
8
(
—
2
9
5
,
0
1
3
)
4
(
7
7
3
1
0
7
,
5
6
3
5
,
5
5
1
)
7
2
2
,
3
0
1
(
7
6
2
,
9
7
2
6
7
4
,
8
4
1
1
5
,
4
3
0
0
0
,
7
7
3
0
0
8
,
1
9
1
1
,
1
0
8
0
,
5
1
)
7
6
8
,
1
6
1
(
3
2
4
,
5
2
2
8
8
5
,
4
6
1
5
4
9
,
5
5
—
2
5
5
,
6
5
7
8
,
0
2
)
7
6
(
)
1
8
3
,
1
6
1
(
5
3
9
,
1
1
3
—
—
—
—
—
—
)
7
2
2
,
3
0
1
(
)
5
2
2
,
4
9
1
(
—
—
—
—
—
—
—
)
7
6
8
,
1
6
1
(
)
2
9
0
,
6
5
3
(
—
—
—
—
—
—
$
)
1
8
3
,
1
6
1
(
)
3
7
4
,
7
1
5
(
—
—
—
—
—
—
)
4
(
—
)
4
(
—
—
—
—
—
—
7
3
—
3
3
—
—
—
—
—
$
)
7
6
(
—
)
4
3
(
—
4
8
5
,
0
1
3
7
7
3
1
0
7
,
5
2
3
5
,
5
5
1
—
—
3
8
4
,
3
7
4
4
7
4
,
8
4
1
1
5
,
4
3
0
0
0
,
7
0
0
8
,
1
9
1
1
,
1
0
8
0
,
5
1
—
—
7
6
4
,
1
8
5
6
8
5
,
4
6
1
4
4
9
,
5
5
—
2
5
5
,
6
5
7
8
,
0
2
—
—
$
9
8
2
,
1
$
$
4
2
4
,
9
2
8
$
1
—
8
4
—
—
—
—
3
1
2
—
—
—
—
—
—
—
5
1
2
1
—
—
—
—
—
8
1
$
$
—
,
9
2
3
8
8
2
4
,
,
3
9
0
0
7
6
5
3
,
,
2
0
2
4
8
4
9
,
—
—
—
3
2
0
7
4
,
,
7
4
6
9
8
4
9
4
,
,
0
1
1
6
1
8
2
,
,
0
0
0
0
0
0
2
,
—
—
—
,
8
0
0
7
3
3
4
8
2
4
9
,
,
9
7
5
0
0
2
,
8
2
6
7
3
9
4
5
,
,
1
8
3
2
1
7
8
,
3
0
1
6
7
,
,
2
7
5
8
2
0
3
,
,
8
3
3
0
6
4
1
,
—
—
—
,
2
2
0
5
1
2
8
6
,
(cid:3)
(cid:3)
(cid:3)
(cid:3)
(cid:3)
s
e
r
a
h
S
d
e
r
r
e
f
e
r
P
e
l
b
i
t
r
e
v
n
o
C
)
C
d
n
a
B
,
A
s
e
i
r
e
S
(
t
n
u
o
m
A
s
e
r
a
h
S
0
7
7
9
1
1
,
2
2
8
0
9
1
,
)
2
9
5
0
1
3
(
,
$
,
2
9
4
5
8
8
2
2
,
,
1
0
6
4
8
7
2
1
,
,
)
3
9
0
0
7
6
5
3
(
,
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
$
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
7
1
0
2
,
1
3
r
e
b
m
e
c
e
D
t
a
s
e
c
n
a
l
a
B
,
8
7
1
9
$
f
o
s
t
s
o
c
e
c
n
a
u
s
s
i
f
o
t
e
n
,
s
e
r
a
h
s
d
e
r
r
e
f
e
r
p
e
l
b
i
t
r
e
v
n
o
c
C
s
e
i
r
e
S
f
o
e
c
n
a
u
s
s
I
.
.
.
.
.
.
.
.
.
.
.
.
s
e
r
a
h
s
n
o
m
m
o
c
o
t
s
e
r
a
h
s
d
e
r
r
e
f
e
r
p
e
l
b
i
t
r
e
v
n
o
c
f
o
n
o
i
s
r
e
v
n
o
C
g
n
i
t
i
r
w
r
e
d
n
u
f
o
t
e
n
,
g
n
i
r
e
f
f
o
c
i
l
b
u
p
l
a
i
t
i
n
i
f
o
n
o
i
t
e
l
p
m
o
c
n
o
p
u
s
e
r
a
h
s
n
o
m
m
o
c
A
s
s
a
l
C
f
o
e
c
n
a
u
s
s
I
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
s
t
s
o
c
g
n
i
r
e
f
f
o
d
n
a
s
n
o
i
s
s
i
m
m
o
c
d
n
a
s
t
n
u
o
c
s
i
d
n
a
l
p
e
s
a
h
c
r
u
p
e
r
a
h
s
e
e
y
o
l
p
m
e
d
n
a
s
n
a
l
p
d
r
a
w
a
e
v
i
t
n
e
c
n
i
r
e
d
n
u
s
e
r
a
h
s
n
o
m
m
o
c
A
s
s
a
l
C
f
o
e
c
n
a
u
s
s
I
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
e
s
n
e
p
x
e
n
o
i
t
a
s
n
e
p
m
o
c
d
e
s
a
b
-
e
r
a
h
S
s
t
n
e
m
t
s
e
v
n
i
m
r
e
t
-
t
r
o
h
s
n
o
s
s
o
l
d
e
z
i
l
a
e
r
n
U
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
s
s
o
l
t
e
N
8
1
0
2
,
1
3
r
e
b
m
e
c
e
D
t
a
s
e
c
n
a
l
a
B
.
.
s
t
s
o
c
g
n
i
r
e
f
f
o
d
n
a
s
n
o
i
s
s
i
m
m
o
c
d
n
a
s
t
n
u
o
c
s
i
d
g
n
i
t
i
r
w
r
e
d
n
u
f
o
t
e
n
,
e
s
i
c
r
e
x
e
n
o
i
t
p
o
t
n
e
m
t
o
l
l
a
-
r
e
v
o
e
h
t
f
o
e
v
i
s
u
l
c
n
i
,
g
n
i
r
e
f
f
o
n
o
-
w
o
l
l
o
f
f
o
n
o
i
t
e
l
p
m
o
c
n
o
p
u
s
e
r
a
h
s
n
o
m
m
o
c
A
s
s
a
l
C
f
o
e
c
n
a
u
s
s
I
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
s
t
s
o
c
g
n
i
r
e
f
f
o
d
n
a
s
n
o
i
s
s
i
m
m
o
c
d
n
a
s
t
n
u
o
c
s
i
d
d
n
a
d
e
u
s
s
i
l
l
a
f
o
n
o
i
t
i
s
i
u
q
c
a
e
h
t
h
t
i
w
n
o
i
t
c
e
n
n
o
c
n
i
d
e
u
s
s
i
e
b
o
t
r
o
d
e
u
s
s
i
s
e
r
a
h
s
n
o
m
m
o
c
A
s
s
a
l
C
g
n
i
t
i
r
w
r
e
d
n
u
f
o
t
e
n
,
t
n
e
m
e
c
a
l
p
e
t
a
v
i
r
p
f
o
n
o
i
t
e
l
p
m
o
c
n
o
p
u
s
e
r
a
h
s
n
o
m
m
o
c
1
A
s
s
a
l
C
f
o
e
c
n
a
u
s
s
I
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
c
n
I
,
s
c
i
t
u
e
p
a
r
e
h
T
e
p
o
t
a
m
i
r
P
f
o
s
e
i
t
i
r
u
c
e
s
y
t
i
u
q
e
g
n
i
d
n
a
t
s
t
u
o
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
c
n
I
,
s
c
i
t
u
e
p
a
r
e
h
T
e
p
o
t
a
m
i
r
P
o
t
e
u
d
t
n
e
m
y
a
p
e
n
o
t
s
e
l
i
m
a
h
t
i
w
n
o
i
t
c
e
n
n
o
c
n
i
d
e
u
s
s
i
e
b
o
t
r
o
d
e
u
s
s
i
s
e
r
a
h
s
n
o
m
m
o
c
A
s
s
a
l
C
n
a
l
p
e
s
a
h
c
r
u
p
e
r
a
h
s
e
e
y
o
l
p
m
e
d
n
a
s
n
a
l
p
d
r
a
w
a
e
v
i
t
n
e
c
n
i
r
e
d
n
u
s
e
r
a
h
s
n
o
m
m
o
c
A
s
s
a
l
C
f
o
e
c
n
a
u
s
s
I
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
e
s
n
e
p
x
e
n
o
i
t
a
s
n
e
p
m
o
c
d
e
s
a
b
-
e
r
a
h
S
s
t
n
e
m
t
s
u
j
d
a
n
o
i
t
a
l
s
n
a
r
t
y
c
n
e
r
r
u
c
d
n
a
s
t
n
e
m
t
s
e
v
n
i
m
r
e
t
-
t
r
o
h
s
n
o
n
i
a
g
d
e
z
i
l
a
e
r
n
U
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
s
s
o
l
t
e
N
9
1
0
2
,
1
3
r
e
b
m
e
c
e
D
t
a
s
e
c
n
a
l
a
B
r
e
h
t
o
d
n
a
s
n
o
i
s
s
i
m
m
o
c
d
n
a
s
t
n
u
o
c
s
i
d
g
n
i
t
i
r
w
r
e
d
n
u
f
o
t
e
n
,
e
s
i
c
r
e
x
e
n
o
i
t
p
o
t
n
e
m
t
o
l
l
a
-
r
e
v
o
e
h
t
f
o
e
v
i
s
u
l
c
n
i
,
s
g
n
i
r
e
f
f
o
n
o
-
w
o
l
l
o
f
f
o
n
o
i
t
e
l
p
m
o
c
n
o
p
u
s
e
r
a
h
s
n
o
m
m
o
c
A
s
s
a
l
C
f
o
e
c
n
a
u
s
s
I
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
s
e
e
f
t
n
e
g
a
t
n
e
m
e
c
a
l
p
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
s
t
s
o
c
g
n
i
r
e
f
f
o
f
o
t
e
n
,
s
t
n
e
m
e
c
a
l
p
e
t
a
v
i
r
p
f
o
n
o
i
t
e
l
p
m
o
c
n
o
p
u
s
e
r
a
h
s
n
o
m
m
o
c
1
A
s
s
a
l
C
f
o
e
c
n
a
u
s
s
I
.
.
.
.
.
.
.
.
.
.
.
c
n
I
,
s
c
i
t
u
e
p
a
r
e
h
T
e
p
o
t
a
m
i
r
P
f
o
s
e
i
t
i
r
u
c
e
s
y
t
i
u
q
e
g
n
i
d
n
a
t
s
t
u
o
d
n
a
d
e
u
s
s
i
l
l
a
f
o
n
o
i
t
i
s
i
u
q
c
a
e
h
t
m
o
r
f
w
o
r
c
s
e
f
o
e
s
a
e
l
e
r
e
h
t
h
t
i
w
n
o
i
t
c
e
n
n
o
c
n
i
s
e
r
a
h
s
n
o
m
m
o
c
A
s
s
a
l
C
f
o
e
c
n
a
u
s
s
I
n
a
l
p
e
s
a
h
c
r
u
p
e
r
a
h
s
e
e
y
o
l
p
m
e
d
n
a
s
n
a
l
p
d
r
a
w
a
e
v
i
t
n
e
c
n
i
r
e
d
n
u
s
e
r
a
h
s
n
o
m
m
o
c
A
s
s
a
l
C
f
o
e
c
n
a
u
s
s
I
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
e
s
n
e
p
x
e
n
o
i
t
a
s
n
e
p
m
o
c
d
e
s
a
b
-
e
r
a
h
S
.
s
t
n
e
m
t
s
u
j
d
a
n
o
i
t
a
l
s
n
a
r
t
y
c
n
e
r
r
u
c
d
n
a
s
t
n
e
m
t
s
e
v
n
i
m
r
e
t
-
t
r
o
h
s
n
o
s
s
o
l
d
e
z
i
l
a
e
r
n
U
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
s
s
o
l
t
e
N
0
2
0
2
,
1
3
r
e
b
m
e
c
e
D
t
a
s
e
c
n
a
l
a
B
F-7
.
s
t
n
e
m
e
t
a
t
s
l
a
i
c
n
a
n
i
f
d
e
t
a
d
i
l
o
s
n
o
c
e
s
e
h
t
f
o
t
r
a
p
l
a
r
g
e
t
n
i
n
a
e
r
a
s
e
t
o
n
g
n
i
y
n
a
p
m
o
c
c
a
e
h
T
KINIKSA PHARMACEUTICALS, LTD.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
Years Ended
December 31,
2019
2018
2020
Cash flows from operating activities:
Net loss . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ (161,381)
Adjustments to reconcile net loss to net cash used in operating activities:
$ (161,867)
$ (103,227)
Depreciation expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Share-based compensation expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Class A common shares issued as consideration for Primatope, including milestone payments . . . .
Loss on disposal of property and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Non-cash lease expense . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Amortization (accretion) of discounts on short-term investments . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Changes in operating assets and liabilities:
Prepaid expenses and other short-term assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other long-term assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accounts payable . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued expenses and other short-term liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued milestones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating lease liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other long-term liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net cash used in operating activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash flows from investing activities:
Purchases of property and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Purchases of short-term investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from the maturities of short-term investments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net cash provided by (used in) investing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash flows from financing activities:
Proceeds from issuance of Series C convertible preferred shares, net of issuance costs . . . . . . . . . . . .
Proceeds from issuance of Class A common shares upon completion of initial public offering, net
of underwriting discounts and commissions, inclusive of the over-allotment option exercise . . . . . .
Proceeds from issuance of Class A common shares from follow-on offerings, net of underwriting
2,405
20,875
—
—
—
1,400
123
4,361
(1,334)
(5,588)
(4,969)
8,797
—
(1,699)
478
(136,532)
(283)
(430,211)
407,050
(23,444)
—
—
2,068
15,080
8,800
21
—
1,211
(3,501)
(3,156)
(1,020)
—
(4,705)
4,638
(15,000)
(1,264)
326
(158,369)
(3,203)
(488,773)
541,190
49,214
—
—
286
5,701
—
66
235
—
(1,423)
(978)
(4,791)
—
8,823
9,296
5,000
—
—
(81,012)
(5,290)
(402,008)
168,100
(239,198)
190,822
159,194
discounts and commissions, inclusive of the over-allotment option exercise . . . . . . . . . . . . . . . . . .
165,725
48,595
—
Proceeds from issuance of Class A1 common shares from private placements, net of placement
agent fees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Payments of offering costs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Proceeds from issuance of Class A common shares under incentive award plans and employee
55,944
(1,136)
share purchase plan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net cash provided by financing activities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net increase (decrease) in cash, cash equivalents and restricted cash . . . . . . . . . . . . . . . . . . . . . .
Cash, cash equivalents and restricted cash at beginning of period . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Cash, cash equivalents and restricted cash at end of period . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
6,553
227,086
67,110
47,138
114,248
$
34,511
(118)
1,119
84,107
(25,048)
72,186
47,138
—
(3,657)
377
346,736
26,526
45,660
72,186
$
Supplemental information:
Cash paid for income taxes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
482
1,724
$
383
Supplemental disclosure of non-cash investing and financing activities:
Right-of-use asset obtained in exchange for operating lease obligation . . . . . . . . . . . . . . . . . . . . . . . . $
Deferred offering costs included in accrued expenses and accounts payable . . . . . . . . . . . . . . . . . . . . $
Property and equipment included in accrued expenses and accounts payable . . . . . . . . . . . . . . . . . . . . $
6,039
—
—
$
$
$
—
—
222
$
$
$
—
404
1,292
The accompanying notes are an integral part of these consolidated financial statements.
F-8
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Amounts in thousands, except share and per share amounts)
1. Nature of the Business and Basis of Presentation
Kiniksa Pharmaceuticals, Ltd. (the “Company”) is a biopharmaceutical company focused on discovering,
acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with
significant unmet medical need. The Company was incorporated in July 2015 as a Bermuda exempted company. The
Company’s pipeline of product candidates are designed to modulate immunological signaling pathways that are
implicated across a spectrum of diseases.
The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical
industry and global health, societal, economic and market conditions, including from the impact from the coronavirus
disease 2019 (“COVID-19”) pandemic. There can be no assurance that the Company’s research and development will be
successfully completed, that adequate protection for the Company’s technology will be obtained, that any products
developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially
viable. For example, while the U.S. Food and Drug Administration (the “FDA”), accepted the supplemental Biologics
License Application (“sBLA”) for rilonacept in recurrent pericarditis with priority review and assigned a Prescription
Drug User Fee Act (“PDUFA”) goal date of March 21, 2021, the Company has not yet demonstrated its ability to obtain
regulatory approvals. The Company does not currently generate revenue from sales of any products, and it may never be
able to develop or commercialize a marketable product. Upon approval from the FDA , if any, of rilonacept for recurrent
pericarditis, the Company will assume the sales and distribution of rilonacept for the approved indications for the
treatment of cryopyrin-associated periodic syndrome (“CAPS”), specifically familial cold autoinflammatory syndrome
and muckle-wells syndrome, and for the treatment of deficiency of IL-1 receptor antagonist (“DIRA”) in the United
States and would evenly split profits on sales with Regeneron, after deducting certain commercialization expenses
subject to specified limits. The Company has never obtained any regulatory approvals, manufactured a commercial-scale
drug, or conducted sales and marketing activities. The Company operates in an environment of rapid technological
innovation and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is
dependent upon the services of its employees, consultants and other third parties, including contract research
organizations (“CROs”), and contract manufacturing organizations (“CMOs”). Even if the Company’s product
development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from
product sales.
Risk and Uncertainties Related to COVID-19
In addition to risks and uncertainties common to the Company’s industry, the Company is subject to global
societal, healthcare, economic and market conditions, including from the impact of the COVID-19 pandemic and
measures taken in response to the pandemic or the easing of such measures, which continue to evolve. In
December 2019, COVID-19 surfaced in Wuhan, China. The virus spread globally, and was declared a pandemic by the
World Health Organization. The impact of this pandemic has been and will likely continue to be extensive on many
aspects of society, which has resulted in and will likely continue to result in significant disruptions to healthcare systems,
the global economy, as well as businesses and capital markets around the world.
In an effort to halt the spread of the COVID-19 pandemic, federal and state governments in the United States
and the governments of other countries around the globe have implemented various measures in response to the
pandemic, including significant restrictions on businesses and travel as well as social-distancing measures and the easing
of such measures. In response to the COVID-19 pandemic and measures introduced by federal and state governments in
the United States, the Company implemented workplace protocols in the jurisdictions where it has facilities. While the
majority of the Company’s employees are able to carry out their responsibilities working outside of the Company’s
physical locations, for the Company’s essential workers and those choosing to return to the Company’s offices to carry
out their responsibilities, the Company implemented additional safety measures, including occupancy limits, restricting
business travel, providing and requiring the use of personal protective equipment, self-screening prior to accessing the
Company’s facilities, among other things. As these measures implemented by federal and state governments in the
F-9
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
United States in response to the pandemic continue to evolve, the Company continues to monitor the developments,
restrictions and requirements in jurisdictions where it has offices, and plans to update the protocols for its offices as
applicable.
The COVID-19 pandemic, and measures undertaken in response to the pandemic, or the easing of any of such
measures, may cause significant disruptions in the Company’s business or operations as well as in the business and
operations of the Company’s CMOs, CROs and other third parties with whom the Company conducts business or
otherwise engages now or in the future, including as a result of staffing shortages or reprioritizations, production
slowdowns or stoppages, and disruptions in delivery systems. The COVID-19 pandemic may also adversely impact the
Company’s preclinical studies and clinical trials, which could impede, delay, limit or prevent the clinical development of
the Company’s product candidates and ultimately lead to the delay or denial of regulatory approval of its product
candidates, which would materially adversely affect the Company’s business and operations, including its ability to
generate revenue. Moreover, the COVID-19 pandemic is impacting the global economy, and the U.S. economy in
particular, with the potential for the economic downturn to be severe and prolonged. A severe or prolonged economic
downturn could result in continued disruptions in the financial markets, which could adversely impact the Company’s
ability to raise additional capital when needed or on acceptable terms, if at all.
While the Company continuously looks to identify business-critical activities and to develop contingencies and
mitigation strategies for those activities to potentially minimize the impact of the COVID-19 pandemic on its business
and operations, there can be no assurance that it will be able to identify all such activities or that any identified
contingencies and mitigation strategies will be effective. Further, the COVID-19 pandemic, and measures undertaken in
response to the pandemic continue to rapidly evolve. There is uncertainty relating to the potential effect of the pandemic
on the Company’s business and operations. The extent of the impact on the Company’s business and operations will
depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the
ultimate spread of the disease, duration of the pandemic, business and travel restrictions and social distancing measures,
and the effectiveness of these and other actions taken to contain and treat the disease as well as the impact of the
easement of any such restrictions, measures and actions.
Principles of Consolidation
The accompanying consolidated financial statements have been prepared in accordance with accounting
principles generally accepted in the United States of America (“GAAP”) and include the accounts of the Company and
its wholly owned subsidiaries, Kiniksa Pharmaceuticals Corp. (“Kiniksa US”), Primatope Therapeutics, Inc.
(“Primatope”) and Kiniksa Pharmaceuticals (UK), Ltd. (“Kiniksa UK”) as well as the subsidiaries of Kiniksa UK,
Kiniksa Pharmaceuticals (Germany) GmbH (“Kiniksa Germany”), Kiniksa Pharmaceuticals (France) SARL (“Kiniksa
France”), and Kiniksa Pharmaceuticals GmbH (“Kiniksa Switzerland”), after elimination of all significant intercompany
accounts and transactions.
In assessing the consolidation requirement for variable interest entities (“VIE”s), the Company focuses on
identifying whether it has both the power to direct the activities that most significantly impact the VIE’s economic
performance and the obligation to absorb losses or the right to receive benefits from the VIE. In the event that the
Company is the primary beneficiary of a VIE, the assets, liabilities, and results of operations of the VIE would be
included in the Company’s consolidated financial statements. At December 31, 2020 and 2019 and during the years then
ended, the Company was not the primary beneficiary of a VIE.
Use of Estimates
The preparation of the Company’s consolidated financial statements in conformity with GAAP requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of
F-10
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial
statements include, but are not limited to, the accrual for research and development expenses and the valuation of
share-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience.
Changes in estimates are recorded in the period in which they become known. Actual results could differ from those
estimates.
Reporting and Functional Currency
The financial results of the Company's global activities are reported in U.S. dollars (“USD”) and its foreign
subsidiaries generally utilize their respective local currency to be their functional currency.
Transactions in other currencies are recorded in the functional currency at the rate of exchange prevailing when
the transactions occur. Monetary assets and liabilities denominated in other currencies are re-measured into the
functional currency at the rate of exchange in effect at the balance sheet date. Exchange rate gains and losses arising
from re-measurement of foreign currency-denominated monetary assets and liabilities are included in income or losses in
the period in which they occur.
For the Company’s foreign subsidiaries where the local currency is the functional currency, assets and liabilities
denominated in local currencies are translated into USD at end-of-period exchange rates and the resulting translation
adjustments are reported as a component of accumulated other comprehensive gain (loss) within shareholders' equity
(deficit).
Reverse Share Split
On May 11, 2018, the Company effected a 1-for-2.73235 reverse share split of its authorized, designated, issued
and outstanding common shares and preferred shares. Accordingly, all share and per share amounts for all periods
presented in the accompanying consolidated financial statements and notes thereto have been adjusted retroactively,
where applicable, to reflect this reverse share split.
Initial Public Offering
On May 23, 2018, the Company’s registration statement on Form S-1 relating to its initial public offering of its
Class A common shares (the “IPO”) was declared effective by the Securities and Exchange Commission (“SEC”). On
May 29, 2018, the Company completed the IPO of 8,477,777 Class A common shares at $18.00 per share for gross
proceeds of $152,600. In addition, on June 22, 2018, the Company completed the sale of 1,006,425 Class A common
shares to the underwriters of the IPO following the exercise of their over-allotment option to purchase additional shares
at $18.00 per share for gross proceeds of $18,116. The aggregate net proceeds to the Company from the IPO, inclusive
of the over-allotment option exercise, was $155,536 after deducting underwriting discounts and commissions and other
offering costs.
Upon the closing of the IPO, all convertible preferred shares then outstanding automatically converted into
5,546,019 Class A common shares, 1,070,502 Class B common shares, 12,995,954 Class A1 common shares and
16,057,618 Class B1 common shares. In connection with the closing of the IPO, the Company amended and restated its
bye-laws (the “Amended & Restated Bye-Laws”).
Follow-on Offerings and Private Placements
On February 4, 2019, the Company completed a follow-on offering of 2,654,984 Class A common shares at a
public offering price of $18.26 and a concurrent private placement of 2,000,000 Class A1 common shares at an offering
price of $18.26 per share for aggregate gross proceeds of $85,000. In addition, on March 1, 2019, the Company
F-11
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
completed the sale of 161,126 Class A common shares to the underwriters of the follow-on offering following the
exercise in part of their over-allotment option to purchase additional shares at a public offering price of $18.26 per share
for gross proceeds of $2,942. The aggregate net proceeds to the Company from the follow-on offering and concurrent
private placement, inclusive of the over-allotment option exercise, was $82,988 after deducting underwriting discounts
and commissions, placement agent fees and other offering costs.
On May 18, 2020, the Company completed a follow-on offering of 2,760,000 Class A common shares,
inclusive of the exercise of the underwriters’ overallotment option at a public offering price of $18.25 and a concurrent
private placement of 1,600,000 Class A1 common shares at an offering price of $18.25 per share for aggregate gross
proceeds of $79,570. The aggregate net proceeds to the Company from the follow-on offering and concurrent private
placement, inclusive of the over-allotment option exercise, was $74,495 after deducting underwriting discounts and
commissions, placement agent fees and other offering costs.
On July 24, 2020, the Company completed a follow-on offering of 5,952,381 Class A common shares, at a
public offering price of $21.00 and a concurrent private placement of 1,428,572 Class A1 common shares at an offering
price of $21.00 per share for aggregate gross proceeds of $155,000. The aggregate net proceeds to the Company from
the follow-on offering and concurrent private placement was $146,037 after deducting underwriting discounts and
commissions, placement agent fees and other offering costs.
Liquidity
In accordance with Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an
Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are
conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue
as a going concern within one year after the date the consolidated financial statements are issued. As of December 31,
2020, the Company had an accumulated deficit of $517,473. During the year ended December 31, 2020, the Company
incurred a net loss of $161,381and used $136,532 of cash in operating activities. The Company expects to continue to
generate operating losses and cash used in operations for the foreseeable future. As of December 31, 2020, the Company
had cash, cash equivalents and short-term investments of $323,482.
Based on its current operating plan, the Company expects that its cash, cash equivalents and short-term
investments will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve
months from the issuance date of these consolidated financial statements. The future viability of the Company beyond
that point is dependent on its ability to raise additional capital to finance its operations. The Company will need to
finance its operations through public or private securities offerings, debt financings, government funding or grants, or
other sources, which may include licensing, collaborations or other strategic transactions or arrangements. Although the
Company has been successful in raising capital in the past, there is no assurance that it will be successful in obtaining
such additional financing on terms acceptable to the Company, if at all. If the Company is unable to obtain funding, the
Company could be forced to delay, reduce or eliminate some or all of its research and development programs for product
candidates, product portfolio expansion or commercialization efforts, which could adversely affect its business
prospects, or the Company may be unable to continue operations.
2. Summary of Significant Accounting Policies
Cash and Cash Equivalents
The Company classifies deposits in banks, money market funds and cash invested temporarily in various
instruments with maturities of three months or less at the time of purchase as cash and cash equivalents. At
December 31, 2020 and 2019, cash and cash equivalents consisted principally of U.S. Treasury notes, amounts held in
money market accounts and cash on deposit at commercial banks.
F-12
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
Short-Term Investments
The Company generally invests its excess cash in money market funds and short-term investments in U.S.
Treasury notes. Such investments which are included in short-term investments on the Company's consolidated balance
sheets are considered available-for-sale debt securities and are reported at fair value with unrealized gains and losses
included as a component of shareholders’ equity (deficit). Realized gains and losses, if any, on short-term investments
are included in interest income.
The Company evaluates its short-term investments with unrealized losses for other-than-temporary impairment.
When assessing short-term investments for other-than-temporary declines in value, the Company considers such factors
as, among other things, how significant the decline in value is as a percentage of the original cost, the Company’s ability
and intent to retain the investment for a period of time sufficient to allow for any anticipated recovery in fair value and
market conditions in general. If any adjustment to fair value reflects a decline in the value of the investment that the
Company considers to be “other than temporary,” the Company reduces the investment to fair value through a charge to
the consolidated statement of operations and comprehensive loss. No such adjustments were necessary during the
periods presented.
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of
cash, cash equivalents and short-term investments. At December 31, 2020 and 2019, substantially all of the Company’s
cash, cash equivalents and short-term investments were held at two financial institutions. The Company generally
maintains balances in various operating accounts at financial institutions that management believes to be of high credit
quality, in amounts that may exceed federally insured limits. The Company has not experienced any losses related to its
cash, cash equivalents and short-term investments and does not believe that it is subject to unusual credit risk beyond the
normal credit risk associated with commercial banking relationships.
Restricted Cash
In conjunction with the Company’s lease agreement entered into in March 2018, the Company maintains a
letter of credit for the benefit of the landlord. A letter of credit to secure the lease is not required under the 2020
Agreement (see Note 5). As of December 31, 2020 and 2019, the underlying cash balance of $210 securing this letter of
credit, was classified as current and non-current, respectively, in its consolidated balance sheet.
Property and Equipment
Property and equipment are recorded at cost and depreciated over the estimated useful lives of the related assets
using the straight-line method. Maintenance and repairs are charged to expense as incurred. When assets are retired or
otherwise disposed of, the cost of these assets and related accumulated depreciation or amortization are eliminated from
the consolidated balance sheet and any resulting gains or losses are included in the consolidated statement of operations
and comprehensive loss in the period of disposal. The expected useful lives of the respective assets are as follows:
Computer hardware and software . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Laboratory equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Furniture, fixtures and vehicles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Leasehold improvements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Estimated Useful Life
3 - 5 years
5 years
5 - 7 years
Shorter of estimated
useful life or lease term
F-13
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
Impairment of Long-Lived Assets
Long-lived assets consist of property and equipment. Long-lived assets to be held and used are tested for
recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may
not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include
significant underperformance of the business in relation to expectations, significant negative industry or economic trends
and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a
long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result
from the use and eventual disposition of the long-lived asset group to its carrying value. An impairment loss would be
recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than
its carrying amount. The impairment loss would be based on the excess of the carrying value of the impaired asset group
over its fair value, determined based on discounted cash flows. To date, the Company has not recorded any impairment
losses on long-lived assets.
Inventory
Prior to the regulatory approval of the Company’s product candidates, the Company incurs expenses for the
manufacture of drug product that could potentially be available to support the commercial launch of those products.
Until the date at which regulatory approval has been received or is otherwise considered probable, the Company records
all such costs as research and development expenses. There were no capitalized inventory costs recorded as of
December 31, 2020 and 2019.
Deferred Offering Costs
The Company capitalizes certain legal, professional accounting and other third-party fees that are directly
associated with in-process equity financings as deferred offering costs until such financings are consummated. After
consummation of the equity financing, these costs are recorded as a reduction to the carrying value of convertible
preferred shares or in shareholders’ equity (deficit) as a reduction of additional paid-in capital generated as a result of the
offering. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately
as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. There were no
deferred offering costs recorded as of December 31, 2020 and 2019.
Fair Value Measurements
Certain assets and liabilities of the Company are carried at fair value under GAAP. Fair value is defined as the
exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most
advantageous market for the asset or liability in an orderly transaction between market participants on the measurement
date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use
of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in one of the
following three levels of the fair value hierarchy, of which the first two are considered observable and the last is
considered unobservable:
•(cid:3) Level 1—Quoted prices in active markets for identical assets or liabilities.
•(cid:3) Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for
similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or
liabilities, or other inputs that are observable or can be corroborated by observable market data.
F-14
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
•(cid:3) Level 3—Unobservable inputs that are supported by little or no market activity that are significant to
determining the fair value of the assets or liabilities, including pricing models, discounted cash flow
methodologies and similar techniques.
The Company’s restricted cash, which is held in a money market fund, is carried at fair value, determined based
on Level 1 inputs in the fair value hierarchy described above (see Note 3). The Company’s cash equivalents and short-
term investments, consisting of money market accounts and U.S. Treasury notes, are carried at fair value, determined
based on Level 1 and 2 inputs in the fair value hierarchy described above (see Note 3). The carrying values of the
Company’s prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair
values due to the short-term nature of these assets and liabilities.
Leases
In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases
(Topic 842) (“ASU 2016-02”), which set forth the principles for recognition, measurement, presentation and disclosure
of lease arrangements to enhance the transparency and comparability of financial reporting related to the arrangements.
ASU 2016-02, including subsequently issued amendments, is collectively referred to as Accounting Standards
Codification, Leases (Topic 842) (“ASC 842”). The Company adopted the new standard on January 1, 2019 using the
modified retrospective transition approach as applied to leases existing as of the adoption date. The standard will be
applied to all leases entered into after the initial adoption date.
At the inception of an arrangement, the Company determines whether the arrangement is or contains a “lease”
as defined by ASC 842. A lease is an arrangement, or part of an arrangement, that conveys the right to control the use of
identified property, plant, or equipment (an identified asset) for a period of time in exchange for consideration. The
Company determines if the arrangement conveys the right to control the use of an identified asset for a period of time. It
assesses throughout the period of use whether the Company has both of the following (1) the right to obtain substantially
all of the economic benefits from use of the identified asset and (2) the right to direct the use of the identified asset. This
determination is reassessed if the terms of the arrangement are changed. Leases are classified as operating or finance
leases based on the terms of the lease agreement and certain characteristics of the identified asset. Right-of-use (“ROU”)
assets and lease liabilities are recognized at lease commencement date based on the present value of the minimum future
lease payments.
Most leases with a term greater than one year are recognized on the balance sheet as ROU assets with
corresponding lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize
leases with a term of one year or less on its balance sheet. Operating leases, ROU assets and their corresponding lease
liabilities are recorded based on the present value of lease payments over the expected remaining lease term. However,
certain adjustments to the ROU assets may be required for items such as incentives received. The interest rate implicit in
lease arrangements is typically not readily determinable. As a result, the Company utilizes its incremental borrowing
rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease
payments in a similar economic environment.
In accordance with the guidance in ASU 2016-02, components of a lease should be split into three categories:
lease components (e.g., land, building, etc.), non-lease components (e.g., common area maintenance, consumables, etc.),
and non-components (e.g., property taxes, insurance, etc.); then the fixed and in-substance fixed contract consideration
(including any related to non-components) must be allocated based on fair values to the lease components and non-lease
components.
Although separation of lease and non-lease components is required, certain practical expedients are available.
Companies may elect the practical expedient to not separate lease and non-lease components. In which case, the
Company would account for each lease component and the related non-lease component together as a single component.
F-15
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
The Company has elected to account for the lease and non-lease components of each of its operating leases as a single
lease component and allocate all of the arrangement consideration to the lease component only. The lease component
results in an operating right-of-use asset being recorded on the balance sheet and amortized on a straight-line basis as
lease expense.
Upon the adoption of ASC 842, the Company recorded operating lease right-of-use assets of $3,682 and
operating lease liabilities of $3,917 for its leases which were in effect and had commenced prior to January 1, 2019 and
had original lease terms of more than 12 months.
Segment Information
The Company manages its operations as a single operating segment for the purposes of assessing performance
and making operating decisions. The Company’s singular focus is on developing and delivering therapeutic medicines
for patients suffering from debilitating diseases with significant unmet medical need.
Research and Development Costs
Research and development costs are expensed as incurred. Research and development expenses consist of costs
incurred to discover, research and develop drug candidates, including personnel expenses, share-based compensation
expense, allocated facility-related and depreciation expenses, third-party license fees and external costs of outside
vendors engaged to conduct preclinical and clinical development activities and clinical trials as well as to manufacture
clinical trial materials. Non-refundable prepayments determined to be used within one year for goods or services that
will be used or rendered for future research and development activities are recorded as prepaid expenses. Non-refundable
prepayments or minimum balance requirements associated to clinical trials determined to not be used within one year are
classified as other long term assets. Such amounts are recognized as an expense as the goods are delivered or the related
services are performed, or until it is no longer expected that the goods will be delivered, or the services rendered.
Milestone and other payments made to third parties with respect to in-process research and development, in accordance
with the Company’s license, acquisition and other similar agreements are expensed when determined to be probable and
estimable.
Research Contract Costs and Accruals
The Company has entered into various research and development-related contracts with companies both inside
and outside of the United States. The related costs are recorded as research and development expenses as incurred. The
Company records accruals for estimated ongoing research and development costs. When billing terms under these
contracts do not coincide with the timing of when the work is performed, the Company is required to make estimates of
outstanding obligations to those third parties as of the end of the reporting period. Any accrual estimates are based on a
number of factors, including the Company’s knowledge of the progress towards completion of the research and
development activities, invoicing to date under the contracts, communication from the research institution or other
companies of any actual costs incurred during the period that have not yet been invoiced, and the costs included in the
contracts. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting
period. Actual results could differ materially from the Company's estimates. The Company's historical accrual estimates
have not been materially different from the actual costs.
Patent Costs
The Company charges patent-related costs in connection with filing and prosecuting patent applications to
operations as incurred as their realization is uncertain. These costs are classified as selling, general and administrative
expenses.
F-16
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
Share-Based Compensation
The Company measures all share-based awards granted to employees and directors based on their fair value on
the date of grant. The Company issues share-based awards with both service-based vesting conditions and performance-
based vesting conditions. The Company recognizes compensation expense for awards with service conditions on a
straight-line basis over the requisite service period. For awards with performance conditions, the Company recognizes
compensation expense when the achievement of the performance milestone is probable and estimable through the vest
date.
For share-based awards granted to consultants and non-employees, compensation expense is recognized over
the vesting period of the awards, which is generally the period during which services are rendered by such consultants
and non-employees until completed.
The Company classifies share-based compensation expense in its consolidated statements of operations and
comprehensive loss in the same manner in which the award recipient's payroll costs are classified or in which the award
recipient's service payments are classified.
The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing
model, which requires inputs based on certain subjective assumptions, including the expected share price volatility, the
expected term of the award, the risk-free interest rate, and expected dividends (see Note 9). Prior to May 2018, the
Company was a private company and, accordingly, lacks company-specific historical and implied volatility information
for its shares. Therefore, it estimates its expected share price volatility based on the historical volatility of publicly traded
peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility
of its own traded share price. The expected term of the Company’s options has been determined utilizing the
“simplified” method for awards that qualify as “plain-vanilla” options. The expected term of options granted to non-
employees is equal to the contractual term of the option award. The risk-free interest rate is determined by reference to
the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the
expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash
dividends on common shares and does not expect to pay any cash dividends in the foreseeable future.
The fair value of each restricted share unit award is based on the closing price of the Company’s Class A
common shares on the date of grant. Restricted share unit awards with an associated performance condition are
evaluated on a regular basis for probability of achievement to determine the timing of recording share-based
compensation expense in the Company’s consolidated statements of operations and comprehensive loss.
Comprehensive Loss
Comprehensive loss includes net loss as well as other changes in shareholders’ equity (deficit) that result from
transactions and economic events other than those with shareholders. For the years ended December 31, 2020, 2019 and
2018 the Company’s other comprehensive loss was comprised of unrealized gain (loss) on short-term investments and
currency translation adjustments, net of tax.
Income Taxes
The Company accounts for income taxes using the asset and liability method, which requires the recognition of
deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the
consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined
based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in
effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are
recorded in the (provision) benefit for income taxes. The Company assesses the likelihood that its deferred tax assets will
F-17
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that
it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is
established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by
estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.
As an exempted company incorporated under the laws of Bermuda, the Company is principally subject to
taxation in Bermuda. Under the current laws of Bermuda, tax on a company’s income is assessed at a zero percent tax
rate. As a result, the Company has not recorded any income tax benefits from losses incurred in Bermuda during each
reporting period, and no net operating loss carryforwards will be available to the Company for those losses. The
Company’s wholly owned U.S. subsidiaries, Kiniksa US and Primatope, are subject to federal and state income taxes in
the United States. The Company’s wholly owned subsidiary Kiniksa UK, and its wholly owned subsidiaries, Kiniksa
Germany, Kiniksa France, and Kiniksa Switzerland, are subject to taxation in their respective countries. Certain of the
Company’s subsidiaries, primarily Kiniksa US, operate under cost-plus arrangements.
The Company’s U.S. provision for income taxes relates to current tax expense associated with the taxable
income in the United States of its wholly owned subsidiary, Kiniksa US, as well as the recognition of a valuation
allowance. The current income tax expense is a result of the taxable income earned by Kiniksa US under its cost-plus
arrangement offset in part by tax benefits from the U.S. federal and state research and development credits. The
Company has recorded an immaterial foreign provision for income taxes related to income in non-U.S. subsidiaries.
The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by
applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be
evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the
tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of
benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the
largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for
income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered
appropriate as well as the related net interest and penalties. In 2020, the Company recognized an uncertain tax position
related to research and development credits (see Note 11).
Net Loss per Share
The Company follows the two-class method when computing net loss per share as the Company has issued
shares that meet the definition of participating securities. The two-class method determines net loss per share for each
class of common and participating securities according to dividends declared or accumulated and participation rights in
undistributed earnings. The two-class method requires income available to common shareholders for the period to be
allocated between common and participating securities based upon their respective rights to receive dividends as if all
income for the period had been distributed.
Basic net loss per share attributable to common shareholders is computed by dividing the net loss attributable to
common shareholders by the weighted average number of common shares outstanding for the period. Diluted net loss
attributable to common shareholders is computed by adjusting net loss attributable to common shareholders to reallocate
undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to
common shareholders is computed by dividing the diluted net loss attributable to common shareholders by the weighted
average number of common shares outstanding for the period, including potential dilutive common shares. For purpose
of this calculation, outstanding share options, unvested restricted common shares and unvested restricted share units are
considered potential dilutive common shares.
F-18
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
Recently Adopted Accounting Pronouncements
In June 2016, the FASB, issued ASU 2016-13, Financial Instruments: Credit Losses (Topic 326), as clarified in
ASU 2019-04 and ASU 2019-05. The objective of the standard is to provide information about expected credit losses on
financial instruments at each reporting date and to change how other-than-temporary impairments on investment
securities are recorded. The standard became effective for the Company beginning on January 1, 2020. The adoption of
this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.
In August 2018, the FASB issued ASU 2018-15, Intangibles—Goodwill and Other— Internal-Use Software
(Subtopic 350-40) (“ASU 2018-15”), which amends ASC 350-40 to address a customer’s accounting for implementation
costs incurred in a cloud computing arrangement (“CCA”) that is a service contract. ASU 2018-15 aligns the accounting
for costs incurred to implement a CCA that is a service contract with the guidance on capitalizing costs associated with
developing or obtaining internal-use software. Specifically, the ASU amends ASC 350 to include in its scope
implementation costs of a CCA that is a service contract and clarifies that a customer should apply ASC 350-40 to
determine which implementation costs should be capitalized in a CCA that is considered a service contract. The standard
became effective for the Company beginning on January 1, 2020. The adoption of this standard did not have a material
impact on the Company’s consolidated financial statements and related disclosures.
Recently Issued Accounting Pronouncements
In December 2019, the FASB issued ASU 2019-12, Simplifying the Accounting for Income Taxes (Topic
740)(“ASU 2019-12”). The objective of the standard is to improve areas of GAAP by removing certain exceptions
permitted by ASC Topic 740 Income Taxes and clarifying existing guidance to facilitate consistent application. The
standard became effective for the Company beginning on January 1, 2021. The Company is currently evaluating the new
standard to determine the potential impact of ASU 2019-12 on its consolidated financial statements and related
disclosures. The adoption of this standard is not expected to have a material impact on the Company’s consolidated
financial statements and related disclosures.
3. Fair Value of Financial Assets and Liabilities
The following tables present information about the Company’s financial instruments measured at fair value on a
recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:
F-19
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
Assets:
Restricted cash — money market funds . . . . . . . .
Cash equivalents — money market funds . . . . . . .
Cash equivalents — U.S. Treasury notes . . . . . . .
Short-term investments — U.S. Treasury notes . .
Assets:
Restricted cash — money market funds . . . . . . . .
Cash equivalents — money market funds . . . . . . .
Cash equivalents — U.S. Treasury notes . . . . . . .
Short-term investments — U.S. Treasury notes . .
Level 1
210
22,942
—
—
23,152
Level 1
210
25,207
—
—
25,417
$
$
$
$
$
$
$
$
Fair Value Measurements
as of December 31, 2020 Using:
Level 2
Level 3
—
—
72,695
209,444
282,139
$
$
—
—
—
—
—
Fair Value Measurements
as of December 31, 2019 Using:
Level 2
Level 3
—
—
10,192
186,452
196,644
$
$
—
—
—
—
—
Total
210
22,942
72,695
209,444
305,291
Total
210
25,207
10,192
186,452
222,061
$
$
$
$
During the years ended December 31, 2020 and 2019 there were no transfers between Level 1, Level 2 and
Level 3. The money market funds were valued using quoted prices in active markets, which represent a Level 1
measurement in the fair value hierarchy. The Company's cash equivalents and short-term investments as of
December 31, 2020 and 2019 included U.S. Treasury notes, which are not traded on a daily basis and, therefore,
represent a Level 2 measurement in the fair value hierarchy at each period end.
Cash equivalents and short-term investments as of December 31, 2020 and 2019 consisted of U.S. Treasury
notes which investments were each due within six months of such date.
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
December 31, 2020
Cash equivalents — U.S. Treasury notes . . . . . . . $
Short-term investments — U.S. Treasury notes . .
$
72,694
209,459
282,153
$
$
1
4
5
$
$
—
(19)
(19)
$
$
72,695
209,444
282,139
Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
December 31, 2019
Cash equivalents — U.S. Treasury notes . . . . . . . $
Short-term investments — U.S. Treasury notes . .
$
10,191
186,415
196,606
$
$
1
44
45
$
$
—
(7)
(7)
$
$
10,192
186,452
196,644
As of December 31, 2020, the Company held 17 securities that were in an unrealized loss position. The
aggregate fair value of securities held by the Company in an unrealized loss position was $107,753 at December 31,
2020. As of December 31, 2019, the Company held seven securities that were in an unrealized loss position. The
aggregate fair value of securities held by the Company in an unrealized loss position was $43,107 at December 31, 2019.
As of both December 31, 2020 and 2019, these securities were held by the Company in an unrealized loss position for
F-20
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
less than 12 months. The Company determined that there was no material change in the credit risk of these securities. As
a result, the Company determined it did not hold any investments with an other-than-temporary impairment as of
December 31, 2020 and 2019.
4. Property and Equipment, Net
Property and equipment, net consisted of the following:
Furniture, fixtures and vehicles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Computer hardware and software . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Leasehold improvements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lab equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Construction in progress . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total property and equipment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Less: Accumulated depreciation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total property and equipment, net . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
2020
62 $
349
3,667
4,602
101
8,781
(4,730)
4,051 $
2019
47
344
3,627
4,685
20
8,723
(2,325)
6,398
December 31, December 31,
As of December 31, 2020, construction in progress is primarily comprised of leasehold improvements which
the Company anticipates will be placed into service in 2021.
Depreciation expense for the years ended December 31, 2020, 2019 and 2018 was $2,405, $2,068 and $286,
respectively.
5. Leases
Kiniksa US leases office and laboratory space under operating leases. Leases with an initial term of 12 months
or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line
basis over the lease term. For lease agreements entered into or reassessed after the Company’s adoption of ASC 842, the
Company will combine lease and non-lease components. Kiniksa US’s leases have remaining lease terms of less than 2
years.
On March 13, 2018, Kiniksa US entered into an operating lease in Lexington, Massachusetts for office and
laboratory space that comprises the headquarters for Kiniksa US and on June 26, 2018, Kiniksa US entered into an
amendment to the lease expanding the rentable space to a total of 27,244 square feet. On November 7, 2018, Kiniksa US
entered into an amendment (the “Third Amendment”) to the lease expanding the rentable space to a total of 55,924
square feet which were occupied in phases through December 2019. On November 6, 2020, Kiniksa US entered into an
amendment (the “Fourth Amendment”) to extend the term of the sublease by one month to August 31, 2021 and entered
into a Recognition and Attornment Agreement and Amendment of Sublease (the “2020 Agreement”) directly with the
prime landlord to continue to lease the space upon the expiration of the Fourth Amendment through August 31, 2023.
Monthly lease payments include base rent, as well as, ancillary charges such as the share of operating expenses and real
estate taxes. Base rent under the Third Amendment and Fourth Amendments were $139 per month and increased to $153
per month in November 2020 with subsequent increases to $233 per month in September 2021 and $240 per month in
September 2022 through the end of the lease. Further, a letter of credit to secure the lease is not required under the 2020
Agreement.
On December 21, 2018, Kiniksa US entered into an operating lease in San Diego, California for office space
comprising a total of 4,400 square feet. The lease commenced on January 1, 2019 and expires on January 31, 2021. On
July 17, 2020, Kiniksa US entered into an amendment to extend the lease through January 31, 2022. Monthly lease
F-21
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
payments for base rent are $13 and increase to $14 in February 2021 in accordance with the extension. Additional fees
for ancillary charges such as the share of operating expenses, parking and real estate taxes are not included in the base
rent.
On December 1, 2020, Kiniksa UK entered into an operating lease in London, UK for office space comprising a
total of 164 square meters. The lease commenced on December 1, 2020 and expires on November 30, 2025 with an
option to terminate on November 30, 2023. Quarterly lease payments for base rent are £20 as of December 2020 and will
increase periodically until the termination of the lease. Additional fees for ancillary charges such as the share of
operating expenses, parking and real estate taxes are not included in the base rent. The lease also includes a requirement
to restore the property to original condition and is estimated to be approximately £22.
Years Ended
December 31,
2020
2019
Operating lease cost . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Variable lease cost . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total lease cost . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
1,578 $
167
1,745 $
Weighted-average remaining lease term (years) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Weighted-average discount rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Maturities of operating leases liabilities were as follows:
As of December 31,
2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
2022 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2023 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2024 and thereafter . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total future minimum lease payments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Less imputed interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Present value of lease liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
December 31,
2020
1,443
152
1,595
2.64
5.60%
2,419
3,055
2,065
—
7,539
(554)
6,985
F-22
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
6. Accrued Expenses
Accrued expenses consisted of the following:
Accrued research and development expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Accrued employee compensation and benefits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued legal and professional fees . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
$
2020
16,945 $
7,704
3,988
562
29,199 $
2019
11,813
7,089
1,087
426
20,415
December 31, December 31,
7. Convertible Preferred Shares
As of December 31, 2017, the Company’s bye-laws, as amended and restated, designated 22,885,492
authorized shares to be issued as convertible preferred shares with a par value of $0.000273235 per share, of which
17,128,120 shares were further designated as Series A convertible preferred shares (the “Series A preferred shares”) and
5,757,372 shares were further designated as Series B convertible preferred shares (the "Series B preferred shares"). In
February 2018, the Company’s bye-laws were further amended and restated to, among other things, effect an increase in
the number of authorized convertible preferred shares with a par value of $0.000273235 per share to 35,670,093 shares,
of which 12,784,601 shares were further designated as Series C convertible preferred shares (the "Series C preferred
shares"). The holders of convertible preferred shares had liquidation rights in the event of a deemed liquidation that, in
certain situations, was not solely within the control of the Company. Therefore, the Series A, Series B and Series C
convertible preferred shares (collectively, the “Preferred Shares”) were classified outside of shareholders' equity
(deficit).
In February 2018, the Company issued and sold 12,784,601 Series C preferred shares at a price of $15.6438 per
share (the “Series C Original Issue Price”) for proceeds of $190,822, net of issuance costs of $9,178.
In May 2018, upon the completion of the Company’s IPO (which qualified as a “Qualified IPO” under the
Company’s bye-laws, as amended and restated), all of the outstanding Preferred Shares were converted into 5,546,019
Class A common shares, 1,070,502 Class B common shares, 12,995,954 Class A1 common shares and 16,057,618 Class
B1 common shares in accordance with the Company’s bye-laws, as amended and restated. In connection with the
completion of its IPO in May 2018, the Company amended and restated its bye-laws to, among other things, authorize
the issuance of undesignated preferred shares. As of December 31, 2020 and 2019, no preferred shares were designated
or issued.
Prior to the conversion to common shares, the holders of the Preferred Shares had the following rights and
preferences:
Voting
The holders of Preferred Shares were entitled to vote, together with the holders of common shares, on all
matters submitted to shareholders for a vote. The holders of Series A preferred shares were entitled to the number of
votes per Series A preferred share equal to the number of whole Class B common shares into which the Series A
preferred shares were convertible at the time of such vote (which is ten votes for each Class B common share). The
holders of Series B preferred shares were entitled to the number of votes per Series B preferred share equal to the
number of whole Class A common shares into which the Series B preferred shares were convertible at the time of such
vote (which was one vote for each Class A common share). The holders of Series C preferred shares were entitled to the
number of votes per Series C preferred share equal to the number of whole Class A common shares into which the Series
F-23
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
C preferred shares were convertible at the time of such vote (which was one vote for each Class A common share).
Except as provided by law or by the other provisions of the Company’s bye-laws, holders of Preferred Shares voted
together with the holders of common shares as a single class.
The holders of Preferred Shares, voting together as a single class, were entitled to elect two directors of the
Company. The holders of Preferred Shares, voting together with the holders of common shares as a single class, were
entitled to elect the remaining directors of the Company, except for the one director that the holders of Class A common
shares and Class B common shares, voting together as a single class were entitled to elect.
Conversion
Each Series A preferred share was convertible, at the option of the holder, at any time and from time to time,
and without the payment of additional consideration by the holder thereof, in such manner as permitted by Bermuda law,
into such number of fully paid and non-assessable Class B common shares determined by dividing the Series A Original
Issue Price by the Series A Conversion Price (as defined below) in effect at the time of conversion. Each Series B
preferred share was convertible, at the option of the holder, at any time and from time to time, and without the payment
of additional consideration by the holder thereof, in such manner as permitted by Bermuda law, into such number of
fully paid and non-assessable Class A common shares determined by dividing the Series B Original Issue Price by the
Series B Conversion Price (as defined below) in effect at the time of conversion. Each Series C preferred share was
convertible, at the option of the holder, at any time and from time to time, and without the payment of additional
consideration by the holder thereof, in such manner as permitted by Bermuda law, into such number of fully paid and
non-assessable Class A common shares determined by dividing the Series C Original Issue Price by the Series C
Conversion Price (as defined below) in effect at the time of conversion.
At the time of the IPO, the Series A Original Issue Price and Series A Conversion Price were equal to $4.6707.
The Series B Original Issue Price and Series B Conversion Price were equal to $6.9475, and the Series C Original Issue
Price and Series C Conversion Price were equal to $15.6438. Therefore, each Series A preferred share was convertible
into one Class B common share, each Series B preferred share was convertible into one Class A common share and each
Series C preferred share was convertible into one Class A common share.
Further, upon either (i) the closing of the sale of Class A common shares or Class B common shares to the
public at a price of at least $15.6438 per share (subject to appropriate adjustment in the event of any share dividend,
share split, combination or other similar recapitalization with respect to the applicable class of common shares) in an
initial public offering resulting in at least $100,000 of gross proceeds to the Company (a “Qualified IPO”) or (ii) the date
and time, or the occurrence of an event, specified by vote or written consent of the holders of a majority of the
outstanding Preferred Shares, voting together as a single class on an as if converted to Class A common shares basis, all
outstanding Series A preferred shares would automatically be converted, in such manner as permitted pursuant to
Bermuda law, into Class B common shares at the then effective conversion rate, and all outstanding Series B and
Series C preferred shares would automatically be converted, in such manner as permitted pursuant to Bermuda law, into
Class A common shares at the then effective conversion rate. Notwithstanding the foregoing, in the event of a mandatory
conversion of preferred shares as a result of a Qualified IPO, (a) holders of Series A preferred shares could elect to
receive Class B1 common shares in lieu of Class B common shares and (b) holders of Series B and Series C preferred
shares could elect to receive Class A1 common shares in lieu of Class A common shares.
Dividends
The holders of the Preferred Shares were entitled to receive noncumulative dividends when and if declared by
the Company’s board of directors. The Company was not permitted to declare, pay or set aside any dividends on any
other class or series of shares of the Company, other than dividends on common shares payable in common shares,
unless the holders of the Preferred Share first received, or simultaneously received, a dividend on each outstanding
F-24
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
Preferred Share equal to (i) in the case of a dividend on any class of common shares or any class or series convertible
into common shares, that dividend per Preferred Share as would have equaled the product of (a) the dividend payable on
each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into
common shares and (b) the number of common shares issuable upon conversion of a share of the applicable series of
Preferred Shares, or (ii) in the case of a dividend on any class or series that was not convertible into common shares, at a
rate per Preferred Share determined by (a) dividing the amount of the dividend payable on each share of such class or
series of shares by the original issue price of such class or series (subject to appropriate adjustment in the event of any
bonus share, share dividend, share split, combination of or other similar recapitalization with respect to such class or
series) and (b) multiplying such fraction by an amount equal to the applicable Series A, Series B or Series C Original
Issue Price. No cash dividends were declared or paid on the Preferred Shares.
Liquidation Preference
In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or deemed
liquidation event (as defined below), the holders of Preferred Shares then outstanding were entitled to be paid out of the
assets of the Company available for distribution to its shareholders, on a pari passu basis, before any payment was made
to the holders of common shares by reason of their ownership thereof, an amount per share equal to the greater of (i) one
times the applicable Original Issue Price, plus any dividends declared but unpaid thereon, and (ii) such amount per share
as would have been payable had all Preferred Shares been converted into common shares immediately prior to such
liquidation, dissolution, winding up or deemed liquidation event. Thereafter, the remaining assets of the Company
available for distribution to its shareholders would have been distributed among the holders of common shares, pro rata
based on the number of shares held by each such holder.
If upon any such liquidation, dissolution or winding up of the Company or deemed liquidation event, the assets
of the Company available for distribution to its shareholders were insufficient to pay the holders of Preferred Shares the
full amount to which they were entitled, the holders of Preferred Shares would have shared ratably in any distribution of
the assets available for distribution in proportion to the respective amounts which would otherwise have been payable in
respect of the shares held by such holders of Preferred Shares upon such distribution if all amounts payable on or with
respect to such shares were paid in full.
Unless a majority of the holders of the then outstanding Preferred Shares elected otherwise, a deemed
liquidation event would include a merger or consolidation (other than one in which shareholders of the Company own a
majority by voting power of the outstanding shares of the surviving or acquiring company or corporation) or a sale,
lease, transfer, exclusive license or other disposition of all or substantially all of the assets of the Company.
Redemption
The Company’s bye-laws, as amended and restated, did not provide redemption rights to the holders of
Preferred Shares.
8. Common Shares
As of December 31, 2017, the Company’s bye-laws, as amended and restated, authorized the Company to issue
43,918,239 total shares with a par value of $0.000273235, of which 5,507,938 and 3,568,353 shares were designated as
Class A and Class B common shares, respectively. In February 2018, the Company’s bye-laws were further amended
and restated to, among other things, effect an increase in the number of authorized common shares to 44,746,463 shares,
of which 5,507,938 shares were designated as Class A common shares and 3,568,353 shares were designated as Class B
common shares. The remaining 11,956,456 shares that were not designated as common shares or Preferred Shares as of
F-25
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
December 31, 2017 could have been designated to any class at any time in the future by the Company’s board of
directors. No Class A1 common shares or Class B1 common shares were designated as of December 31, 2017.
On May 23, 2018, the Company’s registration statement on Form S-1 relating to the IPO was declared effective
by the SEC. On May 29, 2018, the Company completed the IPO of 8,477,777 Class A common shares at a public
offering price of $18.00 per share for gross proceeds of $152,600. In addition, on June 22, 2018, the Company
completed the sale of 1,006,425 Class A common shares to the underwriters of the IPO following the exercise in part of
their over-allotment option to purchase additional shares at a public offering price of $18.00 per share for gross proceeds
of $18,116. The aggregate net proceeds to the Company from the IPO, inclusive of the over-allotment option exercise,
was $155,536 after deducting underwriting discounts and commissions and other offering costs.
In May 2018, upon completion of the IPO (which qualified as a “Qualified IPO” under the Company’s
bye -laws, as amended and restated), all outstanding Preferred Shares were converted into 5,546,019 Class A common
shares, 1,070,502 Class B common shares, 12,995,954 Class A1 common shares and 16,057,618 Class B1 common
shares in accordance with the Company’s bye-laws, as amended and restated. In connection with the completion of the
IPO in May 2018, the Company increased the authorized capital of the Company to $54,647 consisting of 200,000,000
shares of $0.000273235 par value per share and, among other things, amended the description of different classes of
shares under the Amended & Restated Bye-Laws.
On February 4, 2019, the Company completed a follow-on offering of 2,654,984 Class A common shares at a
public offering price of $18.26 and a concurrent private placement of 2,000,000 Class A1 common shares at an offering
price of $18.26 per share for aggregate gross proceeds of $85,000. In addition, on March 1, 2019, the Company
completed the sale of 161,126 Class A common shares to the underwriters of the follow-on offering following the
exercise in part of their over-allotment option to purchase additional shares at a public offering price of $18.26 per share
for gross proceeds of $2,942. The aggregate net proceeds to the Company from the follow-on offering and concurrent
private placement, inclusive of the over-allotment option exercise, was $82,988 after deducting underwriting discounts
and commissions, placement agent fees and other offering costs.
On May 18, 2020, the Company completed a follow-on offering of 2,760,000 Class A common shares,
inclusive of the exercise of the underwriters’ overallotment option at a public offering price of $18.25 and a concurrent
private placement of 1,600,000 Class A1 common shares at an offering price of $18.25 per share for aggregate gross
proceeds of $79,570. The aggregate net proceeds to the Company from the follow-on offering and concurrent private
placement, inclusive of the over-allotment option exercise, was $74,495 after deducting underwriting discounts and
commissions, placement agent fees and other offering costs.
On July 24, 2020, the Company completed a follow-on offering of 5,952,381 Class A common shares, at a
public offering price of $21.00 and a concurrent private placement of 1,428,572 Class A1 common shares at an offering
price of $21.00 per share for aggregate gross proceeds of $155,000. The aggregate net proceeds to the Company from
the follow-on offering and concurrent private placement was $146,037 after deducting underwriting discounts and
commissions, placement agent fees and other offering costs.
The rights of the holders of the Company’s Class A common shares, Class B common shares, Class A1
common shares and Class B1 common shares are identical, except with respect to voting, transferability and conversion,
as described below. As of December 31, 2020, no preferred shares were designated or issued.
Voting
Each Class A common share entitles the holder to one vote on all matters submitted to the shareholders for a
vote. Each Class B common share entitles the holder to ten votes on all matters submitted to the shareholders for a vote.
F-26
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
The holders of Class A and Class B common shares, voting together as a single class, are entitled to elect the directors of
the Company. Holders of Class A1 common shares and Class B1 common shares have no voting rights.
Dividends
The common shareholders are entitled to receive dividends, as may be declared by the Company’s board of
directors. Through December 31, 2020, no cash dividends have been declared or paid.
Conversion
Each Class B common share shall automatically convert into one Class A common share upon certain transfers
of such shares by the holder thereof (subject to certain exceptions). Each Class B common share is convertible, at the
holder’s election into one Class A common share or one Class B1 common share. Each Class A1 common share is
convertible into one Class A common share at the holder’s election (subject to certain exceptions). Each Class B1
common share shall automatically convert into one Class A common share upon certain transfers of such shares by the
holder thereof (subject to certain exceptions). Each Class B1 common share is convertible into one Class A common
share or one Class B common share at the holder’s election (subject to certain exceptions). There are no conversion
rights associated with the Class A common shares.
9. Share-Based Compensation
2018 Incentive Award Plan
In May 2018, the Company’s board of directors and shareholders approved the 2018 Incentive Award Plan (the
“2018 Plan”), which became effective on May 23, 2018. The 2018 Plan provides for the grant of incentive share options,
nonqualified share options, share appreciation rights, restricted shares, dividend equivalents, restricted share units and
other share- or cash- based awards. Upon the effectiveness of the 2018 Plan, the Company ceased granting awards under
its 2015 Equity Incentive Plan (as amended, the “2015 Plan” together with the 2018 Plan, the “Plans”).
A total of 4,466,500 Class A common shares were initially reserved for issuance under the 2018 Plan. The
number of Class A common shares that may be issued under the 2018 Plan will automatically increase on each
January 1, beginning in 2019 and continuing for each fiscal year until, and including, the fiscal year ending
December 31, 2028, equal to the lesser of (1) 4% of the Class A common shares outstanding (on an as-converted basis)
on the final day of the immediately preceding calendar year and (2) a smaller number of Class A common shares
determined by the Company’s board of directors. In December 2019, the board of directors approved the automatic
increase as of January 1, 2020 of 2,197,505 shares, equal to 4% of the as-converted Class A common shares outstanding
on December 31, 2019. No more than 27,915,000 Class A common shares may be issued under the 2018 Plan upon the
exercise of incentive share options. The Class A common shares underlying any awards issued under the 2018 Plan or
the 2015 Plan that on or after the effective date of the 2018 Plan expire, lapses unexercised or are terminated, exchanged
for cash, surrendered, repurchased, canceled without having been fully exercised, or forfeited under the 2018 Plan or the
2015 Plan will be added back to the Class A common shares available for issuance under the 2018 Plan. As of
December 31, 2020, 1,618,474 shares remained available for future grant.
2015 Equity Incentive Plan
Until May 23, 2018 (the effective date of the 2018 Plan), the 2015 Plan provided for the Company to grant
incentive share options, nonqualified share options, share grants and other share-based awards to employees and
non-employees to purchase the Company’s Class A common shares. On the effective date of the 2018 Plan, the
Company ceased granting awards under the 2015 Plan. At that time, the 4,691,213 Class A common shares subject to
outstanding awards under the 2015 Plan remained reserved for issuance under the plan pursuant to such awards and the
F-27
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
92,170 Class A common shares that had been available for future grant under the 2015 Plan were no longer authorized
and reserved for issuance or available for future grant under the 2015 Plan.
As of December 30, 2020, there were 2,794,056 Class A common shares subject to outstanding awards under
the 2015 Plan and reserved for issuance thereunder pursuant to such awards. The 2015 Plan continues to govern the
terms and conditions of the outstanding awards granted under it. Class A common shares subject to awards granted
under the 2015 Plan that expire, lapse unexercised or are terminated, exchanged for cash, surrendered, repurchased,
canceled without having been fully exercised, or forfeited become available for issuance under the 2018 Plan.
The exercise price for share options granted under the 2015 Plan was determined by the Company’s board of
directors. All incentive share options granted to any person possessing 10% or less of the total combined voting power of
all classes of shares could not have an exercise price of less than 100% of the fair market value of the Class A common
shares on the grant date. All incentive share options granted to any person possessing more than 10% of the total
combined voting power of all classes of shares could not have an exercise price of less than 110% of the fair market
value of the Class A common shares on the grant date. The option term for incentive share options could not be greater
than 10 years. Incentive share options granted to persons possessing more than 10% of the total combined voting power
of all classes of shares could not have an option term of greater than five years. The vesting period for equity-based
awards was determined by the board of directors, which was generally four to six years. For awards granted to
employees and non-employees with four year vesting terms, 25% of the option vests on the first anniversary of the grant
date and the remaining shares vest equally each month for three years thereafter. For awards granted to employees with
six year vesting terms, 16% of the option vests on the first anniversary of the grant date and the remaining shares vest
based on a predetermined vesting schedule for five years thereafter.
2018 Employee Share Purchase Plan
In May 2018, the Company’s board of directors and shareholders approved the 2018 Employee Share Purchase
Plan (the “2018 ESPP”), which became effective on May 23, 2018. A total of 670,000 Class A common shares were
initially reserved for issuance under the 2018 ESPP. The number of Class A common shares that may be issued under
the 2018 ESPP will automatically increase on each January 1, beginning in 2019 and continuing for each fiscal year
until, and including, the fiscal year ending December 31, 2028, equal to the lesser of (1) 1% of the Class A common
shares outstanding (on an as-converted basis) on the final day of the immediately preceding calendar year and (2) a
smaller number of Class A common shares determined by the Company’s board of directors, provided that no more than
6,420,000 Class A common shares may be issued under the 2018 ESPP. In December 2020, the board of directors
approved an increase as of January 31, 2021 of 130,000 shares. As of December 31, 2020, 518,794 Class A common
shares were available for future issuance under the 2018 ESPP.
F-28
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
Share Options
The following table summarizes option activity for the year ended December 31, 2020:
Weighted
Average
Weighted Remaining
Average Contractual Aggregate
Intrinsic
Term
Exercise
Value
(in years)
Price
Number of
Shares
Outstanding as of December 31, 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . .
Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Exercised . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Forfeited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Outstanding as of December 31, 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . .
Share options exercisable as of December 31, 2020 . . . . . . . . . . . . . . . .
Share options unvested as of December 31, 2020 . . . . . . . . . . . . . . . . . .
8,491,734 $ 11.17
3,794,735 $ 16.50
(1,324,429) $ 4.57
(1,003,182) $ 14.88
9,958,858 $ 13.53
3,799,854 $ 10.83
6,159,004 $ 15.19
7.88 $ 27,217
8.15 $ 52,394
7.00 $ 31,526
2.79 $ 64,715
The aggregate intrinsic value of share options is calculated as the difference between the exercise price of the
share options and the fair value of the Company’s common shares for those share options that had exercise prices lower
than the fair value of the Company’s common shares.
During the year ended December 31, 2020, share option holders exercised 1,324,429 share options for Class A
common shares with an intrinsic value of $18,271 for total cash proceeds to the Company of $6,058. During the year
ended December 31, 2019, share option holders exercised 150,253 share options for Class A common shares with an
intrinsic value of $1,776 for total cash proceeds to the Company of $590. During the year ended December 31, 2018,
share option holders exercised 25,683 share options for Class A common shares with an intrinsic value of $411 for total
cash proceeds to the Company of $87.
The weighted-average grant-date fair value per share of share options granted during the years ended
December 31, 2020, 2019 and 2018 was $11.38, $9.36 and $11.96, respectively.
The total fair value of share options vested during the years ended December 31, 2020, 2019 and 2018 was
$17,931, $13,997 and $2,255, respectively.
Option Valuation
The assumptions that the Company used to determine the grant-date fair value of share options granted to
employees and directors under the 2015 Plan and the 2018 Plan during the years ended December 31, 2019 and 2018
were as follows, presented on a weighted-average basis:
Risk-free interest rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected term (in years) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected volatility. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected dividend yield . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Years Ended
December 31,
2019
2.07 %
6.22
79.14 %
— %
2020
0.55 %
6.21
80.81% %
— %
2018
2.82 %
6.40
75.04 %
— %
F-29
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
During the year ended December 31, 2020, the Company did not grant share options to non-employees. During
the year ended December 31, 2019 and 2018, the assumptions that the Company used to determine the fair value of share
options granted to non-employees were as follows, presented on a weighted-average basis:
Risk-free interest rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected term (in years) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected volatility. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Expected dividend yield . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rilonacept Long-Term Incentive Plan
Years Ended
December 31,
2019
2018
1.38 %
2.77
68.17 %
— %
2.91 %
7.35
74.18 %
— %
A restricted share unit (“RSU”) represents the right to receive shares of the Company’s Class A common shares
upon vesting of the RSU. The fair value of each RSU is based on the closing price of the Company’s Class A common
shares on the date of grant. In December 2019, the compensation committee of the Company’s board of directors
approved the Company’s Rilonacept Long-Term Incentive Plan (“RLTIP”) under the Company’s 2018 Plan to
incentivize eligible employees of the Company or any of its subsidiaries to achieve U.S. Food and Drug Administration
(“FDA”) approval for the commercial sale and marketing of rilonacept for the treatment of recurrent pericarditis in the
United States (“RLTIP Milestone”). The RLTIP provides for the potential to receive a cash award and two grants of
RSU awards covering Class A common shares under the 2018 Plan. The target award value for each of the cash award
and the two RSU awards will be equal to one-third of a participant’s annual target bonus in the year of grant, as
determined in accordance with the RLTIP.
Depending on the date-range within which the RLTIP Milestone is achieved (such date the “Achievement
Date”) occurs, the RLTIP provides for (i) an earnout percentage that can be achieved as to 100%, 50%, 25% or 0% and
(ii) an upside earnout percentage that can be achieved as to 50%, 25% or 0%. No awards will be earned or vest, and the
second RSU award will not be granted, in the event the Achievement Date does not occur by a specified date.
The cash award is eligible to be earned and vested upon the Achievement Date with respect to an amount
determined in accordance with the RLTIP based on the earnout percentage. The number of Class A common shares
issuable under the first RSU award (“First RSU Award”) as a result of the RLTIP Milestone will be determined in
accordance with the RLTIP based on the earnout percentage, and such RSUs will vest on the first anniversary of the
Achievement Date, subject to continued employment on such date. The second RSU award will be granted on the
Achievement Date with respect to a number of shares determined in accordance with the RLTIP, based on both the
earnout percentage and the upside earnout percentage, and will vest on the second anniversary of the Achievement Date,
subject to continued employment through such date.
Restricted Share Units
In December 2019, the Company granted RSUs with service conditions (“Time-Based RSUs”) that vest in one
installment on December 31, 2020, subject to the recipient’s continued employment through that date. During the years
ended December 31, 2020 and 2019, the Company also granted the First RSU Award to eligible employees as part of the
RLTIP, which becomes eligible to vest upon the Achievement Date and will vest upon the first anniversary of such date,
subject to the recipient’s continued employment through that date. In the event the RLTIP Milestone is not achieved, the
First RSU Award will not vest.
F-30
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
On December 31, 2020, all outstanding Time-Based RSUs vested and 56,369 class A common shares were
issued and remaining shares of 24,332 were withheld for tax purposes. For the year ended December 31, 2020, the
Company recognized $980 in compensation expense related to the Time-Based RSUs. For the year ended December 31,
2019, the Company did not recognize any compensation expense related to the Time-Based RSU. The grant-date fair
value of the First RSU Award remaining as of December 31, 2020 was $2,754 and will be recognized when the RLTIP
Milestone is deemed probable of achievement through the date the First RSU Award will vest. During the years ended
December 31, 2020 and 2019, the Company did not recognize any compensation expense related to the First RSU
Award, as achievement of the RLTIP Milestone was determined to be not probable.
The following table summarizes RSU activity, including the Time-Based RSUs and First RSU Awards under
the RLTIP, for the year ended December 31, 2020:
Unvested RSUs as of December 31, 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Granted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Vested . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Forfeited . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Unvested RSUs as of December 31, 2020 . . . . . . . . . . . . . . . . . . . . . . . . . . .
Share-Based Compensation
Number of
Shares
328,296
17,995
(80,701)
(60,278)
205,312
$
$
$
$
$
Weighted
Average
Grant Date
Fair Value
12.93
19.15
12.95
13.09
13.41
Share-based compensation expense was classified in the consolidated statements of operations and
comprehensive loss as follows:
Research and development expenses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Selling, general and administrative expenses . . . . . . . . . . . . . . . . . . . . . . . . . . .
$
Years Ended
December 31,
2019
5,746 $
9,334
15,080 $
2020
8,866 $
12,009
20,875 $
2018
2,285
3,416
5,701
During the year ended December 31, 2020, the Company recorded compensation expense for share options and
RSUs granted to employees and directors of $20,860. During the year ended December 31, 2020, the Company recorded
compensation expense for share options granted to non-employees of $15.
F-31
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
As of December 31, 2020, total unrecognized compensation expense related to the unvested share option
awards was $64,715 which is expected to be recognized over a weighted average remaining period of 2.79 years. As of
December 31, 2020, the Company has recognized all of the compensation expense related to the Time-Based RSUs and
none remain unvested. As of December 31, 2020, total unrecognized compensation cost related to the First RSU Award
was $2,754 which will be recognized when the RLTIP Milestone is deemed probable of achievement through the date
the First RSU Award vests.
10. License and Acquisition Agreements
Biogen Asset Purchase Agreement
In September 2016, the Company entered into an asset purchase agreement (the "Biogen Agreement") with
Biogen MA Inc. ("Biogen") to acquire all of Biogen's right, title and interest in and to certain assets used in or relating to
vixarelimab and other antibodies covered by certain patent rights, including patents and other intellectual property rights,
clinical data, know-how, and clinical drug supply. In addition, Biogen granted to the Company a non-exclusive,
sublicensable, worldwide license to certain background patent rights related to the vixarelimab program. The Company
is obligated to use commercially reasonable efforts to develop and commercialize such acquired products.
In exchange for these rights, the Company made an upfront payment to Biogen of $11,500 and a technology
transfer payment of $500. The Company accounted for the acquisition of technology as an asset acquisition because it
did not meet the definition of a business. The Company recorded the upfront payment and technology transfer payment
as research and development expense in the consolidated statement of operations and comprehensive loss because the
acquired technology represented in-process research and development and had no alternative future use.
Under the Biogen Agreement, the Company is obligated to make milestone payments to Biogen of up to
$179,000 upon the achievement of specified clinical and regulatory milestones in multiple indications in various
territories, including milestone payments of $4,000 and $10,000 paid during the year ended December 31, 2017 and the
year ended December 31, 2019, respectively, each payment was associated with the achievement of a specified clinical
milestone event. No milestones were achieved or paid during the year ended December 31, 2020. Additionally, the
Company could be obligated to make up to an aggregate of up to $150,000 of payments upon the achievement of
specified annual net sales milestones and to pay tiered royalties on escalating tiers of annual net sales of licensed
products starting in the high single-digit percentages and ending below the teens.
The Company also agreed to pay certain obligations under third-party contracts retained by Biogen that relate to
the vixarelimab program. Under these retained contracts, the Company paid a one-time upfront sublicense fee of $150
and is obligated to pay insignificant annual maintenance fees as well as clinical and regulatory milestone payments of up
to an aggregate of $1,575.
The Biogen Agreement will terminate upon the expiration of all payment obligations with respect to the last
product in all countries in the territory. The Company has the right to terminate the agreement with 90 days’ prior
written notice. Both parties may terminate by mutual written consent or in the event of material breach of the agreement
by the other party that remains uncured for 90 days (or 30 days for payment-related breaches).
During the year ended December 31, 2020, the Company recorded research and development expense of $106
primarily related to a milestone occurring in the first quarter of 2020 and the annual maintenance fee both in connection
with the retained contracts. During the year ended December 31, 2019, the Company recorded research and development
expense of $10,347 primarily related to milestone payments associated with the achievement of a specified clinical
milestone event as well as other payments in connection with the retained contracts due under the Biogen Agreement.
The Company did not incur any research and development expense, other than insignificant payments in connection with
the retained contracts, under the Biogen Agreement during the year ended December 31, 2018.
F-32
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
Primatope Stock Purchase Option Agreement
In September 2017, the Company entered into a stock purchase option agreement (the “Primatope Agreement”)
with Primatope Therapeutics, Inc. (“Primatope”), pursuant to which the Company was granted a license to certain
intellectual property rights owned or controlled by Primatope to research, develop, and manufacture the preclinical
antibody, KPL-404.
The agreement provided the Company with an exclusive call option to purchase all of the outstanding securities
of Primatope. Upon execution of the agreement, the Company made $500 in upfront payments for the initial option
period through April 2018 (the “Initial Option Period”). The Primatope Agreement allowed for up to three extensions of
the Initial Option Period through January 2019 (including the initial option period, the “Option Period”) for total
extension payments of up to $800. Through December 31, 2018, the Company made payments totaling $800 to extend
the Option Period to January 15, 2019. During the Option Period, the Company could conduct research and preclinical
work to assess the viability of the asset.
The Company determined that the call option represented a variable interest in Primatope and that Primatope is
a VIE. However, as the Company had no ability to control the board of directors or direct the ongoing activities of
Primatope during the Option Period, the Company did not have power over the activities that most significantly impact
Primatope’s economic performance and was not the primary beneficiary of Primatope. As a result, the Company did not
consolidate the assets, liabilities, and results of operations of Primatope prior to 2019.
In January 2019, the Company exercised the call option and in March 2019, the Company acquired all of the
outstanding securities of Primatope (the “Primatope Acquisition”). The aggregate amount of upfront and contingent
payments the Company paid to the former Primatope shareholders to acquire the Company was comprised of
(1) $15,000 paid at closing in March 2019, comprised of upfront consideration of $10,000 and milestone payments of
$5,000, which had been achieved as of the closing date, and (2) $3,000 paid in June 2019 for the final milestone
payment, which was achieved following the closing during the six months ended June 30, 2019, each paid in a
combination of cash and Class A common shares (inclusive of escrow and holdback share amounts) in accordance with
the Primatope Agreement. At the closing of the Primatope Acquisition, Primatope became a wholly owned subsidiary of
the Company and the acquisition was accounted for as an asset acquisition as it did not meet the definition of a business.
The Company released the escrow and issued the shares that were held back at closing in June 2020 and issued the
shares that were held back at the final milestone payment in September 2020. The Company recorded the upfront
payment and milestone payments as research and development expense in the consolidated statement of operations and
comprehensive loss because the acquired technology represented in-process research and development and had no
alternative future use.
During the years ended December 31, 2020, the Company did not incur any research and development expense
directly in connection with milestone or other payments related to the Primatope Acquisition or the Primatope
Agreement. During the year ended December 31, 2019, the Company recorded research and development expense of
$18,000 related to the Primatope Acquisition. During the year ended December 31, 2018, the Company recorded
research and development expense of $800, related to the extension of the option period under the Primatope Agreement.
Beth Israel Deaconess Medical Center License Agreement
As a result of the Primatope Acquisition, the Company acquired the rights to an exclusive license to certain
intellectual property rights controlled by Beth Israel Deaconess Medical Center, Inc. (“BIDMC”) to make, use, develop
and commercialize KPL-404 (the “BIDMC Agreement”). Under the BIDMC Agreement, the Company is solely
responsible for all development, regulatory and commercial activities and costs. The Company is also responsible for
costs related to filing, prosecuting and maintaining the licensed patent rights. Under the BIDMC Agreement, the
Company is obligated to pay an insignificant annual maintenance fee as well as clinical and regulatory milestone
F-33
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
payments of up to an aggregate of $1,200 to BIDMC. The Company is also obligated to pay a low single-digit royalty on
annual net sales of products licensed under the agreement.
During the years ended December 31, 2020 and 2019, the Company recorded research and development
expense of $10 and $10, respectively in connection with the BIDMC Agreement.
Regeneron License Agreement
In September 2017, the Company entered into a license agreement (the “Regeneron Agreement”) with
Regeneron Pharmaceuticals, Inc. (“Regeneron”), pursuant to which the Company has been granted an exclusive,
sublicensable license under certain intellectual property rights controlled by Regeneron to develop and commercialize
rilonacept in certain fields and territories. The Company is obligated to use commercially reasonable efforts to develop
and commercialize such licensed products.
In exchange for these rights, the Company made an upfront payment of $5,000. The Company accounted for
the acquisition of technology as an asset acquisition because it did not meet the definition of a business. The Company
recorded the upfront payment as research and development expense in the consolidated statement of operations and
comprehensive loss because the acquired technology represented in-process research and development and had no
alternative future use.
Under the Regeneron Agreement, the Company is also obligated to make payments to Regeneron of up to an
aggregate of $27,500 upon the achievement of specified regulatory milestones, which includes a $7,500 milestone
achieved and paid in the fourth quarter of 2020 and a $20,000 milestone which may be met in the first quarter of 2021.
Upon approval from the FDA, if any, of the sBLA for rilonacept in recurrent pericarditis, the Company will assume the
sales and distribution of rilonacept for the approved indications of CAPS and DIRA in the United States and the
Company would evenly split profits on sales of commercial products with Regeneron, after deducting certain
commercialization expenses subject to specified limits.
During the year ended December 31, 2020, the Company recorded research and development expense of $7,500
in connection with the achievement of a specified regulatory milestone event. The Company did not incur any research
and development expense directly related to milestones due under the Regeneron Agreement during the year ended
December 31, 2019 and 2018.
Under the Regeneron Agreement, the Company is solely responsible for all development and
commercialization activities and costs in its territories. The Company is also responsible for costs related to the filing,
prosecution and maintenance of certain licensed patent rights.
The parties also entered into a clinical supply agreement under which Regeneron agreed to manufacture the
developed product during the clinical phase. During the year ended December 31, 2020, the Company did not incur any
research and development expense related to the purchase of drug materials under this agreement. During the years
ended December 31, 2019 and 2018, the Company recorded research and development expense of $6,854 and $1,835,
respectively, related to the purchase of drug materials under this agreement. As of December 31, 2020, the Company had
non-cancelable purchase commitments under the clinical supply agreement (see Note 13).
The Regeneron Agreement will expire when the Company is no longer developing or commercializing any
licensed product under the Regeneron Agreement. Either party may terminate the agreement upon the other party’s
insolvency or bankruptcy or for material breach of the agreement by the other party that remains uncured for 90 days (or
30 days for payment-related breaches). Regeneron has the right to terminate the agreement if the Company suspends its
development or commercialization activities for a consecutive 12 month period or does not grant a sublicense to a
third-party to perform such activities, or if the Company challenges any of the licensed patent rights. The Company may
F-34
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
terminate the agreement at any time that is 18 months after the effective date of the agreement with 180 days’ written
notice or with one year’s written notice if the Company terminates the agreement following U.S. marketing approval of a
rilonacept product developed by the Company. The Company may also terminate the agreement with three months’
written notice if the products are determined to have certain safety concerns.
MedImmune License Agreement
In December 2017, the Company entered into a license agreement (as amended from time to time, the
“MedImmune Agreement”) with MedImmune, Limited (“MedImmune”), pursuant to which MedImmune granted the
Company an exclusive, sublicensable, worldwide license to certain intellectual property rights to make, use, develop and
commercialize mavrilimumab. Under the MedImmune Agreement, the Company also acquired reference rights to
relevant manufacturing and regulatory documents and MedImmune’s existing supply of mavrilimumab drug substance
and product. The Company is obligated to use commercially reasonable efforts to develop and commercialize the
licensed products.
In exchange for these rights, the Company made an upfront payment of $8,000. The Company accounted for
the acquisition of technology as an asset acquisition because it did not meet the definition of a business. The Company
recorded the upfront payment as research and development expense in the consolidated statement of operations and
comprehensive loss because the acquired technology represented in-process research and development and had no
alternative future use.
In addition, the Company is obligated to make clinical, regulatory and initial sales milestone payments of up to
$72,500 in aggregate for the first two indications, including, a $5,000 pass-through payment due upon the achievement
of a specified clinical milestone event which was achieved in the fourth quarter of 2018. Also included is a milestone
payment of $10,000 due upon the earlier to occur of a specified regulatory milestone and December 31, 2018, unless the
MedImmune Agreement is earlier terminated by either party. During the year ended December 31, 2019, the Company
made both the $5,000 and $10,000 previously accrued milestone payments in accordance with the MedImmune
Agreement. In addition, the Company is obligated to make clinical and regulatory milestone payments of up to $15,000
in the aggregate for each subsequent indication. In July 2020, the Company entered into an amendment to the
MedImmune Agreement to establish a new coronavirus field and defer the payment of certain development and
regulatory milestones as applied to the new coronavirus field. The Company is obligated to make milestone payments to
MedImmune of up to $85,000 upon the achievement of annual net sales thresholds up to, but excluding, $1,000,000 in
annual net sales as well as additional milestone payments aggregating up to $1,100,000 upon the achievement of
additional specified annual net sales thresholds starting at $1,000,000 and higher. The Company has also agreed to pay
tiered royalties on escalating tiers of annual net sales of licensed products starting in the low double-digit percentages
and ending at twenty percent. Royalty rates are subject to reductions upon certain events.
The Company is solely responsible for all development, manufacturing, and commercial activities and costs of
the licensed products, including clinical studies or other tests necessary to support the use of a licensed product. The
Company is also responsible for costs related to the filing, prosecution and maintenance of the licensed patent rights.
The MedImmune Agreement will expire upon the expiration of the royalty term in the last country for the last
indication, as defined in the agreement. Either party may terminate the agreement upon the other party’s insolvency or
bankruptcy or for material breach of the agreement by the other party that remains uncured for 90 days. MedImmune has
the right to terminate the agreement if the Company challenges any of the licensed patent rights. The Company may
terminate the agreement at any time upon 90 days’ prior written notice.
During the years ended December 31, 2020 and 2019, the Company did not record research and development
expense in connection with milestone payments due under the MedImmune Agreement. During the year ended
December 31, 2018, the Company recorded research and development expense and an accrued milestone of $5,000
F-35
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
related to a pass-through payment due upon the achievement of a specified clinical milestone event due under the
MedImmune Agreement.
Kite Clinical Collaboration
In December 2019, the Company entered into a clinical collaboration (the “Kite Agreement”) with Kite
Pharma, Inc., a Gilead Company (“Kite”), to initiate a Phase 2 clinical trial evaluating the combination of Yescarta
(axicabtagene ciloleucel) and mavrilimumab in relapsed or refractory large B-Cell lymphoma. The objective of the
Phase 2 trial is to determine the effect of mavrilimumab on the safety of Yescarta. Treatment related induction of
granulocyte-macrophage colony stimulating factor (“GM-CSF”) has been identified through clinical, translational and
preclinical studies as a potential key signal associated with side effects of chimeric antigen receptor T (“CAR T”), cell
therapy. Preclinical evidence suggest the potential for interruption of GM-CSF signaling to disrupt CAR T cell mediated
inflammation without disrupting anti-tumor activity. In August 2020, Kite as the sponsor of the study which had not
begun to enroll, informed the Company that the clinical collaboration was being discontinued under a portfolio strategy
review and terminated the agreement in accordance with its terms and conditions. During the years ended December 31,
2020 and 2019, the Company did not record any research and development expense in connection with the Kite
Agreement.
11. Income Taxes
As a company incorporated in Bermuda, the Company is principally subject to taxation in Bermuda. Under the
current laws of Bermuda, tax on a company’s income is assessed at a zero percent tax rate. As a result, the Company has
not recorded any income tax benefits from its losses incurred in Bermuda during each reporting period, and no net
operating loss carryforwards will be available to the Company for those losses.
In July 2020, the IRS issued final regulations regarding Foreign Derived Intangible Income (“FDII”), which
was enacted as part of the U.S. Tax Cuts and Jobs Act in December 2017. The final FDII requirements outlined in the
2020 guidance did not materially impact the Company’s income taxes.
On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act ("CARES Act") was enacted to
provide economic relief to those impacted by the COVID-19 pandemic. The CARES Act made various tax law changes,
including, among other things: (i) modifications to the federal net operating loss rules, including permitting federal net
operating losses incurred in 2018, 2019, and 2020 to be carried back to the five preceding taxable years in order to
generate a refund of previously paid income taxes and eliminating the 80% of taxable income limitations in years
2018-2020; (ii) enhanced recoverability of alternative minimum tax credit carryforwards; and (iii) delayed payment of
employer payroll taxes. On December 27, 2020 updates to the CARES Act were enacted which provided the temporary
allowance of a full deduction for business meals paid or incurred between December 31, 2020 and January 1, 2023. The
Company will continue to monitor for any updates but currently the only material impact to the Company’s tax provision
is the ability to defer employer payroll taxes for which the Company will not get a deduction until the amounts are paid.
In August 2015, the Company entered into agreements with its wholly owned subsidiary, Kiniksa US, under
which Kiniksa US provides management and research and development services to the Company for which the
Company pays costs plus a service fee.
In connection with its launch readiness activities, the Company transferred all of its rights, title and interest in,
among other things, certain contracts (including the Regeneron Agreement), intellectual property rights, product filings
and approvals and other information, plans and materials owned or controlled by the Company insofar as they related
exclusively or primarily to rilonacept to Kiniksa UK in January 2021 pursuant to an asset transfer agreement between the
Company and Kiniksa UK for the consideration described therein.
F-36
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
Loss before benefit (provision) for income taxes consisted of the following:
Years Ended
December 31,
2019
2018
2020
Bermuda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ (161,983) $ (168,053) $ (105,562)
2,121
Foreign (U.S., U.K., Germany, France, Switzerland) . . . . . . . . . . . . . . . . .
$ (156,229) $ (163,914) $ (103,441)
4,139
5,754
The components of the Company’s income tax (provision) benefit were as follows:
Years Ended
December 31,
2019
2018
2020
Current income tax provision:
Bermuda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
U.S. federal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U.S. state . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign (U.K., Germany, France, Switzerland) . . . . . . . . . . . . . . . . . . . .
Total current income tax provision . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
— $
— $
(392)
(366)
(33)
(791)
(567)
(530)
(12)
(1,109)
Deferred income tax (provision) benefit:
Bermuda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U.S. federal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U.S. state . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign (U.K., Germany, France, Switzerland) . . . . . . . . . . . . . . . . . . . .
Total deferred income tax (provision) benefit . . . . . . . . . . . . . . . . . . . .
Total (provision) benefit for income taxes . . . . . . . . . . . . . . . . . . . . . . . . . $
—
(3,056)
(1,315)
10
(4,361)
(5,152) $
—
2,397
759
—
3,156
2,047 $
—
(547)
(217)
—
(764)
—
542
436
—
978
214
A reconciliation of the Bermuda statutory income tax rate of 0% to the Company’s effective income tax rate is
as follows:
Bermuda statutory income tax rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Foreign (U.S.) tax rate differential . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Research and development tax credits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Share-based compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Permanent differences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Change in valuation allowance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
U.S. state taxes, net of federal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
FDII . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Uncertain tax positions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Other . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Effective income tax rate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Years Ended
December 31,
2019
2018
2020
— %
(0.8)
2.4
1.3
(0.1)
(5.7)
0.1
0.6
(0.2)
(0.9)
(3.3)%
— %
(0.5)
2.2
(0.5)
(0.1)
(0.1)
(0.3)
0.9
(0.3)
—
1.3 %
— %
(1.0)
1.5
0.1
—
—
(0.4)
—
—
—
0.2 %
F-37
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
Net deferred tax assets consisted of the following:
December 31,
2020
2019
Deferred tax assets:
Research and development tax credit carryforwards . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Share-based compensation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Operating lease liability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued bonus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Accrued expenses and other liabilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Net operating losses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Total deferred tax assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Valuation allowance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Deferred tax liabilities:
Depreciation and amortization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Right of use asset . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1,674 $
6,271
1,764
1,208
634
198
11,749
(9,307)
(786)
(1,646)
Net deferred tax assets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
10 $
238
3,746
712
855
223
190
5,964
(330)
(745)
(517)
4,372
As of December 31, 2020 and 2019, the Company had federal research and development tax credit
carryforwards of approximately $1,383 and $228 respectively, available to reduce future tax liabilities, which begin to
expire in 2040. As of December 31, 2020 and 2019, the Company had state research and development tax credit
carryforwards of approximately $844 and $265 respectively, available to reduce future tax liabilities, which begin to
expire in 2035.
As required by ASC 740, the Company has evaluated the positive and negative evidence bearing upon its
ability to realize the deferred tax assets. As a result of significant cumulative tax benefits associated with share-based
compensation taxable events recognized in 2020, the Company has significant negative evidence in the form of
cumulative losses and thus management has determined that it is more likely than not that the Company will not utilize
the deferred tax assets in the United States. As such, the Company recorded a valuation allowance against its U.S.
deferred tax assets at December 31, 2020 of $9,307. In prior years, the Company recorded a valuation allowance against
certain state research and development tax credits only. In order to utilize state research and development tax credits, the
Company will need taxable income in the jurisdiction of where the credit was generated. The Company currently has no
taxable income in certain state jurisdictions and thus management had determined that it is more likely than not that the
Company will not recognize the benefits of state research and development tax credits generated in those jurisdictions. A
valuation allowance of $330 had been established at December 31, 2019.
Utilization of the state research and development tax credits may be subject to substantial annual limitation
under Section 382 of the Internal Revenue Code of 1986 due to ownership changes that could occur in the future. These
ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income.
In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain
shareholders or public groups in the shares of a corporation by more than 50% over a three-year period.
Changes in the valuation allowance for deferred tax were as follows:
Valuation allowance at beginning of year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
Increases recorded through the balance sheet . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Increases recorded to income tax provision . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(330) $
—
(8,977)
(49) $
(200)
(81)
Valuation allowance at end of year . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $ (9,307) $
(330) $
Years Ended
December 31,
2019
2020
2018
(27)
—
(22)
(49)
F-38
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
The valuation allowance increased by $8,977 in 2020 primarily as a result of the recognition of a valuation
allowance against all U.S. deferred tax assets.
The Company recognizes the tax benefit from an uncertain tax position only if it is more-likely-than-not that the
tax position will be sustained on examination by taxing authorities, based on the technical merits of the position. The tax
benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a
greater than 50% likelihood of being realized upon ultimate settlement. The amount of unrecognized tax benefits is $837
and $528 as of December 31, 2020 and 2019, respectively. The net increase relates to new tax positions on research and
development credits generated in 2020, offset by positions which are no longer outstanding due to the statute of
limitations closing.
A roll forward of the Company’s uncertainties in its income tax provision liability is presented below:
Gross balance at the beginning of year . . . . . . . . . . . . . . . . . . . . . . . . . .
Gross increases based on current period tax positions . . . . . . . . . . . . . .
Gross decreases based on tax positions of the prior periods . . . . . . . . .
Unrecognized tax benefits at the end of the year . . . . . . . . . . . . . . . . . .
$
$
528
411
(102)
837
$
$
—
528
—
528
$
$
Years Ended
December 31,
2019
2020
2018
—
—
—
—
The Company’s policy is to record interest and penalties related to income taxes as part of its income tax
provision. The Company had recorded immaterial interest on the tax positions during the year ended December 31,
2020, 2019 and 2018.
The Company files income tax returns in the United States as well as in certain state and in certain country
jurisdictions. Kiniksa US’s federal and state income tax returns are subject to tax examinations for the tax years ended
December 31, 2017 and subsequent years. To the extent the Company has tax attribute carryforwards, the tax years in
which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service and state tax
authorities to the extent utilized in a future period. There are currently no income tax examinations pending.
12. Net Loss per Share
The rights, including the liquidation and dividend rights, of the holders of Class A, Class B, Class A1 and Class
B1 common shares are identical, except with respect to voting, transferability and conversion (see Note 8). As the
liquidation and dividend rights are identical, losses are allocated on a proportionate basis and the resulting net loss per
share attributed to common shareholders will, therefore, be the same for both Class A and Class B common shares on an
individual or combined basis.
F-39
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
Basic and diluted net loss per share attributable to common shareholders was calculated as follows:
Years Ended
December 31,
2019
2020
2018
Numerator:
Net loss attributable to common shareholders . . . . . . . . . . . . . . . . . . . $
(161,381) $
(161,867) $
(103,227)
Denominator:
Weighted average common shares outstanding—basic and diluted . .
61,842,722
54,049,477
29,547,427
Net loss per share attributable to common shareholders— basic
and diluted . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . $
(2.61) $
(2.99) $
(3.49)
The Company’s unvested restricted shares and restricted share units have been excluded from the computation
of basic net loss per share attributable to common shareholders.
The Company’s potentially dilutive securities, which include share options, unvested restricted shares and
unvested RSUs, have been excluded from the computation of diluted net loss per share attributable to common
shareholders as the effect would be to reduce the net loss per share attributable to common shareholders. Therefore, the
weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share
attributable to common shareholders is the same. The Company excluded the following potential common shares,
presented based on amounts outstanding at each period end, from the computation of diluted net loss per share
attributable to common shareholders for the periods indicated because including them would have had an anti-dilutive
effect:
Share options to purchase common shares . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Unvested restricted common shares . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Unvested RSUs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2020
As of December 31,
2019
9,958,858 8,491,734 5,960,939
877,219
—
10,164,170 8,820,030 6,838,158
—
328,296
—
205,312
2018
13. Commitments and Contingencies
License Agreements
The Company has entered into license agreements with various parties under which it is obligated to make
contingent and non-contingent payments (see Note 10).
Manufacturing Commitments
The Company entered into agreements with several contract manufacturing organizations to provide preclinical
and clinical trial materials. As of December 31, 2020, the Company had committed to minimum payments under these
agreements totaling $16,178 which are due during the year ending December 31, 2021.
Rilonacept Long-Term Incentive Plan
During the year ended December 31, 2020, the Company granted a cash award and the First RSU Award to
employees under the RLTIP. The cash award vests upon the achievement of the RLTIP Milestone, subject to the
recipient’s continued employment. The First RSU Award becomes eligible to vest upon the achievement of the RLTIP
F-40
KINIKSA PHARMACEUTICALS, LTD.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
(Amounts in thousands, except share and per share amounts)
Milestone, and will vest upon the first anniversary of such date, subject to the recipient’s continued employment through
that date. As of December 31, 2020, the Company estimates, but has not accrued the cash payments of $2,013 under the
RLTIP. In the event the RLTIP Milestone is not achieved, the cash award will not be paid and the First RSU Award will
not vest.
Indemnification Agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to
vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses
arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In
addition, the Company has entered into indemnification agreements with members of its board of directors, officers and
other key personnel that will require the Company, among other things, to indemnify them against certain liabilities that
may arise by reason of their status or service as directors, officers or other key personnel. The maximum potential
amount of future payments the Company could be required to make under these indemnification agreements is, in many
cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The
Company does not believe that the outcome of any claims under indemnification arrangements will have a material
effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such
obligations in its consolidated financial statements as of December 31, 2020, 2019 or 2018.
Legal Proceedings
The Company is not a party to any litigation and does not have contingency reserves established for any
litigation liabilities.
14. Benefit Plans
The Company has established a defined-contribution savings plan under Section 401(k) of the Internal Revenue
Code. This plan covers substantially all employees who meet minimum age and service requirements and allows
participants to defer a portion of their annual compensation on a pre-tax basis. The Company provides matching
contributions of 100% of the first 3% of each participant’s salary contributed, plus 50% for each of the next 2%
contributed. Employees are immediately and fully vested in their own contributions and the Company’s match. During
the years ended December 31, 2020, 2019 and 2018, the Company contributed $993, $851 and $315, respectively, to the
plan.
F-41
(cid:3)
WEBSITE
Kiniksa.com
LEGAL COUNSEL
Latham & Watkins LLP
Boston, Massachusetts
Conyers Dill & Pearman Limited
Hamilton, HM CX, Bermuda
INDEPENDENT REGISTERED ACCOUNTING FIRM
PricewaterhouseCoopers LLP
Boston, Massachusetts
TRANSFER AGENT AND REGISTRAR
American Stock Transfer & Trust Company, LLC
Brooklyn, New York
STOCK INFORMATION
Nasdaq Global Select Market: KNSA
INVESTOR RELATIONS
Mark Ragosa
Chief Financial Officer
ir@kiniksa.com
This Annual Report contains forward-looking statements that involve risks, uncer-
tainties and other important factors that could cause results to differ materially
from those projected. In some cases, you can identify these statements by terms
such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“goal,” “design,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,”
“potential” or “continue” or their negative or other similar expressions. These
important factors include those discussed in our Annual Report on Form 10-K for
the year ended December 31, 2020 (which forms a part of this Annual Report)
under the caption “Risk Factors.” Accordingly, you are cautioned not to place
undue reliance on such statements. We undertake no obligation to update any
forward-looking statements.
ARCALYST is a registered trademark of Regeneron Pharmaceuticals, Inc.
Unless otherwise expressly stated, we obtained the industry, business, market and
other data contained in this Annual Report from reports, research surveys, clinical
trials, studies and similar data prepared by market research firms and other third
parties, from industry, medical and general publications, and from government
data and similar sources.
MANAGEMENT TEAM
Sanj K. Patel*
Chief Executive Officer & Chairman of the Board
John F. Paolini, MD, PhD*
Chief Medical Officer
Thomas Beetham*
Executive Vice President,
Corporate Development & Operations, Chief Legal Officer
Mark Ragosa*
Chief Financial Officer
Martina Struck, PhD
Senior Vice President, Regulatory Affairs
Arian Pano
Chief Clinical Development Officer
Eben Tessari
Chief Business Officer
Ross Moat*
Group Vice President & ARCALYST General Manager
Melissa Manno
Chief Human Resources Officer
Dana Martin
Senior Vice President, Global Medical Affairs
Michael Megna
Vice President, Finance & Chief Accounting Officer
* Executive officers as defined under Rule 3b-7 under the
Securities Exchange Act of 1934, as amended.
BOARD OF DIRECTORS
Chairman
Sanj K. Patel
Chief Executive Officer
Lead Independent Director
Felix J. Baker, PhD
Co-Managing Member, Baker Bros. Advisors LP
Directors
Stephen R. Biggar, MD, PhD
Partner, Baker Bros. Advisors LP
G. Bradley Cole
Former Executive Advisor, Exact Sciences Corporation
Richard S. Levy, MD
Biopharmaceutical Consultant
Thomas R. Malley
President, Mossrock Capital, LLC
Tracey L. McCain
Executive Vice President, Chief Legal &
Compliance Officer, Blueprint Medicine Corporation
Kimberly J. Popovits
Former Chief Executive Officer & Chairman of the Board,
Genomic Health, Inc.
Barry D. Quart, PharmD
President, Chief Executive Officer & Chairman of the Board,
Heron Therapeutics, Inc.
ADDRESS
Kiniksa Pharmaceuticals, Ltd.
Clarendon House
2 Church Street
Hamilton HM 11
Bermuda
RELENTLESS.
PASSIONATE.
FOCUSED.™